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ABSTRACT 
Dry powder inhalers (DPIs) are well established as a means of delivering inhaled drugs 
to the lungs. Combination DPIs, containing two or more drugs in a single formulation, 
may improve patient compliance by simplifying medication regimens. The implications 
of co-formulation on the aerosolisation behaviour of the component drugs, however, are 
not fully understood. Using salmeterol xinafoate (SX) and fluticasone propionate (FP) 
as model drug powders, a systematic approach was undertaken to better understand the 
consequences of combination formulation on drug dispersion for inhaled delivery. A 
dry dispersion laser diffraction analysis was developed to characterise the inherent 
dispersibility of bulk powders as well as de-agglomeration of DPI blends. Eight inhaled 
drug/excipient powders displayed different dispersibility (represented by the DA50, the 
dispersing pressure to achieve 50 % de-agglomeration; 0.23-1.45 Bar) and cohesivity 
(represented by the critical primary pressure (CPP); 1.0-3.5 Bar). Upon co-formulation 
(in the absence of a carrier) SX deposition in the Next Generation Impactor (NGI) 
became less efficient as the FP content increased (e.g. fine particle fraction (FPF) 33-18 
% recovered dose (RD) for SX:FP ratios 1:0-1:8). However, FP dispersion was 
generally unaffected when blended with SX (FPF 26-29 % RD, SX:FP ratios 0:1-8:1). 
This was attributed to the greater adhesivity and cohesivity of SX and FP, respectively, 
and changes in bulk blend structure and dispersibility. Intra-batch heterogeneity in 
particle properties within a bulk powder were also studied using solid state, calorimetric 
and inverse gas chromatographic analysis. The NGI was used to isolate aerodynamic 
size fractions which displayed distinct physicochemical and aerosolisation properties. 
For example, FP sub-populations had better dispersibility (FPF 32 vs. 19 % RD, 
respectively) whereas an SX sub-population had higher bulk and surface disorder and 
poorer dispersibility (FPF 21 vs. 33 % RD, respectively) compared to the bulk powders. 
Upon co-formulation (in the absence of a carrier) the fractions responded differently in 
terms of their aerosolisation behaviour compared to the unfractionated powders, 
indicating heterogeneity in the response to co-formulation within a bulk powder. When 
formulated with a carrier, however, there were no modifications to the dispersion (i.e. 
FPF) of unfractionated SX or FP upon co-formulation at different SX:FP ratios, 
however, a fraction of SX co-formulated with FP in a DPI blend exhibited changes to 
SX dispersion that were comparable to those in the absence of a carrier. The effect of 
co-formulation on SX and FP dispersion, therefore, was found to depend on the drug 
ratio, properties of the powder/fraction employed and the presence of a carrier. 
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LIST OF ABBREVIATIONS AND SYMBOLS 
α    Fraction of SX-I re-crystallised from the SX melt 
a    Cross-sectional area of an adsorbate probe molecule (for IGC) 
A   Actual concentration 
ACI   Anderson cascade impactor 
AFM   Atomic force microscopy  
am   Cross sectional area of a solute molecule (for IGC) 
ANOVA  Analysis of variance 
AUC   Area under the curve 
β    Heating rate  
β2   Beta 2 (referring to the receptor or agonist) 
B   Mobility of a particle (i.e. velocity per unit force) 
BDP   Beclometasone dipropionate 
BET   Brunauer-Emmett-Teller 
BN.   Batch number 
BP   British Pharmacopeia 
Bud   Budesonide 
C   Concentration 
C:A ratio  Cohesive to adhesive ratio 
CC   Cunningham correction factor 
CFC   Chlorofluorocarbon 
CFP    Crystallised fluticasone propionate  
CL   Coarse lactose 
COPD   Chronic obstructive pulmonary disease 
Copt   Optical concentration 
CPP   Critical primary pressure 
CSX    Crystallised salmeterol xinafoate 
Cu   Copper 
CV   Coefficient of variance 
ΔP   Pressure drop (across an inhaler device) 
ΔHf   Enthalpy of fusion of SX-II 
ΔHf
βexp   
Enthalpy of fusion of SX-II at an experimental heating rate 
ΔHf
β0.1    





d’    A characteristic dimension of an object (i.e. particle) 
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D4,3   Volume weighted mean particle size (equivalent to the VMD)  
d   Diameter (of a particle) 
D   Detected concentration 
dae   Aerodynamic particle size 
DA   Degree of de-agglomeration 
DA50 Ease of dispersion; primary pressure to achieve 50 % de-
agglomeration 
DAmax   Maximum degree of de-agglomeration 
dg   Geometric particle size 
DNA   Deoxyribonucleic acid  
DPF   Dry powder feeder 
DPI   Dry powder inhaler 
dr   Difference ratio 
DSC   Differential scanning calorimetry 
DUSA   Dose uniformity sampling apparatus 
Dv10 Particle size below which 10 % of the particles, by volume, is 
found  
Dv50 Particle size below which 50 % of the particles, by volume, is 
found 
Dv90  Particle size below which 90 % of the particles, by volume, is 
found 
DH Particle size at the highest pressure employed in dry dispersion 
sizing 
DL   Particle size from liquid dispersion sizing 
Dx Particle size at the primary pressure of interest in dry dispersion 
laser diffraction particle sizing 
η   Dynamic viscosity of a gas 
η    Air viscosity 
ED   Emitted dose 
EMEA   European Medicines Agency 
F   Flow rate 
f2   Similarity factor   
FDA   Food and Drug Administration   
FEV1   Forced expiratory volume 
FF   Fine fraction 
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FID   Flame ionisation detector 
FP   Fluticasone propionate 
FPD   Fine particle dose 
FPM   Fine particle mass 
FPF   Fine particle fraction 
γ    Density of air 
γ+   Acidic component of the surface energy 
γ-   Basic component of the surface energy 
γD   Dispersive surface energy 
γDL    Dispersive surface tension of the adsorbate 
γSP   Specific surface energy 
γT
   
Total surface energy 
g    Acceleration due to gravity 
ΔGP   Specific free energy of adsorption 
GR   Glucocorticoid receptor 
GSD   Geometric standard deviation 
HELOS  Helium neon laser optical system 
HFA   Hydrofluoroalkane 
HPLC   High performance liquid chromatography 
IC   Inhaled corticosteroid 
IF   Intermediate fraction 
IGC   Inverse gas chromatography 
j    James-Martin pressure drop correction factor 
k   Integrated rate constant for the re-crystallisation of SX-II 
KL    Langmuir adsorption/equilibrium constant 
KF    Adsorptive capacity 
LABA   Long acting beta agonist 
LH300   Lactohale 300 
LOD   Limit of detection 
LOQ   Limit of quantification 
m    Particle mass 
m    Sample mass (packed into an IGC column) 
MFP (or SX)  Micronised fluticasone propionate (or salmeterol xinafoate) 
MMAD  Mass median aerodynamic diameter 
MOC   Micro-orifice collector 
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MSLI   Multistage liquid impinger 
mRNA   Messenger ribonucleic acid  
n   Avrami exponent of the Avrami-Erofe’ev-type equation 
n   Amount adsorbed 
N   Number of time points (in the dissolution profile) 
NA   Avagadro’s number 
nm    Number of moles of solute adsorbed for monolayer coverage 
NGI   Next generation impactor 
PD   Molar deformation polarisation of the IGC probes 
PEG   Polyethyleneglycol 
pMDI   Pressurised metered dose inhaler  
p   Equilibrium partial pressure 
po   Saturation pressure (of a liquid) 
PIF   Peak inspiratory flow rate 
PP   Primary pressure 
PPG   Polypropylene glycol 
PR   Percentage recovery 
PS   Pre-separator 
PSD   Particle size distribution 
PTFE   Polytetrafluoroethylene 
PXRD   Powder x-ray diffraction 
Q Flow rate corresponding to a pressure drop of 4 kPa across an 
inhaler device 
ρ   Particle density 
ρg    Gas density 
R   Gas constant 
R
2   
Coefficient of determination 
RD   Specific resistance (of an inhaler device) 
Re   Reynolds number 
RD   Recovered dose 
RH   Relative humidity 
RODOS  Rotating dosing and dispersing system 
Rpm   Rotations per minute 
Rt Mean percentage of drug dissolved of a reference product at a 
specific time point in a dissolution curve 
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S   Stopping distance (of a particle) 
S1-7   Stage 1 – 7 
SA100 (or 500) Seretide Accuhaler 100 (or 500) 
SB    Standard error of the y estimate (i.e. y intercept) 
SB   Salbutamol base 
SD   Standard deviation 
Sccm   Standard cubic centimetres per minute 
SEA   Surface energy analyser 
SEM   Scanning electron microscopy 
Span 80 (or 85) Sorbitan monooleate 80 (or 85) 
SS   Salbutamol sulphate 
SSA   Specific surface area 
Stk   Stokes number 
SX   Salmeterol xinafoate 
SX-I   Salmeterol xinafoate polymorph form I 
SX-II    Salmeterol xinafoate polymorph form II 
to   Dead volume of the IGC probes 
T   Temperature  
Tof   Tofimilast 
tR   Gross retention time of the IGC probes 
Tref   Reference temperature 
Ts    Column temperature 
Tt Mean percentage of drug dissolved of a test product at a specific 
time point in the dissolution curve 
TSI   Twin Stage Impinger 
U   Initial velocity of a particle 
U   Air velocity 
USP   United States Pharmacopeia 
V   Gas velocity 
VN   Net retention volume 
VDW   Van der Waals forces 
VMD   Volume mean diameter 
WHO   World Health Organisation 
YB   y intercept (from the regression equation) 
Ф   Packing fraction 
























1 GENERAL INTRODUCTION 
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1.1 BACKGROUND 
Respiratory disease, such as asthma and chronic obstructive pulmonary disease 
(COPD), is a major, global, public health problem. The World Health Organisation 
(WHO) estimates that asthma and COPD affects 235 million (WHO, 2011) and 65 
million individuals, respectively, worldwide (WHO, 2012). Many patients with these 
diseases require treatment with more than one inhaled drug, specifically inhaled 
corticosteroids (ICs) and long acting beta agonists (LABAs). Inhalers containing both 
classes of drug in a single formulation are commercially available, and include Seretide, 
Symbicort, Flutiform and Fostair (BNF, 2013).  
 
In combination dry powder inhaler (DPI) formulations, two micron-sized drug powders 
are present in a physical mixture, which may also contain a carrier and ternary agent. A 
major challenge in DPI development is achieving efficient de-agglomeration of the 
small, inherently cohesive, drug particles. The particulate interactions that exist within 
each powder component, and between the drug and any excipient particles, are an 
important factor in dictating the dispersion and aerodynamic deposition profile of the 
drug. The incorporation of a second drug powder therefore introduces a further level of 
complexity in combination formulations. The physicochemical properties of the two 
drug powders may be different, which will not only influence the inter-particulate 
interactions within the blend, but also the resulting powder structure. This could lead to 
differences in the dispersibility of the drugs upon co-formulation, and may ultimately 
manifest as altered drug bioavailability. Micronised powders show variability in their 
properties, and therefore a distribution in the magnitude of drug interactions and powder 
microstructure may also occur. In order to gain a fundamental understanding of the 
effects of co-formulation on aerosolisation performance in these complex systems, 
investigations into the influence of physicochemical interactions using model drug 
powders are required. In introducing the importance of this research, it is pertinent to 
review the structure and function of the lungs, the role of inhaled delivery in the 
treatment of respiratory disease, and the most common delivery devices employed for 
inhaled drugs. This will be followed by considering the fate of particles in the lungs, 
including particle deposition and dissolution, and finally, combination therapy, focusing 
on the two most extensively used drugs: salmeterol xinafoate (SX) and fluticasone 
propionate (FP), and outlining the rationale for formulating two drugs in a single inhaler 
product. 
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1.2 THE STRUCTURE AND FUNCTION OF THE LUNGS 
The lung is a complex, heterogeneous organ occupying the majority of the volume of 
the thoracic cavity. Each lung is divided into several lobes consisting of a series of 
dichotomously branching airways (Martonen, 1993; Sherwood, 2001). The lung is the 
site of gas exchange between oxygen and carbon dioxide, and therefore has the main 
role of respiration in the body (Sherwood, 2001). The lungs consist of two main 
functional areas, the conducting zone (i.e. trachea, bronchi, bronchioles and terminal 
bronchioles) and the respiratory zone (i.e. respiratory bronchioles, alveolar ducts and 
alveolar sacs), the latter of which represents the site of gas exchange (Martonen, 1993). 
The airways are often characterised into generations, starting from the trachea (I = 0), 
the bronchi, bronchioles and terminal bronchioles (I = 1 - 16), the partially alveolated 
respiratory bronchioles (I = 17 – 19), the alveolar ducts (I = 20 – 22) and finally the 
alveolar sacs/alveoli (I = 23) (Martonen, 1993). 
 
The respiratory tract is considered to consist of three main regions. The nasopharynx 
which comprises the airways of the head and are often referred to as the extrathoracic 
airways. The tracheobronchial region which comprises the bronchial airways and 
includes the trachea and terminal bronchioles; these airways are lined with smooth 
muscle thus maintaining the physical integrity of the lungs, and have ciliated epithelium 
which is covered in mucus. Finally, the pulmonary region, which comprises the 
respiratory bronchioles and alveolar ducts, and is the site of gas exchange. The 
epithelium of these airways is non-ciliated and covered in surfactant (Martonen, 1993). 
The large number of densely packed alveoli in the lungs (approximately 300 million, 
Weibel and Gomez, 1962) results in a very large surface area for gas exchange of 
approximately 143 m
2
 (Gehr et al., 1978). The air-blood tissue barrier and the 
epithelium are also very thin, exhibiting mean values of 2.2 µm and 0.61 µm, 
respectively, in the human lung (Gehr et al., 1978). The cellular composition of this 
organ is also heterogeneous, and is often described in terms of the main tissue 
compartments i.e. the endothelium, epithelium and interstitium. The endothelium is 
composed of a layer of squamous cells, whereas the epithelium comprises two main cell 
types. Type I epithelial cells are similar to those of the endothelium (i.e. large, 
squamous) whereas Type II epithelial cells are round or cuboidal, have microvilli and 
secrete pulmonary surfactant (Gehr et al., 1978; Sherwood, 2001). The interstitium on 
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the other hand contains a range of cell types such as fibroblasts, lymphocytes and mast 
cells (Gehr et al., 1978). 
 
1.3 INHALED THERAPY 
The inhalation of medicinal agents dates back over 4000 years to smoking of the leaves 
of the Atropa belladonna plant to supress coughing, and inhalation of sea mists, hot 
vapours and aerosols to ease airway obstruction. Over the years, the direct delivery of 
drugs to the lungs to treat respiratory diseases has grown into a multi-billion dollar 
market. Not only have formulation and device technologies generated convenient and 
portable delivery systems, but the inhaled route has provided an alternative, non-
invasive means to deliver pharmaceuticals, particularly including biologics such as 
insulin. With research in this area proceeding at a fast rate, not only will it be possible to 
improve the efficiency and reproducibility of delivery via this route, but also greater 
exploit the favourable features of the lungs for the delivery of systemic therapies 
(Gonda, 2000; Weers et al., 2010). 
 
1.3.1 RESPIRATORY DISEASES 
Inhaled therapy is widely accepted as the optimal route of drug administration for local 
diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis 
and chronic bronchitis. By delivering high doses of drug directly to the site of action, a 
rapid clinical response is elicited and systemic side effects are minimised. Furthermore, 
by bypassing processes such as first-pass metabolism and gastro-intestinal absorption, a 
similar or superior therapeutic response is achievable using much lower doses than 
would be required following systemic delivery, for example, an oral dose of 2 – 4 mg of 




Asthma is a common respiratory condition affecting people of all ages. It is estimated 
that there are 300 million individuals with asthma worldwide, and therefore the 
condition poses a serious public health problem (GINA, 2012). Asthma is a chronic 
inflammatory disorder of the airways, which is associated with airway hyper-
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responsiveness. This leads to symptoms of wheezing, breathlessness, chest tightness and 
coughing, particularly in the early morning or night. There may also be airway 
obstruction which although reversible, may require treatment (GINA, 2012). There is 
currently no standard definition of asthma pathogenesis, and diagnosis is therefore 
clinical and relates to the presence of symptoms and variable airflow obstruction 
(BTS/SIGN, 2008 (revised 2012); GINA, 2012).  With appropriate treatment, using 
inhaled therapies in the first instance, it is possible to attain good asthma control such 
that the occurrence of symptoms is minimal and severe exacerbations should be rare 
(GINA, 2012). 
 
1.3.1.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
COPD is estimated to affect three million people in the UK. Of these individuals, 
approximately 900,000 are diagnosed but two million are thought to be undiagnosed 
(Healthcare Commission, 2006). COPD is the fourth leading cause of death in the 
world, despite being both preventable and treatable (GOLD, 2013). The condition is 
characterised by persistent airflow limitation that may be stable over several months but 
which deteriorates progressively in the longer term. There is also an enhanced chronic 
inflammatory response to noxious particles/gases (NICE, 2010; GOLD, 2013). Airflow 
obstruction arises from a combination of small airways disease (obstructive 
bronchiolitis) and parenchymal damage (emphysema), as a result of chronic 
inflammation (GOLD, 2013). Tobacco smoke is a major risk factor for COPD, along 
with other occupational exposures. There may be significant airflow obstruction prior to 
the patient becoming aware of it, therefore diagnosis tends to occur later in life and is 
based on a combination of patient history, physical examination, spirometry and the 
presence of symptoms (e.g. exertional breathlessness, chronic cough, regular sputum 
production and wheeze) (NICE, 2010). Exacerbations can also occur in COPD patients, 
triggered by bacterial/viral infections, environmental pollutants, or unknown factors, in 
which there is rapid worsening of symptoms (GOLD, 2013). Smoking cessation and 
inhaled therapy are the first steps in the management of stable COPD, in order to 
improve lung function, provide symptomatic relief, minimise exacerbations and 
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1.4 DELIVERY DEVICES 
Aerosol drug delivery systems consist of a drug formulation, metering system and 
device technology (Hickey, 2013), and must fulfil a number of key requirements. 
Primarily, the system must generate an aerosol in which the majority of the particles 
have an aerodynamic particle size (dae) less than 10 µm, but ideally in the size range 0.5 
– 5.0 µm, in order to attain deposition in the peripheral regions of the lungs (Zeng et al, 
2001). The delivery system must provide reproducible dosing, drug physicochemical 
stability, ease of use, portability, and must also be economically viable (Zeng et al, 
2001). There are three major categories of dosage forms used to deliver therapeutic 
aerosols to the lungs; these are nebulisers, pressurised metered dose inhalers (pMDIs) 
and dry powder inhalers (DPIs). 
 
1.4.1 NEBULISERS 
The first nebulisers (initially called atomisers) were developed in the mid-19
th
 century 
in France. By the 1930s, early electric and compressor nebulisers had been developed, 
and with further technological advancements, nebulisers still remain in routine use for 
aerosol delivery today (Anderson, 2005). Despite a low delivery efficiency of 
approximately 10 % and high variability between formulations, they afford better 
stability for sensitive drugs such as antibiotics, mucolytics and other high dose drugs 
(Watts et al., 2008).  Drug particles are formulated as aqueous solutions or suspensions 
contained within nebules. The nebule contents are dispensed into the reservoir chamber 
via an air-jet, ultrasonic or vibrating mesh nebuliser device (Hickey, 2013).  Air-jet 
nebulisers operate under a venturi principle using compressed oxygen/air, and are 
generally used in acute and home care settings to deliver aerosolised drugs to 
nonambulatory patients. Despite being generally large and cumbersome, design 
improvements have increased delivery efficiency and allowed for breath actuated 
delivery. Ultrasonic devices have a piezoelectric crystal which vibrates at a high 
frequency (1 – 3 MHz) to generate respirable droplets, described by the capillary wave 
and cavitation theory. Although they have higher delivery efficiencies, they exhibit a 
number of limitations compared to air-jet nebulisers such as settling of suspensions and 
the degradation of heat sensitive drugs. Modifications to ultrasonic devices led to the 
development of the vibrating mesh devices, which retain the piezoelectric crystal but 
instead utilise mesh oscillation to drive aerosol production (Watts et al., 2008). These 
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latter devices benefit from low velocity aerosols, high respirable fractions and high fine 
particle fractions (FPFs) due to narrow droplet size distributions and low aerosol losses, 
as well as high output rates leading to shortening of treatment times (Lass et al., 2006; 
Watts et al., 2008). 
 
1.4.2 PRESSURISED METERED DOSE INHALERS 
The first pMDI was developed in the 1950s. The formulations consist of drug particles 
either dissolved and in solution or micronised and in suspension (Lewis, 2007). 
Hydrofluoroalkanes (HFAs) are typically used as the suspending media, and these were 
preceded by the chlorofluorocarbons (CFCs). Both HFAs and CFCs also function as 
propellants (Michael et al., 2001). Generation of the respirable dose for inhalation 
requires atomisation of the liquid formulation. Upon exiting the metering chamber, the 
formulation expands and this is followed by rapid evaporation of the highly volatile 
propellant as the dose is emitted from the inhaler mouthpiece. Although pMDIs show 
cost-effectiveness, portability and apparent simplicity, they are not without their 
drawbacks (Lewis, 2007). These include patient difficulty in co-ordinating breathing 
with pMDI actuation, and poor stability either due to creaming (i.e. phase separation) 
and coalescence (i.e. aggregation) particularly in suspension formulations, and reduced 
drug chemical stability and drug loss due to partitioning to container walls/values for 
solution based formulations (Smyth, 2003; Lewis, 2007). Additionally there is high 
plume velocity and high oropharyngeal deposition, which can limit the efficiency of 
these inhalers to deliver drug particles to the lungs (Lewis, 2007). For example, the CFC 
containing suspension-based beclometasone dipropionate pMDI produced 90 – 94 % 
deposition of the ex-actuator dose in the oropharynx and only 4 – 7 % in the lungs. 
When formulated as a solution based HFA formulation, the extra-fine particles (mass 
median aerodynamic diameter (MMAD) of 1.1 µm compared to 3.5 µm for the 
suspension formulation) were able to lower deposition in the oropharynx to 55 – 60 % 
and increase lung deposition to 29 – 30 % compared to the CFC formulation (Leach et 
al., 1998). 
 
1.4.3 DRY POWDER INHALERS  
The initial development of DPIs was guided by the limitations of previously available 
portable inhalation devices; solution nebulisers were limited by the physicochemical 
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properties of drug solubility and solution viscosity, whereas for pMDIs only small 
quantities of inhalant (approx. maximum 5 mg) could be delivered before problems, 
such as mechanical obstruction of the valves, occurred (Bell et al., 1971; Labiris and 
Dolovich, 2003b). Over the years, interest in DPI devices has grown for a number of 
reasons. DPIs do not require co-ordination between the breath and actuation, thus 
improving ease of use for patients. Furthermore, they do not require propellant gases 
hence providing a ‘greener’ alternative to pMDIs. A range of DPI devices are available 
on the market and are generally characterised as single-unit devices which require each 
individual dose to be loaded by the patient prior to use (e.g. Aerolizer, Rotahaler), 
multi-unit devices which contain multiple doses that are either provided as a blister pack 
(e.g. Diskhaler) or a sealed blister strip that moves within the device (e.g. Diskus) or 
reservoir type, bulk powder systems (e.g. Turbuhaler). The majority of DPI devices are 
passive, and depend on the patient’s inspiratory effort in order to generate an aerosol 
within the respirable particle size range. Active DPIs conversely do not depend on 
patient inspiration, and instead utilise an energy source for powder entrainment and de-
agglomeration (Labiris and Dolovich, 2003b). Examples of active dispersion include the 
use of compressed air e.g. Aspirair
TM
 (Tobyn et al., 2004), battery-powered propellers 
e.g. Spiros (Nelson et al., 1999) and the use of high frequency piezoelectric vibrators 
e.g. Microdose DPI (Crowder, 2005; Fleming, 2007), although currently these devices 
are not available on the market in the UK. 
 
1.4.3.1 PARTICLE PRODUCTION FOR INHALATION  
Particles for inhalation are typically produced by batch crystallisation of the drug from 
solution, followed by a filtering and drying step. During crystallisation, the particle size 
of the drug is not well controlled and is often large, thus requiring a comminution step 
such as micronisation/milling to reduce the size to within the respirable size range (i.e. 
< 5 µm) (Telko and Hickey, 2005; Chow et al., 2007). A jet or ball mill is usually 
employed. In the jet mill, high pressure nitrogen gas is fed into the mill and causes 
particle acceleration. Particle attrition occurs as a result of high velocity particle-particle 
collisions, whereby it is possible to obtain a particle size as small as 1 µm by controlling 
the milling conditions. A ball mill conversely consists of a cylinder containing the 
powder and milling balls. As the cylinder is rotated, particle attrition occurs as the balls 
tumble within the vessel. Ball milling is much slower and less scalable than jet milling, 
which is therefore generally favoured (Telko and Hickey, 2005). 
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Following micronisation, the particle size distribution (PSD) is broad and poorly 
controlled (Steckel et al., 2003a; Steckel et al., 2003b). Subjecting particles to such a 
high energy process results in disorder, defects, and/or amorphous regions on crystal 
surfaces (Ward and Schultz, 1995; Brodka-Pfeiffer et al., 2003b; Gaisford et al., 2010). 
Amorphous regions are metastable, and at a higher energy state than crystalline regions. 
Depending on the environmental conditions, water adsorption and re-conversion to the 
more stable crystalline form can occur and often coincides with particle growth 
(Brodka-Pfeiffer et al., 2003b). Even low levels of amorphous content can have marked 
effects on the physical and chemical stability of the powder. For example, micronisation 
can increase surface energy (Feeley et al., 1998; Newell et al., 2001; Gamble et al., 
2012) and surface energy heterogeneity (Thielmann et al., 2007), affect powder flow 
(Feeley et al., 1998), alter inter-facial chemistry and thus the cohesive-adhesive balance 
(Kubavat et al., 2012) and induce agglomeration (Zhou et al., 2010b; Le et al., 2012b; 
Han et al., 2013). The inability to control the changes in particle properties both within 
and between powder batches (Feeley et al., 1998; Ticehurst et al., 2000; Marek et al., 
2011; Le et al., 2012b) also has implications for the reproducibility of formulation 
performance. For example, different batches of powder can exhibit different tendencies 
for agglomeration and thus agglomerate sizes upon dispersion (Le et al., 2012b), may 
respond differently to processing stresses which may impair the flowability and 
dispersion of the formulation (Marek et al., 2011), and have different powder stabilities 
dictated by the rate of re-crystallisation of amorphous regions induced during 
micronisation (Brodka-Pfeiffer et al., 2003a). 
 
1.4.3.2 DRY POWDER INHALER FORMULATIONS AND THE ROLE OF 
EXCIPIENTS 
DPI formulations in their simplest form consist of agglomerated micron-sized drug 
particles. By their nature, small particles have a large surface area and high 
cohesive/adhesive forces, therefore not only do they form agglomerates, they are highly 
adhesive towards surfaces such as inhaler walls, and exhibit poor flow, entrainment and 
dispersion. Depending on the drug, the dose required can vary from a few micrograms 
(e.g. formoterol fumarate) to 10s or 100s of milligrams (e.g. tobramycin). Particularly 
when the dose is low, the handling, dispensing and metering of drug particles, in 
addition to achieving dose reproducibility, is difficult. A well-established strategy is to 
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formulate drug particles with larger carrier particles, which play a number of key roles 
in the formulation (Frijlink and De Boer, 2004; Telko and Hickey, 2005). 
 
1.4.3.2.1 THE ROLE OF THE CARRIER 
The coarse excipient in a DPI formulation is generally an inert material that is at least 
one order of magnitude larger (i.e. 50 – 100 µm) than the drug particles in the 
formulation. The excipient is generally referred to as a carrier as drug particles associate 
with the surface of these particles. Consequently, there is a reduction in cohesivity and 
improvement in the flow and fluidisation properties of the powder formulation. The 
coarse excipient forms the major component of the formulation, thus further having a 
role as a diluent to improve powder handling and dose reproducibility (Pilcer et al., 
2012). During aerosolisation, drug particles must be liberated from the surface of the 
carrier in order to penetrate into the lungs, and therefore drug-carrier adhesion needs to 
be carefully considered. The choice of carrier is critical, and depends on the nature, 
quality and source, as well as size distribution, morphology and surface properties of the 
particles. All these factors need to be considered with a view to maintaining an adequate 
balance between drug-carrier adhesion and drug-drug cohesion (Ho et al., 2010; Pilcer 
et al., 2012). 
 
Although lactose is most commonly employed as a carrier, alternative sugars such as 
mannitol, erythritol, trehalose and sorbitol have been investigated (Tee et al., 2000; 
Jones et al., 2008a). A great deal of research has focussed on determining the optimal 
carrier properties for drug dispersibility, including carrier particle size (Larhrib et al., 
2003; Donovan and Smyth, 2010; Ooi et al., 2011), shape e.g. elongation ratio (Larhrib 
et al., 2003; Kaialy et al., 2011), surface roughness (Adi et al., 2008b; Donovan and 
Smyth, 2010), pseudopolymorphic form (Traini et al., 2008), cohesive-adhesive balance 
(Jones et al., 2008a; Jones et al., 2008b) and fines concentration (Ho et al., 2010; Le et 
al., 2012a). These properties, however, have complex and interacting effects on 
dispersion which are thought to be drug-specific (Jones et al., 2008b) and therefore the 
selection and optimisation of a carrier needs to occur in tandem with a knowledge of the 
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1.4.3.2.2 THE ROLE OF TERNARY AGENTS/FINES 
The addition of ternary agents (or fines) to DPI formulations is well established as a 
means of improving de-agglomeration efficiency (e.g. Lucas et al., 1998; Zeng et al., 
1998). A small quantity of fine excipient particles with a similar particle size to the drug 
in the formulation is either added extrinsically or may be generated in situ during 
processing of the excipient and/or formulation (Shur et al., 2008). Lactose particles are 
most commonly used however alternative sugars such as mannitol, sorbitol and glucose 
have been investigated for their use as ternary agents (Tee et al., 2000; Louey and 
Stewart, 2002), as well as amino acids such as leucine, although a fine particle (rather 
than coarse) lactose was included in the formulation as the ‘carrier’ (Lucas et al., 1999). 
The ability of lactose, mannitol and sorbital fines, for example, to improve the FPF, 
suggests that it may be the presence of the fine particle, and not its chemical entity, 
which is important in order to improve formulation performance. For example, there 
may be changes in the work of cohesion/adhesion between the particles which may 
affect the powder structure and thus powder dispersibility. The exact mechanism by 
which ‘fines’ exert their performance modifying effects are still unclear. Two 
mechanisms are currently suggested. The first is the ‘active sites’ mechanism, which 
arises from the interactions which occur between coarse and fine particles during 
ordered mixing (Hersey, 1975). It is proposed that active binding sites exist on the 
surface of large carrier particles, which are unevenly distributed across the surface 
(Hersey, 1975). During formulation with a fine excipient, the ‘fines’ preferentially 
associate with the most energetic active sites on the carrier surface such that the drug 
particles associate with less energetic regions. Upon inhalation, the drug particles are 
therefore more readily liberated from the carrier (Jones and Price, 2006). The second 
proposed mechanism is called the ‘agglomerates’ mechanism, in which during mixing 
agglomerates form comprising particles of both the drug and fines particles. 
Improvements in performance are considered to arise due to lower adhesive forces 
between particles in the drug-fines agglomerates leading to more efficient dispersal, as 
well as the direct liberation and deposition of these agglomerates due to their small 
aerodynamic particle size (dae) (Lucas et al., 1998).  
 
A further component that may be involved is a change in the powder structure that may 
arise from the introduction of fine particles to the bulk powder. With increasing drug 
loadings in carrier based blends, it is suggested that upon saturation of active sites on 
the carrier surface, multiple agglomerate systems will be present due to the carrier 
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surface reaching monolayer (and even multilayer) coverage. At very high drug loadings, 
there will be drug particle agglomeration and drug carrier segregation, which may result 
in changes in aerosol performance and blend uniformity (Young et al., 2011). The 
presence of fines may also alter the bulk properties of a powder; high fines contents can 
increase the cohesive inter-particulate interactions within a powder bed and thus 
increase the tensile strength. This has been associated with a change in the fluidisation 
and dispersion mechanism of the powder, from an erosion mechanism typical of 
powders with low cohesivity, to the entrainment of powder plugs due to fracture of the 
powder bed, which is typical of the fluidisation behaviour of highly cohesive powders 
(Shur et al., 2008). This increase in cohesive strength of the powder bed has been shown 
to increase the DPI performance of budesonide particles when formulated with a lactose 
carrier and lactose fines (Kinnunen, 2010), whereby the entrainment of large powder 
plugs increases the number of particle-particle and particle-device collisions and can 
enhance the detachment of drug from a carrier (Shur et al., 2008; Kinnunen, 2010). A 
more subtle improvement in performance by the addition of milled compared to 
micronised lactose fines (both having Dv50 values < ~ 5 µm) was attributed to stronger 
interactions between the milled lactose and drug particles compared to the micronised 
lactose (Kinnunen, 2010), further highlighting the complex inter-play between inter-
particulate forces and bulk powder properties in determining aerosolisation behaviour. 
Furthermore, in addition to each powder constituent having its own PSD, work of 
cohesion, and density which contribute towards its powder strength, there will also be a 
distribution in powder strengths within the bulk powder due to micro-areas which 
exhibit different powder structures (Das et al., 2012). This non-homogeneity in powder 
bed microstructure is likely to be greater in powder mixtures, which would exhibit 
broader distributions in particle size, surface energy (and hence work of cohesion) and 
packing fraction across the bulk powder. 
 
1.4.3.3 INTER-PARTICULATE FORCES 
The particles in any powdered dosage form will interact with each other via cohesive 
and/or adhesive interactions (Zeng et al, 2001). The attractive physical forces in DPI 
formulations are classified into three major categories: van der Waals, electrostatic, and 
capillary forces. Other forces, such as frictional forces, exist and are important, but are 
generally less frequently studied (Xu et al., 2010b). The particle-particle interactions 
within powders have implications not only in handling processes such as comminution, 
blending and storage, but also affect bulk powder properties such as flowability, de-
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agglomeration and dissolution (Zeng et al, 2001). Furthermore, particle-capsule and 
particle-device interactions will also arise in the final formulated product, and affect the 
overall efficiency of aerosolisation. 
 
1.4.3.3.1 VAN DER WAALS FORCES 
Of the major categories of inter-particulate force, van der Waals (VDW) forces are 
generally dominant in uncharged dry powders, particularly where the magnitude of the 
particle size (i.e. < 10 µm) and separation distance (< 100 nm) are both small. VDW 
forces are typically two orders of magnitude greater than electrostatic and capillary 
forces, however, they decay rapidly with separation distance (Xu et al., 2010b). VDW 
forces are also sensitive to particle shape and surface roughness, as surface asperities 
can limit how close particles are able to come (Pilcer et al., 2012). Depending on 
particle shape, particles in close contact may experience very strong VDW forces, 
resulting in possible mechanical inter-locking (Pilcer et al., 2012).  
 
1.4.3.3.2 ELECTROSTATIC FORCES 
Electrostatic charges arise within a powder bulk when an uncharged particle makes 
contact with a charged particle, upon which a transfer of electrons/ions occurs between 
them. Positively or negatively charged particles will experience electrostatic 
attractive/repulsive forces with neighbouring particles depending on their charge. 
Powder processing steps such as mixing, handling and filling can induce electrical 
charges, as can the fluidisation and de-agglomeration process itself, therefore the term 
triboelectrification is generally used to describe this effect (Zeng et al, 2001; Pilcer et 
al., 2012). 
 
1.4.3.3.3 CAPILLARY FORCES 
Capillary forces can arise as a result of water adsorption onto particle surfaces leading 
to the formation of liquid bridges which can greatly increase the attractive forces 
between particles. Capillary forces prevail at high relative humidity (RH), usually in 
excess of 60 %, where liquid capture can also increase the surface energy and surface 
conductivity of the particle (Zeng et al, 2001; Xu et al., 2010b). However, even storage 
at relatively low RHs in the range 15 – 75 % for short periods of time (12 h) can have 
detrimental effects on the achievable FPF, and was attributed to the increasing 
dominance of capillary forces of increasing magnitude as the RH increased (Young et 
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al., 2003, Young et al., 2004). Not all drugs however exhibit this change in FPF, and the 
generation of higher FPFs has been postulated to occur due to the dissipation of surface 
charges induced by triboelectrifcation due to electron mobilisation. Therefore, even at 
high RHs aerosolisation behaviour is dependent on the balance of inter-particulate 
forces, which are related to the physical and chemical properties of the powder (Young 
et al., 2003). 
 
1.4.3.4 AEROSOL GENERATION TO DELIVER PARTICLES TO THE LUNGS 
The aerosolisation process in DPI systems comprises four phases during which a 
powder, which is initially at rest in a static bed, must undergo dilation, fluidisation and 
drug re-suspension/de-agglomeration. These phases are considered to occur 
concurrently rather than in sequence (Xu et al., 2010b). Inter-particulate forces and 
aerosolisation must be considered in tandem, as it is attractive forces that cause particles 
to agglomerate, and it is these attractive forces that must be overcome in order to 
generate an aerosol for particle delivery to the lungs (Xu et al., 2010b). In passive DPI 
systems, detachment forces arise from the airflow generated by patient inspiration, and 
include aerodynamic forces (drag and lift), inertial forces (vibration, rotation, 
centrifugal and collision) and shear and frictional forces (Louey et al., 2006; Xu et al., 
2010b). As the patient inhales through the device, the flow rate continually changes, 
increasing to a maximum peak inspiratory flow rate (PIF) before reducing back down to 
a baseline. Consequently, the flow rate through a DPI is not static and varies according 
to the time from the start of inhalation. Although perhaps paradoxically, in vitro inhaler 
testing is generally carried out at a constant flow rate. The metered dose is typically 
released prior to the patient achieving their PIF, as the patient vital capacity exceeds the 
internal volume of the inhaler; faster initial flow rates may therefore promote the 
entrainment and de-agglomeration of the initially static dose within the device (Martin 
et al., 2007). The efficiency of de-agglomeration determines the fine particle delivery of 
the drug, and is dependent on device, patient and particle factors. 
 
1.4.3.4.1 DEVICE FACTORS 
When a patient inhales through a passive DPI device, the airflow transfers kinetic 
energy into the powder bed as a result of the continuous bombardment of air molecules, 
and therefore provides detachment forces to overcome the inter-particulate interactions 
within the powder (Louey et al., 2006; Xu et al., 2010b). The airflow within a device 
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can be laminar or turbulent, and is described by the Reynolds number (Re), Equation 
1.1, where ρg is the gas density, V is the gas velocity, d’ is a characteristic dimension of 
the object, and η is the dynamic viscosity of the gas (Zeng et al, 2001). 
 
Equation 1.1      





DPI devices are often designed to generate turbulent air flows (i.e. Re > 4000), using 
design features such as tortuous airflow paths, grids or impactor plates in order to 
optimise de-agglomeration efficiency  (Louey et al., 2006; Xu et al., 2010). The internal 
dimensions and geometry also influence the specific resistance (RD) of the device, and 
is related to the pressure drop (ΔP) and the flow rate (Q), according to Equation 1.2 
(Louey et al., 2006). A high RD is generally considered to generate greater turbulence 
and higher FPFs at a given flow rate compared to devices with a lower RD. However, 
devices with high RD values require a greater respiratory effort by the patient in order to 
achieve the required flow rate (Labiris and Dolovich, 2003b; Louey et al., 2006), and 
this might pose difficulties to respiratory compromised patients. 
 
Equation 1.2    √         
 
1.4.3.4.2 PATIENT FACTORS 
A number of patient factors influence the efficiency of aerosol generation from DPIs. 
The inhalation flow rate generated by the patient is critical. Although high flow rates 
may promote de-agglomeration, there may also be a reduction in the amount of drug 
reaching the lungs due to impaction of rapidly moving aerosol particles in the 
oropharyngeal region and the larynx (Dolovich, 1993; Labiris and Dolovich, 2003a). 
The flow rate also varies with time during a single inhalation, between inhalations, and 
between patients. In an attempt to account for this, the electronic lung was developed 
for use during in vitro cascade impactor testing which utilises simulated or replicated 
inhalation profiles with varying flow rates and flow accelerations (Burnell et al., 1998). 
The inhalation manoeuvre adopted by the patient can, however, further modify 
deposition, for example increasing the breath holding time allows greater time for 
particles to deposit by sedimentation (Burnell et al., 1998).  
 
 Page | 46  
 
Airway calibre and anatomy also differs between individuals, and in the diseased lung. 
Bronchoconstriction, inflammation and airway narrowing can alter drug deposition, and 
may require the inhalation of more drug in order to achieve an optimal clinical response 
(Dolovich, 1993; Labiris and Dolovich, 2003a). Airway disease can alter the 
architecture of the lungs and thus the deposition and distribution pattern of aerosols. For 
example, changes to bifurcation angles and airway obstruction can occur, which in the 
latter case causes higher air velocities and higher turbulence due a reduced cross-
sectional area in areas of the lung where air flow is usually laminar (Labiris and 
Dolovich, 2003a). 
 
1.4.3.4.3 PARTICLE FACTORS 
The particle properties that influence dry powder aerosol generation are numerous. 
Particle engineering is therefore well established as a means of obtaining particles with 
controlled physicochemical attributes.  The aerodynamic particle size (dae) is a critical 
factor in both the dispersion and site of deposition in the lungs. The aerodynamic 
diameter relates the particle to the diameter of a sphere which has unit density and the 
same settling velocity as the particle of interest (Labiris and Dolovich, 2003a). The 
aerodynamic particle size is linked to the geometric particle size according to Equation 
1.3 (Louey et al., 2004a), where dg in the geometric particle size and ρ is particle 
density. A small aerodynamic diameter can therefore be attained by reducing particle 
density whilst maintaining a large geometric particle size. Geometrically large, low 
density porous particles have hence been prepared which exhibit superior dispersion 
compared to non-porous particles with the same aerodynamic diameter, which further 
exhibit smaller surface area-to-volume ratios and a lower tendency for particle 
agglomeration (Edwards et al., 1997).  This approach has been used to prepare drug 
particles (e.g. Steckel and Brandes, 2004), as well carriers for therapeutic agents such as 
insulin (e.g. Ungaro et al., 2009). 
 
Equation 1.3            √   
 
In DPI formulations, particles exist as agglomerates. The particle size affects the tensile 
strength of agglomerates which is directly related to the packing fraction (ɸ) i.e. the 
volume of particles/volume of the agglomerate, and inversely related to particle 
diameter (Kendall and Stainton, 2001). Whilst airborne, larger agglomerates experience 
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higher aerodynamic drag forces and kinetic energy, as these are proportional to the 
square and cube of agglomerate diameter, respectively, and thus would be expected to 
de-agglomerate more efficiently (Begat et al., 2004b). The shape of the drug particle is 
also important, and can be modified either in an uncontrolled way due to micronisation 
or using controlled crystallisation methods. Needle-like particles, for example, although 
displaying poorer homogeneity when blended with lactose have better dispersibility 
than micronised particles due to a greater propensity for needle-like particles to remain 
airborne and disperse (Larhrib et al., 2003; Kaialy et al., 2011). The degree of surface 
corrugation/roughness can alter the contact area of particles for example with a carrier 
and therefore affect dispersion. The reduction in adhesive forces as a result of a rougher 
surface generates higher FPFs following aerosolisation (Adi et al., 2008b). 
 
Particle surface energy can influence dispersibility, as it affects the magnitude of 
interactive forces and therefore the cohesivity and adhesivity of the particles. Changes 
to particle surface energy can occur during processing, particularly micronisation, 
during which particle fracture occurs along the weakest attachment energy facet of the 
crystal. This subsequently becomes the dominant facet and generally causes higher 
surface energy, in addition to changes to the surface chemistry of the particle (Heng et 
al., 2006b). The resulting changes to the crystal shape/aspect ratio can cause secondary 
fractures to occur along a different facet, inducing further alterations to the surface 
energy/chemistry of the final milled product (Heng et al., 2006b).  In the absence of a 
carrier, higher surface energy has increased the FPF of salbutamol sulphate (Shariare et 
al., 2011) but had the opposite effect on the FPF of salmeterol xinafoate samples (Tong 
et al., 2006; Das et al., 2009b). Conflicting trends have also been observed in carrier 
formulations, in which surface energies were used to calculate the work of adhesion 
between the drug and carrier particles. Higher drug-carrier adhesion was associated with 
both higher (Cline and Dalby, 2002) and lower FPFs (Traini et al., 2008) for dry powder 
formulations. This highlights the complexity in terms of the range of factors that affect 
the aerosolisation process, and indicates that any correlation between surface energy and 
FPF may be drug and/or carrier specific. Furthermore, it is necessary to consider 
changes in the dispersive, specific and total surface energy (Das et al., 2009b) and the 
non-homogeneity in particle properties within a bulk powder (Das et al., 2012), as the 
surface energy, and balance of interactions, can change with for example drug 
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polymorphic form (Tong et al., 2006; Traini et al., 2008) and particle crystallinity (Tong 
et al., 2001; Rehman et al., 2003; Shekunov et al., 2003).  
 
1.5 THE FATE OF PARTICLES IN THE LUNGS 
1.5.1 DEPOSITION 
The process of deposition in the lungs involves inhaled particles separating from the air 
flow and contacting a surface without any rebound or re-suspension (Zeng et al, 2001). 
Particle deposition in the airways is complex, and can occur by any one of five 
mechanisms; these are inertial impaction, sedimentation, diffusion, interception and 
electrostatic precipitation. The first three are considered to be the principal mechanisms 
(Newman et al., 1982). Any particles that remain airborne during the respiratory cycle 
are exhaled, and this occurs most frequently with very small particles (< 0.5 µm) (Zeng 
et al, 2001). 
 
1.5.1.1 INTERTIAL IMPACTION 
Inertial impaction is the most important mechanism of deposition, particularly for 
particles larger than 1 µm. Deposition by impaction is predominant in the extrathoracic 
(nose, mouth, larynx) and large, more central, conducting airways of the lungs where air 
flow velocities are high and there are rapid changes in airflow direction (Newman et al., 
1982; Schulz, 1998). When an airstream changes direction, an airborne particle will 
continue to move along its original trajectory for a stopping distance (S) according to 
Equation 1.4, where B is the mobility of the particle (i.e. velocity per unit force), m is 
particle mass and U is the initial velocity of the particle (De Boer et al., 2002a).  
  
Equation 1.4             
 
If the stopping distance is greater than the diameter of the airway, the particle will 
deposit by impaction (De Boer et al., 2002a).  Large, heavy particles travelling at high 
velocities, and therefore possessing high momentum, are less able to follow gas 
airstreams as they change direction in the respiratory tract, and instead undergo 
deposition by impaction (Newman et al., 1982; Zeng et al, 2001). The probability that a 
particle will deposit by impaction is therefore dependent on its size, density and 
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travelling velocity (Schulz, 1998), and is represented by the dimensionless Stokes 
Number (Stk) described in Equation 1.5, where ρ is particle density, d is particle 
diameter, U is air velocity, η is air viscosity, R is airway radius and Cc is the 
Cunningham correction factor for slip flow for particles in the size range 0.1 – 3.0 µm 
(Zeng et al, 2001; De Boer et al., 2002a). 
 
Equation 1.5       
     
     
 
 
The higher the value of Stk the more readily a particle will deposit by impaction. 
Although any particle > 1 µm can deposit by impaction, this mechanism is particularly 
relevant in the case of large particles i.e. those with an aerodynamic particle size greater 
than 3 µm, and when air flow rates are high (Zeng et al, 2001; De Boer et al., 2002a; 
Scheuch et al., 2006). 
 
1.5.1.2 SEDIMENTATION 
Deposition by sedimentation occurs when a particle travelling through the airways 
settles under the influence of gravity, and is therefore a time-dependent process 
(Newman et al., 1982). When airborne, initially a particle will accelerate before 
reaching a terminal velocity, at which the gravitational force is equal to the frictional, 
drag forces experienced as the particle travels through the air. The probability of 
sedimentation is proportional to the settling distance of the particle within the airways, 
which depends on the particle residence time and terminal settling velocity (Schulz, 
1998). The latter is proportional to the square of particle diameter, as shown in Equation 
1.6, where γ and η are the density and viscosity of the air, respectively, ρ and d are the 
density and diameter of the particle, respectively, and g is the acceleration due to 
gravity.   
 
Equation 1.6    




Deposition by sedimentation is therefore supported by a relatively large size (0.5 – 5.0 
µm), and when particle residence time is increased such as during breath holding, low 
frequency steady breathing, and in the small conducting airways and alveolar regions of 
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the lung. In the latter regions, air flow velocities are low and the airway dimensions are 




Diffusion (sometimes referred to as Brownian diffusion) is the most important 
mechanism of deposition for ultrafine particles (i.e. < 1 µm). As these particles travel 
through the airways, they undergo random bombardment with gas molecules causing 
them to collide with airway walls and deposit (Newman et al., 1982). This random 
displacement of particles from the airstream increases with particle residence time and 
decreasing particle diameter, thus occurs with the highest probability for very small 
particles in the lung periphery, where the airway dimensions are small (Schulz, 1998). 
 
1.5.1.4 INTERCEPTION AND ELECTROSTATIC PRECIPITATION 
Two, more minor, deposition mechanisms are interception and electrostatic 
precipitation. Deposition by interception will occur when a particle’s centre of gravity is 
within the gas streamline, however, a distal part of the particle has made contact with 
and therefore deposits on a respiratory surface. Interception is likely to occur when a 
particle has dimensions that are comparable with the airway radius. As therapeutic 
particles generally have a particle size that is much smaller than the airways, deposition 
by interception should not be important, but may play a role for irregularly shaped 
particles such as those with elongated shapes (Zeng et al, 2001). Electrostatic 
precipitation occurs as a result of electrostatic charges imparted on a particle as it is 
inhaled. Subsequently, a charge can be induced on a respiratory surface and thus 
deposition can occur as a result of mutual charge attraction (Zeng et al, 2001). 
 
1.5.2 DISSOLUTION  
The efficiency and clinical safety of an inhaled drug will depend on the dose delivered, 
the site of deposition, and the physicochemical properties of the drug, including the 
aerodynamic particle size distribution (Davies and Feddah, 2003; Riley et al., 2012). 
The latter are important in determining the rate of drug dissolution and subsequent 
systemic absorption, metabolism and elimination. Standardised, pharmacopoeial 
dissolution test methods exist for solid and semi-solid dosage forms as a quality control 
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tool to assess batch to batch variability, and to predict in vivo release, however, there is 
currently no such method to assess the dissolution behaviour of inhaled powders 
(Davies and Feddah, 2003; May et al., 2012; Riley et al., 2012).  
 
Following deposition, undissolved particles may be cleared by the mucociliary escalator 
in the upper airways or by uptake into macrophages in the lower airways (May et al., 
2012; Riley et al., 2012).  The bioavailability and therapeutic action of the drug will 
therefore depend on the dissolution of the particles in the fluid lining of the lungs (Riley 
et al., 2012). Dissolution is defined as the process in which a solid enters a solvent to 
generate a solution, and is controlled by the affinity between the solid and the solvent 
(Davies and Feddah, 2003). Furthermore, the small volume of the lung lining fluid, 
approximately 10 – 20 mL/100 m2, might also be expected to limit the dissolution 
process (May et al., 2012). 
 
A range of dissolution methodologies have been employed to date to study inhaled 
dosage forms. These include the compendial USP 2 paddle apparatus (Son and 
McConville, 2009; Son et al., 2010), a modified USP 4 flow-through apparatus which is 
custom made (Davies and Feddah, 2003) and diffusion-controlled systems using the 
Franz cell (Salama et al., 2008; Salama et al., 2009) or Transwell
®
 systems (Arora et al., 
2010). In the latter system, the inclusion of a respiratory cell monolayer further provides 
a more realistic in vitro model (e.g. Grainger et al., 2009; Ong et al., 2012; Haghi et al., 
2013). In addition to the dissolution apparatus, other factors such as particle 
presentation and dissolution media are important considerations. It is likely to be 
advantageous to test aerosolised particles in the respirable particle size range, and using 
representative dissolution media (e.g. simulated lung fluids) at the correct temperature 
and pH in order to mimic the in vivo environment as closely as possible (Riley et al., 
2012). Dissolution profiling of inhaled products has indicated that drug solubility 
(Davies and Feddah, 2003; Arora et al., 2010), particle size/mass (Son and McConville, 
2009; Arora et al., 2010; Son et al., 2010), and aerosol delivery (e.g. inhaler device, 
Arora et al., 2010, and single vs. co-delivery, Haghi et al., 2013) are important factors 
that may influence the dissolution rate of an inhaled drug.  
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1.6 COMBINATION THERAPY 
The National Heart, Lung and Blood Institute expert panel classifies asthma into four 
levels of severity depending upon the symptoms and lung function prior to the initiation 
of treatment. These are: (1) mild intermittent asthma, (2) mild persistent asthma, (3) 
moderate persistent asthma and (4) persistent asthma (Nelson et al., 2003; NHLBI, 
2007). Long acting beta agonists (LABAs) are used in combination with inhaled 
corticosteroids (ICs) for long term control and prevention of symptoms in moderate or 
severe persistent asthma. Due to the heterogeneous nature of COPD, the severity of the 
disease is assessed based on the individual patient. Combination therapy is therefore 
advocated in stable disease where the patient has breathlessness or exacerbations despite 
the use of short-acting bronchodilators (NICE, 2010). Combination DPIs currently 
available on the market contain salmeterol xinafoate (SX) and fluticasone propionate 
(FP; Seretide Accuhaler) or formoterol fumarate and budesonide (Symbicort) (BNF, 
2013). SX and FP were therefore selected as model drug powders in order to assess the 
influence of co-formulation on drug dispersion. 
 
1.6.1 SALMETEROL XINAFOATE  
1.6.1.1 PHARMACOLOGICAL AND PHYSICOCHEMICAL PROPERTIES 
Salmeterol xinafoate ((4-hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-
benzenedimethanol,1-hydroxy-2-naphthalenecarboxylate; SX) was developed as a long 
acting bronchodilator to provide control for nocturnal asthma symptoms and therefore a 
more convenient maintenance therapy for patients with asthma (NICE, 2010).  SX is a 
LABA with a chemical structure as shown in Figure 1.1. SX consists of a racemic form 
of the 1-hydroxy-2-naphthoic acid salt of salmeterol, possessing a long carbon side 
chain which contributes towards its high lipophilicity (Michael et al., 2000). 
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Figure 1.1 Chemical structure of salmeterol xinafoate (SX) taken from Michael et al. 
(2000). 
 
SX is highly selective towards the β2 receptor, and primarily causes bronchial smooth 
muscle relaxation (Lofdahl, 1990; Dransfield and Bailey, 2004). SX has a higher 
affinity for the β2 receptor than salbutamol, and is over 10,000 times more lipophilic. 
The lipophilic nature of SX causes it to partition into the cell membrane, before 
diffusing to the active site of the β2 receptor. Although having a slower onset of action 
than other β2 agonists such as salbutamol and formoterol, SX has a much longer 
duration of action of up to 12 h (Lofdahl, 1990; Johnson et al., 1993). 
 
The physical appearance of SX is a white powder, which is freely soluble in methanol, 
slightly soluble in ethanol, chloroform and isopropanol, and sparingly soluble in water 
(Kim et al., 2009). SX exists in two crystalline polymorphic forms, Form I (SXI) and 
Form II (SXII), which are enantiotropically related (Tong et al., 2002). SXI is the 
thermodynamically stable form at ambient temperature and pressure, compared to the 
metastable SXII form. Polymorphs display different properties, for example surface 
energy and solubility, and may therefore have consequences for the performance of the 
final formulated product (Tong et al., 2001, Tong et al., 2006). 
 
1.6.1.2 ROLE IN ASTHMA AND COPD TREATMENT 
LABAs (e.g. SX) are indicated as the first choice add on therapy for asthma patients not 
adequately controlled with short acting bronchodilators (treatment step 1) and regular 
preventer therapy using inhaled steroids (treatment step 2) (BTS/SIGN, 2008 (revised 
2012)). Due to safety concerns regarding the use of LABAs, including the increased risk 
of severe exacerbations and even death, the FDA now recommends that LABAs should 
only be used in conjunction with a steroid and never alone in the treatment of asthma 
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(FDA, 2010). In COPD, LABAs are indicated as maintenance therapy in patients 
remaining symptomatic whilst using short acting bronchodilators, either alone or in 
combination with an inhaled steroid and depending on patient force expiratory volume 
(FEV1) (NICE, 2010). 
 
1.6.2 FLUTICASONE PROPIONATE  
1.6.2.1 PHARMACOLOGICAL AND PHYSICOCHEMICAL PROPERTIES 
Fluticasone propionate (FP) is a synthetic corticosteroid having the chemical structure  
shown in Figure 1.2, that was developed to obtain a more potent corticosteroid that 
exhibited improved airway selectivity (Johnson, 1998; Kim et al., 2009). FP is used 
both intra-nasally and via the inhaled route as a topical anti-inflammatory agent (Shaw 
et al., 1994; Kim et al., 2009).  
 
Figure 1.2 Chemical structure of fluticasone propionate (FP)  taken from Michael et al. 
(2000). 
 
FP is a potent agonist at the cytosolic glucocorticoid receptor (GR) and has little activity 
at the progesterone receptor (Shaw et al., 1994). FP is highly selective for the GR and 
has a long duration of action, with a half-life greater than 10 h (Shaw et al., 1994; 
Johnson, 1998). Following binding, the corticosteroid-GR complex is internalised into 
the nucleus of the cell where it binds to DNA sequences, altering the mRNA for the 
production of anti-inflammatory cytokines, mediators and proteins in order to elicit its 
anti-inflammatory effect (Shaw et al., 1994).  FP has low oral bioavailability, and 
undergoes efficient hepatic first pass metabolism to the inactive 17β-carboxylic acid 
derivative, which is rapidly excreted from the body (Harding, 1990; Shaw et al., 1994). 
 
FP has the physical appearance of a white powder, and is extremely lipophilic, being 3 
and 300 times more lipophilic than beclomethasone dipropionate and budesonide, 
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respectively (Johnson, 1998). As a result, FP is practically insoluble in water, but has 
varying solubility in dimethyl sulfoxide, dimethylformamide, methanol and 95 % 
ethanol (Shaw et al., 1994; Kim et al., 2009). When inhaled, this degree of lipophilicity 
limits the dissolution of FP in the lung lining fluids, slows release from the lung lipid 
compartment, and therefore prolongs the retention time in the lungs (Shaw et al., 1994; 
Johnson, 1998). 
 
1.6.2.2 ROLE IN ASTHMA AND COPD TREATMENT 
Inhaled steroids, such as FP, are indicated for asthma patients not adequately controlled 
with short acting bronchodilators (treatment step 1), and are considered if the patient 
uses their inhaled β2 agonists more than three times a week, are symptomatic more than 
three times a week, wake one night a week and/or have experienced exacerbations 
within the last two years (BTS/SIGN, 2008 (revised 2012)). In COPD, inhaled steroids 
are added to treatment as maintenance therapy in combination with a LABA, for 
patients in which symptoms persist with short acting bronchodilators and having an 
FEV1 less than 50 % predicted (NICE, 2010). 
 
1.6.3 RATIONALE FOR COMBINATION THERAPY 
Many patients with asthma and COPD require the concurrent administration of an anti-
inflammatory agent and bronchodilator. Combination inhalers containing both drugs in 
a single formulation are therefore more convenient and simpler to use (NICE, 2010). 
Adherence may be improved due to the simplification of complicated medication 
regimens, thus encouraging the refill persistence of the SX and FP combination inhaler 
compared to separate inhalers. There is also greater chance of the patient inhaling both 
drugs (Stoloff et al., 2004; Stempel et al., 2005).  
 
1.6.3.1 PHARMACOLOGICAL RATIONALE 
When more than one drug is administered simultaneously there is the potential for 
additive, complementary and/or synergistic effects between the drugs which may 
improve the clinical outcome (Johnson, 2004). Synergy between SX and FP has been 
suggested at the cellular level, however, this remains controversial. Various 
mechanisms have been proposed. At the receptor level, LABAs may ‘prime’ GR 
receptors such that they are more sensitive to activation (Johnson, 2004; Caramori et al., 
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2006) and increase translocation of the GR receptor into the nucleus and increase DNA 
binding (Johnson, 2004; Akabane et al., 2006), whereas the corticosteroid may reduce 
the down-regulation of β2 receptors which can occur with long term treatment 
(Caramori et al., 2006). A reduction in the release of inflammatory mediators has also 
been suggested (e.g. Pang and Knox, 2000; Akabane et al., 2006). It has been suggested 
that both drugs should be present on the same airway target cell, at adequate 
concentrations, and simultaneously, in order to aid in a pharmacologically synergistic 
effect, and that the likelihood of this occurring may be increased by combination 
inhalers (Theophilus et al., 2006). 
 
1.6.3.2 EVIDENCE FOR PHYSICOCHEMICAL INTERACTIONS 
By formulating two drugs in a single product, there is the potential for physicochemical 
interactions between the particles, and this may result in altered drug dispersibility and 
deposition in the lungs. Physicochemical interactions between SX and FP have been 
reported in solution and suspension (CFC and HFA) environments. The altered 
behaviour of SX and FP in combination was suggested to arise from heterofloc 
formation in which the drug components had interacted, and was found to be dependent 
on the chemical and physical properties of the drugs, as well as the solvent environment 
(Michael et al., 2000; Michael et al., 2001). In such systems, SX and FP may be 
inextricably bound, potentially being chemical in nature, however, further studies are 
required to confirm this (Michael et al., 2001; Rogueda et al., 2011). Association 
between SX and FP has also been identified following co-delivery using the Raman 
microscope for pMDI formulations (Theophilus et al., 2006; Rogueda et al., 2011) in 
which greater co-association was identified for the combination product (Theophilus et 
al., 2006). These interactions in pMDIs have also reported implications for the 
deposition of both drugs to pMDI canister walls (Michael et al., 2000). However, 
combination delivery has been shown to produce no change in the FPF of FP compared 
to single-drug pMDI delivery (Hoe et al., 2009). 
 
DPI systems differ from pMDIs in that they lack a solvent in the formulation, therefore 
the mechanism for any altered dispersibility/deposition is likely to be different. A 
second fine drug particle may function as a performance modifying agent or fine, and 
will depend on the interactive affinities between SX and FP particles as well as with any 
excipients in the formulation. When measured using the atomic force microscope 
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(AFM), SX-SX cohesive forces were found to be stronger than SX-lactose adhesive 
forces, whereas the converse trend was true for FP in terms of its adhesivity with 
lactose. Overall, SX-FP interactions were found to be the strongest of all the 
interactions (Young, 2004a). The physicochemical properties of the drugs (Kubavat et 
al., 2012) including heterogeneity in properties (Das et al., 2012), as well as the 
storage/processing history (Das et al., 2009b), will also influence the magnitude and 
distribution of the interactive forces adding a further level of complexity in studying 
particulate interactions, especially in combination formulations. 
 
Following assessment of the aerodynamic deposition performance of commercial 
single-active and combination DPI formulations, differences between single and co-
delivery was observed for SX and FP (Taki et al., 2011).  Regardless of the inhaler 
device used, combination delivery generated comparable MMADs but lower and higher 
FPFs for SX and FP, respectively, compared to single delivery. There were also 
significant differences between the mass deposited across the stages, in which 
combination delivery resulted in a lower total fine particle dose (FPD) in the deeper 
stages of the Next Generation Impactor (NGI), i.e. at and beyond stage 4 (Taki et al., 
2011). This suggests altered dispersibility/deposition when formulated in combination, 
however, it is not only the presence of the second drug that may be important but also 
the physicochemical properties of the drug particle. For example, changes in the FPF of 
FP and SX varied depending on the mechanical properties and interfacial chemistry of 
the FP particles (Kubavat et al., 2012). As physicochemical properties affect the 
interactive inter-particulate forces between particles, it is important to take these into 
consideration when studying the formulation performance of combination DPI products. 
Associations between SX and FP that are suggested to occur in combination 
formulations are thought to play a role in the improved patient outcomes from 
combination delivery, as a result of increasing the chances of the proposed 
pharmacological requirement of simultaneous deposition of both drugs on the same site 
in the airways for a potential synergistic effect (Theophilus et al., 2006). Combination 
delivery may however alter the dispersion of one or both drugs from the formulation, 
leading to optimised deposition profiles in the lungs. It may therefore be these effects, 
rather than the co-association and ‘co-deposition’ of the particles in the airways that 
promote improved outcomes and long term management of the disease by combination 
delivery.  
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1.7 OVERALL AIM OF THE THESIS 
The overall aim of this thesis is to study the factors affecting drug particle interactions, 
the de-agglomeration of particles and deposition from dry powder systems at a 
particulate level and in formulations with a view to attempting to understand some of 
the factors affecting aerosolisation performance. This will enable drug co-delivery from 
combination formulations to be studied systematically in order to gain insight into the 
influence of inter-particulate interactions on fine particle delivery to the lungs. 
 
The objectives of this thesis are to: 
1. Develop a dry dispersion laser diffraction analysis method to characterise 
powder de-agglomeration. 
2. Determine the influence of particle interactions on drug dispersibility in fine 
particle blends. 
3. Characterise the physicochemical properties of aerodynamically size-
fractionated and re-crystallised drug particles, and the influence on particle 
agglomeration and aerosolisation. 
4. Trace the potential dispersion modifying effects and co-association of drug 
particles in co-formulated pre-blends and DPI formulations.  
5. Determine the ability to engineer drug aerosolisation and dissolution upon co-
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2.1 INTRODUCTION 
Achieving drug deposition within the respiratory tract is dependent foremost on 
attaining an appropriate particle size during aerosol delivery. It is generally accepted 
that an aerodynamic size of 3 – 5 µm is required in order for particles to reach the 
central airways and peripheral regions of the lung (Shekunov et al., 2003).  The intrinsic 
cohesivity of such fine and often irregularly shaped particles means that there is a 
tendency for agglomeration to occur (Adi et al., 2011). The interactive cohesive forces 
involved in the agglomeration of drug particles include van der Waals, electrostatic, 
capillary and frictional forces, and mechanical interlocking (Louey et al., 2006). The 
magnitude and type of such interactive forces is further dependent on particle properties 
(Podczeck et al., 1994) including intrinsic physicochemical properties, particle size, 
shape, morphology and surface area (Telko and Hickey, 2005). Heterogeneity in particle 
properties can lead to mixed populations of agglomerates with different dispersion 
behaviours (Behara et al., 2011b) thus rendering the situation highly complex. 
  
During delivery it is essential that attractive interparticulate forces are overcome in 
order to restore drug particles to their primary de-agglomerated state. In passive DPIs, 
detachment forces arise from the turbulent airflow generated as a patient inhales through 
the inhaler device. The efficiency of de-agglomeration is therefore dependent on the 
patient’s inhalation profile and device characteristics such as geometry and resistance, 
as these factors determine the level of turbulence, shear and impaction events that the 
powder is subjected to (Louey et al., 2006; Islam and Cleary, 2012). The inherent 
dispersibility of the powder is also important (Louey et al., 2006). The balance of 
cohesive and adhesive forces between drug and carrier particles can dictate the ease 
with which de-agglomeration occurs; an excess of either may prevent de-agglomeration 
resulting in poor aerosolisation and increased deposition in the upper airways (Begat et 
al., 2004b). DPI efficiency is generally very low, with drug dispersion from commercial 
devices and formulations varying from 12 – 40 % of the load dose. This is also 
complicated by variability between the delivered dose between uses (i.e. intra-patient) 
and between patients (i.e. inter-patient) (Islam and Cleary, 2012). It is therefore clear 
that there is a need to improve DPI performance, with knowledge of the dispersibility of 
powders being an important factor for consideration. 
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A number of approaches are available to study powder dispersibility/de-agglomeration, 
each of which has advantages and limitations (Table 2.1). Dry dispersion laser 
diffraction is more frequently being adopted and provides a fast, reproducible approach 
to characterising inhalation aerosols, allowing automated data recording and processing 
(De Boer et al., 2002a; Marriott et al., 2006). As well as being easy to use, the absence 
of liquids and high optical contrast between sample particles and the gas phase make the 
technique ideal in the study of dry powders (Calvert et al., 2009). A drawback of laser 
diffraction is that an assumption is made that particles are spherical; however, the 
difference in the measured size may not be critical, demonstrated by De Boer et al. 
(2002b) where a difference of only 3 % was observed between the calculated laser 
diffraction diameter and equivalent volume diameter of wedge shaped lactose 
monohydrate particles. Laser diffraction may therefore provide a useful tool in 
characterising DPI formulations under well-controlled conditions, allowing powder de-
agglomeration efficiency to be assessed as a function of air flow rate, inhaler design or 
formulation (De Boer et al., 2002a). 
 
Laser diffraction systems used by researchers to study de-agglomeration have included 
the Malvern Spraytec (Adi et al., 2006, Adi et al., 2008a), Malvern Mastersizer 2000 
(Das et al., 2009a) and Sympatec HELOS (Shekunov et al., 2003). The particle size 
distributions (PSDs) generated under controlled dispersing conditions have been used to 
provide a qualitative indication of de-agglomeration where the numbers of modes and 
their location have been used to describe the composition of powders at differing stages 
of de-agglomeration. These findings were developed further by Behara et al. (2011b), 
where the Malvern Spraytec was used to quantitatively characterise the de-
agglomeration of cohesive pharmaceutical powders and a number of de-agglomeration 
parameters were derived. However, although these studies provided useful information 
regarding the de-agglomeration characteristics of the samples, the powders were filled 
into gelatine capsules and aerosolised from a Rotahaler resulting in both device and 
capsule-specific effects contributing to the dispersion of the powders. It therefore 
remains desirable to develop methods to assess the fundamental de-agglomeration 
properties of dry powders which are not influenced by device/capsule characteristics. 
 
Sympatec GmbH (Clausthal-Zellerfeld, Germany) have developed and produced an in-
line Helium Neon Laser Optical System (HELOS) laser diffractometer for particle size 
analysis. This instrument has been used alongside the dry dispersion RODOS unit by a 
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number of researchers to analyse the dispersibility of pharmaceutical powders 
(Shekunov et al., 2003; Kaye et al., 2009; Ghoroi et al., 2013). The RODOS unit 
disperses particles using pressurised air that accelerates particles once they reach a 
dispersing line. Control over dispersing conditions can be achieved by varying the 
pressure of the air feed to the unit from 0.1 – 6 Bar with the potential to disperse 
particles down to 0.1 µm (Calvert et al., 2009). The dosing method is selected based on 
the sample; the vibratory feeder is used for large, free flowing samples requiring 
quantities of material in the order of magnitude of grams. However, for smaller sample 
sizes consisting of fine cohesive particles as is the case for inhaled powders, the 
ASPIROS or rotary feeder are more appropriate. The evaluation of particle size as a 
function of dispersion pressure in a system such as Sympatec HELOS/RODOS is 
generally accepted to provide a semi-quantitative assessment of the degree of 
agglomeration/de-agglomeration (Ghoroi et al., 2013). The gradient of the Dv90, for 
example, over a dispersion pressure range can be used to assess the extent of 
dispersibility, where shallower gradients would imply better dispersibility (Shekunov et 
al., 2003; Kaye et al., 2009). It was therefore proposed that the Sympatec 
HELOS/RODOS could form the basis of a quantitative tool to analyse the de-
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Table 2.1 A summary of current methods used to study powder de -agglomeration and the associated advantages and limitations of each technique.  
Technique Output Advantages Limitations References 
Atomic force microscopy (AFM) Interactive force 
Cohesive-adhesive balance 
ratio 
1. Direct force measurement of 
colloid size particles 
 
1. Time consuming and labour 
intensive sample preparation 
2. Small number of particles 
3. Unknown particle orientation  
4. Measures only a single interaction 
5. Contact area/nature unknown 
6. Requires highly crystalline 
substrates of controlled geometry 
Begat et al. 
(2004a); Tsukada 
et al. (2004); 
Bunker et al. 
(2005); Jones et 
al. (2008b)  
Inverse gas chromatography (IGC) Surface energy arising from 
dispersive and specific 
interactions 
1. Derivation of cohesive and 
adhesive forces from the 
surface energy  
2. Uses bulk powder rather 
than individual powder 
particles  
1. Large sample quantity 
2. Long analysis time 
3. Different probes/data analysis 
approaches limit data comparison 
between research groups 
4. Infinite dilution unable to reveal 
surface heterogeneity  
Das et al. 
(2011a);  Jones et 
al. (2012) 
Centrifugation Interactive force 1. Direct measurement of  
autoadhesion (i.e. cohesive) 
forces 
2. Uses larger numbers of 
particles than AFM 
1. Specialist equipment 
2. Long experimental time 
3. Contact surface (e.g. roughness) 
needs to be quantified 
4. Centrifugal and adhesion force is  
sensitive to small variations in 
particle size 
Podczeck et al. 
(1994); Nguyen 
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Table 2.1 A summary of current methods used to study powder de-agglomeration and the associated advantages and limitations of each technique 
(continued). 
Technique Output Advantages Limitations References 
Time of flight aerosol beam 
spectrometry e.g. Aerosizer 
Particle size following the 
application of a known level 
of shear and de-
agglomeration 
1. 1. Aerodynamic particle size 
(range 0.2 – 700 µm) 
2. 2. Sample delivery via a dry 
dispersion unit or inhaler cell 
attachment 
1. Particle detection on a one at a 
time basis 
2. Measurement discrepancies at high 
particle densities 
3. Assumes spherical particles  
4. Cannot distinguish between 
particles e.g. drug and excipient 
Holzner and 
Müller (1997); 
Begat et al. 
(2004b); Adi et 
al. (2006); Das et 
al. (2011b) 




1. Malvern Spraytec 
2. Malvern Mastersizer 
3. Sympatec HELOS/RODOS 








2. Reproducible  
3. Sample delivery via a dry 
dispersion unit or inhaler 
cell attachment 
4. Controlled dispersion 
conditions 
 
1. Not an aerodynamic particle size 
2. Scirocco feeder (for Malvern 
Mastersizer) vibrates powder prior 
to dispersion 
3. Inhaler dosing attachments 
(Malvern Spraytec/Sympatec) limit 
determination of fundamental 
dispersibility 
4. Limited approaches to quantify 
dispersion 
Shekunov et al. 
(2003); Adi et al. 
(2006); Marriott 
et al. (2006); Adi 
et al. (2008a); 
Behara et al. 
(2011b)   
 
Specific de-agglomeration 
apparatus e.g. de-agglomeration 
rigs, standard entrainment tubes 
 
 
Outcome dependent on the 
apparatus/experimental set-
up 
1. Precise control and 
characterisation of airflow 
conditions 
2. Can be used in conjunction 
with established methods 
e.g. cascade impactors 
1. Specialist equipment therefore 
difficult to reproduce between 
research labs 
2. Complex designs 
3. Also requires lengthy impactor 
analysis 
Voss and Finlay 
(2002); Louey et 
al. (2006); 
Kurkela et al. 
(2008) 
Impactors and impingers Fine particle fraction, mass 
median aerodynamic 
diameter, emitted dose 
1. Widely accepted ‘gold 
standard’ for product 
development and quality 
control 
1. Laborious and time consuming 
2. Classifies particles into a small 
number of class sizes 
Marriott et al. 
(2006) 
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2.2 AIM AND OBJECTIVES 
The aim of this study was to develop a laser diffraction technique to quantify powder 
de-agglomeration through studying powder dispersion in the dry state.  The specific 
objectives were to: 
a) Establish the geometric primary particle size of beclometasone dipropionate (BDP), 
budesonide (Bud), fluticasone propionate (FP), lactose monohydrate (Lactohale 300, 
LH300), PF-00613322 (PF), salbutamol base (SB), salmeterol xinafoate (SX) and 
tofimilast (Tof) powders when fully dispersed in a liquid medium. 
b) Generate geometric size measurements for each powder using dry dispersion laser 
diffraction under different dispersion conditions, achieved by varying the dispersing 
pressure used to aerosolise the powder. 
c) Analyse the particle size of each powder as a function of the primary pressure (PP) 
imposed during the dry dispersion laser diffraction sizing method with a view to 
generating relevant parameter(s) to describe the resultant de-agglomeration profile.  
d) Compare the de-agglomeration parameter(s) with the cohesivity of each powder, 


















The materials and equipment used in this chapter are summarised in Table 2.2. 
 
Table 2.2 Suppliers of materials and equipment (Chapter 2).  
Material / Equipment Supplier 
Beclometasone dipropionate (BDP; BN. 
WC60329)  
Pharm Dev Europe, GWRD, UK 
Budsonide (Bud; BN. U0015/1V040) LGM Pharma, USA 
Tofimilast (Tof; BN. CP-325366) Pfizer Ltd, PGRD Sandwich Laboratories, UK 
Fluticasone propionate (FP; BN. 458763) LGM Pharma, USA 
PF-00613322 (PF; BN. PF-00613322)  Pfizer Ltd, PGRD Sandwich Laboratories, UK 
Lactohale 300 (LH300; BN. 6125224/S) Frieslands Foods, Domo, The Netherlands 
Salbutamol base (SB; BN. WC46269) Pharm Dev Europe, GWRD, UK 
Salmeterol xinafoate (SX; BN. SX-0081010) Vamsi Labs, India  
Cyclohexane (BN. 10D120503) VWR international Ltd, UK 
Methanol (HPLC Grade) Sigma Aldrich Ltd, UK 
Hexane Fisher Scientific, UK 
Sorbitan monooleate 80 (Span 80) Sigma Aldrich Ltd, UK 
Sorbitan monooleate 85 (Span 85) Merck, Germany 
Tween 80 Merck, Germany 
Malvern Mastersizer X  Malvern Instruments Ltd, UK 
Ultrasonic water bath Sonorex, Bandelin Electronic, Germany 
Cellulose acetate syringe filters (pore size 
0.2 µm) 
Gema Medical S.L., Spain 
Aluminium pin stubs (0.5 inches) and 
double-sided adhesive carbon tabs 
Agar Scientific Ltd, England 
K550X sputter coater Emitech, Quorum Technologies Limited, 
England 
Quanta 200F field emission scanning 
electron microscope 
FEI UK Ltd, England 
Sympatec HELOS BF and RODOS 
dispersing unit 
Sympatec GmbH, Clausthal-Zellerfeld, 
Germany 
SMS Inverse Gas Chromatograph (Serial No. 
031112-01) and silanised glass columns 
Surface Measurement Systems Ltd, UK 
 




2.4.1 PARTICLE SIZE ANALYSIS BY LIQUID DISPERSION LASER 
DIFFRACTION 
Laser diffraction particle sizing was carried out using the Malvern Mastersizer X fitted 
with a 100 mm focal length lens (0.5 – 180 µm) and an MS7 magnetically stirred cell. 
Dispersant was prepared by saturating an appropriate solvent (containing surfactant to 
aid dispersion) with sample and sonicating in an ultrasonic water bath for 30 min. The 
dispersant was visually checked for saturation and stirred overnight using a magnetic 
flea. Prior to sizing, the laser was switched on for 30 min. The sample cell was cleaned 
with methanol, allowed to air dry and filled with dispersant filtered through a 0.2 µm 
cellulose acetate syringe filter. Approximately 1 mg of powder was added to 2 mL 
filtered dispersant in a 7 mL glass vial and sonicated (Sonicleaner, DAWE, Ultrasonics 
Ltd, USA) for the required time. The presentation was selected, laser aligned and a 
background reading taken. The suspension was added drop wise to the sample cell until 
the obscuration was within range (~ 10 – 30 %) with the appropriate stirrer speed 
setting. The sample was allowed to equilibrate in the cell for 30 – 60 s prior to initiating 
the sizing sequence. Ten individual measurements were taken for n = 3 samples to 
obtain particle size measurements calculated using Fraunhofer theory.  The Dv10, Dv50 
and Dv90 which correspond to the particle size below which 10 %, 50 % and 90 % of the 
particles by volume are smaller than and the D4,3 were recorded. The D4,3 or volume 
mean diameter (VMD), is the volume weighted mean particle size of the sample and is 
sometimes referred to as the volume moment mean diameter, as it represents the central 
point of the frequency in terms of volume from which the distribution would rotate, 
Equation 2.1, where d is particle diameter (Rawle, 1993).  The mean values of each 
parameter were averaged to obtain the final particle size result. A summary of the 
dispersant, sonication time, stir setting, sweeps, and equilibration time used to size each 
powder are summarised in Table 2.3. For PF and Tof, the sizing parameters were 
validated according to ISO 13320-1 (1990) (data not shown). 
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Table 2.3 A summary of the liquid dispersion laser diffraction parameters used to size  
beclometasone dipropionate (BDP), budesonide (Bud), fluticasone propionate (FP), 
lactohale 300 (LH300), PF-00613322 (PF), salbutamol base (SB), salmeterol xinafoate 
(SX) and tofimilast (Tof).  
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PF 0.1 % Span 80 in 
cyclohexane 
1 5 2500 60 
SB 1.0 % Span 85 in 
hexane 
1 3 3500 30 
SX
c













Tof 0.05 % Tween 80 in 
5 % v/v methanol in 
water 
5 5 2500 60 
1
Sonication time required to ensure dispersion of powder particles in the dispersant prior to the size 
measurement. 
2
Setting corresponding to the speed of rotation of a magnetic flea in the bottom of the 
measurement cell.  
3
Measurement sweeps corresponding to the measurement time in s, where 2500 
sweeps is equivalent to 5 s and 3500 sweeps equivalent to 7.5 s. 
4
Sample equilibration time within the cell 
prior to the size measurement. 
a
Zeng et al. (2000), 
b






2.4.2 SCANNING ELECTRON MICROSCOPY  
Aluminium pin stubs were cleaned with acetone, labelled and a double-sided adhesive 
carbon tab mounted onto each. Circular coverslips (10 mm diameter) were cut roughly 
in half using a diamond cutter and compressed air used to remove any glass particles. 
The coverslip was placed onto the carbon tab in order to cover approximately half of the 
stub. A small spatula was loaded with powder (5 – 10 mg) and held above the stub. The 
spatula was gently tapped so that the powder fell onto the stub; excess powder was 
removed by tilting and gently tapping to ensure an even coverage of powder over the 
stub surface. The samples were sputter coated with gold (approx. 15 – 20 nm) for 2 min 
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using a K550X sputter coater. The samples were viewed, using the glass mounted half 
of the stub where possible, using a Quanta 200F field emission scanning electron 
microscope operated at 10 kV in low vacuum mode and using a working distance of 
approximately 10 mm. Images were taken at a high and low magnification using the 
highest possible resolution (3584 x 3094).  
 
2.4.3 DRY DISPERSION LASER DIFFRACTION METHOD 
DEVELOPMENT  
Method development was carried out using the Sympatec HELOS and RODOS 
dispersing unit, using SX as a model powder, in order to ensure selection of the optimal 
experimental parameters for determining particle size as a function of primary pressure 
(PP) using the rotary feeder.  
 
2.4.3.1 CHOICE OF LENS, TRIGGER CONDITIONS, MEASUREMENT TIME 
AND TIMEBASE 
The choice of lens, trigger conditions, measurement time and timebase were 
investigated. The lenses available were the R3 and R5 lens which are employed to 
determine particles within a size range of 0.9 – 175 µm and 4.5 - 875 µm, respectively. 
Particle size measurements (n = 1) were carried out for SX at 0.5 and 4.0 Bar PP using 
both lenses.  The trigger conditions refer to the optical concentration of powder (Copt, 
%) detected on the detector channels in order to initiate (start Copt) and end (end Copt) a 
particle size measurement. The start Copt was investigated in the range 0.1 – 5 % and the 
end Copt in the range 0.1 – 2 % for SX particle size measurements (n = 1) taken at 2.0 
Bar PP. The detector channel on which the Copt was detected was also investigated in the 
Channel range 10 – 31, corresponding to trigger sizes of 3.99 to 160.39 µm. The 
measurement time i.e. the duration of time that particle size data is collected whilst the 
Copt was within the trigger condition range was investigated, within the time range of 1 
– 20 s for SX particle size measurements (n = 1) taken at 2.0 Bar PP. The timebase was 
investigated in the range 0.001 – 0.500 s, representing the frequency at which the 
software collects data during a measurement, for SX measurements taken at 0.3 Bar PP. 
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2.4.4 PARTICLE SIZE-PRIMARY PRESSURE PROFILES 
Pressure titration curves were generated using the Sympatec HELOS/RODOS using the 
rotary feeder with protruding aspiration tube (Figure 2.1). Powder sample was hand-
filled into the u-shaped groove of a rotating table to cover a length of approximately 1 
cm. The sample passed under a plough scraper and roller to remove any excess and was 
subsequently drawn up into the dispersing line via the protruding aspiration tube from a 
static bed. During sample delivery the rotating table was maintained at a constant 




Figure 2.1 The Sympatec HELOS/RODOS rotary feeder comprising a rotating ring 
and protruding aspiration tube (image taken from 
www.sympatec.com/EN/LaserDiffraction/RODOS.html,  accessed on 27.08.13). 
 
The PP was manually set using the adjustment valve to values in the range 0.2 to 4.5 
Bar. Three measurements were taken at each pressure setting using freshly loaded 
powder. All measurements for a single powder were generated on a single day. PSDs 
were calculated using Fraunhofer theory and analysed in WINDOX 4.0 software 
(Sympatec GmbH, Clausthal-Zellerfeld, Germany). Each measurement generated a PSD 
and the Dv10, Dv50 and Dv90 were measured and recorded. The volume mean diameter 
(VMD) was also recorded.  A summary of the operational parameters used are 
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Table 2.4 A summary of the dry dispersion laser diffraction parameters used to size 
the powders using the Sympatec HELOS/RODOS laser diffractometer. 
Parameter  
Feeder Rotary 
Lens R3 (0.9 – 175 µm) 
Start optical concentration (Copt, %) 1.1 
Trigger channel None specified 
End optical concentration (Copt, %) 1 
Measurement time (s) 5 or 60 s real time 
Time base (ms) 100 
Forced stability 4 
 
2.4.4.1 CRITICAL PRIMARY PRESSURE DERIVATION 
The PP at which the particle size-primary pressure profile reached a plateau size was 
considered to represent the pressure required to overcome the interactive forces holding 
agglomerates together and therefore provide a measure of the cohesivity of the powder. 
The parameter was called the critical primary pressure (CPP) and derived as follows. 
The mean particle size (Dv50, Dv90 and VMD) at each PP was calculated, followed by 
the difference between the mean size and the preceding mean size. A difference ratio 
(dr) was calculated by expressing the mean particle size in question as a proportion of 
the difference between the sizes, as shown in Equation 2.2, where PP1 and PP2 are two 
consecutive PPs, where PP2 > PP1. 
 
Equation 2.2       
    
         
     
    
    
 
If the difference ratio was within the range -0.06 < dr < 0.06 for the Dv50 and VMD, or -
0.10 < dr < 0.10 for the Dv90 then the particle size was considered to be the same (ISO 
13320:1990). When no difference was observed for three consecutive increases in the 
PP, this was taken to represent the plateau. The PP at which the particle size was first 
observed to be the same as that recorded at the preceding PP (i.e. difference ratio within 
the above range) was taken to represent the CPP. 
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2.4.5 NORMALISATION OF PARTICLE SIZING DATA AND DE-
AGGLOMERATION ANALYSIS 
The particle size data were normalised to account for differences in the primary particle 
size of each powder. The particle size at each PP (Dx) was expressed as a proportion of 
the fully dispersed particle size as shown in Equation 2.3. The fully dispersed size was 
represented by both the dry dispersion particle size at the highest PP employed (DH) and 
the liquid dispersion size (DL). The parameter was termed the degree of de-
agglomeration (DA) and represented the extent of de-agglomeration achieved at a 
particular PP. When DA = 1 complete dispersion of the powder to primary particles 
would have occurred. 
 
Equation 2.3        
       
  
              
 
DA was plotted as a function of PP in order to generate de-agglomeration profiles. The 
de-agglomeration data exhibited rectangular hyperbolas therefore equations describing 
the same trend were selected with a view to empirically modelling the data. These were 
the Langmuir (Equation 2.4), Frendlich (Equation 2.5) and Michaelis Menten (Equation 
2.6) equations where DA is the degree of de-agglomeration, DAmax is the asymptote 
degree of de-agglomeration and PP is the primary pressure. KL is the Langmuir 
adsorption/equilibrium constant and KF is a measure of adsorptive capacity. The term 
1/n in the Freundlich equation is a measure of the intensity of adsorption. The DA50 in 
the modified Michaelis Menten equation (Equation 2.6) represents the PP required to 
achieve 50 % de-agglomeration and is derived from the intercept and slope of the 
trendline fitted to the linearised data. 
 
Equation 2.4  Langmuir Equation:        
                
          
  
Equation 2.5  Freundlich Equation:             
 
   
Equation 2.6  Michaelis Menten Equation:       
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The de-agglomeration profiles were linearised in order to undertake data fitting. For the 
Langmuir and Michaelis Menten equation the Hanes Woolf method was used in order to 
prevent bias towards data points in the low PP region (Equation 2.7 and Equation 2.8, 
respectively) and for the Freundlich equation this involved log10 transformation 
(Equation 2.9).  The goodness of fit of each model to the data was deduced by 




Equation 2.7     
  
  
   
 
     
     
 
       
 
Equation 2.8     
  
  
   
 
      
      
    
     
 
Equation 2.9                    (
 
 
)       
  
2.4.6 INVERSE GAS CHROMATOGRAPHY AT INFINITE DILUTION 
A 30 cm silanised glass column with an internal diameter of 3 mm was filled with 200 – 
300 mg of sample and sealed at each end with silanised glass wool. Columns were 
packed by placing a small funnel in the top of the column, transferring sample into the 
funnel and gently tapping and rotating the column. Samples were analysed using an 
SMS Inverse Gas Chromatograph. The columns were conditioned under dry nitrogen 
for 12 h at 0 % relative humidity (RH), total flow of 10 standard cubic centimetres per 
min (sccm) and eluent temperature of 303 K. A flame ionisation detector (FID) was 
used with a data saving interval of 2 s. Infinite dilution analysis was conducted using 
fixed probe volume injections at a partial pressure of 0.03 p/po, where p is the partial 
pressure of the vapour and po is the saturation pressure of the liquid (Newell and 
Buckton, 2004). The probe and column temperature were set at 303 K, and analysis was 
conducted at 0 % RH using a total flow of 10 sccm and nitrogen as the carrier gas. The 
non-polar probes employed were nonane, octane, heptane and hexane with run times of 
40, 20, 10 and 10 min, respectively. The polar probes were acetone, acetonitrile and 
ethanol and were injected with a run time of 20 min each. The dead time was calculated 
using methane. A single column was analysed in triplicate using each probe with a 60 
min delay between each analysis in order to allow the column to be purged of residual 
solvent between replicates. 




2.5.1 SCANNING ELECTRON MICROSCOPY 
SEM imaging revealed differences in the morphology of the powders (Figure 2.2 and 
Figure 2.3). All the powders were agglomerated and displayed a range of agglomerate 
sizes. Upon visual assessment, the agglomerates of all the powders appeared to be 
densely packed. The agglomerates were also observed to be in association with each 
other, suggesting that inter-agglomerate interactions occurred leading to the formation 
of larger agglomerated structures within the powder. Considering particle morphology, 
all the powders showed a variety of irregular particle shapes. Overall the particles of 
each powder appeared flat/plate-like and SB had the smallest particle size. Tof and SX 
had smooth particle surfaces whereas the remaining powders seemed to have rougher 
surfaces. There was little uniformity in particle morphology within and between 
powders. 
 
2.5.2 DRY DISPERSION LASER DIFFRACTION METHOD 
DEVELOPMENT 
The particle size of the powders was generally within the low micron size range, 
therefore the R3 lens (0.9 – 175 µm) was considered more suitable than the R5 lens (4.5 
– 875 µm). Nevertheless, it was important to determine whether larger agglomerates 
were present. Measurements were taken at low and high PPs using both lenses for 
confirmation (Figure 2.4). Use of the R5 led to a loss in part of the PSD at the fine 
particle size range for SX at both PPs. Furthermore, the lowest limit of the R5 lens (4.5 
µm) was larger than the Dv50 of all the powders (Table 2.5). For these reasons, the R3 











Figure 2.2 Morphology of beclometasone dipropionate (BDP), budesonide (Bud), fluticasone propionate (FP) and lactohale 300 (LH300) imaged by 
scanning electron microscopy at x 700 and x 10500 magnification. 
Magnification x 700 Magnification x 10500 Magnification x 700 Magnification x 10500 
Beclometasone dipropionate (BDP) Budesonide (Bud) 
100 µm 100 µm 5 µm 5 µm 
100 µm 100 µm 5 µm 5 µm 
Magnification x 700 Magnification x 10500 Magnification x 10500 
Fluticasone propionate (FP) Lactohale 300 (LH300) 
Magnification x 700 






       
Figure 2.3 Morphology of PF, salbutamol base (SB), salmeterol xinafoate (SX) and tofimilast (Tof) imaged by scanning electron microscopy at x 
700 and x 10500 magnification. 
100 µm 100 µm 5 µm 5 µm 
Magnification x 700 Magnification x 10500 Magnification x 700 Magnification x 10500 
PF Salbutamol base (SB) 
100 µm 100 µm 5 µm 5 µm 
Magnification x 700 Magnification x 10500 Magnification x 700 Magnification x 10500 
Salmeterol xinafoate (SX) Tofimilast (Tof) 





















Figure 2.4 The particle size distribution of salmeterol xinafoate (SX) sized by 
Sympatec HELOS/RODOS laser diffraction (using the rotary feeder) at 4.0 Bar and 
0.5 Bar primary pressure using the R3 (0.9 – 175 µm) and R5 (4.5 – 875 µm) lens (n = 
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The trigger conditions were found to have little effect on the particle size data. Altering 
the start (0.1 – 5 %) and end (0.1 – 2 %) Copt and measurement time (1 – 20 s) had no 
effect on the Dv10 (p > 0.05), Dv50 (p > 0.05) and Dv90 (p > 0.05) values of SX (one-way 
ANOVA with post-hoc Tukey’s test, GraphPad Prism 5), when sized at 2.0 Bar PP, 
which was selected as an intermediate dispersal pressure (Figure 2.5). The timebase i.e. 
the frequency at which the software collects data during a measurement was varied in 
the range 0.001 – 0.500 s at 0.3 Bar pressure. At low dispersal pressures, fewer particles 
are likely to be present due to less efficient powder de-agglomeration. The timebase at 
low pressures was therefore considered to be critical, as the combination of fewer 
particles and a low sampling rate may have reduced the sensitivity of the measurement 
and led to the misinterpretation of large particles as noise. However, altering the time 
base had no effect on the measured particle size of SX (Dv50 = 3.68 ± 0.17 µm, mean of 
n = 1 measurement taken at n = 11 different timebases). When the trigger channel was 
altered to cover the Channel range 10 – 31, corresponding to trigger sizes of 3.99 to 
160.39 µm, there was also no change in the measured particle size of SX at 0.3 Bar 
pressure (Dv50 = 3.70 ± 0.13 µm, mean of n = 1 measurements taken using n = 4 
different trigger channels), where again due to the presence of larger agglomerates at the 
low pressures, the trigger condition was considered to be critical. 
 







































































Figure 2.5 The particle size, represented by the Dv10, Dv50 and Dv90, of salmeterol 
xinafoate (SX) sized by Sympatec HELOS/RODOS laser diffraction (using the rotary 
feeder) at 2.0 Bar primary pressure (mean ± SD, n ≥ 2) using different trigger 
conditions (i.e. optical concentration (Copt)) to start and end a measurement, and 
measurement times. 
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While measuring the PSDs, a particle size mode was observed in some replicate 
measurements suggesting the presence of large particles (Figure 2.6). This was 
confirmed to be a measurement artefact as there was a lack of particles/agglomerates 
greater than 100 µm when viewed by SEM (Figure 2.2 and Figure 2.3). Forced stability 
was therefore incorporated into the method in order to eliminate this peak from 
calculations and to enable accurate data analysis to be conducted. The minimum number 
of channels was excluded from the size measurement in order to remove this peak and 
was found to be a forced stability of ‘4’ corresponding to exclusion of channels 
measuring particles larger than ~ 100 µm.  
 
 
Figure 2.6 The particle size distribution of salmeterol xinafoate (SX) sized by 
Sympatec HELOS/RODOS laser diffraction (using the rotary feeder) at 3.0 Bar 
primary pressure (n = 1 measurement shown).  
 
2.5.3 DRY DISPERSION LASER DIFFRACTION TO STUDY POWDER 
AGGLOMERATION STATE 
2.5.3.1 VALIDATION OF PARTICLE SIZE DISTRIBUTION MEASUREMENTS 
BY LASER DIFFRACTION 
The geometric particle size results (Dv10, Dv50, Dv90, and VMD) obtained using liquid 
and dry dispersion laser diffraction are presented in Table 2.5. All the powders were 
found to possess a PSD within the micron size range with Dv50 values less than 4 μm. 
The liquid dispersion particle size results enabled the primary, fully dispersed particle 
size in a liquid medium to be determined. BDP, Bud, FP, PF, SB and SX showed 
significant differences between liquid and dry dispersion particle sizes whereas Tof and 
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Table 2.5 The measured particle size (represented by the Dv10, Dv50, Dv90 and volume 
mean diameter, VMD) and span of beclometasone dipropionate (BDP), budesonide 
(Bud), fluticasone propionate (FP), lactohale 300 (LH300), PF-00613322 (PF), 
salbutamol base (SB), salmeterol xinafoate (SX), and tofimilast (Tof) by dry 
dispersion laser diffraction (at 5.0 Bar pressure) and liquid dispersion laser diffraction 
(mean ± SD, n ≥ 3). 
Powder Dispersion Dv10 (µm) Dv50 (µm) Dv90 (µm) VMD (µm) Span 
BDP Dry 0.70 ± 0.00 1.65 ± 0.00 3.50 ± 0.00 1.90 ± 0.01 1.70 
 Liquid 1.20 ± 0.02 2.62 ± 0.24  4.75 ± 0.71 2.87 ± 0.32 1.36 
Bud Dry 0.70 ± 0.00 1.74 ± 0.00 4.08 ± 0.01 2.12 ± 0.00 1.94 
 Liquid 1.02 ± 0.02 2.17 ± 0.03 4.39 ± 0.03 2.49 ± 0.02 1.55 
FP Dry 0.88 ± 0.03 2.44 ± 0.12 5.75 ± 0.23 3.01 ± 0.13 1.90 
 Liquid 1.25 ± 0.01 2.81 ± 0.03 5.18 ± 0.13 3.06 ± 0.05 1.40 
LH300 Dry 0.91 ± 0.01 3.32 ± 0.01 8.26 ± 0.02 4.06 ± 0.01 2.22 
 Liquid 1.78 ± 0.08 3.74 ± 0.41 6.57 ± 1.14 4.02 ± 0.52 1.28 
PF Dry 0.68 ± 0.00 1.59 ± 0.01 3.90 ± 0.01  2.00 ± 0.01 2.02 
 Liquid 0.92 ± 0.00 2.05 ± 0.01 4.34 ± 0.04 2.43 ± 0.02 1.67 
SB Dry 0.60 ± 0.01 1.07 ± 0.01 2.17 ± 0.01 1.25 ± 0.01 1.46 
 Liquid 0.78 ± 0.08 1.44 ± 0.16 2.51 ± 0.29 1.57 ± 0.17 1.19 
SX Dry 0.67 ± 0.00 1.51 ± 0.03 3.47 ± 0.03 1.84 ± 0.01 1.83 
 Liquid 0.81 ± 0.01 2.05 ± 0.12 4.33 ± 0.25 2.39 ± 0.18 1.71 
Tof Dry 1.13 ± 0.02 2.78 ± 0.02 5.48 ± 0.01 3.08 ± 0.01 1.56 
 Liquid 0.87 ± 0.01 2.62 ± 0.02 4.98 ± 0.06 2.81 ± 0.02 1.57 
 
2.5.3.2 EFFECT OF PRIMARY PRESSURE ON THE PARTICLE SIZE 
DISTRIBUTION 
Changes in the PSD were seen for all the powders when the PP was increased, and the 
powders became more fully dispersed. Using the rotary feeder, BDP, Bud, PF, LH300 
and Tof showed a shift in the distribution towards the smaller particle size range with 
increasing PP, along with the appearance of a small shoulder in the curve due to very 
fine particles. This shoulder may arise as a result of particle fracture occurring at high 
pressures leading to the production of fine particles. SB conversely showed no shift and 
only a narrowing in the PSD. FP and SX demonstrated bimodal distributions at low PPs 
attributed to fine particles and agglomerate formation. Both showed a shift of the peak 
corresponding to the fine particle fraction towards smaller particle sizes and a tendency 
to eliminate agglomerates. Representative PSDs for Bud, SB and SX at 0.5, 1.0, 2.0 and 
4.0 Bar generated using the rotary feeder are shown in Figure 2.7. Considering the PSDs 
numerically, a gradual reduction in the Dv10, Dv50, Dv90 and VMD was observed for all 
the powders with increasing PP. For all the powders the particle size reduced until a 
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plateau size was reached, which was comparable to the particle size from liquid 
dispersion measurements. The pre-plateau region differed between the powders 





Figure 2.7 The particle size distribution of budesonide, salbutamol base and 
salmeterol xinafoate at 0.5, 1.0, 2.0 and 4.0 Bar primary pressure sized by Sympatec 
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Figure 2.8 Particle size-primary pressure profiles of beclometasone dipropionate 
(BDP), budesonide (Bud), fluticasone propionate (FP), lactohale 300 (LH300), PF-
00613322 (PF), salbutamol base (SB), salmeterol xinafoate (SX) and tofimilast (Tof) 
sized by Sympatec HELOS/RODOS laser diffraction (using the rotary feeder) (mean ± 
SD, n = 3). SX had a large Dv50 at the lowest pressure employed; this value was 
omitted from the main graph but is shown in the inset graph. 
 
2.5.3.3 CRITICAL PRIMARY PRESSURE DERIVATION 
The CPP of all the powders when sized using the rotary feeder are summarised in Table 
2.6.  In all instances (except for BDP and LH300) the CPP determined from the Dv50 
and VMD was identical and varied from 1.0 Bar for SB to 3.5 Bar for SX, representing 
the least and most cohesive powders respectively. For FP, the particle size only 
remained consistent for two increases in the PP, 3.0 and 3.5 Bar, therefore 3.0 Bar was 
taken to represent the CPP. In some instances the Dv50 and Dv90 predicted the same CPP 
value; this occurred for PF and SB. For the remaining powders (except FP and SX), the 
CPP calculated from the Dv90 was smaller than for the Dv50. Again, FP only showed 
particle size consistency at two increases in the PP (3.0 and 3.5 Bar) using the Dv90. For 
SX, it was only at 4.5 Bar that the dr indicated no difference between the particle sizes 
for the Dv90 thus it was not possible to assign a CPP value. Although the CPP of the 
Dv90 may allow comparison between the powders, it would represent a population of 
powder comprising both fully disrupted and partially disrupted agglomerates. As the 
contribution of each of these to the size measurements is not known, the CPP generated 
using the Dv90 was considered to be of less value than the CPP generated using Dv50 
values. 
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Table 2.6 A summary of the critical primary pressure (CPP) values of the powders 
determined from Sympatec HELOS/RODOS dry dispersion laser diffraction  (using the 
rotary feeder). The CPP value was derived using the mean Dv50, Dv90 and volume mean 
diameter (VMD) values. 
Powder Critical Primary Pressure (CPP, Bar) 
Particle Size Dv50 Dv90 VMD 
BDP 2.5 2.0 2.0 
Bud 2.0 1.0 2.0 
FP 3.0* 3.0* 3.0* 
LH300 2.0 0.7 1.5 
PF 2.5 2.5 2.5 
SB 1.0 1.0 1.0 
SX 3.5 - 3.5 
Tof 3.0 2.0 3.0 
* Measured size unchanged for 2 consecutive dispersing pressures only, 3.0 and 3.5 Bar. 
 
2.5.4 CHARACTERISATION OF DE-AGGLOMERATION BEHAVIOUR 
OF MICRONISED POWDERS BY LASER DIFFRACTION 
Figure 2.9 shows the de-agglomeration profiles of the powders generated using dry 
dispersion laser diffraction and the DH/Dx approach. The profiles exhibited rectangular 
hyperbolas with subtle differences in the shape of the curve suggestive of different de-
agglomeration behaviours. When the de-agglomeration data (calculated from the Dv50 
values) were fitted to the linearised forms of the Langmuir, Freundlich and Michealis 
Menten equations, the Freundlich equation exhibited poorer linearity (R
2
 = 0.69 – 0.92 
and 0.73 – 0.94 for the DL/Dx and DH/Dx de-agglomeration data, respectively) 
compared to the Langmuir or Michaelis Menten equation (R
2
 = 0.92 – 1.00 and 0.91 – 
1.00 for the DL/Dx and DH/Dx de-agglomeration data, respectively) and on this basis it 
was not considered further as a potential model. The linearised plot for the Langmuir 
and Michealis Menten equations were identical and hence the fit of the data was also 
identical. As neither of the original equation derivations can be directly compared to de-
agglomeration, the choice of model was arbitrary. Whereas in the Langmuir adsorption 
isotherm k represents an equilibrium constant, in Michelis Menten it is the substrate 
concentration required to reach 50 % of the limiting rate of the reaction. The Michealis-
Menten equation was therefore selected, where k would represent the PP required to 
achieve 50 % de-agglomeration and called DA50. 
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Figure 2.9 De-agglomeration profiles derived from particle size data generated by 
Sympatec HELOS/RODOS laser diffraction (using the rotary feeder) at primary 
pressures in the range 0.2 – 4.5 Bar. Particle size data (i.e. Dv50 values) were 
normalised using the DH/Dx approach for the powders beclometasone dipropionate 
(BDP), budesonide (Bud), fluticasone propionate (FP), lactohale 300 (LH300), PF-
00613322 (PF), salbutamol base (SB), salmeterol xinafoate (SX) and tofimilast (Tof)  
(mean ± SD, n = 3). 
 
The derived DA50 and DAmax from DL/Dx and DH/Dx de-agglomeration plots (using the 
Dv50) are shown in Table 2.7.  Considering the Dv50 data, both the DL/Dx and DH/Dx de-
agglomeration data showed excellent linearity (R
2
 > 0.91) and the derived DA50 values 
were similar. The DAmax values, however, differed. The values were generally higher 
for DL/Dx rather than DH/Dx de-agglomeration data. When assuming DL to represent 
the fully dispersed particle size in liquid medium, higher DAmax values (generally > 1) 
could indicate that particles were fractured at high pressures in the dispersing line of the 
Sympatec laser diffractometer. As different instruments were used, differences in the 
numerical algorithms used to calculate the particle sizes may also have contributed to 
this effect. Using the DH approach, the theoretical DAmax is 1, and in most instances the 
derived values were ≤ 1.20 with the exception of SX where DAmax = 1.35, where slight 
deviations are likely from the goodness of fit of the model. When considering the R
2
 
values, DAmax, and the fact that all particle size measurements were derived from a 
single instrument, the DH/Dx approach was deemed to be the most appropriate for data 
analysis. 
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Table 2.7 The R
2
, primary pressure required for 50 % de-agglomeration (DA50) and 
maximum degree of de-agglomeration (DAmax) of the powders derived from de-
agglomeration data obtained by dry dispersion laser diffraction. The values correspond 
to the DL/Dx and DH/Dx data analysis approach, determined from the mean Dv50 values 





 DA50 DAmax 
BDP 0.9990 0.44 1.70 
Bud 0.9979 0.38 1.33 
FP 0.9169 1.15 1.28 
LH300 0.9997 0.23 1.18 
PF 0.9981 0.33 1.31 
SB 0.9976 0.23 1.29 
SX* 0.9742 1.45 1.63 





 DA50 DAmax 
BDP 0.9990 0.44 1.11 
Bud 0.9995 0.32 1.08 
FP 0.9049 1.15 1.13 
LH300 0.9997 0.23 1.06 
PF 0.9980 0.33 0.94 
SB 0.9979 0.25 1.06 
SX* 0.9711 1.45 1.35 
Tof 0.9964 0.28 1.07 
*Particle size data generated at the lowest PP (i.e. 0.3 Bar) were removed from data fitting due to poor 
linearity with these data included (DL/Dx R
2
 = 0.4548, DH/Dx R
2
 = 0.4532) 
 
De-agglomeration data generated using the Dv90 and VMD overall showed good 
linearity, although it was generally poorer than for the Dv50 data (Table 2.8). SX, 
however, showed very poor linearity (R
2
 = 0.17 – 0.20) and therefore it was not possible 
to derive de-agglomeration parameters for this powder. The de-agglomeration 
parameters (DAmax and DA50) were higher for BDP, Bud, FP and SB using the Dv90 and 
VMD compared to the Dv50 data. For Tof they were comparable, and for LH300 they 
were lower. For PF, they were lower and higher for the Dv90 and VMD, respectively. 
These differences may reflect heterogeniety in particulate properties and agglomerate 
strength/structures within the powder bulk. Furthermore, when using the Dv90, DH may 
comprise agglomerates as well as individual particles, such that LH300 for example 
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may have weaker inter-agglomerate interactions compared to intra-agglomerate 
interactions. However, due to the uncertainty in the powder structure for the Dv90, such 
interpretations must be made with caution. The Dv50 was therefore selected for further 
analysis, as it represents the median particle size of the powder, enabled parameters to 
be derived for SX, and the DH would be less likely to include agglomerates. 
 
Table 2.8 The R
2
, primary pressure required for 50 % de-agglomeration (DA50) and 
maximum degree of de-agglomeration (DAmax) of the powders derived from de-
agglomeration data obtained by dry dispersion laser diffraction. The values were 
determined using the DH/Dx approach, calculated from the mean Dv90 or volume mean 
diameter (VMD) of the powders.  
Approach: DH/Dx
 
Particle Size Data used: Dv90 
Powder R
2
 DA50 DAmax 
BDP 0.9608 0.58 1.16 
Bud 0.8679 0.88 1.26 
FP 0.8838 2.27 1.40 
LH300 0.9991 0.12 1.03 
PF 0.9951 0.30 0.93 
SB* 0.9767 0.60 1.16 
SX 0.1737 - - 
Tof 0.9989 0.24 1.06 
Approach: DH/Dx
 
Particle Size Data used: VMD 
Powder R
2
 DA50 DAmax 
BDP 0.9870 0.60 1.16 
Bud 0.9588 0.72 1.21 
FP 0.9092 1.76 1.28 
LH300 0.9994 0.19 1.05 
PF 0.9956 0.38 0.92 
SB 0.8872 0.96 1.28 
SX 0.1957 - - 
Tof 0.9974 0.27 1.06 
* Particle size data generated at the lowest (i.e. 0.2 Bar) PP removed from data fitting due to poor 
linearity with these data included (R
2
 = 0.4073). 
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2.5.5 INVERSE GAS CHROMATOGRAPHY AT INFINITE DILUTION 
The dispersive surface energy was determined from IGC analysis at infinite dilution for 
a selection of powders displaying varying behaviour; BDP, SX, FP and LH300. The 
gross retention time of each probe (tR), determined from the peak maximum, was used 
to calculate the retention volume (VN) according to Equation 2.10, and was corrected 
for the dead volume (to) i.e. the time a probe molecule would take to travel through the 
column without interacting with the sample. In Equation 2.10, F is the carrier gas flow 
rate at standard temperature and pressure, Ts is the column temperature in Kelvin, Tref  is 
the reference temperature for flow rate determination, m is the sample mass packed into 
the column and j is the James-Martin pressure drop correction factor which corrects the 
retention time for the pressure drop along the packed column (Thielmann, 2004; Jones 
et al., 2012). 
 
Equation 2.10        
 
  
    (     ) 
  
    
        
Equation 2.11                         (     )
 
    
  
The dispersive surface energy was calculated by the Schultz method (Schultz et al., 
1987). Four non-polar probes were injected onto the column and a plot of RT(ln VN) 
against a(γDL)
1/2 
constructed where R is the gas constant, T is the column temperature, 
VN is the net retention volume, a is the cross-sectional area of the adsorbate probe 
molecule and γDL is the dispersive surface tension of the adsorbate. The plot yields a 
straight line with gradient 2NA(γD)
1/2
 where NA is Avagadro’s number and from which 
the dispersive surface energy of the solid (γD) can be determined. A representative plot 
used to determine the dispersive surface energy of SX is shown in Figure 2.10. The 
polar probe data were added to the plot and the vertical distance of the data points from 
the alkane line is equal to the specific free energy of adsorption (ΔGP) arising due to 
polar interactions with the sample material. The dispersive surface energy of the 
powders differed and ranged from 36.2 ± 0.14 mJ.m
-2 
for SX to 49.9 ± 0.08 mJ.m
-2 
for 
FP. The work of cohesion arising from the dispersive interactions was calculated using 
Equation 2.11 (Azioune et al., 2002; Voelkel et al., 2009) where γD is the dispersive 
surface energy of the sample. A summary of the dispersive surface energies (γD), 
specific free energy of adsorption (ΔGP) and work of cohesion of BDP, FP, LH300 and 
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SX are shown in Table 2.9. As well as having the highest dispersive surface energy, FP 
also had the highest work of cohesion. This was followed by LH300, BDP and SX, 
representing a rank order of reducing cohesivity. For FP, the run time of the polar 
probes was not sufficiently long enough for complete elution of the acetone and ethanol 
peaks therefore it was not possible to calculate the ΔGP for these probes. Considering 
the other three powders, overall LH300 had the greatest polar component, followed by 
BDP and finally SX.  
 
 










Polar probes: Acetone Acetonitrile Ethanol












 for the determination of 
the dispersive surface energy using the Schultz method. The data presented are for 
salmeterol xinafoate (SX). 
 
Table 2.9 The dispersive surface energy, free energy of adsorption (generated from 
acetone, acetonitrile and ethanol probes) and work of cohesion of beclometasone 
dipropionate (BDP), fluticasone propionate (FP), lactohale 300 (LH300) and 
salmeterol xinafoate (SX) (mean ± SD, n = 3 injections onto a single column).  
Sample Dispersive 












   Acetone Acetonitrile Ethanol 
BDP 40.6 ± 1.22 81.3 ± 2.44 7.9 ± 0.21 7.9 ± 0.26 8.0 ± 0.12 
FP 49.9 ± 0.08 99.9 ±  0.16  - 14 ± 0.09 - 
LH300 44.9 ± 0.92 89.8 ± 1.85 9.5 ± 0.16 11 ± 0.16 13 ± 0.19 
SX 36.2 ± 0.14 72.5 ± 0.29 7.0 ± 0.11 6.2 ± 0.07 5.0 ± 0.04 
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2.6 DISCUSSION AND CONCLUSIONS 
The difficulty in achieving efficient delivery of drug particles to the lungs has resulted 
in extensive efforts to engineer DPI device and formulation characteristics. Consistent 
performance of a DPI product depends on the properties of the formulation and the 
interaction of the formulation with the commercial device. Specifically, each of the 
components are required to work together to provide efficient de-agglomeration of the 
drug from the carrier system.  Complex variables are involved including PSD, particle 
shape, surface energy and environmental conditions all of which affect powder 
behaviour (Wong et al., 2011). Furthermore such properties are not straightforward to 
quantify in relation to de-agglomeration. Production and processing steps such as 
micronisation result in different surface energy distributions and potential heterogeneity 
in powder properties. However, approaches to determine the dispersibility of a powder 
can not only aid in rational formulation and device design, but also allow the influence 
of drug/formulation properties on dispersibilty to be ascertained. Of particular 
importance is an understanding of the cohesivity/adhesivity of agglomerated systems, as 
it is such interactive forces that need to be overcome in order to achieve aerosol 
dispersion. The balance of cohesive forces with adhesive interactions within a 
formulation e.g. with a second drug or carrier, can be used to predict the blending, 
segregation and de-agglomeration characteristics of DPI formulations (Begat et al., 
2004a, Begat et al., 2004b).  The aim of this chapter was to seek to develop a 
methodology which provided a realistic characterisation of powder dispersion using 
readily available equipment through the use of dry dispersion laser diffraction. 
 
The liquid dispersed particle size (DL) confirmed that the powders were micronised and 
of a size suitable for inhaled delivery to the conducting airways, each having a Dv50 less 
than 4 µm. The SEM images further supported this finding, showing micron-sized 
particles (i.e. approximately 1 – 10 μm) that formed agglomerates which in most cases 
were also agglomerated with each other. The median particle size (Dv50) obtained at the 
highest PP using the dry dispersion laser diffraction method (DH) where complete 
dispersion is assumed was in good agreement with the liquid dispersed size. In most 
instances (except for Tof and LH300) there were significant differences in the dry and 
liquid dispersed size (Dv50) however the order of magnitude of the differences was 
small. For example, SX was found to have a Dv50 of 1.51 ± 0.03 μm and 2.05 ± 0.12 μm 
in the dry and liquid dispersed state, respectively. Differences between the liquid and 
 Page | 90  
 
dry dispersed particle sizes would not be unexpected due to the use of different laser 
diffraction apparatus and dispersing media. 
 
2.6.1 DEVELOPMENT OF THE LASER DIFFRACTION DATA 
ANALYSIS TECHNIQUE 
Method development for the Sympatec HELOS/RODOS was conducted to investigate 
the influence of parameters such as the trigger conditions (comprising start and end 
optical concentration, Copt), measurement time, trigger channel and timebase on the 
particle size measurement. These parameters were found to have negligible effects on 
the measured particle size. Each paramater was varied univariantly rather that using a 
multivariate design of experiment approach, which would have involved validation at 
each PP, which was not the objective of the study. The objective was to develop rather 
than validate a method of dry dispersion laser diffraction for de-agglomeration analysis. 
The reported findings were therefore deemed sufficient to proceed with the study. Based 
on these objectives, it was not overly critical to generate a ‘true’ particle size 
measurement at each PP, instead it was necessary to ensure that the parameters 
employed provided a true and reproducible reflection of the sample performance under 
a specfic dispersion condition. This would therefore allow de-agglomeration to be 
assessed over a range of dispersing conditions (Marriott et al., 2006). 
 
When calculating the degree of de-agglomeration (DA) both the DL and DH were 
considered. Incorporating either parameter in subsequent calculations resulted in similar 
linearity and powder dispersibility (represented by DA50) for the powders. The 
maximum degree of de-agglomeration (DAmax) however was generally larger when 
using DL than DH. In the first instance, the choice of approach is important in order to 
retain consistency in data analysis between powders/studies, as it is influenced by the 
assumptions made with regards to complete dispersion to primary particles. The use of 
either DH or DL each has limitations. Powders subjected to high PPs in the Sympatec 
may undergo a degree of particle attrition/erosion due to high gas velocities and 
impactions in the dispersing line (Leschonski et al., 1984; Ghoroi et al., 2013)  such that 
DH may be smaller than the true particle size. The use of DL on the other hand requires 
the use of validated methods to ensure that primary particles are sized. The method also 
accommodates the potential for interactions with liquid media which may alter 
properties such a particle shape, size and volume; the orientation of the particles within 
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the liquid sample cell may also affect the measured size (Berthold et al., 2000). 
Furthermore, in the current study, DL was generated using a different laser diffraction 
apparatus whereas ideally particle size data should be generated from the same 
instrument (e.g. Sympatec SUCELL wet dispersing unit), to maintain consistency in 
particle size calculations, although in both instruments Fraunhofer theory was used. 
Overall, the use of DH was considered most appropriate in subsequent analysis. 
 
2.6.2 CHARACTERISATION OF DE-AGGLOMERATION BEHAVIOUR  
The dry dispersion particle size results at low PPs indicated that under low shear 
conditions the powders were agglomerated, a finding corroborated by SEM images. 
Following the application of a low level of shear the powders showed some de-
agglomeration. The dispersing line of the Sympatec HELOS/RODOS is optimised for 
dispersion, with the release of compressed air into the dispersing line generating a 
primary/driving air flow which initiates particle acceleration and subsequent dispersion. 
As the air is released into the dispersing line, its path is contoured to generate a high 
shear zone to further promote powder break-up. As the sample passes along the 
dispersing line it is subjected to frictional, shear and centrifugal forces that result in 
collisions beween gas and powder particles, and particle-particle and particle-wall 
collisions (Röthele, 1990). At the end of the dispersing line the powder is subjected to 
an impact cascade to aid dispersion (Leschonski et al., 1984). Due to the dispersion 
promoting features of the dispersing line, it is likely that the powders exhibited de-
agglomeration even under very low PP/shear conditions. These geometric effects 
however would be consistant between all the powders allowing differences in cohesion 
and de-agglomeration to be studied. 
 
Dry dispersion sizing showed differing degrees of agglomeration and therefore powder 
structures between the samples. At low PPs e.g. 0.3 Bar, SX and FP had the largest 
agglomerate size (Dv50 = 21.35 ± 1.52 and 8.08 ± 0.74 µm, respectively). LH300 and 
Tof had intermediate sizes (Dv50 = 5.26 ± 0.08 and 4.91 ± 0.09 µm, respectively), and 
BDP and Bud had small sizes (Dv50 = 3.32 ± 0.15 and 3.88 ± 0.75 µm, respectively). SB 
had the smallest size (Dv50 = 1.86 ± 0.03 µm). Therefore, it is likely that under these 
conditions SB, for example, would have a powder structure mainly comprising 
individual particles and small SB–SB agglomerates, whereas SX would consist of large 
SX–SX agglomerates. Differences in powder structure arise due to the propensity for, 
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and extent of, agglomeration, which is determined by the magnitude, type and 
heterogeneity in interactive forces between powder particles. Such forces are dependent 
on particle size, shape, rugosity, hardness, press-on forces exerted during handling and 
relative humidity (De Boer et al., 2003) which will ultimately affect the dispersibility of 
the powders. The agglomeration state at low PPs cannot in isolation be used as an 
indicator of dispersion, but allows for a qualitative distinction between powders of 
different cohesivity and structure. 
 
Increasing the PP and therefore the initial driving airflow resulted in a change in the 
PSD of the powders. Upon increasing the dispersing pressure, there was a gradual shift 
towards smaller particle sizes suggesting that powder dispersion was better effected. 
Higher flow rates are associated with greater viscous shear stress in the Sympatec 
HELOS/RODOS (Shekunov et al., 2003) and the increased turbulent forces leads to 
improved de-agglomeration (Voss and Finlay, 2002; Louey et al., 2006; Kurkela et al., 
2008). Turbulence alone, however, is not the only mechanism involved in de-
agglomeration (Voss and Finlay, 2002). Increasing air flow rates increase the velocity 
gradient between the gas and powder thus promoting greater dispersion through 
acceleration of powder agglomerates (Calvert et al., 2009) and also increases wall 
impactions (Wong et al., 2011), and it is therefore likely that a combination of factors 
were involved. 
 
2.6.2.1 DETERMINATION OF DE-AGGLOMERATION PARAMETERS 
It was proposed that the developed laser diffraction method would enable 
parameterisation of the de-agglomeration behaviour of inhaled powders. De-
agglomeration is related to powder flowability. The FT4 powder rheometer is 
traditionally used to study flow by measuring the behaviour of powders under the 
application of stress, and can provide insight into the relative cohesivity of powders 
(Shur et al., 2008). Rheometer testing however involves a conditioning step, where the 
powder is gently disturbed by a blade (Freeman, 2007). By removing the packing 
history and generating a homogenised, uniform powder with a low packing stress (Shur 
et al., 2008) it can be argued that the measurements do not represent the intrinsic 
flowability/compressability of the powders. Outcomes will also be of little relevance in 
understanding inhaled formulation performance due to the absence of conditioning steps 
during powder delivery. Technologies such as entrainment tubes which are used in 
tandem with cascade impactors provide an aerodynamic assessment of powder de-
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agglomeration and deposition, and show greater relevance to inhalation delivery (Louey 
et al., 2006). Dispersion is achieved under airflow conditions which can be controlled 
by the user, and characterised in terms of for example the pressure drop, Re, and shear 
stress (τS) (Louey et al., 2006). This is however at the expense of the tubes needing to be 
engineered and manufactured in-house for the required application, and involves 
lengthy, labour intensive, impactor testing. Dry dispersion laser diffraction removes the 
need for the latter thus providing a more rapid tool for assessing de-agglomeration 
under different shear conditions. Single particle techniques such as AFM can also 
provide useful insights e.g. Bud has demonstrated stronger cohesive interactive forces 
than lactose (Begat et al., 2004a), whereas those of SX and FP were indicated to be of 
comparable magnitude (Young, 2004a). However, as AFM only employs a small 
number of isolated particles then extrapolation of the results to the aerosolisation 
behaviour of a powder bed should only be effected with caution, particularly as a 
distribution of particles is likely due to inter- and intra-batch variability in properties 
(Feeley et al., 1998; Price, 2011), which could lead to an overestimation of the cohesive 
force of a bulk powder. Being a bulk measurement technique, laser diffraction, if 
conducted within a controlled environment, is able to account for every factor which 
may influence de-agglomeration, including particulate, bulk, and external factors. As 
there is little powder manipulation prior to analysis, there is minimal disturbance to the 
powder structure/packing. These advantages provide a convenient, accessible and 
highly relevant tool in powder characterisation and the necessary preceding step in 
formulation development. 
 
The particle size-primary pressure profiles were distinctive, undergoing an initial 
reduction in size until a plateau was reached, and provided a mechanistic insight into the 
de-agglomeration process. For example, the rapid drop in the Dv50 of SB under the 
application of a dispersing pressure, and rapid attainment of the plateau particle size, 
indicated efficient de-agglomeration to near complete agglomerate dispersal occurring 
very readily under the application of shear. However, for FP, the drop in the Dv50 was 
more progressive suggesting a more gradual de-agglomeration process, in which a 
flatter gradient may have initially been considered to indicate better dispersibility 
(Begat et al., 2004b; Adi et al., 2006; Kaye et al., 2009; Ghoroi et al., 2013). Unlike 
previous studies, by using multiple dispersing pressures over a wide titration range, it is 
clear that that it is necessary to consider the entire particle size-primary pressure curve 
when evaluating powder de-agglomeration. For example, when SB and FP were 
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empirically modelled, FP was found to have poorer dispersibility than SB. It was also 
possible to obtain information regarding powder structure, for example, high standard 
deviations were obtained in the measured agglomerate size at each dispersing pressure 
for FP, and highlighted agglomerate size heterogeneity during dispersion, leading to 
mixed populations of agglomerate and/or particle sizes. 
 
2.6.2.1.1 POWDER COHESIVITY 
The plateau region of the curve was investigated as a measure of powder cohesivity. 
The PP at which the plateau occurred (CPP), was derived and varied between the 
powders in the range 1.0 to 3.5 Bar. The absence of further changes in the particle size 
was considered to reflect the particles in their dispersed state, and therefore the PP 
required to achieve 100 % de-agglomeration to primary particles. The parameter 
therefore provided a measure of interparticulate cohesive interactions, and in particular 
the most cohesive particle populations. Comparing the CPP derived from the Dv50 and 
Dv90 provided an indication of the heterogeniety in interactive forces within the powder. 
For example Bud, CP, and PF had identical CPPs to achieve the dispersed Dv50 and Dv90, 
however, for the remaining powders, the values were different. In the case of BDP and 
LH300 the CPP value was lower, and for SB and SX the CPP was higher, using the 
Dv90. However, by utilising the Dv90 i.e. the particle size below which 90 % of the 
particles, by volume, are smaller than, the plateau region may consist of mixtures of 
agglomerates and dispersed particles. Therefore, comparisons must be made with 
caution, as the composition of the Dv90 powder structure is not known and may differ 
between powders. 
 
2.6.2.1.2 DEGREE OF DE-AGGLOMERATION 
In order to characterise de-agglomeration behaviour, the degree of de-agglomeration 
(DA) representing the extent to which a powder has de-agglomerated at a specific PP 
was plotted as a function of PP. The de-agglomeration profiles were empirically 
modelled to derive de-agglomeration parameters. The linearised Langmuir and 
Michealis Menten equations had excellent linearity (e.g. using the DH/Dx approach and 
Dv50 values, R
2
 = 0.91 – 1.0), and was superior to the Freundlich equation (R2 = 0.73 – 
0.94) which was subsequently not considered further. Linearisation of the Langmuir and 
MM equation was conducted using the Hanes Woolf method rather a double 
reciprocal/Lineweaver-burk plot as there is less bias in the data points towards low PPs 
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and it provides a more faithful representation of experimental errors (Cornish-Bowden, 
2004). The fits were empirical as it is not applicable to draw analogies between 
adsorption theory or enzyme kinetics respectively and powder de-agglomeration. The 
median particle size (i.e. Dv50) was selected for use in the study, as there was marginally 
improved linearity compared to the Dv90 or VMD, and it was not possible to derive de-
agglomeration parameters for SX. Furthermore, by using the Dv50 and not the Dv90, or a 
fixed particle size e.g. 5.4 µm (Behara et al., 2011b), the DA would represent the degree 
of de-agglomeration to primary particles rather than a size which may also comprise a 
proportion of small agglomerates. Using this analysis, the DA indicated that under low 
shear, the proportion of de-agglomerated particles would be low (e.g. DA = 0.30 ± 0.02 
for FP and DA = 0.07 ± 0.01 for SX). 
 
Two parameters were obtained following empirical modelling. Considering the DAmax, 
all the powders attained a value close to 1.0 under the dispersing conditions employed, 
as would be expected based on the normalisation data analysis approach adopted. The 
DAmax also provided a further measure of the degree of fit of each data set to the model, 
as powders showing the greatest deviation in this parameter from the theoretical value 
of 1.0 (i.e. SX and FP) also had the poorest linearity owing to them possessing the 
largest variability (i.e. highest standard deviations) for replicate particle size 
measurements particularly at low dispersing pressures. The DA50 values described the 
PP required to achieve 50 % de-agglomeration. The DA50 provided an indication of how 
readily a powder disperses to its primary particles, with smaller DA50 values suggesting 
more ready dispersal. The derived values were in the correct region when compared to 
the raw de-agglomeration data and the powders showed a range of behaviours. Being 
directly determined from linear regression parameters (i.e. gradient and intercept), the 
use of the DA50 avoided any errors of interpolation which may occur with other indices 
(e.g. 10th percentile). Based on the DA50, the powders could be characterised into those 
that were poor (SX and FP, DA50 = 1.45 and 1.15 Bar, respectively), intermediate 
(BDP, DA50 = 0.44 Bar) and good (Bud, LH300, SB, Tof, DA50 = 0.32, 0.23, 0.25, 0.28 
Bar, respectively) dispersers.  
 
The shape of the particle size-primary pressure profile, CPP and DA50 values further 
allowed the de-agglomeration mechanisms of the powders to be postulated. The 
difference between the DA50 and the CPP value can be used to estimate the degree of 
heterogeneity in cohesive forces of the sample powder. A low CPP and DA50 were 
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obtained for LH300, SB and Bud, and resulted in a powder that dispersed very readily, 
and de-agglomerated completely, under a range of shear stresses. The PSDs of these 
powders were monomodal, consistent with low cohesive forces between the particles 
and fluidisation via an erosion mechanism, where a stream of de-agglomerated particles 
is continually entrained into the airflow (Shur et al., 2008; Tuley et al., 2008). In 
contrast, when the CPP and DA50 values were both large, e.g. SX and FP, an explosive 
de-agglomeration is indicated. At low shear the powders would undergo very little 
dispersion, due to the entrainment of large agglomerates (Shur et al., 2008; Tuley et al., 
2008), some of which are so tightly associated that a bimodal PSD is observed 
indicative of a distinct population of fine particles/small agglomerates and tightly 
associated large agglomerates within the powder structure. As the level of shear 
increased, the size of the fine mode increased, and the agglomerate mode reduced, until 
it was eliminated, suggesting a step-wise de-agglomeration with progressive break-up of 
powder agglomerates under increasing shear (Behara et al., 2011b). Upon the 
application of levels of shear equal to or greater than the CPP, instantaneous de-
agglomeration to primary particles would occur as the inter-particulate forces are 
overcome. The CPP values suggested that both SX and FP had high cohesive inter-
particulate interactions and therefore potentially high agglomerate tensile strength, 
which is directly related to the work of cohesion of the interacting particles, their size, 
and packing fraction (Kendall and Stainton, 2001). Therefore, a high level of shear 
and/or impaction events would be required for complete dispersion; this would be 
provided by the faster flow rates, induced by higher PPs in the Sympatec, providing 
greater energy for dispersion (Shekunov et al., 2003; Behara et al., 2011b). Complete 
agglomerate break-up would therefore not occur unless high PPs were employed, and 
consequently it was only at high PPs that the PSDs of these powders became 
monomodal. One of the powders, Tof, had a high CPP but a low DA50. This may 
suggest heterogeneity in the magnitude of inter-particulate forces as some powder 
agglomerates will break-up readily (hence a low DA50) but others will require a much 
higher dispersing pressure (hence a high CPP) for de-agglomeration. Powders with 
inter-particulate force homogeneity would conversely have similar DA50 and CPP 
values, with complete dispersion of agglomerates occurring upon the application of the 
appropriate level of shear. 
 
By means of comparison with a well establised technique, the dispersive surface 
energies of BDP, FP, LH300 and SX were assessed by IGC analysis at infinite dilution 
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(Table 2.10). Surface energy is directly proportional to adhesive/cohesive forces (Traini 
et al., 2008; Das et al., 2011b) and has been used by researchers to investigate aerosol 
performance and efficiency (e.g. Cline and Dalby, 2002; Traini et al., 2008). The 
dispersive surface energy, and corresponding work of cohesion, ranked the powders in 
the order: SX < BDP < LH300 < FP in terms of increasing cohesivity.  The CPP values 
from laser diffraction predicted a different rank:  LH300 < BDP < FP < SX. There are a 
number of possible reasons for the discrepancies in the ranks. Firstly, dispersive surface 
energy represents the contribution of van der Waals forces only towards the interaction, 
and therefore does not account for polar (and other) interactions. By adopting infinite 
dilution, where probes are injected at very low concentrations, solute molecules cover 
only a small proportion of the surface, often less than 0.1 % (Ylä-Mäihäniemi et al., 
2008). Subsequently, there is preferential adsorption of the probes to high energy sites 
on the particle surface resulting in an overestimation of the surface energy (Ylä-
Mäihäniemi et al., 2008) and therefore it may not represent true powder cohesivity. 
Micronised particles for inhalation are also heterogenous as a result of the varying and 
uncontrolled degree of disruption to the crystal structure during the micronisation 
process (Feeley et al., 1998). Differences in surface functional groups, irregular surface 
crevices and impurities can result in a range of surface energies on the particle surface; 
therefore a single value of surface energy may not represent the entire surface 
characteristics of the powder (Das et al., 2011a).  By adopting a technique such as the 
laser diffraction methodology described in this study, it is possible to account for 
powder heterogeneity, and in doing so provide a more accurate representation of 
powder properties compared to existing techniques.  
 
2.6.3 CONCLUSIONS 
In conclusion, an approach to analyse powder de-agglomeration using dry dispersion 
laser diffraction was successfully developed. A method of data analysis was applied 
which enabled parameters to be generated to describe de-agglomeration. The parameters 
were able to differentiate de-agglomeration behaviour in a range of inhaled powders. 
The relationship between the cohesivity (represented by the CPP) and ease of dispersion 
(represented by the DA50) revealed inter-particulate force heterogeneity and potential 
de-agglomeration mechanisms. The method could also be considered more 
representative of powder cohesivity compared to the work of cohesion derived from 
dispersive surface energy measurements at infinite dilution. The method has the 
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potential for use in powder characterisation and the design of DPI formulations and 
devices. The derived parameters would provide an initial screen of intrinsic powder 
dispersibility to enable the rational engineering of formulation and device characteristics 























3 EVALUATION OF DISPERSION 
MODIFICATION IN COMBINATION 
DRUG-DRUG POWDER MIXTURES 
CONTAINING SALMETEROL 
XINAFOATE AND FLUTICASONE 
PROPIONATE  
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3.1 INTRODUCTION 
Combination DPI formulations contain two different types of drug particles either 




 of a 
coarse fraction of lactose which functions as a carrier particle and having an 
aerodynamic size usually greater than 60 μm. The carrier excipient often contains 
intrinsic fine lactose particles (less than 5 μm) termed ‘fines’ (Taki et al., 2011a) or 
these can be added extrinsically at a known concentration as a means of improving 
aerosolisation efficiency (Jones et al., 2008b). In the case of Symbicort, the drug 
particles are tumbled with micronised lactose particles to form larger agglomerates 
which have improved flowability and ease of handling (Borgstrom, 2002). There is 
therefore the potential for a range of physicochemical interactions between particles in a 
formulation. Interactions involving the drug include drug-drug (occurring both within 
and between drug powders in a co-formulation), drug-coarse excipient and drug-fine 
excipient. Furthermore fine-fine, coarse-coarse and coarse-fine excipient interactions 
may occur. The relative magnitude of the interactions will be specific to the 
formulation, and will contribute towards the dispersibility and bioavailability of the 
delivered drugs (Taki et al., 2011a). The multitude of interactions between different 
particle types, both in terms of the origin of the interaction forces e.g. van der Waals, 
electrostatic etc., and their relative magnitude renders studies involving multi-
component formulations such as combinations highly complex. A common rationale in 
studying DPI performance has therefore involved sequential analysis of drug particle 
interactions with different components of a formulation (Young et al., 2004a; Adi et al., 
2008a). Therefore, in this study, the implications of blending two fine particle drug 
powders in combination in the absence of a carrier particle was determined using the 
model powders salmeterol xinafoate (SX) and fluticasone propionate (FP); both of these 
powders were found to be poorly dispersible and highly cohesive (represented by the 
high DA50 and CPP values) according to dry dispersion laser diffraction analysis in 
Chapter 2. 
 





contains the drugs SX and FP as the long acting beta agonist and corticosteroid, 
respectively. Aggregation of SX and FP in pMDI propellants has been reported, 
including the formation of hetero-flocs in 1,1,2-trichlorotrifloroethane (CFC-113), 
leading the authors to suggest that the two drugs interact inter-molecularly (Michael et 
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al., 2000; Michael et al., 2001). The aggregation behaviour was found to be dependent 
on the physical and chemical properties of the drug particles, and also the solvent 
environment (Michael et al., 2001) such that it is not possible to translate these findings 
directly to dry powder inhaler formulations. In powder formulations, the second fine 
particle drug has the potential to function as a performance modifier for the other drug 
in the system. SX-FP interactions have been reported to be stronger than SX-SX and 
FP-FP cohesive interactions when measured by AFM indicating that when blended in 
combination there are likely to be implications for the aerosolisation performance of the 
drugs (Young et al., 2004a). If cohesive drug-drug interactions dominate, the 
aerosolisation of each drug is likely to be independent of each other, however, when 
adhesive forces dominate as is reported to be the case for SX-FP interactions, 
aerosolisation of the drugs may differ compared to mono-delivery (Jetmalani et al., 
2012). Studies have suggested that SX has a small but significant positive effect on the 
aerosolisation of FP from commercial Seretide Accuhaler devices, however, the 
inability to control the grade and concentration of coarse and fine lactose in the 
formulation, along with any differences in the blending/manufacturing process between 
the single drug and combination inhalers, hindered any firm conclusions to be drawn 
(Taki et al., 2011). The deposition profile of SX was also found to change when 
aerosolised from the inhaler containing the highest FP concentration, however, again it 
was not possible to deduce whether this was due to the increased FP content, reduced 
lactose content or an increasing FP to lactose ratio (Taki et al., 2011). Furthermore, the 
adhesive affinity of FP towards lactose and SX can change following processing, 
therefore requiring the manufacturing process and history of the powders to also be 
considered (Kubavat et al., 2012). 
 
The balance of SX, FP and lactose (coarse and fine) interactions, particularly in terms of 
the cohesivity and adhesivity of each component, will play a major role in the 
aerosolisation of the drugs in the formulation. Atomic force microscopy and centrifuge 
investigations have revealed that SX-lactose interactions are weaker than SX-SX 
interactions (Podczeck et al., 1994; Young et al, 2004a), which increases emission (Adi 
et al., 2006), and may arise in part due to improved release of SX from a carrier surface. 
Conversely, FP-lactose interactions are stronger than FP-FP interactions (Young et al, 
2004a), however, formulating with a carrier has also improved the emission and FPF of 
FP compared to drug-only formations (Louey et al., 2004b) indicating that the cohesive-
adhesive balance is not the only factor important in dictating aerosolisation. Bulk 
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powder properties such as flowability, fluidisation, air permeability and powder strength 
distribution play an important role in the entrainability and de-agglomeration of powder 
particles (Le et al., 2010; Zhou et al., 2010a; Das et al., 2012). Furthermore, 
heterogeneity in particle properties such as surface energy and surface roughness, may 
alter the adhesive tendencies of individual particles within the bulk, and have 
implications for the bulk powder dispersibility (Podczeck et al., 1994; Das et al., 2012; 
Das and Stewart, 2012). Studies to determine the implication of inter-particulate drug-
drug interactions on dispersibility in combination systems must therefore be undertaken 
systematically to determine the influence of each individual formulation component, 
take into account the inherent heterogeneity in particulate properties, as well as the 
influence of bulk powder properties on aerosol performance. 
 
3.2 AIM AND OBJECTIVES 
The aim of this study was to prepare fine particle blends consisting of two drugs with 
comparable particle sizes and evaluate the cohesive and adhesive tendencies in order to 
investigate the performance modifying effects on drug dispersibility. The objectives 
were therefore to: 
a) Prepare homogenous fine particle blends containing micronised SX and FP. 
b) Assess the de-agglomeration of the blends using a novel dry dispersion laser 
diffraction methodology (developed as described in Chapter 2), to determine 
whether it can be used as a predictive tool to assess blend performance. 
c) Measure the dispersibility (in terms of ED and FPF) and deposition profiles (in 
terms of MMAD and GSD) of micronised SX and FP particles using Next 
Generation Impactor (NGI) analysis and assess the effect of blending each of these 
drugs with a second fine particle on dispersion and deposition. 
d) Calculate the cohesivity and adhesivity of micronised SX and FP particles using 
surface energy measurements generated by inverse gas chromatography (IGC) in 
order to evaluate the effect of cohesivity/adhesivity on particle dispersion and 
deposition when in combination. 
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3.3 MATERIALS  
The materials and equipment used in Chapter 3, not listed in Section 2.3, are shown in 
Table 3.1.  
 
Table 3.1 Suppliers of materials and equipment (Chapter 3). 
Material / Equipment Supplier 
Methanol; HPLC grade Fisher Scientific Ltd, UK 
Ammonium acetate; HPLC grade Chromanorm Hipersolv for HPLC, BDH 
Prolabo, VWR International Ltd, UK 




 (now part of GE Healthcare, 
purchased from Fisher Scientific Ltd, UK) 
Next Generation Impactor MSP Corporation, USA (supplied by Copley 
Scientific, UK) 




Riedel-de Haen AG, Germany (now part of the 
Sigma-Aldrich group, UK) 
Polypropylene glycol; average Mn approx. 
1000 
Aldrich Chemistry, Sigma-Aldrich Company 
Ltd, UK 
Monodose Inhaler Miat S.p.A, Italy (supplied by Pfizer Ltd, UK) 
Capsules; gelatin, size 3 Capsugel, France 
Flow meter; model 4040 TSI Inc, UK 
Hexane Fisher Scientific Ltd, UK 
Phenomenex Luna 3u C18 column, 150 x 4.60 
mm, 3 μm 
Phenomenex UK Ltd, UK 
PureLab Ultra system; for type I, resistivity 
18 MΩ-cm, (water for HPLC, referred to as 
ultrapure water) 
Elga LabWater, UK (part of Veolia Water 
Solutions and Technologies) 
Whirlimixer Fisons, UK 
Turbula mixer; Type 2C Willy A. Bachofen AG Machinenfabrik, 
Switzerland 
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3.4 METHODS 
3.4.1 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
VALIDATION 
3.4.1.1 ASSAY CONDITIONS  
High performance liquid chromatography (HPLC) analysis was conducted as previously 
described (Murnane et al., 2006). The column was a Phenomenex Luna 3u C18 column 
(150 x 4.60 mm, 3 μm) maintained at a temperature of 40 oC. The mobile phase flow 




injection volume 20 µL, run time 6 min and triplicate injections 
were made per sample. The detection wavelength was 228 nm. The mobile phase 
consisted of 0.6 % w/v ammonium acetate dissolved in ultrapure water, which was then 
mixed with methanol in the ratio 25:75 v/v. The solution was filtered through a 0.45 μm 
nylon filter using a Milipore filter unit. The HPLC system consisted of a Waters 
Alliance HT 2795 separations module, a Waters 2996 photodiode array detector and 
Waters column heater.  Due to an in-built degasser, the mobile phase was not de-gassed 
prior to use. Samples were maintained at 10.0 ± 1.0 
o
C in the autosampler chamber. 
Peak integration was conducted using Empower Pro software (Empower 2 software, 
Build 2154, Waters Corporation, USA).  
 
3.4.1.1.1 LINEARITY 
Calibration standards were prepared in the range 0.5 - 50 µg.mL
-1 
containing SX and FP 
in co-solution. To prepare the standards, 2 mg of drug was accurately weighed and 
dissolved in mobile phase with sonication for approximately 10 min. Upon visual 
inspection to check for complete drug dissolution, the solutions were made to final 
volume (50 mL) to prepare a 50 µg.mL
-1
 stock solution. Six standards were prepared 
(0.5, 1, 2, 5, 12.5, and 25 µg.mL-1), each involving a direct dilution of the stock solution 
with mobile phase. Three replicate injections of each sample were performed. Linearity 
was assessed by plotting the individual data points (i.e. the peak areas of the salmeterol 
base peak and fluticasone propionate peak, integrated from the chromatograms using the 
Empower Pro software, plotted against the concentration), and using the LINEST 
function in Microsoft Excel. 
 
3.4.1.1.2 PRECISION 
To assess intra-day precision, a single set of standards was analysed in duplicate on the 
same day, with three replicate injections of each standard. The peak areas were 
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normalised by dividing the detected peak area by the concentration of the standard. The 
normalised data for each standard were pooled (n = 6) and the percentage coefficient of 
variance (% CV) calculated. To assess inter-day precision, three sets of standards were 
freshly prepared and analysed on three separate days. The peak areas were normalised, 
the data for each standard pooled (n = 9) and the % CV calculated.  
 
3.4.1.1.3 LIMIT OF DETECTION AND QUANTIFICATION  
The limit of detection (LOD) and limit of quantification (LOQ) were calculated using 
Equation 3.1 and Equation 3.2 for each calibration curve, where YB is the y intercept 
from the regression equation and SB the standard error of the y estimate (i.e. y intercept) 
calculated using the LINEST function in Microsoft Excel. The peak areas for the 
calibration curves prepared on three separate days were pooled to establish the LOD and 
LOQ of the method. 
 
Equation 3.1                   
Equation 3.2                      
 
3.4.1.1.4 ACCURACY AND THE INTERFERENCE OF CO-SOLUTES 
The accuracy of the assay was assessed by injecting six co-solutions onto the column. 
Each sample consisted of 1.50 mg of each drug, accurately weighed and dissolved in 50 
mL mobile phase. The detected concentration (D) of each sample was calculated from 
the standard calibration curve and expressed as a percentage of the actual concentration 
(A) (calculated based on the sample mass) using Equation 3.3 . 
 
Equation 3.3               ( ) (
 
 
)        
      
3.4.2 BLEND PREPARATION 
Drug-drug blends (1:8, 1:4, 4:1, 8:1) were prepared in 5 g batches. Blend preparation 
involved geometric mixing, where additions approximately equal in volume (i.e. 1 
spatula full) of each drug were sequentially made into a 100 mL Duran bottle.  
Following each addition the blending vessel was placed on a Whirlimixer and subjected 
 Page | 106  
 
to agitation for 60 s, followed by 60 s of stirring with a spatula to break up any large 
agglomerates. Three ceramic beads (approx. 10 mm diameter) were added to the vessel 
and the blend was tumbled using a Turbula mixer at 62 rpm for 40 min. Blends were 
stored at room temperature in a desiccator over dry silica and allowed to rest for 7 d 
prior to testing. 
 
3.4.3 BLEND HOMOGENEITY 
To assess blend homogeneity, approximately 2 mg of blend was accurately weighed and 
dissolved in mobile phase with the aid of sonication (≥ 10 min). The sample was 
visually checked for complete drug dissolution prior to being made to final volume (50 
mL) and an aliquot removed for HPLC analysis. The detected concentration (D) was 
compared to the concentration of each sample (C), calculated from the sample mass, 
and expressed as a percentage recovery (PR, %) according to Equation 3.4. The blend 
was considered homogenous when the CV of the PR values of n ≥ 6 samples was less 
than or equal to 6 %. The SX and FP content was calculated by converting the detected 
drug concentration into a drug mass, which was then expressed as a proportion of the 
weighed sample mass (in µg.mg
-1
) for each content uniformity sample.  The mean drug 
content of the samples was then used to calculate the actual SX:FP ratio in the product 
blend. 
 
Equation 3.4                       (    )  (
 
 
)         
 
3.4.4 PARTICLE SIZE ANALYSIS BY LIQUID DISPERSION LASER 
DIFFRACTION 
The particle size of the blends was measured by liquid dispersion laser diffraction (n = 
4) using the Malvern Mastersizer X as described in Chapter 2, Section 2.4.1 using 
Fraunhofer theory.  A summary of the sizing parameters used is given in Table 3.2. 
 
Table 3.2 A summary of the liquid dispersion laser diffraction parameters used to size  
combination salmeterol xinafoate (SX) and fluticasone propionate (FP) blends . 
Dispersant (% w/v) Sonication 
time (min) 
Stir Setting Sweeps Equilibration 
time (min) 
0.5 % span 80 in cyclohexane 5 3 3500 1 
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3.4.5 DISPERSIBILITY BY DRY DISPERSION LASER DIFFRACTION 
The dispersibility of the blends was assessed using the Sympatec HELOS/RODOS and 
rotary feeder with protruding aspiration tube. Particle size/primary pressure profiles 
were constructed over the PP range 0.2 – 5.0 Bar (n = 3) as described in Chapter 2 from 
which the CPP was deduced. The liquid dispersion Dv50 was used as the reference size 
to determine whether ‘complete’ dispersion of the powder or blend had occurred at the 
highest PP. The Dv50 at each PP was expressed as a proportion of the Dv50 at the highest 
PP (DH) in order to calculate the DA, and de-agglomeration profiles constructed. The 
profiles were empirically modelled to derive the DA50 and the DAmax as described in 
Chapter 2 using Equation 2.8. 
 
3.4.6 NEXT GENERATION IMPACTOR ANALYSIS  
3.4.6.1 CAPSULE FILLING 
Size 3 gelatin capsules were hand-filled with sample. The cap was removed, the base 
placed in a holder and ‘tared’ on a balance. Powdered sample was transferred into the 
capsule to obtain a fill weight of 15.00 ± 2.00 mg and the cap replaced. All capsules 
were analysed within 24 h of filling. One capsule was filled and actuated into the NGI 
per analysis.  
 
3.4.6.2 AEROSOLISATION INTO THE NEXT GENERATION IMPACTOR  
The impactor plates were first coated with 10 mL of coating solution per plate in order 
to minimise particle bounce and re-entrainment. The coating solution consisted of 11 % 
w/v PPG dissolved in hexane, prepared by accurately weighing 11.00 g of PPG into a 
100 mL volumetric flask, making to volume with hexane, and shaking thoroughly.  The 
solution was swirled in the plate to ensure complete and uniform coverage of coating 
solution on the entire surface of the plate. Excess solution was tipped out and the plates 
left to air dry in a fume hood for 10 – 15 min. The NGI was assembled with 15 mL of 
mobile phase accurately pipetted into the pre-separator. A vacuum pump was attached 
to the airflow outlet of the NGI and a flow meter attached to the throat via a tightly–
fitting mouthpiece. The flow control value was adjusted to attain a flow rate of 60 
L.min
-1
 ± 5 % (corresponding to a pressure drop of 1.4 kPa), the vacuum pump was then 
switched off and the flow meter removed. A single capsule was loaded into the 
Monodose inhaler device and the side buttons depressed so that the capsule was pierced 
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at each end by a single needle. The device was attached to the throat using an 
appropriate mouthpiece ensuring a tight seal. The vacuum pump was switched on and 
after a period of 4 s switched off corresponding to the amount of time required for 4 L 
of air to be drawn through the device and NGI. The empty capsule was removed from 
the device and set aside.  The device was carefully rinsed with mobile phase (20 – 50 
mL) to collect the drug deposited. The capsule was taken apart and both the cap and 
bottom portion were thoroughly rinsed with mobile phase (20 mL). The NGI was then 
sequentially taken apart, starting with the throat and pre-separator which were rinsed 
with 50 and 100 mL mobile phase, respectively. The four samples (device, capsules, 
throat and pre-separator) were sonicated for ≥ 5 min and visually checked to ensure 
complete drug dissolution prior to being made to final volume. A sample was removed 
from each for HPLC analysis. In order to assess drug deposition on the impactor plates, 
10 mL mobile phase was accurately pipetted into plates corresponding to stages 1 – 5 
and 5 mL pipetted into plates corresponding to stages 6 – 8. The solution was swirled in 
the plate to ensure coverage of the entire surface and each plate sonicated for ≥ 1 min. 
The solutions were visually inspected for dissolution and a sample removed for HPLC 
analysis. Following quantification of the amount of drug deposited in the device, 
capsules and component parts of the NGI, the following parameters were calculated: 
 
 Recovered dose (RD) – the total recovered dose of drug (including the device, 
capsules, throat, pre-separator and stages) expressed as a percentage of the total 
actuated dose (i.e. mass weighed into capsule), 
 Emission (or emitted dose, ED) – the recovered dose, excluding drug deposited 
in the device and capsules, expressed as a percentage of the RD, 
 Fine particle fraction (FPF) – the percentage of the RD or ED with a particle 
size < 5 µm, determined from a log normal-probability plot of the cumulative 
mass percent of drug deposited on the stages versus the stage cut sizes, 
 Fine particle mass (FPM) – the mass of deposited drug with a particle size < 5 
µm, calculated by converting the FPF (% RD) into a mass, 
 Mass median aerodynamic diameter (MMAD) and geometric standard 
deviation (GSD) – the median aerodynamic diameter (50th percentile) and 
standard deviation (ratio of the 84.1 and 15.9
th
 percentile) of the drug obtained 
from interpolation of the log normal-probability plot of the cumulative 
undersize distribution of the impactor sizing stages. 
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3.4.7 QUANTIFICATION OF DRUG RECOVERY BY HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHY  
Content uniformity and NGI samples were quantified using pooled calibration curves 
consisting of mixed SX and FP standards in the range 0.5 – 50 µg.mL-1. Each curve was 
prepared and analysed on the same day (n = 5).  The linearity, LOD and LOQ of SX 
were R
2
 = 0.9991, 0.24 µg.mL
-1
 and 0.80 µg.mL
-1





 and 0.54 µg.mL
-1
, respectively. Where individual NGI samples 
were outside this range, quantification was using pooled curves in the range 20 – 400 
µg.mL
-1
. SX had linearity, LOD and LOQ of R
2
 = 0.9982, 3.12 µg.mL
-1
 and 10.4 
µg.mL
-1
, respectively. For FP, they were R
2
 = 0.9967, 4.25 µg.mL
-1





3.4.8 INVERSE GAS CHROMATOGRAPHY  
3.4.8.1 FINITE DILUTION 
Surface energy mapping was conducted using an IGC Surface Energy Analyser (SEA). 
Approximately 200 mg of sample was packed into a 300 mm silanised glass column 
with an internal diameter of 3 mm. Columns were pre-conditioned for 2 h at 30 
o
C and 0 
% RH using helium carrier gas to remove adsorbed water. A series of non-polar 
(nonane, octane, heptane and hexane) and polar probes (ethanol, acetone, ethyl acetate, 
acetonitrile and dichloromethane) were injected onto the columns at a range of surface 
coverages. The experiments were carried out at 30 
o
C using helium carrier gas at 10 
sccm. Methane gas was used for dead volume corrections. 
 
3.4.8.2 SURFACE COVERAGE 
The surface coverage was calculated by first determining the Brunauer-Emmett-Teller 
(BET) specific surface area (SSA) of the sample using the octane isotherm data, and 
was obtained directly from the SEA. This enabled calculation of the monolayer capacity 
(nm, the number of moles of solute adsorbed for monolayer coverage) using Equation 
3.5, where am is the cross sectional area of a solute molecule and NA is the Avagadro’s 
number. The surface coverage (n/nm) at each injection concentration could then be 
calculated from the amount adsorbed (n) obtained from integration of the net retention 
volume (VN) versus the equilibrium partial pressure (p) of each injection (Ho et al., 
2010). 
 
 Page | 110  
 
Equation 3.5    SSA              
 
3.4.8.3 SURFACE ENERGY AND WORK OF ADHESION AND COHESION 
The dispersive surface energy (γD) was obtained by first measuring the VN of the alkane 
probes (nonane, octane, heptane and hexane) using the peak centre of mass approach. 
The Dorris and Gray method (Dorris and Gray, 1980) was then used, whereby a plot of 
RTln(VN) versus the carbon number of the alkanes was generated and the slope of the 
linear regression used to obtain the dispersive surface energy. The construction of a plot 
for each surface coverage enabled the surface energy distribution of the sample to be 
determined.  
 
To determine the specific surface energy (γSP), the van Oss approach (Traini et al., 
2008) and Della Volpe scale (Della Volpe and Siboni, 1997) was adopted. This 
involved injecting two monopolar probes onto the column of material, these were 
dichloromethane (γ+ 124.58 mJ.m-2) and ethyl acetate (γ- 475.67 mJ.m-2), and 
measuring the retention volume. Using the polarisation approach (Dong et al., 1989), a 
plot of RTln(VN) versus the molar deformation polarisation of the probes (PD) was 
generated from the alkane data to generate a straight line, above which the polar probe 
data points were located. The vertical distance between the polar probe data points and 
the straight line was equal to the specific component of the free energy of adsorption 
(ΔGP) (Dong et al., 1989), from which the specific surface energy (γSP) was determined.  
 
The total surface energy (γT) was determined from summing the dispersive and specific 
surface energies. The work of cohesion and adhesion was calculated from Equation 
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3.5 RESULTS 
3.5.1 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
VALIDATION 
Calibration standards containing SX and FP in co-solution in the concentration range 
0.5 - 50 µg.mL
-1
 showed good linearity, with R
2
 values of 0.9995 and 0.9993 for SX 
and FP, respectively (Figure 3.1 and Table 3.3). The intra-day precision of the standards 
indicated good reproducibility with % CV values < 4 % (Table 3.3). The inter-day 
precision was poorer than the intra-day precision, but the % CV was < 8 % for both 
drugs (Table 3.3).  The LOD and LOQ calculated from pooled data generated over three 




 for SX and 0.21 µg.mL
-1
 and 0.69 µg.mL
-1
 
for FP, respectively. The accuracy of drug recovery from co-solutions of known 
concentration was 97.05 ± 1.11 % and 98.04 ± 1.12 % for SX and FP, respectively (n = 
6).  
 





















Figure 3.1 Salmeterol xinafoate and fluticasone propionate calibration  curves 
comprising standards containing both drugs in co-solution in the concentration range 
0.5 – 50 µg.mL-1. The standards were freshly prepared on three  separate days and the 
data plotted are the individual peak areas for triplicate injections made on the three 
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Table 3.3 The intra- and inter-day precision of salmeterol xinafoate (SX) and 
fluticasone propionate (FP) calibration standards in co-solution (0.5 – 50 µg.mL-1) 
according to high performance liquid chromatography analysis. 
Precision (% CV) Drug Concentration (µg.mL
-1
) 
0.5 1.0 2.0 5.0 12.5 25 50 
Intra-day SX 1.21 2.48 0.78 0.21 0.71 0.32 0.40 
 FP 3.21 1.38 0.63 1.05 0.61 0.21 0.38 
Inter-day SX 7.75 6.80 3.53 3.35 3.00 2.85 1.21 
 FP 3.53 2.63 1.68 2.60 1.76 2.33 1.95 
 
3.5.2 BLEND HOMOGENEITY AND DRUG CONTENT 
The blend homogeneity of the drug-drug blends is shown in Table 3.4. The blend with 
the lowest SX content (i.e. SX:FP 1:8) was subjected to two 40 min tumbling sessions 
in the Turbula at 62 rpm however the CV value of SX still remained high at 5.51 %. 
Overall FP displayed optimal homogeneity at high FP concentrations. Although the 
homogeneity of the blends in some instances was poor it was deemed appropriate for 
the study. 
 
Table 3.4 The blend homogeneity expressed as the coefficient of variance (% CV) and 
drug content (µg.mg
-1
) of salmeterol xinafoate (SX) and fluticasone propionate (FP)  
co-formulated in fine particle blends. 
 Homogeneity (% CV) Drug Content (µg.mg
-1
) Detected Ratio 
SX:FP Ratio SX FP SX FP  
1:8 5.51 1.37 92.6  836.0  1.0:9.0 
1:4 2.15 0.84 183.9 750.8 1.0:4.1 
4:1 3.98 5.28 750.1 178.5 4.2:1.0 
8:1 4.31  5.61 875.0 92.8 9.4:1.0 
 
3.5.3 PARTICLE SIZE ANALYSIS BY LIQUID DISPERSION LASER 
DIFFRACTION 
Table 3.5 shows the PSD of the blends measured by liquid dispersion laser diffraction. 
The measured particle size was comparable between the blends indicating that the 
particles were physically mixed and thus could be re-dispersed in a liquid medium. 
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Table 3.5 The particle size distribution (represented by the D v10, Dv50, Dv90, and 
volume mean diameter, VMD) and span of salmeterol xinafoate (SX) and f luticasone 
propionate (FP) combination fine particle blends assessed by liquid dispersion laser 
diffraction (mean ± SD, n = 4). 
SX:FP Ratio Dv10 Dv50 Dv90 VMD Span 
1:8 0.94 ± 0.02 2.00 ± 0.06 3.85 ± 0.19 2.24 ± 0.09 1.46 
1:4 0.95 ± 0.04 2.03 ± 0.12 3.79 ± 0.20 2.23 ± 0.13 1.40 
4:1 0.80 ± 0.02 2.12 ± 0.06 4.45 ± 0.15 2.44 ± 0.08 1.72 
8:1 0.77 ± 0.01 2.06 ± 0.08 4.52 ± 0.25 2.56 ± 0.27 1.82 
 
3.5.4  DISPERSIBILITY BY DRY DISPERSION LASER DIFFRACTION 
The particle size-primary pressure profiles of the blends exhibited the characteristic 
reduction in measured size until a plateau size was reached. The Dv50 at the highest 
primary pressure employed was smaller compared to that measured by liquid dispersion 
(Table 3.5); the fully dispersed Dv50 in the dry state was 1.63 ± 0.01 µm, 1.52 ± 0.03 
µm, 1.55 ± 0.01 µm and 1.66 ± 0.01 µm for the 1:8, 1:4, 4:1 and 8:1 blends, 
respectively. Table 3.6 shows the de-agglomeration parameters for the blends. The DA50 
values suggested that the dispersibility of the blend improved when FP was present, 
compared to SX alone. However, when the amount of FP was greater than the amount 
of SX in a combination blend, the DA50 increased beyond that of SX alone indicating 
poorer dispersibility. For FP, the converse was true, where a small amount of SX 
worsened the dispersibiliy of the blend compared to FP alone. However, when the 
amount of SX exceeded the amount of FP, dispersibility improved beyond that of FP 
alone. When considering only the combination blends, as the amount of FP in the blend 
increased, the bulk dispersibility of the powder became worse (i.e. higher DA50 values). 
 
The CPP values indicated that FP was more cohesive than SX. In combination, the 
cohesivity of the blend reduced at every SX:FP ratio compared to FP alone, but there 
were only small/no differences compared to SX alone. Although there was no precise 
trend, generally the FP-rich blends were more cohesive (i.e. CPP = 1.20 – 1.70 Bar) 
than the SX-rich blends (CPP = 1.0 – 1.20 Bar). There were also differences in the 
relative magnitude of the DA50 and CPP values, which indicated differences in bulk 
powder structure. Although a lower DA50 is indicative of a powder that disperses well, 
due to proportions of weakly associated agglomerates, if the powder also had a high 
CPP value then there would also be populations of particles within the bulk that 
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exhibited very strong agglomeration. There would therefore be high heterogeniety in 
agglomerate strengths, as was the case for the FP powder when compared to the SX 
powder. In the combination blends, generally as the amount of FP in the blend 
increased, the heterogeniety in agglomerate strengths reduced. 
 
Table 3.6 The primary pressure for 50 % de-agglomeration (DA50), maximum degree 
of de-agglomeration (DAmax) and critical primary pressure (CPP) of salmeterol 
xinafoate (SX) and fluticasone propionate (FP) co-formulated in fine particle blends. 
The values were derived from de-agglomeration data obtained by dry dispersion laser  
diffraction using the mean Dv50 values. 
SX:FP Ratio R
2
 DA50 (Bar) DAmax CPP (Bar) 
0.0:1.0 0.9832 0.48 1.04 4.00 
1.0:9.0 0.9890 0.89 1.13 1.20 
1.0:4.1 0.9906 0.57 1.17 1.70 
4.2:1.0 0.9980 0.30 1.08 1.00 
9.4:1.0 0.9981 0.20 1.02 1.20 
1.0:0.0 0.9968 0.36 1.10 1.20 
 
3.5.5 NEXT GENERATION IMPACTOR ANALYSIS 
Figure 3.2, Figure 3.3 and Table 3.7 show the NGI analysis of SX:FP blends with 
various drug ratios. Considering the aerosolisation of SX, when blended with FP, there 
was an increase in the MMAD (p < 0.05, one-way ANOVA with post-hoc Tukey’s test, 
GraphPad Prism 5), but no change in the GSD at all drug ratios. The MMAD 
progressively increased as the amount of FP in the blend increased. This could indicate 
the presence of SX agglomerates that were more difficult to disperse; interactions 
between SX and FP may have led to the formation of mixed agglomerates in which the 
presence of FP was detrimental to the dispersibility of SX from agglomerates. The FPF 
(ED and RD) of SX reduced by almost half when blended with the largest quantity of 
FP (i.e. 1.0:9.0, p < 0.05). For example, the FPF ED was 54.2 ± 5.28 % for SX alone 
compared to 25.5 ± 10.1 % when in combination with FP in the ratio 1.0:9.0. 
Comparing between the ratios, the FPF (ED and RD) from the 1.0:9.0 blend was also 
lower when compared to the 1.0:4.1, 4.2:1.0 and 9.4:1.0 blends (p < 0.05). Overall, SX 
emission was unchanged across the ratios (p > 0.05), except for an increase in SX 
emission when blended in the ratio 1.0:4.1 (p < 0.05) compared to SX alone. 
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Considering the aerosolisation of FP when blended with SX, different trends were 
observed compared to those seen for SX following co-formulation. The MMAD of FP 
reduced in the presence of SX at all SX:FP ratios (p < 0.05), and there was no change in 
the GSD (Table 3.7). This indicates that the presence of SX may have weakened FP 
agglomerates rendering them more readily dispersed compared to those of FP alone. 
Overall, however, there was no change in the FPF RD or ED of FP when blended with 
SX compared to FP aerosolised alone (p > 0.05, Figure 3.3). There were differences 
between the drug ratios; the FPF ED of FP was lower when aerosolised from the 1.0:9.0 
ratio compared to the 1.0:4.1 ratio (p < 0.05), and the FPF RD was lower from the 
1.0:9.0 ratio compared to the 1.0:4.1 and 4.2:1.0 ratio. This suggests that the relative 
amount of SX present in a co-formulation may affect FP dispersion, with higher FPFs 
being generated in the presence of larger amounts of SX. In terms of the emission, 
larger amounts of SX resulted in lower FP emission compared to smaller amounts of SX 
when in combination (i.e. 9.4:1.0 vs. 1.0:4.1 and 1.0:9.0, 4.2:1.0 vs. 1.0:4.1, p < 0.05). 
 
Table 3.7 The recovery (% of the actuated dose), mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD) of salmeterol xinafoate (SX) and 
fluticasone propionate (FP) aerosolised at different SX:FP ratios into the Next 
Generation Impactor (mean ± SD, n = 4 - 6). 
SX:FP Ratio Recovery (%) MMAD (µm) GSD 
Salmeterol xinafoate 
1.0:0.0 82.6 ± 5.46 2.45 ± 0.12 1.92 ± 0.04 
9.4:1.0 95.4 ± 5.70 2.88 ± 0.07 1.86 ± 0.01 
4.2:1.0 91.0 ± 4.52 3.13 ± 0.24 1.85 ± 0.03 
1.0:4.1 106 ± 2.92 3.63 ± 0.30 1.77 ± 0.05 
1.0:9.0 106 ± 5.99 3.89 ± 0.15 1.84 ± 0.06 
Fluticasone propionate 
0.0:1.0 81.9 ± 6.76 4.52 ± 0.14 2.09 ± 0.09 
1.0:9.0 94.6 ± 1.85 3.75 ± 0.08 1.80 ± 0.05 
1.0:4.1 109 ± 9.97 3.87 ± 0.30 1.72 ± 0.05 
4.2:1.0 93.5 ± 12.7 3.77 ± 0.24 1.73 ± 0.03 
9.0:1.0 104 ± 10.5 3.80 ± 0.27 1.95 ± 0.07 
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Figure 3.2 The fine particle fraction (FPF < 5 μm, expressed as a percentage of the  
emitted dose, ED, and recovered dose, RD) and emission (% RD) of salmeterol 
xinafoate (SX) when blended in combination with fluticasone propionate (FP) at 
different SX:FP ratios assessed by Next Generation Impactor analysis (mean ± SD, n = 
4 - 6); * = p < 0.05 for single drug vs. combination blends using a one-way ANOVA 
with post-hoc Tukey’s test. 
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Figure 3.3 The fine particle fraction (FPF < 5 μm, expressed as a percentage of the  
emitted dose, ED, and recovered dose, RD) and emission (% RD) of fluticasone 
propionate (FP) when blended with salmeterol xinafoate (SX) at different SX:FP 
ratios assessed by Next Generation Impactor analysis (mean ± SD, n = 4 - 6); * = p < 
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3.5.6  INVERSE GAS CHROMATOGRAPHY 
3.5.6.1 WORK OF COHESION AND ADHESION FROM INFINITE DILUTION 
In Chapter 2, the gross retention times of the probes (tR) were obtained from IGC 
analysis at infinite dilution and used to calculate the net retention volume (VN) and 
dispersive surface energy (γD) of both SX (36.23 ± 0.14 mJ.m
-2
) and FP (49.92 ± 0.08 
mJ.m
-2
). Using Equation 2.11, these values were used to calculate the work of cohesion 
and adhesion, shown in Table 3.8. FP was found to be more cohesive than SX. SX-FP 
interactions were stronger that SX-SX interactions and weaker than FP-FP interactions. 
 
Table 3.8 The work of cohesion and work of adhesion of salmeterol xinafoate (SX) 
and fluticasone propionate (FP) from inverse gas chromatography at infinite dilution 
(mean ± SD, triplicate injections of the probes were made onto a single column). 
 Salmeterol xinafoate Fluticasone propionate 
Work of Cohesion (mJ.m
-2
) 72.45 ± 0.29 99.85 ± 0.16 
Work of Adhesion (mJ.m
-2
) 85.05 ± 0.23 
 
3.5.6.2 SURFACE ENERGY AND WORK OF COHESION/ADHESION FROM 
FINITE DILUTION 
Finite dilution IGC enabled surface energy heterogeneity maps to be constructed, and 
confirmed that FP had higher surface energy than SX (Figure 3.4). The results indicated 
that dispersive interactions formed the major contribution towards the total surface 
energy of both powders. Surface energy mapping further revealed that FP had much 
higher surface energy heterogeneity compared to SX. For example, the dispersive 
surface energy ranged from 40.18 to 48.33 mJ.m
-2 
for FP compared to 36.9 to 38.5 
mJ.m
-2
 for SX. The surface energy values were lower compared to those generated from 
infinite dilution, particularly for FP. This difference is likely to arise from the 
overestimation of surface energy using the latter method due to low solute 
concentrations probing only the most energetic surface sites (Ylä-Mäihäniemi et al., 
2008). The total surface energy was calculated by summing the dispersive and specific 
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Figure 3.4 The dispersive, specific and total surface energy distributions of salmeterol xinafoate (SX) and fluticasone propionate (FP) assessed by 
finite dilution inverse gas chromatography.   
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The work of cohesion, determined from the total surface energy, also showed 
heterogeneity for both drugs ranging from 87.66 – 109.43 mJ.m-2 for FP and 78.74 – 
83.83 mJ.m
-2 
for SX (Figure 3.5). The work of adhesion between SX and FP was larger 
than the work of cohesion of SX but smaller than the work of cohesion of FP. The work 
of cohesion or adhesion was calculated according to Equation 2.11 by matching the 
surface energy at equivalent surface coverages. However, due to the random orientation 
of particles within a bulk powder, situations may arise where for example an FP surface 
with high surface energy is adjacent to an FP surface with low surface energy. There 
will therefore be a complex distribution in the magnitude of interactive forces within the 
bulk, bracketed by the largest and smallest interactive forces shown in Figure 3.5 arising 
from interactions between the most energetic and least energetic surfaces on the 
particles. This will result in a complex blend structure and heterogeneity in agglomerate 
properties. 
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Figure 3.5 The work of cohesion and work of adhesion of salmeterol xinafoate (SX) 
and fluticasone propionate (FP) determined from the total surface energy distributions 
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3.6 DISCUSSION AND CONCLUSIONS 
Combination DPIs can contain up to four distinct particulate powders; two drugs, a 
coarse carrier and a fine/ternary agent. Inter-particulate interactions govern the 
efficiency of drug aerosolisation from such formulations and it is clear that a number of 
interactions are possible. It is well established that fine particles can improve the 
aerosolisation of a drug in the presence of carrier. This improvement is postulated to 
arise through the ‘active sites’ and/or ‘agglomerates’ mechanisms, both of which 
involve carrier particles (Shur et al., 2008). According to the ‘agglomerates’ 
mechanism, the drug and fines form mixed agglomerates which associate with the 
carrier. Fine particles however have the potential to alter the aerosolisation of drugs in 
the absence of carrier. For example, mixed SX and fine lactose agglomerates have been 
observed in carrier-free blends by SEM which exhibited reduced agglomerate strength 
compared to SX agglomerates (Adi et al., 2008a). In the current study, the ability of fine 
particles to alter the aerosolisation of the inhaled drugs SX and FP was investigated; 
these drugs are found in commercial combination DPIs and have demonstrated different 
deposition patterns compared to single-drug DPIs (Taki et al., 2011). In order to probe 
the origin of the altered deposition patterns, a systematic approach was taken to 
investigate the agglomerate behaviour of the drugs in the absence of a carrier to 
ascertain the performance modifying capabilities and any changes in dispersibility that 
might arise due to interactions between the drug particles. The implications of these 
interactions on the performance of DPI blends will be studied in a later chapter. 
 
3.6.1 DISPERSION BEHAVIOUR OF SALMETEROL XINAFOATE AND 
FLUTICASONE PROPIONATE 
An awareness of the dispersion modifying effects of drugs in combination formulations 
is important in order to optimise drug delivery. SX and FP have been found to have 
contrasting effects on each other’s aerosolisation when formulated in combination (Taki 
et al., 2011). Interactions between SX and FP particles have been proposed (Michael et 
al., 2000; Michael et al., 2001; Taki et al., 2011) and the formation and deposition of the 
drugs as mixed agglomerates in the NGI has been suggested (Theophilus et al., 2006; 
Vernall et al, 2012). Comparing the aerosolisation of each drug separately, SX was 
found to have a lower emission (61.7 ± 4.65 % RD) than FP (73.3 ± 3.05 % RD). This 
may arise from high levels of adhesion between SX and the device and capsule walls 
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(Podczeck et al., 1996; Adi et al., 2008a). The FPF (% RD) of the drugs was 
comparable (33.4 ± 4.19 and 26.2 ± 2.17 %, respectively) however the FPF (% ED) of 
SX was much higher (54.2 ± 5.28 %) than FP (35.9 ± 3.17 %) indicating a greater de-
agglomeration efficiency for SX. Less cohesive SX-SX agglomerates were therefore 
less well entrained but de-agglomerated in the turbulent airflow more readily than the 
more cohesive FP-FP agglomerates when the drugs were aerosolised into the NGI. The 
higher cohesivity and poorer dispersibility of FP compared to SX was supported by 
dispersibility assessment by dry dispersion laser diffraction. The CPP (4.0 Bar and 1.20 
Bar, respectively) and DA50 values (0.48 Bar and 0.36 Bar, respectively) were both 
higher for FP than SX. The magnitude of the difference in these parameters was also 
larger for FP, indicating that although there was a proportion of FP agglomerates that 
dispersed readily (i.e. at 0.48 Bar for dispersion of 50 % of the bulk powder), there was 
also a proportion of very poorly dispersible agglomerates which required a much higher 
dispersing pressure for agglomerate break-up (i.e. 4.0 Bar). FP therefore had greater 
heterogeneity in agglomerate strengths within the bulk compared to SX, and this was 
further supported by the surface energy measurements from IGC. FP had higher surface 
energy and a higher work of cohesion than SX, and also showed higher surface energy 
heterogeneity across the particle surface as observed in the surface energy distributions. 
 
The aerosolisation characteristics of SX and FP, in terms of their emission and FPF 
when aerosolised into the NGI may also be explained by their agglomerate sizes and the 
formation of metastable agglomerates, determined by their cohesivity. Micronised FP 
has previously demonstrated a high emission but low FPF when aerosolised alone into 
an impactor (Louey et al., 2004b). It was proposed that highly cohesive FP particles 
formed large agglomerates, which owing to their size provided good flow and 
entrainment properties, but poorer de-agglomeration (Louey et al., 2004b). It is also 
important to consider the powder emission process from a Monodose inhaler which is 
highly complex. Upon the introduction of an airflow through the device, the capsule 
begins to rotate. Powder within the capsule is then entrained and exits the holes at either 
end of the capsule, however, it may also undergo a degree of de-agglomeration as a 
result of mechanical impaction as the capsule rattles, and due to the complex airflows 
that arise. The mass of powder exiting the device therefore depends both on a 
combination of how well the powder entrains and de-agglomerates (Coates et al., 2005; 
Zhou et al., 2010a). 
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The distribution of agglomerates of different sizes and strengths comprising the powder 
structure will also be different between the powders. The theoretical tensile strength of 
an agglomerate is directly proportional to its work of cohesion, inversely proportional to 
its particle size, and is also related to the packing fraction and structure of the 
agglomerate (Kendall and Stainton, 2001). Begat et al. (2004b) describe a situation in 
which during dispersion the intra-agglomerate forces are equal to the forces available 
for agglomerate dispersion, resulting in metastable agglomerates; these metastable 
agglomerates will not disperse under the specific set of de-agglomeration conditions and 
will remain agglomerated in the airstream. The higher heterogeneity in the work of 
cohesion of FP would lead to the formation of a wider range of agglomerate 
sizes/strengths compared to SX, and therefore a higher propensity for metastable 
agglomerate formation. These agglomerates would deposit on stages of the NGI 
corresponding to larger aerodynamic particle sizes compared to individual FP particles, 
and may have contributed towards the lower FPF of FP. The greater heterogeneity in 
agglomerate strengths for FP was also apparent from dry dispersion laser diffraction 
analysis. The large difference between the DA50 and CPP parameters indicated that for 
complete dispersion of FP to individual particles high dispersal forces are required; if 
these high dispersal forces are not available then there will remain populations of tightly 
associated FP agglomerates in the airstream which would not disperse and therefore 
would deposit on the higher stages of the NGI. 
 
3.6.2 DISPERSION MODIFICATION IN CO-FORMULATED POWDER 
BLENDS 
In drug-only fine particle combination blends, the aerosolisation of SX became poorer 
in the presence of FP. The MMAD showed a gradual increase from 2.45 ± 0.12 µm for 
SX alone to 3.89 ± 0.15 µm in the presence of the largest amount of FP. The emission 
and FPF (% RD) were unchanged compared to SX alone except for when FP was 
incorporated in the highest ratio, whereupon the FPF RD and ED was reduced (p < 
0.05) and the emission was higher, although not significantly, compared to SX alone. 
This was an important finding considering that commercial DPI formulations contain a 
small amount of SX (50 µg) and a larger amount of FP (100 – 500 µg). A comparison of 
single-active versus combination DPI inhalers also reported significantly altered 
deposition profiles for SX in the presence of FP, where the presence of FP caused a 
reduction in the FPD in the deeper stages of the NGI (Taki et al., 2011).  It was 
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postulated by the authors that increasing FP concentration might be a factor in reducing 
the FPD. However, due to the presence of a carrier and the maintenance of a constant 
SX content whilst the FP content per 12.5 mg powder dose increased, it was not 
possible to deduce whether increasing FP content, reduced lactose content, or increased 
FP-to-lactose ratio were responsible for the changes observed. The results in the current 
study suggest that SX dispersion can be modified by FP only at high FP concentrations, 
at which point de-agglomeration efficiency becomes worse. These findings may not 
however be directly translatable to SX dispersion upon co-formulation in carrier-based 
DPI blends, and therefore would require the preparation and testing of co-formulated 
SX and FP in the presence of a carrier in order to confirm these effects on aerosolisation 
behaviour. 
 
Considering FP, the alteration in aerosolisation was different compared to SX, when 
blended in combination. The MMAD of FP reduced (p < 0.05) from 4.52 ± 0.14 µm for 
FP alone to 3.75 ± 0.08 µm – 3.87 ± 0.30 µm in the presence of SX.  The reduction in 
MMAD of FP was independent of the amount of SX in the blend. This suggested that 
there was weaker agglomeration of FP in the presence of SX, however, there was no 
change (p > 0.05) in the FPF (% RD) or FPF (% ED) of FP from the drug combinations 
compared to micronised FP alone, and there was a trend towards lower emission in 
higher SX content blends, significant only at the SX:FP ratio 9.4:1.0 compared to FP 
alone. Higher FPFs have been reported for FP in combination compared to single-active 
DPI products, where it was suggested that SX might have a small but significantly 
positive performance modifying effect on FP (Taki et al., 2011). However, once more in 
the latter study it was not possible to further determine whether this was due to SX 
content, the grade and/or content of coarse and fine lactose, or SX-FP agglomerates that 
had different dispersibility compared to FP-FP or FP-FL agglomerates between the 
single drug and combination inhaler products. It is also possible that all these factors 
may have contributed to the overall net improvement in the deposition of FP. 
Nevertheless, the results suggest that SX and FP particles may interact in combination, 
as the aerosolisation profiles of each drug were modified compared to those obtained 
after the aersolisation of each drug alone. Such a finding has also been reported for 
salbutamol sulphate (SS) and beclometasone dipropionate (BDP) when blended in 
combination in the absence of carrier (Jetmalani et al., 2012). These drugs were both 
predominantly adhesive, undergoing a physical interaction which resulted in lower 
aerosolisation efficiency (i.e. emission) for both drugs and lower FPF for BDP only 
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compared to drug alone. When comparing the FPF of SS and BDP between different 
drug ratios there was no significant change, indicating that the presence of a second 
drug, but not the quantity of that second drug, altered aerosol performance in this 
instance (Jetmalani et al., 2012).  
 
In the current work, the presence of a second drug resulted in significant differences in 
the FPF of SX and the emission of FP in an SX-rich blend, when compared to the 
aerosol performance of the drug on its own. IGC analysis revealed that FP-FP 
interactions were the strongest, followed by SX-FP and SX-SX interactions (Figure 
3.5). This explained the poorer homogeneity of SX in FP-rich compared to SX-rich 
blends (Table 3.4), due to poor SX interaction with FP leading to inadequate mixing. 
Therefore, in an FP-rich blend, FP-FP forces would dominate but in an SX-rich blend 
SX-FP forces would dominate.  When cohesive FP forces dominate, the aerosolisation 
of FP would be unchanged in the presence of a small amount of SX due to little 
interaction between SX and FP particles; the excess amount of FP and strong FP-FP 
interactions would result in FP aerosolisation that was generally unchanged compared to 
that of FP alone. Any interactions between SX and FP which may arise for example due 
to the energy input during blending and the adhesive tendency of SX, would result in 
the formation of mixed agglomerates that were more tightly associated than SX-SX 
agglomerates but more weakly associated than FP-FP agglomerates. It is therefore not 
unexpected that the de-agglomeration efficiency of SX was generally reduced in the 
presence of FP whereas FP was unaffected due to more strongly and more weakly 
associated mixed agglomerates, if present, compared to the cohesive drug agglomerates 
of each powder, respectively.  
 
Conversely, in SX-rich blends, a dominance of SX-FP interactions due to the adhesive 
tendency of SX would aid in the disruption of cohesive FP agglomerates. Although 
when in combination with SX, FP exhibited a smaller MMAD regardless of the amount 
of SX in the blend, this was insufficient to improve the emission or FPF. Any SX-FP 
agglomerates that formed would be weaker than FP-FP agglomerates and therefore be 
expected to entrain and disperse more readily. The fact that the FPF did not improve, 
and the emission was lower, was therefore unusual. This may have arisen from FP 
becoming ‘trapped’ in SX agglomerates which were retained in the device and/or 
capsules prior to agglomerate dispersion due to high SX adhesivity towards these 
surfaces. FP deposition in the device and capsules was observed to increase from 25.1 ± 
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2.35 % RD to 35.9 ± 3.22 % RD between the 1.0:9.0 and 9.4:1.0 SX:FP ratios, 
respectively. Alternatively, greater FP dispersion to individual particles due to weaker 
FP agglomeration may have increased FP retention in the device and capsules; 
individual FP particles, due to their smaller particle size and larger surface area, would 
be more likely to remain in the device/capsule compared to larger FP agglomerates 
which would exhibit better flow and entrainability. It is also necessary to consider the 
heterogeneity in the work of cohesion and adhesion, particularly for FP. For example, 
SX may have only been able to interact with the less cohesive FP particles within the 
bulk to form mixed agglomerates. There may have remained proportions of FP particles 
that were agglomerated by very cohesive interactions and thus their dispersion was not 
altered by the presence of SX, and these particles may have dictated the dispersion 
behaviour of FP, particularly in terms of the FPF, from the blends. For SX in an SX-rich 
blend, SX-FP forces would dominate and support the formation of mixed SX-FP 
agglomerates, however, due to the smaller amount of FP in the blend relative to SX, the 
proportion of these would be low such that the dispersion of SX was affected to a lesser 
extent in the presence of a small amount of FP compared to a large amount of FP. 
 
The particle size-primary pressure profiles of the blends retained the distinctive shape 
seen for the micronised powders in Chapter 2. The particle size measured at the highest 
dispersing pressure in the dry state (Dv50 = 2.00 ± 0.06 µm, 2.03 ± 0.12 µm, 2.12 ± 0.06 
µm, 2.06 ± 0.08 µm) was comparable with the liquid dispersion size, however, the dry 
dispersed Dv50 was always smaller (1.63 ± 0.01 µm, 1.52 ± 0.03 µm, 1.55 ± 0.01 µm 
and 1.66 ± 0.01 µm for the 1:8, 1:4, 4:1 and 8:1 ratios, respectively; p < 0.05, unpaired 
t-test). Differences may arise due to the use of different dispersing media, different laser 
diffractometers, incomplete dispersion in liquid media or particle attrition at high 
dispersing pressures in the air stream. Following empirical data modelling, the linearity 
of the data was good (R
2
 > 0.98). The DA50, a measure of the ease of dispersion, 
indicated that as the amount of FP in the co-formulated blend increased, the 
dispersibility of the blend became worse. The CPP (i.e. cohesivity) of the FP-rich 
blends was also higher (1.20 – 1.70 Bar) than the SX-rich blends (1.00 – 1.20 Bar). FP 
was more cohesive than SX (CPP 4.00 Bar and 1.20 Bar, respectively), therefore in the 
presence of SX the cohesivity of the blend reduced compared to FP alone, and 
suggested modifications in particulate interactions and agglomerate break-up within the 
blend. This may explain the smaller MMAD obtained for FP when in combination with 
 Page | 126  
 
SX (regardless of the amount of SX) and the increasing MMAD of SX in the more 
cohesive, FP-rich blends. 
 
Compared to both SX alone and FP alone, the bulk dispersibility of the blend improved 
in SX-rich blends, and became worse in FP-rich blends. This showed some agreement 
with the aerosol characteristics of the drugs when aerosolised in the NGI. For SX, the 
lowest FPF and largest MMAD were obtained in the highest FP-content blend when 
comparing SX aerosolisation between single drug and co-delivery, and between the 
ratios. Conversely for FP, although the MMAD was lower, the FPF across the ratios 
was unchanged compared to single drug delivery and the emission worsened in the 
highest SX content blend. This method could therefore be used as a pre-formulation 
screening tool to assess the influence of fine particles on bulk blend aerosolisability. 
Although this information does not in isolation allow the aerosolisation behaviour of the 
drugs to be predicted following cascade impaction, it will help guide the formulation 
and device characteristics that may be required to optimise aerosolisation. Further 
development of the method to discriminate between the different de-agglomeration 
behaviours of individual powders within mixtures could further strengthen the method 
for use in dispersibility screening. 
 
3.6.3 CONCLUSIONS 
In conclusion, the study completed in this chapter has demonstrated that the 
dispersibility of SX and FP drug particles was modified by the presence of a second fine 
drug particle in the absence of a carrier. The fine particles investigated are components 
of combination dry powder inhaler formulations, and therefore determining their 
influence on drug aerosolisation might assist optimal formulation design. FP had a 
lower MMAD in the presence of SX regardless of SX concentration however the FPF 
was generally unchanged but the emission reduced in high SX content blends. The 
aerosolisation of SX was poorest at high FP concentrations, where the FPF reduced, and 
the MMAD sequentially increased as the amount of FP in the blend increased. Dry 
dispersion laser diffraction de-agglomeration analysis was able to detect differences in 
the bulk dispersibility/de-agglomeration of the blends, but differences in the dispersion 
mechanisms (i.e. those attained in the feeding/dispersing line of the Sympatec versus 
those imparted by the device/capsule after aerosolisation for impactor analysis) resulted 
in some discrepancies between the trends seen in the laser diffractometer and impactor. 
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The different adhesive and cohesive tendencies of the drugs were able to explain the 
changes in agglomeration that in turn affected the overall aerosolisation behaviour. This 
work has indicated that SX and FP particles have the potential to interact resulting in a 
range of agglomerate populations with different dispersibilities. The implications of 
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4.1  INTRODUCTION 
Micron-sized particles for delivery to the lungs can be produced using a number of 
different methods. Crystallisation is the most common process employed, however, 
drug particles are rarely crystallised directly to the required or optimum particle size. 
Therefore, a comminution step such as micronisation/milling is required (Ward and 
Schultz, 1995). Traditionally particles are placed in a fluid-energy, often an air jet mill, 
and undergo comminution as a result of mechanical fracture from particle collisions at 
high speeds (Malcolmson and Embleton, 1998). There is, however, poor control over 
the physicochemical properties of the particles, including the particle size and size 
distribution, shape, morphology, electrostatic charge and surface properties (Steckel et 
al., 2003b; Steckel et al., 2006; Perkins et al., 2009). The high energy input and 
mechanical stress that particles experience can introduce disorder onto surfaces as a 
result of disruptions to the crystal structure beyond that of an occasional molecular 
dislocation, such as extensive crystal fracture and lattice rearrangement (Ward and 
Schultz, 1995). This can result in the conversion of crystalline surfaces into partially 
amorphous surfaces (Brodka-Pfeiffer et al., 2003b; Steckel et al., 2003b; Gaisford et al., 
2010). Thermodynamically, amorphous regions are at a higher energy state and 
metastable, and in time may revert back to their crystalline form (Ward and Schultz, 
1995). The amorphisation of micronised particles can lead to the creation of more 
energetic surfaces possessing higher surface energy (Perkins et al., 2009; Das and 
Stewart, 2012; Gamble et al., 2012), which can increase inter-particulate attractive 
forces resulting in greater adhesion and cohesion to other materials (Cline and Dalby, 
2002; Perkins et al., 2009). 
 
The process induced changes resulting from the micronisation process can lead to batch-
to-batch variability between powders in terms of their surface energy (Ticehurst et al., 
1994; Feeley et al., 1998), flow (Feeley et al., 1998), cohesive properties/agglomeration 
(Kubavat et al., 2012; Le et al., 2012b) and physical stability (Ward and Schultz, 1995). 
This has important implications in the performance characteristics of inhaled drugs, 
where the cohesive-adhesive balance of the formulation is a major determinant of the 
efficiency at which a drug is delivered from a DPI and deposits in the lungs. For 
example, FP has demonstrated a shift from an initial cohesive FP-FP led system to a 
more adhesive FP-SX led system with increasing numbers of milling cycles (Kubavat et 
al., 2012). Furthermore, intra-batch variability may also arise. Differing levels of 
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processing stress experienced across various sites within a bulk powder may lead to 
micro-areas of powder which possess different properties (Marek et al., 2011). This may 
manifest as altered flowability and aerosol dispersion/de-agglomeration behaviour 
(Marek et al., 2011; Das et al., 2012) and have implications following formulation. In 
Chapter 3, it was observed that the aerosolisation behaviour of salmeterol xinafoate 
(SX) and fluticasone propionate (FP) powders altered following co-formulation in the 
absence of a carrier, and there were changes in powder structure. These effects may 
have been specific to the batches of powder tested, and the specific powder micro-
structures arising from intra-batch variability in powder properties within the bulk 
powder. There is therefore merit in attempting to characterise bulk micronised powders 
for their variability in particle, agglomeration and dispersion properties. 
 
Particle engineering approaches have been developed as alternatives to micronisation. 
The direct crystallisation of particles to the appropriate size can be achieved by anti-
solvent precipitation from conventional or supercritical fluids. This has the potential to 
overcome problems associated with the introduction of amorphous content whilst 
allowing for a degree of control in surface solid state (Murnane et al., 2008a). By 
controlling the experimental parameters, specifically the stirring speed and addition rate 
of the anti-solvent, it was possible to produce particles with a size suitable for inhalation 
(Murnane et al., 2008a; Murnane et al., 2008b). Furthermore, both SX and FP were 
found to crystallise into their most stable polymorphic form and display either similar, 
in the case of FP (Murnane et al., 2008b), or higher (for SX) crystalline content 
(Murnane et al., 2008d) than micronised material. Particles which are directly 
crystallised to their required particle size have exhibited lower surface energy than 
particles which are micronised after crystallisation (e.g. Rehman et al., 2003; Shekunov 
et al., 2003) and have displayed more favourable aerosolisation, for example higher 
FPFs following cascade impaction (e.g. Steckel et al., 2003a; Steckel et al., 2003b).  
 
Although particle engineering technologies enable particle production in the micron-
size range, there remains an inability to control the aerodynamic particle size. It is the 
aerodynamic size which is generally accepted as a key parameter in determining lung 
deposition (Usmani et al., 2005), and takes into consideration the geometric size, shape 
and density of the particle (De Boer et al., 2002a). Impactors such as the NGI 
fractionate aerosolised particles on the basis of aerodynamic particle size. They are 
typically used for the assessment of inhaler performance; however, the NGI has recently 
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been used to isolate SX, FP and fine lactose particles with a controlled aerodynamic 
particle size (Taki et al., 2011b). Powder depositing on stages 1 to 6 demonstrated 
sequentially smaller aerodynamic diameters, along with a statistically significant linear 
relationship with the geometric particle size of each fraction. The deposits also showed 
lower span values compared to the unfractionated powder, indicating a reduction in the 
polydispersity of the deposited powder (Taki et al., 2011b). The technique has therefore 
been proposed as a useful research tool to investigate drug-drug interactions because 
operation of the impactor is not affected by powder physicochemical properties. Hence, 
differences in the performance of aerosols of fractionated powders may be attributed to 
differences in the physicochemical properties or processing of particles within the bulk 
powder rather than the aerodynamic particle size (Taki et al., 2011b).  
 
4.2 AIM AND OBJECTIVES 
The aim of this study was to isolate SX and FP fractions of known aerodynamic particle 
size from the bulk starting powder, and then characterise the particles within each 
fraction with regard to their physicochemical properties and dispersibility. The 
objectives were to: 
a) Determine the geometric particle size of commercial micronised SX and FP 
powders. 
b) Crystallise SX and FP with a view to generating powders of equivalent size but with 
altered solid state properties compared to the micronised powders.  
c) Fractionate the commercial micronised SX and FP powders to isolate fractions with 
different aerodynamic particle sizes. 
d) Characterise unfractionated, fractionated and recrystallised SX and FP powders so 
as to determine the following: 
a. Geometric particle size, 
b. Morphology, 
c. Crystalline/amorphous content, 
d. Surface energy distribution, 
e. Dispersibility. 
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4.3 MATERIALS 
The materials and equipment used in Chapter 4, not listed in Section 2.3 and 3.3, are 
shown in Table 4.1. 
 
Table 4.1 Suppliers of materials and equipment (Chapter 4).  
Material / Equipment Supplier 
Fluticasone propionate (FP); BN. 5501-B-
11030 
LGM Pharma, USA  
Polypropylene glycol 400 (PEG400) Sigma Aldrich Ltd, UK 
Malvern QSpec dry powder feeder (DPF) Malvern Instruments Ltd, UK 
High shear mixer (Model L4RT laboratory 
homogeniser) 
Silverson Machines, USA 




 (now part of GE Healthcare, 
supplied by Fisher Scientific Ltd, UK) 
Heidolph overhead stirrer (RZR 2051 2051) Heidolph, UK 
Brucker D8 Advance X-ray diffractometer 
system 
Brucker AXS Ltd, USA 
Q Series differential scanning calorimeter; 
Q20-5023 for SX samples, Q200-1934 for FP 
samples 
TA Instruments, UK 
Aluminum DSC pans and lids TA Instruments, UK 
Hermetic Press for SX samples and Tzero 
press for FP samples 
TA Instruments, UK 
IGC Surface Energy Analyser (SEA) Surface Measurement Systems Ltd, UK 
Helium penta-pycnometer Quantachrome Instruments, USA 
 
4.4 METHODS 
4.4.1 AERODYNAMIC FRACTIONATION OF DRUG POWDERS  
Aerodynamic fractionation was conducted using an NGI in preparative mode as 
described previously (Taki et al., 2011b).  The NGI was assembled and connected to a 
vacuum pump (Twin Impinger Model, TI2). The flow rate through the NGI was 
measured at the air inlet i.e. throat using a flow meter with a tightly fitting seal. The 
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flow was adjusted to 60 L.min
-1
 using the flow control valve on the pump. The NGI 
plates were used uncoated and the drug was aerosolised into the NGI using a Malvern 
QSpec dry powder feeder. The DPF was placed on a lab jack and the height adjusted so 
that the outlet of the DPF was in line with the centre of the NGI throat. The DPF was 
connected to a supply of compressed air and vacuum using the appropriate ports on the 
feeder via vacuum tubing. The jet pressure was set between dial marks 2 and 3 and the 
feed rate was set between dials 4 and 7 depending on the amount of powder that was 
visualised leaving the feeder and depositing on the stages in order to ensure a sufficient 
amount of powder was aerosolised per fractionation cycle but not too much as to 
overload the NGI. Approximately 1- 2 g of powder was loaded into the DPF feeding 
tray, the DPF switched on and the airflow dial set to ‘airflow’. The vacuum pump 
connected to the NGI was then switched on, followed a few seconds later by the airflow 
dial being set to ‘feed’ for a period of 2 min. The airflow dial was then switched back to 
‘airflow’ and after 10 – 15 s the vacuum pump switched off. The NGI was disassembled 
and the powder deposits recovered. The deposits were carefully removed using a plastic 
scraper and transferred into clean, dry pre-weighed glass vials. Each vial was labelled 
with the stage and the mass of recovered powder recorded. As the quantity of powder in 
the DPF reduced, it was necessary to run each cycle for up to 4 min at the highest feed 
rate in order for sufficient material to be deposited for recovery. The fractionation 
cycles were repeated until a yield of approximately 1 g was obtained on any two of the 
stages. 
 
4.4.2 RE-CRYSTALLISATION OF DRUG POWDERS 
Precipitation by anti-solvent crystallisation was undertaken as previously described 
(Murnane et al., 2008a-d) to generate re-crystallised control particles. PEG400 solutions 
were prepared containing 4.5 % w/w SX or 0.65 % w/w FP by weighing approximately 
1 g of each drug into a glass beaker and making to final weight with PEG. SX solutions 
were subjected to high shear mixing (Silverson model L4RT laboratory homogeniser) at 
2100 rpm for SX and according to the following protocol for FP: 2000 rpm for 10 min, 
3000 rpm for 10 min, and 1000 rpm for 5 min until the powder dissolved. This was 
followed by ultrasound sonication for 5 min to degas the solutions. The solutions were 
then filtered through a 0.2 µm hydrophobic PTFE syringe filter prior to anti-solvent 
addition. The addition of anti-solvent (water) was carried out until a ratio of 1:11 
(solution:water) for SX and 1:7 for FP was obtained, and occurred at a rate of 20 g.min
-





 of solution, whilst the mixture was stirred using an Heidolph overhead stirrer. 
During addition, water was passed through a funnel which was positioned such that the 
water entered along the inside wall of the vessel. Stir speeds were 1000 rpm for SX 
solutions and ramped from 700 to 1430 rpm during the period of water addition for FP 
solutions. The crystals were then harvested by vacuum filtration (0.2 µm nylon filter) 
and dried overnight at 50 
º
C in a vacuum oven. The following day the dried powder 
was washed with 200 mL cold water (pre-cooled to 4 
º
C) with the aid of stirring at 1470 
rpm for 5 min. The crystals were again harvested by filtration and dried overnight. 
Finally, the crystals were de-caked by sonicating (5 – 6 min) with 15 mL cyclohexane 
and vacuum drying at 50 
º
C for 3 h. The crystals were transferred into glass vials and 
stored in a desiccator until required. 
 
4.4.3 PARTICLE SIZE ANALYSIS BY LASER DIFFRACTION 
Laser diffraction particle sizing of SX (n = 4) and FP samples (n = 6) was carried out 
using the Malvern Mastersizer X as described in Section 2.4.1. Particle size calculations 
were based on Mie theory, using the presentations 2OHD and 2NHE for SX and FP, 
respectively.  
 
4.4.4 SCANNING ELECTRON MICROSCOPY  
The morphology of crystallised and fractionated SX and FP powders was viewed using 
an FEI Quanta 200F field emission scanning electron microscope. The samples were 
mounted and images generated as described in Section 2.4.2. 
 
4.4.5 DISPERSIBILITY ASSESSMENT BY LASER DIFFRACTION 
The dispersibility of the SX and FP samples was assessed using the dry dispersion laser 
diffraction methodology developed in Chapter 2. The Sympatec HELOS/RODOS was 
used with the rotary feeder and protruding aspiration tube as described in Section 2.4.4, 
using a timebase of 100 ms, and trigger conditions of Copt ≥ 1.1 % to start a 
measurement and Copt ≤ 1.0 % for 5 s (or 60 s real time) to end a measurement. Particle 
size measurements (preceded each time by a reference measurement) were taken at PPs 
in the range 0.3 – 5.0 Bar (n = 1) for each sample. The data were analysed as described 
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in Section 2.4.4.1 and Section 2.4.5, using the DH/Dx approach calculated using DV50 
measurements, and empirically modelled according to Equation 2.8. 
 
4.4.6 CRYSTALLINE/AMORPHOUS CONTENT DETERMINATION  
4.4.6.1 DIFFERENTIAL SCANNING CALORIMETRY  
DSC thermographs for SX samples were produced using a Q20 – 5023 Q Series 
differential scanning calorimeter. Approximately 1 mg of sample was accurately 
weighed into an aluminium pan and the latter hermetically sealed using a press. An 
empty pan was weighed and sealed for use as the reference. Prior to analysis the 
instrument was calibrated by heating an indium standard at the required heating rate to 
170 – 200 oC. SX samples were equilibrated at 30 oC and maintained isothermal for 10 
min. The sample was then heated to 160 
o





under a nitrogen purge at 50 mL.min
-1
 (n = 3). The onset and peak 
melting temperatures, and the enthalpies of fusion were derived from integration of the 
relevant peaks using TA Universal Analysis 2000 software (version 4.5.2, TA 
Instruments, UK). 
 
DSC thermographs for FP were generated using a Q200 – 1934 Q series differential 
scanning calorimeter. FP samples (including the reference sample) were prepared as for 
SX except a pinhole was made in the lid prior to sample preparation (using a BD 
microlance 3, 21G x 2” 0.8 x 50 mm needle) and pans were sealed using a Tzero press. 





samples were equilibrated at 30 
o
C, held isothermal for 5 min and ramped to 320 
o
C at a 




. Analysis was conducted in triplicate (n = 3) under a nitrogen 
purge of 50 mL.min
-1
. Analysis of the thermographs was conducted using TA Universal 
Analysis 2000 software, version 4.5.2 (TA Instruments, UK). 
 
4.4.6.2 POWDER X-RAY DIFFRACTION  
Powder x-ray diffraction (PXRD) was conducted using a Brucker D8 Advance x-ray 
diffractometer system.  X-rays were generated by a copper (Cu) source operated at a 40 
kV tension and 40 mA current. Powder samples were mounted onto a zero background 
sample holder and scanned from 2θ = 4 – 30o for SX samples and 2θ = 4 – 35o for FP 
samples, with a step size of 0.039
o
 and count time of 0.5 s per step. 
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4.4.7 INVERSE GAS CHROMATOGRAPHY AT FINITE DILUTION 
Surface energy analysis of the crystallised and fractionated samples was conducted 
using an IGC Surface Energy Analyser as described in Section 3.4.8.1 to determine the 
surface energy distributions of the samples.    
 
4.4.8 HELIUM PENTAPYCNOMETRY 
A helium penta-pycnometer was used to measure the true density of micronised (i.e. 
unfractionated) SX and FP powders. Each sample was weighed directly into a sample 
cell (1.0 – 1.5 g) and placed in the instrument which was operated using flow purge 
mode. The maximum number of runs and run deviation were set at 3 and 0.005 % 
respectively, such that measurements would continue until three that were within 0.005 
% of each other were obtained. The maximum purge time was 60 min. 
 
4.4.9 NEXT GENERATION IMPACTOR ANALYSIS 
NGI analysis was conducted as described in Section 3.4.6, using a reduced fill weight of 
10.00 ± 1.00 mg for each capsule due to the more limited quantity of each sample that 
was available. Powder was aerosolised into the NGI at 60 L.min
-1
 for 4 s from a 
Monodose inhaler device (ΔP = 1.4 kPa). Drug recovery quantification was effected 
using the HPLC method described in Section 3.4.1.1. Pooled mixed standard calibration 





; SX = 0.998, FP = 0.997) in which each curve was freshly prepared on 
separate days, were used to quantify drug recovery. The LOD and LOQ values were 0.2 
µg.mL
-1
 and 0.7 µg.mL
-1
, and 4.0 µg.mL
-1
 and 13.5 µg.mL
-1
 for the lower and upper 





, and 5.1 µg.mL
-1
 and 16.9 µg.mL
-1
, for the lower and upper 
concentration ranges of FP, respectively. Quantification of individual samples was 
routinely made using the lower concentration range curve, except where samples were 
outside this range in which case the upper range curve was used. 
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4.5 RESULTS 
4.5.1 AERODYNAMIC FRACTIONATION 
Both SX and FP were fractionated at 60 L.min
-1
 and required approximately 12 – 15 g 
of material to be fed through the NGI to achieve a sufficient yield (approx. 1 g) on the 
individual stages for further analysis. The fractionation process was therefore labour-
intensive and inefficient in terms of material and operator time. For both powders losses 
occurred in the DPF, via deposition in the throat and during powder recovery from the 
stages. SX was more difficult to recover from the stages due to the powder being highly 
electrostatic, leading to greater losses compared to FP. For SX the largest recovery was 
on stage 4 (dae = 1.66 – 2.82 µm) followed by stage 5 (dae = 0.94 – 1.66 µm). 
Recoveries on the remaining stages were much lower, and this was attributed to the 
narrow particle size distribution of the original micronised material. During 
fractionation, it was noticed that a large proportion of SX deposited in the pre-separator 
(dae > 12.8 µm) therefore this material was collected as an additional fraction. For FP, 
maximum deposition occurred on stage 4 followed by stage 3 (dae = 2.82 – 4.46 µm). 
Once more, powder recovery from the remaining stages was much lower and there was 
negligible deposition on stage 7 (dae = 0.34 – 0.55 µm) and the micro-orifice collector 
(MOC). The shift in yield towards stages corresponding to larger aerodynamic particle 
sizes for FP compared to SX was attributed to the larger particle size of the original 
micronised FP material. Like SX, a large proportion of material deposited in the pre-
separator and this was therefore collected as an additional fraction (Table 4.2). 
 
4.5.2 POWDER PRODUCTION BY RE-CRYSTALLISATION 
Ampiphilic crystallisation was successfully employed to produce SX and FP crystals. 
The differing concentrations of SX and FP in the drug-PEG400 solutions reflected the 
different solubility values of the drugs in PEG400, where FP has poorer solubility. Two 
batches of re-crystallised SX were produced; the first employed a drug to anti-solvent 
ratio of 1:11 and the second a ratio of 1:7 in an attempt to reduce the particle size of the 
crystals.  However, both batches of particles were found to have comparable particle 
sizes. The batches were therefore combined and washed as described in Section 4.4.2 to 
generate the final batch of crystals for testing.  
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4.5.3 PARTICLE SIZE ANALYSIS BY LASER DIFFRACTION 
The PSDs of unfractionated, crystallised, pre-separator and stage fractionated SX sized 
using liquid dispersion laser diffraction are shown in Figure 4.1 and Table 4.2. 
Crystallised SX (CSX) was larger in size than unfractionated SX however both had a 
Dv50 smaller than 5 µm and therefore may be deemed as suitable (in terms of 
appropriate particle size) for inhaled delivery. Material depositing in the pre-separator 
and stages 1 – 4 was comparable in particle size and these samples also were similar in 
size to the unfractionated material following dispersal in liquid, despite the aerodynamic 
particle sizes of the stages being markedly different. It is postulated that powder 
depositing on these stages remained agglomerated, and that agglomerates with an 
equivalent aerodynamic size to the stage in question deposited rather than discrete 
particles. Hence, following dispersion in liquid to individual particles, the measured 
particle size between the samples was comparable. Material depositing on stages 5, 6 
and 7 showed a gradual shift towards a smaller particle size, and displayed geometric 
particle sizes that were comparable with the aerodynamic size of the respective stage. 





Figure 4.1 The particle size distribution of micronised (i.e. unfractionated) salmeterol 
xinafoate (MSX), crystallised salmeterol xinafoate (CSX), pre-separator salmeterol 
xinafoate (SXPS) and stage fractionated salmeterol xinafoate (SXS1-7) samples sized 
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Table 4.2 The particle size distribution (represented by the Dv10, Dv50 and Dv90) of unfractionated, crystallised, and fractionated salmeterol xinafoa te 
(SX) and fluticasone propionate (FP) sized by liquid dispersion laser diffraction (mean ± SD, n = 4 and 6, respectively) and the aerodynamic cut 
sizes across the Next Generation Impactor  when operated at 60 L.min
-1
, representing the minimum size of particles depositing on the corresponding 
stage. 
  Salmeterol xinafoate Fluticasone propionate 
Sample Stage dae 
(Minimum, µm) 
Yield (mg) Dv10 (µm) Dv50  (µm) Dv90  (µm) Yield (mg) Dv10 (µm) Dv50 (µm) Dv90 (µm) 
Unfractionated n.a n.a. 0.62 ± 0.00  1.42 ± 0.08 3.78 ± 0.23 n.a. 1.04 ± 0.40 2.94 ± 1.22 6.10 ± 2.65 
Crystallised n.a 840.1 0.72 ± 0.01 4.93 ± 0.37 17.4 ± 1.07 1157.0 1.09 ± 0.42 3.62 ± 1.43 10.8 ± 4.67 
Pre-separator* 12.8 704.2 0.64 ± 0.00  1.51 ± 0.05 3.65 ± 0.23 2887.5 0.97 ± 0.01  2.39 ± 0.09 4.83 ± 0.49 
Stage 1 8.06 20.0 0.65 ± 0.01 1.51 ± 0.06 3.32 ± 0.10 87.5 0.99 ± 0.03 2.41 ± 0.13 5.07 ± 0.58 
Stage 2 4.46 100.1 0.65 ± 0.00 1.54 ± 0.06 3.54 ± 0.12 464.5 1.00 ± 0.03 2.48 ± 0.22 5.03 ± 0.66 
Stage 3 2.82 423.2 0.66 ± 0.01 1.72 ± 0.11 3.86 ± 0.29 1029.6 0.95 ± 0.02 2.14 ± 0.18 3.93 ± 0.54 
Stage 4 1.66 1704.2 0.64 ± 0.01 1.51 ± 0.06 3.51 ± 0.18 1362.5 0.88 ± 0.01 1.91 ± 0.09 3.56 ± 0.35 
Stage 5 0.94 1158.7 0.61 ± 0.00 1.12 ± 0.04 2.78 ± 0.23 318.7 0.71 ± 0.02 1.59 ± 0.12 3.28 ± 0.29 
Stage 6 0.55 162.8 0.59 ± 0.03 0.93 ± 0.02 2.10 ± 0.42 44.8 0.65 ± 0.02 1.46 ± 0.23 3.50 ± 0.61 
Stage 7 0.34 35.9 0.55 ± 0.01 0.87 ± 0.05 1.92 ± 0.33 - - - - 
*The pre-separator SX fraction was not collected throughout the whole fractionation process and hence does not reflect the total yield of the fraction isolated from the unfractionated 
powder. 
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The PSDs of unfractionated, crystallised, pre-separator and stage deposits of FP sized 
using liquid dispersion laser diffraction are shown in Figure 4.2 and Table 4.2. As for 
SX, the particle size of the crystallised FP (CFP) material was larger than the 
micronised (i.e. unfractionated) material but once more the Dv50 was smaller than 5 µm. 
The particle size of deposits in the pre-separator and stages 1 – 4 were comparable in 
magnitude both to each other and to that of the unfractionated material, indicating that 
powder may have deposited in an agglomerated state. There was however also a slight 
shift towards smaller particle sizes, which was not seen with SX. Samples of powder 
depositing on stages 5 and 6 had a smaller geometric size and therefore may indicate the 




Figure 4.2 The particle size distribution of micronised (i.e.  unfractionated) fluticasone 
propionate (MFP), crystallised fluticasone propionate (CFP), pre-separator fluticasone 
propionate (FPPS) and stage fractionated fluticasone propionate (FPS1-6) samples 
sized by liquid dispersion laser diffraction (n = 1 measurement shown). 
 
4.5.4 SCANNING ELECTRON MICROSCOPY  
The morphology of unfractionated and crystallised SX is shown in Figure 4.4. The 
unfractionated material displayed agglomerates of variable size with individual particles 
that were irregular in shape. The crystallised material comprised larger agglomerates 
and individual particles that were flatter than the unfractionated particles. The 
morphology of the fractionated SX powders is shown in Figure 4.5. Once more 
agglomeration was observed in all the samples. There was negligible difference between 
the agglomeration and particle morphology of the fractionated and unfractionated SX 
material. The morphology of unfractionated and crystallised FP is also shown in Figure 
4.4. FP particles had a more regular, rounded morphology than SX and formed tightly 
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morphology, the particles were needle-like and the powder appeared to form smaller 
agglomerates. The morphology of the fractionated FP powders is shown in Figure 4.6. 
The pre-separator fraction appeared to form larger agglomerates compared to the 
unfractionated and stage deposited powder. Visually, there was no apparent change in 
agglomerate and particle morphology between the fractionated and unfractionated FP 
material. 
 
4.5.5 CRYSTALLINE/AMORPHOUS ASSESSMENT 
4.5.5.1 DIFFERENTIAL SCANNING CALORIMETRY  
DSC thermographs revealed differences in the melting behaviour of unfractionated, 
crystallised and fractionated SX (Figure 4.3). Each sample displayed an initial melting 
peak corresponding to the melting of SX-I followed by an exotherm corresponding to 
the re-crystallisation of SX-II from the melt. This was followed by a second melting 
peak corresponding to the melting of SX-II. Unfractionated and crystallised SX showed 
a much smaller SX-II melting peak compared to the fractionated samples. Increasing the 
heating rate inhibited the crystallisation and subsequent melting of the SX-II polymorph 








 was required. 
 
 
Figure 4.3 Differential scanning calorimetry thermographs of unfractionated, 
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Figure 4.4 Morphology of unfractionated and crystallised salmeterol xinafoate and fluticasone propionate viewed by scanning electron microscopy 
at x 700 and x 10500 magnification. 
100 µm 5 µm 
Magnification x 700 Magnification x 10500 Magnification x 10500 Magnification x 700 
Unfractionated salmeterol xinafoate   Crystallised salmeterol xinafoate 
100 µm 5 µm 
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Figure 4.5 Morphology of fractionated salmeterol xinafoate viewed by scanning electron microscopy at x 700 and x 10500 magnification. 
100 µm 5 µm 
Magnification x 700 Magnification x 10500 
Pre-separator salmeterol xinafoate 
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Magnification x 700 Magnification x 700 Magnification x 10500 Magnification x 10500 
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Figure 4.6 Morphology of fractionated fluticasone propionate viewed by scanning electron microscopy at x 700 and x 10500 magnification.  
100 µm 5 µm 100 µm 5 µm 
Magnification x 700 Magnification x 700 Magnification x 10500 Magnification x 10500 
Stage 3 fluticasone propionate Stage 4 fluticasone propionate 
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Pre-separator fluticasone propionate 
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Thermo-kinetic analysis of the re-crystallisation process was undertaken by constructing 
α-heating rate (β, oC.min-1) curves for the fractionated samples, where α is the fraction 
of SX-II re-crystallised from the melt. This enabled data fitting to an Avrami-Erofe’ev-
type equation (Equation 4.1) to determine the kinetic parameters k and n, representing 
the integrated rate constant for the re-crystallisation of SX-II and the Avrami exponent 
of the model, respectively (Murnane et al., 2008d).  
 





The α-heating rate curves of the SX samples are shown in Figure 4.7. Initially α was 
calculated by expressing the experimentally determined enthalpy of fusion (ΔHf) of SX-
II as a proportion of the standard literature value as previously described (Murnane et 
al., 2008d), but this generated poor fits to the data (R
2
 = 0.64 – 0.79).  The data were 
therefore normalised as follows. The enthalpy of fusion at the lowest heating rate was 
used to represent complete conversion of SX-I to SX-II. The degree of conversion at 
each heating rate was calculating by expressing the enthalpy of fusion at each heating 
rate employed (ΔHf
βexp
) as a proportion of the enthalpy of fusion at the lowest heating 
rate (ΔHf
β0.1
), as shown in Equation 4.2. 
 
Equation 4.2       
   
    
   
     
 
Following normalisation, the fit improved (R
2
 = 0.96 – 0.98) and allowed the kinetic 
parameters k and n to be determined (Table 4.3). The Avrami exponent was close to 2 
for each sample, which is expected as SX particles have a platelet shape and therefore 
predominantly grow in two directions (Tong et al., 2003). The k values revealed a 
different degree (or rate) of re-crystallisation between the fractionated samples. Stage 4 
and 5 particles had comparable k values whereas pre-separator particles had a much 
higher k value, indicating a higher degree of crystalline disorder. 
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Figure 4.7 α-heating rate curves of salmeterol xinafoate fractions recovered from the 
pre-separator (SXPS), Stage 4 (SXS4) and Stage 5 (SXS5) of the Next Generation 
Impactor assessed by differential scanning calorimetry, where α is the fraction of the 
SX-II polymorph that re-crystallises after melting of the SX-I polymorph, and β-1 is 
the heating rate expressed in min per 
o
C (n = 3 data points per heating rate).  
 
Table 4.3 The degree of re-crystallisation (k) and Avrami exponent (n) of pre-
separator, Stage 4 and Stage 5 salmeterol xinafoate (SX) samples determined from 
thermo-kinetic analysis of the differential scanning calorimetry thermographs of the 
samples. 




.min) Avrami Component (n) 
Pre-separator SX 8.12 ± 0.26 2.08 ± 0.17 
Stage 4 SX 6.29 ± 0.28 2.18 ± 0.25 
Stage 5 SX 6.66 ± 0.27 1.96 ± 0.18 
 
DSC thermographs for FP were typical for this compound, which indicated melting 
followed by degradation (Figure 4.8) and agreed with results reported previously 
(Westmeier and Steckel, 2008; Xu et al., 2010a). Therefore, it was not possible to model 
the crystallisation kinetics as described for SX. Integration of the onset temperature of 
the melting peaks indicated negligible differences in the melting point between the 
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Table 4.4 The melting point of unfractionated, crystallised and fractionated 





 (mean ± SD, n = 3). 
Particle Type Melting Point (
o
C) 
Unfractionated FP 293.4 ± 2.44 
Crystallised  FP 294.2 ± 3.10 
Pre-separator FP 293.8 ± 0.92 
Stage 3  FP 295.5 ± 1.24 
Stage 4 FP 297.3 ± 2.25 
 
 
Figure 4.8 Differential scanning calorimetry thermographs of unfractionated, 





= 1 measurement shown). 
 
4.5.5.2 POWDER X-RAY DIFFRACTION   
The PXRD traces of the SX and FP samples are shown in Figure 4.9. Changes to the 
diffraction patterns, including peak widening and worsened resolution, are indicative of 
changes to the crystal structure of the material (Steckel et al., 2003b) and a very broad 
peak generally referred to as a ‘halo’ would indicate an amorphous material. As no 
changes were observed between the different isolated samples of either SX or FP, this 
indicated that there was no change in the polymorphic form between the different 
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Figure 4.9 Powder x-ray diffraction traces of unfractionated, crystallised and fractionated salmeterol xinafoate (SX) and fluticasone propionate (FP)  
samples (n = 1). 
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4.5.6 INVERSE GAS CHROMATOGRAPHY AT FINITE DILUTION 
4.5.6.1 BRUNAUER-EMMETT-TELLER SURFACE AREA 
The BET SSA of the samples were determined from the octane sorption isotherm (at 
303.15 K) and obtained directly from the IGC SEA (Table 4.5). Differences between the 
SSA of the SX samples generally reflected the different particle sizes of the samples. 
For example, unfractionated (Dv50 = 1.42 ± 0.08 µm) and Stage 5 SX powders (Dv50 = 








, respectively. The 
FP samples also followed the trend of increasing SSA with a smaller particle size. 
However, when comparing the fractionated samples, pre-separator particles displayed a 
larger SSA than the stage fractions, despite also having a larger particle size (Table 4.2). 
Such differences may arise from different particle shape/surface properties between the 
powders. 
 
Table 4.5 The Brunauer-Emmett-Teller (BET) specific surface area of salmeterol 
xinafoate and fluticasone propionate samples obtained from the octane sorption 
isotherm of the inverse gas chromatography surface energy analyser. 
Sample 





Salmeterol xinafoate Fluticasone propionate 
Unfractionated  8.37 7.50 
Crystallised  9.74 5.00 
Pre-separator  7.01 10.67 
Stage 3 7.10 8.02 
Stage 4  7.88 8.56 
Stage 5  12.75 8.12 
 
4.5.6.2 DISPERSIVE SURFACE ENERGY  
Table 4.6 shows the dispersive surface energy measurements of the samples at the 
lowest surface coverage from finite dilution, and is equivalent to an infinite dilution 
measurement. Overall FP was found to have higher surface energy than SX. For both 
drugs, the crystallised material displayed the lowest surface energy. Whereas for FP the 
dispersive surface energy was comparable between the fractionated samples, for SX 
there was an increase in surface energy as the aerodynamic size reduced. 
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Table 4.6 The dispersive surface energy of salmeterol xinafoate and fluticasone 
propionate samples by inverse gas chromatograpgy at infinite dilution (i.e. 0.01 n/nm 
surface coverage of the probes). 
Sample 
Dispersive surface energy (mJ.m
-2
) 
Salmeterol xinafoate Fluticasone propionate 
Unfractionated  37.94 43.08 
Crystallised  34.13 38.12 
Pre-separator  37.04 43.16 
Stage 3 38.87 43.48 
Stage 4  38.78 42.74 
Stage 5  40.14 43.05 
 
Figure 4.10 shows the dispersive surface energy distributions of the different SX and FP 
powder fractions and crystals from finite dilution. The results indicated that for every 
powder, dispersive interactions formed the major component of the surface energy. The 
dispersive surface energy of unfractionated FP was higher than unfractionated SX. Both 
powders showed heterogeneity in the dispersive surface energy values, but the 
difference in heterogeneity of the two drugs was negligible. The dispersive surface 
energy of the crystallised particles of FP was lower, and less heterogeneous, compared 
to the respective micronised (i.e. unfractionated) powders. When the fractionated 
powders are considered there were found to be different trends in the surface energy 
between the SX and FP samples. In the case of FP, there was little difference in the 
surface energy and heterogeneity between the powders; the fractionated samples 
appeared to have marginally lower surface energy than the unfractionated powders. For 
SX, the differences between the surface energies of the unfractionated, pre-separator, 
Stage 3, and Stage 4 SX samples were also small. However, the surface energy of the 
Stage 5 SX powder, particularly at low surface coverage, was found to be higher, and 
displayed greater surface energy heterogeneity compared to the other SX powders.  
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 (a) Surface energy distributions of unfractionated, fractionated and crystallised salmeterol xinafoate 




























































































 (b) Surface energy distributions of unfractionated, fractionated and crystallised fluticasone propionate 
Figure 4.10 The dispersive, specific and total surface energy distributions of unfractionated, crystallised, and fractionated (a) salmeterol xinafoate and (b) 
fluticasone propionate powders by inverse gas chromatography at finite dilution. Note that the same legend is used for each graph. 
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4.5.6.3 SPECIFIC SURFACE ENERGY  
The specific surface energies of SX and FP were much lower than their dispersive 
surface energies (Figure 4.10). The specific surface energy component of FP was larger 
than that of SX, indicating the different surface chemistry between the powders, with a 
larger proportion of polar surface groups for FP which facilitated polar inter-particulate 
interactions. The specific surface energy of crystallised particles of FP was lower, with 
decreased surface energy heterogeneity, compared to unfractionated FP, whereas the 
converse occurred for SX. Between the fractionated powders, there was little difference 
in the specific surface energy for unfractionated, Stage 3, Stage 4 and Stage 5 FP 
samples, but pre-separator particles were found to have the lowest surface energy. 
Differences between unfractionated and fractioned SX samples were also small, with 
Stage 4 particles having the lowest specific surface energy.  
 
4.5.6.4 TOTAL SURFACE ENERGY 
When  considering the total surface energy, i.e. the sum of the dispersive and specific 
surface energies, for both SX and FP, then the crystallised particles were found to have 
the lowest surface energy of all the powders. For FP, all the fractionated samples had a 
lower surface energy than that obtained for unfractionated samples, although these 
differences were small, and the pre-separator sample had the lowest surface energy. 
Unfractionated SX was found to have an identical surface energy to the sample isolated 
from Stage 4, whereas Stage 3 particles had a slightly higher and more heterogeneous 
surface energy and the fraction obtained from Stage 5 had the highest and most 
heterogeneous surface energy of all the samples. Pre-separator SX particles again had 
the lowest surface energy of the fractionated particles.  
 
4.5.7 TRUE DENSITY AND AERODYNAMIC PARTICLE SIZE 
The true density of unfractionated SX was 1.2103 g.cc
-1
 and 1.4885 g.cc
-1
 for 
unfractionated FP. This enabled the aerodynamic particle size to be calculated using 
Equation 4.3, where dae is the aerodynamic diameter, d is the geometric diameter and ρ 
is the particle density (Louey et al., 2004a).  The calculated aerodynamic sizes in terms 
of the Dv10, Dv50, Dv90 and VMD are shown in Table 4.7. 
.  
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Equation 4.3             √   
 
Table 4.7 The geometric and calculated aerodynamic particle sizes (represented by the 
Dv10, Dv50, Dv90 and volume mean diameter, VMD) of micronised (i.e. unfractionated) 
salmeterol xinafoate and fluticasone propionate.  
Particle Size (µm) Geometric Aerodynamic Geometric Aerodynamic 
 Salmeterol xinafoate Fluticasone propionate 
Dv10 0.62 0.68 1.04 1.27 
Dv50 1.42 1.56 2.94 3.59 
Dv90 3.78 4.16 6.10 7.44 
VMD 1.94 2.13 3.41 4.16 
 
4.5.8 DISPERSIBILITY ASSESSMENT BY LASER DIFFRACTION 
Dry dispersion laser diffraction revealed differences in dispersibility between the 
powders (Table 4.8). The cohesive strength, CPP, was derived from the particle size-
primary pressure profiles. For SX, only pre-separator particles showed a lower CPP 
compared to unfractionated SX; the CPPs of Stage 4 and Stage 5 particles were 
comparable and similar also to the CPP of the unfractionated powder. For some of the 
powders, including the majority of the FP samples, it was not possible to deduce a CPP 
due to the Dv50 fluctuating in the ‘plateau’ region.  This could arise as a result of high 
heterogeneity in particle properties, incomplete de-agglomeration even at the highest 
dispersing pressure employed, or conversely occur due to particle fracture/attrition. It 
was therefore not possible to compare the CPP values of all the FP samples. For SX, 
only pre-separator particles showed a reduction in cohesive strength compared to the 
unfractionated particles. 
 
Following data normalisation and linearisation, the linearity of each data set was good 
and the DAmax was close to 1.0. Once more, the powders that showed the greatest 
deviation from the theoretical value of DAmax = 1.0 had the poorest linearity. 
Considering SX, in all instances the DA50, a measure of the ease of dispersion, 
improved except for Stage 5 SX in which the ease of dispersion was comparable to 
unfractionated SX. Pre-separator and Stage 4 SX showed the largest improvement in 
dispersibility compared to unfractionated powder, and the former samples were found to 
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have similar DA50 values. For crystallised SX any improvement was less marked. FP 
particles showed a different behaviour, with pre-separator particles displaying a much 
poorer dispersibility (by almost 2-fold) compared to unfractionated particles. The 
remaining powder fractions showed improved ease of dispersion compared to 
unfractionated FP with the following rank: FPS3 > CFP > FPS4. 
 
Table 4.8 The primary pressure for 50 % de-agglomeration (DA50), maximum degree 
of de-agglomeration (DAmax) and critical primary pressure (CPP) of unfractionated, 
crystallised, pre-separator and stage fractionated salmeterol xinafoate and fluticasone 
propionate determined from dry dispersion laser diffraction analysis . 
Salmeterol xinafoate R
2
 DA50 (Bar) DAmax CPP (Bar) 
Unfractionated  0.9711 1.45 1.35 3.50 
Crystallised  0.9823 1.21 1.18 n.a 
Pre-separator  0.9984 0.54 1.11 1.20 
Stage 4  0.9931 0.51 1.10 3.50 
Stage 5* 0.8921 1.40 1.40 3.00 
Fluticasone propionate R
2
 DA50 (Bar) DAmax CPP (Bar) 
Unfractionated  0.9338 1.72 1.34 n.a. 
Crystallised  0.9680 1.05 1.13 3.50 
Pre-separator 0.9462 2.36 1.45 n.a 
Stage 3  0.9545 0.85 1.07 n.a. 
Stage 4  0.9057 1.50 1.27 n.a. 
*Data modelled in the PP range 0.3 – 5.0 Bar (due to poor linearity when the data for 0.2 Bar was 
included); for all other samples PPs were in the range 0.2 – 5.0 Bar; n.a. = not possible to assign a CPP.  
 
4.5.9 NEXT GENERATION IMPACTOR ANALYSIS 
Cascade impactor analysis of the SX powder samples revealed differences in the 
aerosolisation of the particles (Figure 4.11 and Table 4.9). The FPF RD, FPF ED, and 
emission of unfractionated SX were 33.2 ± 2.18 %, 61.2 ± 2.51 %, and 54.4 ± 5.17 %, 
respectively. Despite a larger particle size, crystallised SX was emitted in higher 
amounts (91.0 ± 2.07 %, p < 0.05, one-way ANOVA with post-hoc Tukey’s test, 
GraphPad Prism 5) than the unfractionated material, potentially as a result of reduced 
adhesion to device/capsule walls, reduced cohesivity, and the larger particle size which 
would act to improve flow and increase entrainment. The FPF RD of CSX did not 
change (p > 0.05) but the FPF ED was reduced (p < 0.05) compared to that obtained 
using unfractionated SX. This was due to greater deposition (~ 3-fold) in the throat and 
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pre-separator, reflecting a reduced retention in the device/capsules for crystallised 
particles. The SX obtained from the pre-separator sample also exhibited higher emission 
than unfractionated SX, although the increase was smaller than for the crystallised 
particles and not significant (p > 0.05). The similarity of the FPF (RD and ED) for 
unfractionated and pre-separator SX indicated that although the particles within the pre-
separator sample were entrained more readily, the de-agglomeration efficiency of this 
material to primary particles was worsened. The emission of unfractionated, Stage 4 and 
Stage 5 SX did not differ significantly. There was no difference between the FPF RD of 
Stage 4 and unfractionated SX (p > 0.05), but an increase in the FPF ED (p < 0.05) 
suggesting that this powder may have improved de-agglomeration efficiency compared 
to the unfractionated material. For Stage 5 SX, the FPF RD and ED reduced 
significantly compared to unfractionated SX, reflecting the worsened de-agglomeration 
efficiency compared to unfractionated SX. The MMAD of the majority of SX samples 
was unchanged compared to unfractionated SX (p > 0.05), apart from the crystallised 
material for which the MMAD was bigger (p < 0.05).  The FPM was also unchanged for 
all the samples compared to unfractionated SX (p > 0.05) except for Stage 5 SX, when 
the FPM was found to be markedly lower than for the other SX samples (p < 0.05). 
 
The different FP samples also displayed altered aerosolisation behaviour (Figure 4.12 
and Table 4.9). The emission of micronised FP (62.2 ± 7.60 % RD) was unchanged 
compared to the crystallised, pre-separator, Stage 3 and Stage 4 material (p > 0.05), 
although there was a reduction in the variability (i.e. SD) between replicate analyses. 
The latter could potentially be a consequence of a narrower distribution in particle 
properties, which might be expected to improve the reproducibility of entrainment and 
the emitted dose. The FPF ED and RD of pre-separator FP did not change compared to 
unfractionated FP. However, crystallised, Stage 3 and Stage 4 FP produced higher FPFs 
(p < 0.05) than the unfractionated sample, indicating improved de-agglomeration 
efficiency. There was no significant difference in the FPF between Stage 3 and Stage 4 
FP indicating equivalent de-agglomeration efficiency between the two sub-populations. 
The MMAD of the FP samples did not change compared to unfractionated FP (p > 
0.05), except for the Stage 4 FP for which the MMAD was smaller. The FPM of 
crystallised, Stage 3 and Stage 4 FP was higher than the FPM generated by 
unfractionated FP (p < 0.05) whereas the FPM of pre-separator FP was unchanged 
compared to the unfractionated FP powder (p > 0.05). 
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Table 4.9 The recovery (% of the actuated dose), fine particle mass (FPM), mass 
median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of 
unfractionated, crystallised and fractionated salmeterol xinafoate and fluticasone 
propionate aerosolised into the Next Generation Impactor (mean ± SD, n = 3 - 4). 
Salmeterol xinafoate Recovery (%) FPM (mg) MMAD (µm) GSD  
Unfractionated 77.8 ± 6.5 2.7 ± 0.2  2.7 ± 0.1 1.8 ± 0.0 
Crystallised 87.1 ± 1.3 2.4 ± 0.2 3.5 ± 0.2 2.1 ± 0.0 
Pre-separator 79.5 ± 1.9 3.0 ± 0.4 2.6 ± 0.1 1.8 ± 0.0 
Stage 4 78.9 ± 6.7 2.7 ± 0.5 2.5 ± 0.1 1.8 ± 0.0 
Stage 5 71.5 ± 2.6 1.4 ± 0.0 2.7 ± 0.1 2.0 ± 0.0 
Fluticasone propionate Recovery (%) FPM (mg) MMAD (µm) GSD  
Unfractionated 78.0 ± 3.1 1.5 ± 0.1 4.1 ± 0.3 2.0 ± 0.1 
Crystallised 89.5 ± 2.0 2.2 ± 0.3 4.1 ± 0.2 2.0 ± 0.1 
Pre-separator 78.9 ± 3.8 1.8 ± 0.1 4.1 ± 0.1 2.1 ± 0.2 
Stage 3 78.6 ± 3.5 2.5 ± 0.1 3.7 ± 0.1 1.9 ± 0.0 
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Figure 4.11 The fine particle fraction (FPF < 5 µm, expressed as a percentage of the 
emitted dose, ED, and recovered dose, RD) and emission (% RD) of salmeterol 
xinafoate samples (crystallised, unfractionated, pre-separator, stage 4 and stage 5) 
assessed by Next Generation Impactor analysis (mean ± SD, n = 3 - 4); * = p < 0.05 
for crystallised or fractionated powders vs. unfractionated powder using a one-way 
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Figure 4.12 The fine particle fraction (FPF < 5 µm, expressed as a percentage of the 
emitted dose, ED, and recovered dose, RD) and emission (% RD) of fluticasone 
propionate samples (crystallised, unfractionated, pre-separator, stage 3 and stage 4) 
assessed by Next Generation Impactor analysis (mean ± SD, n = 3 - 4); * = p < 0.05 
for crystallised or fractionated powders vs. unfractionated powder using a one-way 
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4.6 DISCUSSION AND CONCLUSIONS 
Particles produced with the intent of efficient delivery to the lungs are derived most 
commonly by crystallisation. These are then subjected to a comminution step such as 
micronisation, in order to achieve an appropriate particle size for deposition. Such a 
highly energetic micronisation process can result in poor control over the 
physicochemical properties of the particles, with the potential for both intra- and inter-
batch variability (Feeley et al., 1998). A consequence of this could be the formation of 
sub-populations of particles which display different aerosolisation behaviour compared 
to the bulk of the powder. For example, amorphous regions may be introduced onto 
crystalline drug surfaces, which can increase surface energy and adhesive/cohesive 
forces (Steckel et al., 2003b; Perkins et al., 2009) such that the particles are more 
difficult to fluidise and/or de-agglomerate. In addition, the processing may create a 
proportion of particles that are so tightly agglomerated that they do not disperse during 
dry powder delivery. A recently developed aerodynamic technique which enables 
powders to be separated based on their aerodynamic particle size has therefore provided 
the possibility of isolating discrete powder fractions (Taki et al., 2011b). The latter 
study identified differences in the formulation performance when particles of drug and 
excipient with a different particle size were incorporated into carrier-based blends (Taki, 
2008). This use of the fractionation methodology should provide a means of 
characterising the physicochemical properties of aerodynamically differentiated 
material, and therefore allow the effect of intra-batch variability in particle properties 
present within bulk powders to be better determined.  
 
4.6.1 POWDER PREPARATION BY AERODYNAMIC FRACTIONATION 
AND ANTI-SOLVENT CRYSTALLISATION 
Aerodynamic fractionation using the NGI was successfully conducted to isolate powder 
samples with a known aerodynamic size, however, it was found to be an inefficient 
process leading to the loss of large quantities of material. The stages upon which the 
largest yields were obtained were therefore selected for further analysis. For both SX 
and FP this included the pre-separator fraction comprising the coarsest particles 
(aerodynamic size > 12.8 µm). Deposition across the NGI stages differed between the 
powders, and was found to be the largest on stages 4 and 5 for SX and stages 3 and 4 for 
FP. This was attributed to the smaller particle size of SX (dae; Dv50 1.56 µm, span 2.23) 
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compared to FP (dae; Dv50 3.59 µm, span 1.72). For both powders, the geometric particle 
size measured by liquid dispersion laser diffraction (Table 4.2), which measures the 
fully dispersed particle size, revealed that the powders were depositing as agglomerates 
within the NGI.  
 
During DPI delivery, powder agglomerates need to disperse within an airstream in order 
to attain a particle size which is able to enter and deposit in the lungs. The geometric 
Dv50 of the pre-separator and stage 1 – 4 fractions following dispersion in liquid media 
were comparable for SX powders. When operated at 60 L.min
-1
, powder depositing in 
the pre-separator and on stages 1 - 4 of the NGI comprises particles with an 
aerodynamic size > 12.8 µm and 1.66 – 12.80 µm, respectively. Therefore, the particles 
remained agglomerated during fractionation and when depositing in the NGI. The 
aerodynamic particle cut size therefore represented the aerodynamic size of the 
agglomerate rather than the individual particles. The agglomerates therefore possessed 
an aerodynamic diameter equivalent to a single particle with a similar size, shape and 
density (Taki et al., 2011b). The geometric Dv50 of SX particles depositing on stages 5, 
6 and 7 (1.12 ± 0.04 µm – 0.87 ± 0.05 µm) were smaller than the unfractionated 
material (1.42 ± 0.08 µm) and more closely matched the aerodynamic particle size of 
the stages (1.66 - 0.34 µm) suggesting that these particles may have deposited in a 
dispersed state. A similar finding was observed for FP samples; powder depositing in 
the pre-separator and stages 1 – 3 had comparable geometric Dv50 values after liquid 
dispersion indicating agglomeration of deposited particles on these stages. Beyond stage 
3 the particles became increasingly smaller, and may have been more fully dispersed 
before depositing. Although efficient fractionation was achieved by Taki et al. (2011b), 
the deposition of powder agglomerates was not discounted. This was postulated to be 
the cause of a degree of overlap in the geometric PSDs of fractionated samples, and the 
presence of tailing/secondary modes in the distributions following dispersion in liquid.  
 
As a comparator for the unfractionated and fractionated particles, ampiphilic 
crystallisation was undertaken to produce crystallised particles which would have been 
expected to comprise a molecular lattice in the lowest energy state. Although the re-
crystallised particles were larger than the micronised material (Dv50 4.93 ± 0.37 µm and 
3.62 ± 1.43 µm for SX and FP, respectively) they each had a Dv50 that was below 5 µm 
and therefore within the required particle size range for pulmonary aerosol delivery. 
Achieving an appropriate particle size is one of the major challenges of controlled 
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crystallisation methods, as small molecules tend to form relatively large crystals (10 – 
100 µm) (Chow et al., 2007). The crystal size distribution is dependent on the 
crystallisation conditions such as the mixing regimen (Chow et al., 2007), as well as the 
solvent (Murnane et al., 2008a; Murnane et al., 2008c) and anti-solvent (Kubavat et al., 
2012) employed. As the purpose of the study was to obtain particles which had not been 
subjected to secondary processing in order to function as a control, rather than obtain 
the smallest possible crystal size, the crystallisation method was not further optimised in 
order to attain optimum sizing.    
 
4.6.2 PHYSICOCHEMICAL CHARACTERISATION OF BULK, 
FRACTIONATED AND RE-CRYSTALLISED DRUG POWDERS 
There were negligible changes in the morphology and agglomeration, following a visual 
assessment, of the unfractionated and fractionated powders of both drugs. Pre-separator 
FP appeared to form the largest agglomerates of the FP samples, which would not be 
unexpected as this sample was the coarsest fraction with an aerodynamic particle size 
greater than 12.8 µm. The crystallised particles showed different particle morphology to 
the unfractionated and fractionated particles. Crystallised SX particles were flatter and 
more plate-like and formed larger more densely packed agglomerates compared to the 
unfractionated material. Crystallised FP particles were needle-like, formed smaller 
agglomerates and appeared to be less agglomerated than the unfractionated material. 
These changes in morphology were consistent with those observed by Murnane et al. 
(2008c) following ampiphilic crystallisation from PEG solutions. 
 
Differences in crystallinity and surface energy were observed between the samples. The 
PXRD traces of SX and FP were typical of those reported for each of the two drugs 
(Steckel et al., 2003b; Westmeier and Steckel, 2008; Kumon et al., 2010). Qualitatively, 
there were no changes in the traces between the respective SX and FP samples, 
indicating no change in polymorphic form and that all the samples were crystalline. The 
crystallinity (subsequently referred to as bulk disorder) of SX was further assessed 
using DSC. The DSC traces were characteristic for SX, attributable to the two 
crystalline polymorphs of the drug, form I (SX-I) which is the more stable form and 
form II (SX-II) which is the metastable polymorph under ambient conditions (Tong et 
al., 2001). Unfractionated and crystallised SX displayed smaller SX-II endotherms than 
those derived from powder fractions depositing in the pre-separator or on Stages 4 and 
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5, when obtained at low heating rates, indicating that a smaller degree of conversion 
between the SX-I to SX-II form was occurring. Upon increasing the heating rate, the 
SX-II melting peak was eliminated at much lower heating rates for these two samples 
(i.e. unfractionated and crystalline) compared to the fractionated samples. Differences in 
polymorphic conversion rates between SX samples have been attributed to the presence 
of SX-II seeds that can arise from particle damage during powder processing such as 
micronisation (Tong et al., 2001). Following manual trituration, a pure SX-I polymorph 
which would have been initially absent of any seeds, generated a DSC trace that 
resembled that of micronised SX (Tong et al., 2001). This suggests that the fractionated 
particles contained greater crystal damage in comparison to the unfractionated and 
crystallised samples. 
 
Thermokinetic analysis using a modified Avrami Erofe’ev equation enabled 
quantification of a re-crystallisation rate constant (k) for the samples (Murnane et al., 
2008d). Whereas the k values of Stage 4 and 5 particles were comparable, pre-separator 
particles had a much higher k value, indicating greater bulk disorder in these particles. 
Differences in bulk disorder arise due to uncontrolled and variable amorphisation of 
particles during micronisation. The levels of amorphous content detected in micronised 
particles increases with the amount of energy imparted during size reduction, including 
the micronisation grind pressure (Ticehurst et al., 2000; Brodka-Pfeiffer et al., 2003b) 
and milling time (Young et al., 2007; Gaisford et al., 2010). Such processing leads to a 
distribution in the degree of damage/disorder within a single batch of powder. The 
crystal damage observed for fractionated SX particles may not have been detected in the 
unfractionated material due to the more severely damaged particles, as represented by 
the pre-separator and stage fraction samples, being present in a much smaller proportion 
in the bulk material. The most damaged particles in terms of bulk disorder, i.e. the pre-
separator sample, was found to have the lowest propensity for de-agglomeration during 
fractionation, as pre-separator particles formed larger agglomerates (dae > 12.8 µm) 
compared to Stage 4 and 5 particles (dae 0.55 – 1.66 µm). 
 
Changes to the crystal structure of a particle leading to disordered or amorphous regions 
on particle surfaces are also known to manifest as higher surface energy (Feeley et al., 
1998; Tong et al., 2001). These changes rarely distribute uniformly throughout the 
powder and can affect the powder’s processing and formulation characteristics (Feeley 
et al., 1998). IGC employed using the traditional method of infinite dilution, in which 
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very low solute concentrations are injected, probes only the highest energy sites and 
results in an overestimation of the surface energy. It also provides no indication of the 
heterogeneity of the particle surface (Ylä-Mäihäniemi et al., 2008). Finite dilution IGC 
enables an understanding of the surface energy across the particle surface to be attained. 
Although the dispersive surface energy values at low surface coverage revealed some 
differences between the samples, examining the surface energy distributions using finite 
dilution provided greater insight.  
 
Pre-separator SX particles had the lowest dispersive and total surface energy of the 
unfractionated and fractionated SX samples, despite having the highest bulk disorder 
when assessed by DSC. Stage 4 particles also exhibited comparable dispersive and total 
surface energy to the unfractionated material. Whereas the material isolated from Stage 
5 possessed the highest and most heterogeneous dispersive and total surface energy of 
all the samples. Surface energy arising from specific interactions provided a small 
contribution to the total surface energy for all the SX samples. There was little 
difference in the specific surface energy between the SX samples, with Stage 4 particles 
displaying the lowest and least heterogeneous specific surface energy. High dispersive 
and total surface energy for the Stage 5 particles, i.e. those with the smallest net 
individual mean particle size and largest surface area, may have arisen due to these 
particles having been subjected to the highest degree of particle attrition during 
comminution. These particles would therefore display a high degree of particle damage 
(Ticehurst et al., 2000; Brodka-Pfeiffer et al., 2003b; Young et al., 2007; Gaisford et al., 
2010) both to the bulk (represented by the k value) and surface (represented by the 
surface energy) of the particle. Higher dispersive surface energies have been reported 
with increasing milling energy and grinding pressures, and these exhibited an inverse 
relationship with reducing geometric particle size. It was suggested that greater forces 
experienced during micronisation leads to greater crystal disruption, and the formation 
of new highly energetic interaction sites and/or exposure of more energetic crystal faces 
(Shariare et al., 2011; Gamble et al., 2012).  Furthermore, size reduction of the particles 
may have occurred by different particle size reduction mechanisms (e.g. brittle fracture 
or attrition) and/or at different cleavage planes resulting in altered exposure of 
functional groups at the crystal surface, as the balance of dispersive and specific 
interactions differed for the particles. For example, Stage 4 SX exhibited higher 
dispersive and lower specific surface energy compared to unfractionated SX, whereas 
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pre-separator particles displayed lower dispersive and lower specific surface energy 
compared to unfractionated particles.  
 
In contrast to SX, the differences in surface energy between FP samples were less 
marked. There were only small differences in the surface energies between the 
unfractionated and fractionated samples; however, the fractionated samples appeared to 
possess lower dispersive and specific surface energy than unfractionated FP. Of these, 
the pre-separator particles displayed the lowest surface energy. Like SX, differences in 
the relative contributions of the dispersive and specific surface energies were observed, 
indicating that the fractionated materials consisted of particles with differing electron 
donating and accepting functional groups at the exposed crystal surface (Shariare et al., 
2011). 
 
The re-crystallised particles of both SX and FP displayed the lowest dispersive and total 
surface energy, as a consequence of the lack of process-induced damage (Rehman et al., 
2003; Shariare et al., 2011). For SX, the specific surface energy of the re-crystallised 
sample was higher and more heterogeneous than the unfractionated powder. This 
indicated an altered surface chemistry of particles within this sample. It has been 
suggested that this is due to greater exposure of proton donor and acceptor groups e.g. 
OH or COOH, and NH, respectively, compared to bulky non-polar groups such as 
benzene and naphthalene at the SX crystal surface, although molecular modeling would 
be required for confirmation (Tong et al., 2001). 
 
4.6.3 DISPERSIBILITY OF BULK, FRACTIONATED AND RE-
CRYSTALLISED DRUG POWDERS  
Each powder fraction displayed distinct aerosolisation behaviours when the fraction was 
considered as a bulk powder and re-aerosolised. A powder composed of pre-separator 
material would be likely to have a structure that comprised large agglomerates (> 12.8 
µm) exhibiting good flow (Hickey et al., 2007). Low inter-agglomerate cohesive forces 
are likely due to the relatively large agglomerate sizes, however, poor dispersal during 
fractionation would suggest that intra-agglomerate cohesive forces between the 
individual component particles was high. Both SX and FP pre-separator particles 
demonstrated a higher emission and a higher FPF than the respective unfractionated 
particles, although the differences were not significant (p > 0.05). Low inter-
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agglomerate cohesive forces would assist the efficient entrainment of powder 
agglomerates into the airstream during aerosolisation. High inter-particulate forces 
between individual particles may have restricted the efficiency of the fractionation, but 
during re-aerosolisation of the smaller powder mass into the NGI then the powder 
structure would be altered compared to the unfractionated starting material. The 
efficiency of de-agglomeration hence depends on the balance between high inter-
particulate cohesive forces, which is related to the powder structure, and the high 
aerodynamic drag forces and kinetic energy experienced by large agglomerates 
(compared to smaller agglomerates). The latter of which may increase de-agglomeration 
efficiency, for example through a greater number of collisions/impaction within the 
device (Begat et al., 2004). 
 
Changes in the intrinsic dispersibility of the pre-separator fractions as assessed by dry 
dispersion laser diffraction, however, differed between the two drugs. Whereas SX pre-
separator particles showed an improvement in the ease of de-agglomeration (DA50), for 
FP the DA50 of this fraction was worse compared to the respective unfractionated 
powder. The CPP also revealed a difference in the cohesive strength of the fractionated 
SX particles; there were negligible differences between the CPP of the stage fractions, 
but the CPP of the pre-separator SX particles was lower than that of the unfractionated 
material. These results correlated well with those relating to the total surface energy of 
the pre-separator sample which displayed the lowest energy in comparison to the 
powder derived from the stage fractions and the unfractionated material.  Whereas 
cascade impactor analysis considers powder entrainability (i.e. emission) and de-
agglomeration efficiency (i.e. FPF) as separate parameters, the ease of dispersibility (i.e. 
DA50) as determined using the laser diffraction technique incorporates the flow, 
entrainment and de-agglomeration of the powder, independent of the method of delivery 
(i.e. device and flow rate), into a single, powerful parameter for assessing powder 
dispersion. Measurements also take into account every type of interactive force present, 
as well as powder structure and history. The structural characteristics of a powder play 
an important role in dictating de-agglomeration patterns (Behara et al., 2011a; Behara et 
al., 2011b), and are influenced by the physicochemical properties of the individual 
particles. The work of cohesion (dependent on factors including the surface energy 
distribution of the particles), agglomerate structures resulting from the magnitude and 
distribution of interactive forces, packing fraction (i.e. volume of particles/volume of 
the agglomerate), and the size of the individual particles, dictate powder structure, and 
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can result in a lack of structure homogeneity across the powder bed (Kendall and 
Stainton, 2001; Behara et al., 2011b). It is therefore necessary to consider both the 
fundamental dispersibility of the powder and the powder delivery system, including the 
device, formulation and flow rate, when assessing powders for their de-agglomeration 
efficiency and developing delivery systems for optimised fine particle delivery to the 
lungs.  
 
The aerosol performance of the stage fractions differed between the drugs. The Stage 4 
SX powdered sample, despite having an improved DA50, showed no change in emission 
or FPF RD, but a higher FPF ED suggesting a degree of improved dispersibility, 
compared to unfractionated SX. Stage 5 deposited SX powder when re-aerosolised, 
however, displayed a comparable, poor, DA50 and a reduced FPF ED and RD (p < 0.05 
compared to unfractionated SX). When combined with the absence of change in the 
emission, the high DA50 and reduced FPF indicated a poorer de-agglomeration 
efficiency of Stage 5 SX particles. In this instance, a combination of a small particle 
size, high bulk disorder, and high surface energy resulted in a reduction in aerosol 
performance, where it is likely that strong cohesive forces (CPP = 3.0 Bar, Table 4.8) 
between the particles led to the formation of stable agglomerates that were difficult to 
disperse (Louey et al., 2004a). Conversely, stage fractionated FP (i.e. both Stage 3 and 4 
particles) showed an improvement in the DA50 and an increase in the FPF ED and RD 
(p < 0.05) in comparison to unfractionated material. Since there was no change in 
emission of the two fractions this indicated an improvement in de-agglomeration 
efficiency compared to unfractionated material. This improvement could not be 
attributed to changes in crystallanity or surface energy between the unfractionated and 
stage fractionated FP particles, and highlights the complexity in the factors that 
influence the de-agglomeration process. It was also not possible to deduce a CPP for the 
unfractionated or fractionated FP samples, despite a change in the DA50. The particle 
size-primary pressure profiles flattened as the dispersing pressure increased, however, 
examination of this region of the curve indicated that the particle size continued to 
reduce up to 5.0 Bar. The magnitude of the reduction was small in comparison to the 
early region of the curve (e.g. for Stage 3 FP, Dv50 = 12.29 µm at 0.2 Bar, Dv50 = 2.75 
µm at 1.5 Bar and Dv50 = 1.80 µm at 5.0 Bar). It is likely that a combination of particle 
heterogeneity and particle fracture/attrition (as a result of high dispersing pressures) 
resulted in the lack of a plateau region in the profile. 
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The lower surface energy and larger size of the re-crystallised control particles resulted 
in improved dispersibility in terms of the DA50 for both drugs, as well as the 
entrainability of SX and the de-agglomeration efficiency (i.e. FPF) of FP compared to 
the unfractionated powders. Although the FPF of SX was lower than for the 
unfractionated particles, there was higher retention in the throat and pre-separator, 
which was attributed to the larger particle size of the re-crystallised material resulting in 
greater impaction. Had the PSD been reduced by modifying and optimising the 
crystallisation conditions, it can be postulated that the FPF may have been improved 
compared to that achieved using unfractionated particles. The FPFs of precipitated drug 
crystals have been shown to be higher than jet-milled particles for both disodium 
chromoglycate (Steckel et al., 2003a), and salbutamol sulphate (Shariare et al., 2011), 
and equivalent for SX (Murnane et al., 2009). FP crystals have demonstrated improved 
(Steckel et al., 2003b), or similar (Murnane et al., 2009) FPFs depending on the 
crystallisation conditions employed.  In addition to the omission of the high energy 
micronisation step, other factors such as altered surface chemistry, and changes to 
particle shape, particularly for FP, would also have contributed to the difference in 
aerosolisation behaviour that occurred.  
 
4.6.4 CONCLUSIONS 
This study has shown that SX and FP powders fractionated into distinct aerodynamic 
size classes comprised sub-populations of the bulk micronised powder. These sub-
populations consisted of individual particles agglomerated to varying extents and 
displaying distinct physicochemical properties of crystallinity and surface energy. The 
sub-populations showed differences in both their intrinsic dispersibility and aerosol 
performance when aerosolised into the NGI. This may have implications for the 
performance of the drug powders when co-formulated, and will be studied in later 
chapters. This study has highlighted the importance of considering powders as 
collections of particle populations with their own distinct properties, the need to 
consider powder properties as distributions, and on an individual basis according to the 
drug. By gaining better control over the generation and properties of sub-populations of 
particles, this can lead to the optimisation of powder properties for the efficient delivery 
of drug particles to the lungs. 
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5.1 INTRODUCTION 
Asthma and COPD are characterised by airway inflammation, smooth muscle 
dysfunction and airway limitation (Nelson et al., 2003; ATS/ERS Task Force, 2004). In 
order to target the different components of the disease, corticosteroids and 
bronchodilators are often administered together (Aubier et al., 1999). In Europe, there 
are currently four commercially available combination LABA/ICS products containing 
fluticasone propionate (FP) and salmeterol xinafaote (SX), FP and formoterol fumarate, 
budesonide (Bud) and formoterol fumarate, and beclometasone dipropionate (BDP) and 
formoterol fumarate (Tamm et al., 2012). The use of combination inhalers has been 
shown to be at least as effective as separate delivery of each drug (Bateman et al., 1998; 
Aubier et al., 1999; Chapman, 1999; Hagedorn et al., 2013). Improved patient outcomes 
(Kavuru et al., 2000; Nelson et al., 2003), steroid sparing effects (Busse et al., 2003; 
Jarjour et al., 2006) and improved patient adherence due to the simplification of 
medication regimens (BTS/SIGN, 2008 (revised 2012)) are also likely. By delivering 
two drugs from a single inhaler rather than separate devices, differences in deposition 
patterns arising from natural variations in inspiratory manoeuvres (both intra- and inter-
patient) may also be avoided (Theophilus et al., 2006). 
 
A physicochemical interaction between the two drugs during manufacture/delivery may 
alter the aerosolisation of drugs from combination formulations. This has the potential 
to enhance patient outcomes if there is an altered deposition profile leading to improved 
fine particle delivery of the drug/s to the target regions of the lungs (Taki et al., 2011). 
In Chapter 3, SX and FP aerosolisation performance, in terms of the FPF for SX, and 
the MMAD for FP, were altered upon co-formulation. However, these blends did not 
contain a carrier. In a carrier-based formulation, the range of physicochemical 
interactions that may occur between the different components in a combination DPI is 
numerous, resulting in a complicated multi-factorial scenario (Taki et al., 2011a). The 
role of carriers and fines as dispersion aids is well established, although the exact 
mechanism of action of fines is still not fully understood. The addition of a second drug 
to a formulation therefore adds an extra level of complexity in attempting to determine 
any potential performance modifying effects of the drug/s. For example, alterations in 
the aerosolisation profiles of SX and FP when delivered in combination have been 
reported, but it was not possible to attribute these to SX/FP interactions, as the grade 
and concentration of the coarse and fine lactose in the formulation, and the 
 Page | 169  
 
manufacturing history of the inhaler products were not known (Taki et al., 2011). As 
identified in Chapter 4, intra-batch variability in properties within a bulk micronised 
powder can also occur, and may alter the aerosolisability of powder sub-populations 
when compared to the bulk powder. This may further influence the aerosolisation 
performance of drug powders following co-formulation, and the implications of this 
will be studied in a later chapter. 
 
Drug co-association in combination formulations has been studied using the Raman 
microscope for both pMDI (Steele et al., 2004; Theophilus et al., 2006; Rogueda et al., 
2011) and DPI formulations (Jetmalani et al., 2012; Traini et al., 2012; Vernall et al, 
2012) containing the drug combinations SX and FP, Bud and formoterol fumarate, and 
salbutamol base and BDP. This technique is useful in multicomponent formulations as it 
enables individual drugs to be chemically identified. Imaging of NGI plates following 
aerosol delivery of combination DPIs and pMDIs has suggested that drug particles may 
deposit as mixed agglomerates. In these studies, co-association was assessed through 
qualitative interpretation of Raman images and spectra, using the PSD/particle and 
agglomerate counts, and novel statistical analysis. Single particle techniques such as 
aerosol time of flight mass spectroscopy also allows the chemical identity of particles to 
be determined, and has also identified co-association between SX and FP particles in 
combination DPI and pMDI formulations (New et al., 2008). Another approach has 
been to consider the stage deposition across an impactor for formulations containing 
particles of each drug in a physical powder mix, or combination particles which contain 
both drug entities in a single particle (Kumon et al., 2010). Whereas parameters such as 
the emission and FPF provide an indication of powder entrainability and de-
agglomeration efficiency, the stage-by-stage deposition provides an indication of how 
uniformly each drug is delivered across the impactor (Pitchayajittipong et al., 2009). 
Where both drugs in a formulation have demonstrated concomitant in vitro deposition 
patterns, this has been attributed to co-deposition of the drugs (Westmeier and Steckel, 
2008; Pitchayajittipong et al., 2009; Kumon et al., 2010; Adi et al., 2012; Traini et al., 
2012). 
 
Although studies have investigated the presence of co-association, the cause of particle 
association is still not clear. Whereas SX and FP interactions and co-aggregation to 
form hetero-flocs have been identified in pMDI formulations (Michael et al., 2000; 
Michael et al., 2001), DPI formulations differ greatly in their composition. For example, 
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a 30 % increase in co-associated SX and FP particles from the Seretide DPI has been 
reported compared to the pMDI (New et al., 2008). An interactive affinity between SX 
and FP powder particles has been reported (Young et al, 2004a; Kubavat et al., 2012), 
and this may alter the aerosolisation performance of one or both drugs in combination 
formulations. To identify this, test formulations need to be prepared that are matched in 
terms of their manufacturing, storage and drug content, as well as fines and carrier 
properties and load. Also, to identify the origin of any altered performance, it is 
necessary to assess the performance of the combination drug-drug powder mixes 
(subsequently referred to as pre-blends) prior to formulating with lactose, to allow any 
carrier effects to be discounted. Any drug-drug interactions within DPI formulations 
which may lead to co-association of the particles can therefore occur at a number of 
stages during manufacture and delivery. These include processing steps such as 
blending and capsule filling/device manufacture, upon storage, as well as in the aerosol 
plume during and following actuation (New et al., 2008). Any property/process which 
affects agglomeration has the potential to influence particle co-association and mixed 
agglomerate formation. It is currently not known at what stage co-association of SX and 
FP particles may occur in powder formulations, however, gaining such understanding 
would enable formulations to be designed for optimal dispersion performance. For 
example, the generation of agglomerates consisting of FP nanoparticles and salbutamol 
sulphate (SS) did not change the dispersion (in terms of FPF) of FP compared to the 
single drug nanoparticle agglomerates, but changes to the dispersion of SS were 
attributed to FP agglomerates functioning as a carrier for SS in the mixed agglomerate 
formulations (El-Gendy et al., 2011). Further complexity also arises as particle co-
association may not be a class effect and thus may differ depending on the specific drug 
combination in the formulation (Rogueda et al., 2011).  
 
Whether or not particle co-association occurs in DPI formulations, the presence of a 
second drug has the potential to alter bulk powder properties including powder flow, 
packing, and tensile strength (Shur et al., 2008). The cohesive and adhesive tendencies 
of the drugs will alter the balance of interactions in the formulation and thus the powder 
structure. The combination formulation may have a higher fine particle content, which 
in a similar manner to the presence of in situ or ex situ lactose fines, may increase the 
tensile strength of the powder bed. The resulting stabilisation of the powder bed towards 
disturbance by an airflow may alter the mechanism of powder entrainment and 
subsequent dispersion (Shur et al., 2008). An increase in cohesive/adhesive forces 
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between individual particles can increase agglomerate strength, but the latter is also 
influenced by the packing fraction (i.e. volume of particles/volume of agglomerate), 
particle size and agglomerate structure (Kendall and Stainton, 2001). A high drug 
concentration, particularly of inherently cohesive drugs, may also be detrimental to 
mixing and content uniformity of powder blends, due to powder agglomeration and thus 
segregation (Le et al., 2012d). An understanding of bulk powder properties is therefore 
also necessary in the development of combination DPI formulations. 
 
5.2 AIM AND OBJECTIVES 
The aim of this study was to probe the occurrence of SX and FP co-association in 
combination formulations and determine the implications on powder aerosolisation. The 
objectives were therefore to: 
a) Establish benchmark data for the aerodynamic PSD and intrinsic dispersibility of 
Seretide Accuhalers to determine the effect of drug ratio and flow rate on the 
aerosolisation of co-formulations. 
b) As a measure of co-association, use the SX:FP ratio of the deposited masses across 
the NGI to determine SX and FP co-association in Seretide Accuhalers as a function 
of product strength and flow rate. 
c) Measure the aerodynamic PSD and intrinsic dispersibility of SX and FP when 
formulated as representative DPI formulations and SX:FP pre-blends to ascertain: 
a. The dispersion modifying effects of SX and FP when blended in different 
ratios in the absence and presence of a carrier. 
b. Co-association of the drugs as a function of drug ratio and in the absence and 
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5.3 MATERIALS 
The materials and equipment used in Chapter 5, not listed in Section 2.3, 3.3 and 4.3, 
are shown in Table 5.1.   
 
Table 5.1 Suppliers of materials and equipment (Chapter 5). 
Material / Equipment Supplier 
Coarse lactose (CL; BN: 120904-25) Pfizer Ltd, PGRD Sandwich Laboratories, UK  
Minisart single use filter unit (0.2 µm pore 
size)  
Sartorius Stedium biotech, UK 
Seretide Accuhalers Allen and Hanburys Ltd, UK (supplied by AAH 
Pharmaceuticals, UK. See Table 5.2 for BN.) 
Sympatec INHALER 2000 Sympatec GmbH, Clausthal-Zellerfeld, Germany 
Critical flow controller TPK  Copley Scientific Ltd, UK 
 
5.4 METHODS 
5.4.1 BLEND PREPARATION 
5.4.1.1 PRE-BLENDS 
Pre-blends containing micronised (i.e. unfractionated) SX and FP particles were 
prepared in the ratios 1:8, 1:1 and 8:1 by geometric mixing. Equal quantities of each 
drug (27.78 mg for the 1:8 and 8:1 ratios, 31.25 mg for the 1:1 ratio) were weighed 
directly into the blending vessel (a 4 mL glass HPLC vial) and subjected to 
whirlimixing for 60 s. The vial was tapped to remove any powder adhered to the inside 
walls and a second addition of drug was made, in an equal quantity, such that the total 
powder mass was doubled. The vessel was then whirlimixed and tapped as above. This 
procedure was repeated until the required amount of each drug had been added to a final 
total blend mass of 250 mg. A single glass bead (diameter approx. 5 mm) was added to 
the vessel and the blend was placed in a Turbula blender for 40 min at 62 rpm. 
 
5.4.1.2  DRY POWDER INHALER BLENDS 
DPI blends were prepared containing 1.38 % w/w micronised (i.e. unfractionated) SX, 
FP or SX:FP pre-blend (SX:FP ratio 8:1, 1:1, 1:8). The total blend size was 3 g. First, 
41.4 mg of SX, FP or pre-blend was sandwiched between two layers (41.4 mg each) of 
CL (Dv10 = 28.5 ± 0.78 µm, Dv50 = 56.4 ± 0.20 µm, Dv90 = 88.8 ± 0.43 µm, determined 
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by Sympatec HELOS/RODOS dry dispersion laser diffraction at 3.0 Bar PP) in the 
blending vessel (15 mL glass vial) and subjected to whirlimixing for 60 s. Lactose 
additions were made geometrically, followed by whirlimixing after each addition, such 
that the mass of the blend doubled, up to the final blend mass. Blend homogeneity 
samples were removed (10 x 12.5 mg) as well as a further sample (approx. 75 mg) for 
ad hoc analysis. Two ceramic balls (diameter approx. 10 mm) were then added to the 
vessel and placed in a Turbula blender for 40 min at 62 rpm.  
 
5.4.2 BLEND HOMOGENEITY 
5.4.2.1 PRE-BLENDS 
To assess the homogeneity of the pre-blends, approximately 2 mg of blend was 
accurately weighed and dissolved in mobile phase (prepared as described in Section 
3.4.1.1) with the aid of sonication prior to being made to final volume (10 mL). Drug 
recovery was assessed by HPLC analysis (as described in Section 3.4.1.1) using freshly 
prepared mixed standard calibration curves in the range 20 – 400 µg.mL-1. To assess 
homogeneity, the theoretical concentration of SX and FP in each sample was calculated 
from the sample mass, compared to the detected concentration, and expressed as a 
percentage recovery (PR, %). The blend was considered homogenous when the CV of 
the PR values of the samples (n = 6) was less than 10 %. The SX and FP content was 
calculated by converting the detected drug concentration into a drug mass, which was 
then expressed as a proportion of the weighed sample mass (in µg.mg
-1
) for each 
content uniformity sample. The mean drug content of the samples was then used to 
calculate the detected SX:FP ratio. 
 
5.4.2.2 DRY POWDER INHALER BLENDS 
The content uniformity of the DPI blends was assessed at two time points. The first was 
after geometric mixing of the powders i.e. prior to tumbling (n = 10) and the second was 
following tumbling in the Turbula blender (n = 6). Samples were prepared by accurately 
weighing 12.5 mg of blend and dissolving in 20 mL mobile phase (see Section 3.4.1.1) 
for SX and FP in the ratio 1:1, and 10 mL for the ratios 1:8, 8:1, 1:0 and 0:1 with the aid 
of sonication for approx. 10 min until the powder dissolved. The samples were syringe 
filtered (0.20 µm pore size filter unit), to remove any un-dissolved lactose particles prior 
to analysis. Drug recovery was assessed by HPLC (see Section 3.4.1.1.) using freshly 
prepared mixed standard calibration curves in the range 0.5 - 50 µg.mL
-1
. The % CV of 
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the PR values and the detected drug ratios were calculated as described in Section 3.4.3 
at both time points. The blend was considered homogenous when the % CV of the PR 
values at time point two was < 10 %.  
 
5.4.3 SCANNING ELECTRON MICROSCOPY  
SEM imaging to view the morphology of the pre-blends and DPI blends was undertaken 
as described in Chapter 2, Section 2.4.2, using an FEI Quanta 200F field emission SEM 
however high vacuum mode was employed and the microscope was operated at 3.5 kV. 
 
5.4.4 WORK OF COHESION AND ADHESION 
Surface energy analysis of CL was conducted using an IGC Surface Energy Analyser as 
described in Chapter 3, Section 3.4.8, and the dispersive, specific and total surface 
energy distributions were determined. The work of cohesion and work of adhesion 
between the different powders was calculated according to Equation 2.11. 
 
5.4.5 NEXT GENERATION IMPACTOR ANALYSIS 
5.4.5.1 SERETIDE DRY POWDER INHALER PRODUCTS  
NGI analysis was conducted as described in Chapter 3, Section 3.4.6 with the following 
modifications. The flow rate through the NGI was adjusted to 67 ± 5 %  L.min
-1
 and 90 
± 5 % L.min
-1
 corresponding to pressure drops across the device of approximately 2 and 
4 kPa, respectively. These flow rates were determined using a dose uniformity sampling 
apparatus (DUSA). The DUSA was attached to a vacuum pump, and a critical flow 
controller TPK was used to set the pressure drop required. The inhaler was attached to 
the DUSA, the vacuum pump switched on, and the flow rate measured using a flow 
meter. For each NGI analysis, the vacuum pump was switched on for 3.6 s and 2.7 s, 
respectively, for the two flow rates in order to correspond to 4 L of air being drawn 
through the NGI. To quantify the amount of drug depositing, the throat and pre-
separator were rinsed with 50 mL and 100 mL of mobile phase (Section 3.4.1.1) 
respectively. The samples were sonicated (approx. 5 min and 20 min, respectively) prior 
to being made up to final volume; the pre-separator sample was filtered (syringe filter 
unit, 0.20 µm pore size) to remove un-dissolved lactose as necessary prior to 
quantification.  The stages were rinsed with 10 mL and 5 mL mobile phase for stages 1 
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– 5 and 6 – 8, respectively, with the aid of sonication (approx. 1 min per plate). Three 
batches of SA100 and SA500 were tested at each flow rate (10 actuations per run, n = 
3), and are subsequently referred to as B1 – 3 as shown in Table 5.2. 
 
Table 5.2 Batch characteristics of the Seretide Accuhalers tested  in the study. 
Identifier Batch Number Expiry Date (month.year) 
Seretide Accuhaler 100 (SA100) 
Batch 1 (B1) R174041 10.2006 
Batch 2 (B2) R564583 04.2013 
Batch 3 (B3) 0241-1 01.2014 
Seretide Accuhaler 500 (SA500) 
Batch 1 (B1) R177573 11.2006 
Batch 2 (B2) R572744 07.2013 
Batch 3 (B3) 1413-2-1 12.2013 
 
5.4.5.2 PRE-BLENDS 
NGI analysis of the pre-blends (n = 3) was conducted as described in Chapter 3, Section 
3.4.6 using a flow rate of 60 L.min
-1
 ± 5 % (corresponding to a pressure drop of 1.4 
kPa) for 4 s. The Monodose inhaler device was used as previously except in this 
instance a capsule fill weight of 10.0 ± 1.0 mg was employed and a single capsule was 
actuated per NGI analysis. The device, capsules, throat and pre-separator were rinsed 
with 50 mL, 20 mL, 50 mL and 100 mL of mobile phase (Section 3.4.1.1), respectively, 
with the aid of sonication (approx. 5 min) prior to being made up to final volume. The 
stages were rinsed with 10 mL and 5 mL of mobile phase for stages 1 – 5 and 6 – 8, 
respectively, with sonication (approx. 1 min per plate). 
 
5.4.5.3 DRY POWDER INHALER BLENDS 
NGI analysis of the DPI blends was carried out as described in Chapter 3, Section 3.4.6, 
using a flow rate of 60 L.min
-1
 ± 5 % for 4 s and a Monodose inhaler device, with the 
following modifications. The capsule fill weight was 12.5 ± 0.5 mg and the number of 
capsules actuated was six for the SX-only (1:0) and the FP-only (0:1) DPIs, and fifteen 
capsules for the 1:8, 1:1 and 8:1 DPIs.  For the DPIs with SX:FP ratios 1:0 and 0:1, the 
device, capsules, throat and pre-separator were rinsed with 50 mL, 20 mL, 50 mL and 
100 mL of mobile phase (Section 3.4.1.1), respectively, with sonication (approx. 5 min; 
10 min for the pre-separator sample) prior to being made up to final volume. Stages 1 – 
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5 were rinsed with 5 mL and stages 6 - 8 with 2.5 mL of mobile phase, with the aid of 
sonication (approx. 1 min and 30 s, respectively). For the DPIs containing SX:FP in the 
ratio 1:8. 1:1 and 8:1, due to the larger number of capsules employed, 50 mL mobile 
phase was used to recover the drug remaining in the capsules; the pre-separator sample 
was also sonicated for 20 min, after which the sample was filtered (syringe filter, 0.20 
µm pore size) if undissolved lactose was visible. For the 1:8 and 8:1 DPIs, rinse 
solutions from the stages were pooled to ensure that the deposited drug was detectable 
using the HPLC method described (Section 3.4.1.1). The protocol adopted was as 
follows: stage 1 was rinsed with 5 mL mobile phase with sonication (1 min), stage 2 
was rinsed with 2.5 mL mobile phase with sonication (30 s). For stage 3, rinsing was 
with 2.5 mL mobile phase followed by sonication (30 s). The sample was then 
transferred into stage 4, to which a further 2.5 mL of mobile phase was added and 
sonicated (30 s) to form a single sample for stages 3 – 4. This process was repeated for 
stages 5 – 6 and stages 7 – 8. Each NGI run therefore consisted of samples 
corresponding to drug deposition in the device, capsules, throat, pre-separator, stage 1, 
stage 2, stages 3 – 4, stages 5 – 6, and stages 7 – 8.    
 
5.4.5.4 QUANTIFICATION BY HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY  
The quantification of drug recovery for the NGI samples was using the HPLC method 
described in Chapter 3, Section 3.4.1.1. For the SA100 and SA500, B1, freshly prepared 
calibration curves were pooled (n = 5) in the range 0.5 – 25 µg.mL-1 for SX and 0.5 - 50 
µg.mL
-1
 for FP.  For the remaining batches, new calibration curves were prepared on the 
day of sample analysis. For the pre-blends, fresh calibration curves were pooled (n = 5) 
in the range 0.5 – 50 µg.mL-1 (or 20 – 400 µg.mL-1 for individual samples outside this 
range). For the DPI blends, calibration curves were prepared on the day in the range 0.1 
– 50 µg.mL-1 (standards below 0.5 µg.mL-1 were prepared by dilution of the lowest 
standard) and 20 – 100 µg.mL-1 where necessary, and the range of standards used was 
selected based on the samples.  
 
5.4.6 DISPERSIBILITY ASSESSMENT BY LASER DIFFRACTION 
5.4.6.1 SYMPATEC HELOS/RODOS 
De-agglomeration analysis was conducted using the Sympatec HELOS/RODOS and 
protruding aspiration tube as described in Chapter 2, Section 2.4.4. The Dv50 particle 
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size data were normalised using the DH/Dx approach and empirically modelled using 
Equation 2.8. The SA100 (B3, BN. 0241-1) and SA500 (B3, BN. 1412-2-1) inhalers 
were opened by hand and the contents of the blister strip transferred into glass vials and 
stored in a desiccator until required. Particle size measurements for the DPI blends and 
SA inhalers were made at primary pressures (PPs) in the range 0.2 – 5.0 Bar (n = 1) 
with the following modifications. The Copt to trigger the start of the measurement was 
reduced to ≥ 0.5 %. In order to remove the influence of coarse particles in the 
calculation of the PSD to allow changes in the fine particle PSD as a function of 
primary pressure to be deduced, a forced stability of ‘9’ was applied. This removed data 
corresponding to particles larger than 40 µm, providing insight into the de-
agglomeration behaviour of the fine fraction. At each PP, the Dv10, Dv50, Dv90 and VMD 
were recorded. 
 
5.4.6.2 SYMPATEC INHALER 2000 
Particle size measurements were made using the Sympatec INHALER 2000 for the 
SA100 (B1, BN. R174041) and SA500 (B1, BN. R177573) products. An empty 
Accuhaler device was first used to determine the instrument pressure drop required to 
achieve the flow rates of interest i.e. 67 L.min
-1
 ± 5 % and 90 L.min
-1
 ± 5 %. The R3 
lens was used (0.5 – 175 µm), timebase 1 ms, and trigger conditions of Copt ≥ 0.1 % to 
start a measurement and Copt ≤ 0.2 % for 4 s (or 4 s real time) to end a measurement. A 
reference was taken; the inhaler was primed and then held firmly in place at the inlet 
prior to initiating the measurement using the instrument software (WINDOX 5.0, 
Sympatec GmbH, Clausthal-Zellerfeld, Germany). In order to determine the change in 
the fine fraction (FF) during the measurement, the time slice feature was used, with the 
particle size data being recorded by the instrument every 250 ms over a 4 s period.  If 16 
time slice measurements were not generated, which would correspond to a total 
measurement duration of 4 s, the measurement was repeated (n = 3 - 4). The PSD was 
calculated using Fraunhofer theory. The cumulative distribution was used to monitor the 
change in the percentage of particles < 5 µm and < 15 µm during the 4 s measurement. 
The area under the curve (AUC) over the 4 s period was calculated in Origin Pro 8 
using the ‘Integrate Multiple Peaks’ function. The AUC was divided into eight sections 
covering 0.50 s segments of the measurement period (except for 0.25 – 0.50 s, for which 
a 0.25 s segment was used), using a constant y baseline (i.e. y = 0). The total AUC was 
calculated by summing the AUC values derived from each of the eight sections. 
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5.5 RESULTS 
5.5.1 SERETIDE DRY POWDER INHALER PRODUCTS  
5.5.1.1  NEXT GENERATION IMPACTOR ANALYSIS 
5.5.1.1.1 BATCH EFFECTS 
In order to determine batch-to-batch consistency prior to probing the effect of product 
strength and flow rate on aerosolisation behaviour, the reproducibility of three batches 
of SA100 and SA500 in terms of their aerodynamic deposition profile was assessed. 
The European Medicines Agency (EMEA) guidance for demonstrating bioequivalence 
states that inhalation products should show no greater than ± 15 % variability with 
regards to the individual stage deposition, or four justified grouped stages, which 
incorporate the fine particle mass and the upper stages of the impactor (EMEA, 2009). 
The BP (2012) further stipulates that products should show no greater than 15 % 
deviation in their dosage uniformity. In order to account for variability in the recovered 
doses between NGI analyses, the amounts of drug depositing on the stages (per 
actuation) were normalised to the recovered dose (Equation 5.1).  
 
Equation 5.1                       
                            
                    ⁄
                    
 
 
Figure 5.1 and Figure 5.2 show the amount of SX and FP deposited, normalised to the 
recovered dose, for the grouped stages as follows: throat and pre-separator, stages 1 – 2, 
stage 3 and stages 4 – 7. In the majority of instances the deposition profiles were within 
the ± 15 % variability limits indicated by the EMEA. On a few occasions the deposition 
was within ± 20 %, indicated by an unfilled star in Figure 5.1 and Figure 5.2 (i.e. FP, 
SA500, stage 4 – 7, 60 and 90 L.min-1; SX, SA500, stage 3, 90 L.min-1). A limit of 20 
% was recommended when assessing the accuracy and precision of dose delivery for a 
number of inhaler devices, including DPIs (Prime et al., 1999). Three grouped stages 
remained outside the ± 20 % limit, however, the magnitude of these deviations was 
considered to be small (indicated by a filled star in Figure 5.1 and Figure 5.2). 
Therefore, although the SA products did not fully align with the EMEA guidance on 
variability, they were considered equivalent for the purposes of this study. 
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Figure 5.1 The amount of salmeterol xinafoate (SX) deposited per actuation, normalised to the total recovered dose, in the Next Generation Impactor for three 
batches of Seretide Accuhaler 100 (SA100) and 500 (SA500) aerosolised at 67 and 90 L.min
-1
 (n = 3 per batch, values are within the range mean ± 15 % deviation, 
except      where the deviation was ± 20 % and      where the deviation exceeded ± 20 %). 





Stage 4 - 7
0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09
Amount Deposited per Actuation (normalised to recovered dose)
SA100 at 67 L.min
-1





Stage 4 - 7
0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09
Amount Deposited per Actuation (normalised to recovered dose)
SA500 at 67 L.min
-1





Stage 4 - 7
0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09
Amount Deposited per Actuation (normalised to recovered dose)
SA100 at 90 L.min
-1





Stage 4 - 7
0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09
Amount Deposited per Actuation (normalised to recovered dose)
SA500 at 90 L.min
-1
 Batch 1  Batch 2  Batch 3
 
Figure 5.2 The amount of fluticasone propionate (FP) deposited per actuation, normalised to the total recovered dose, in the Next Generation 
Impactor for three batches of Seretide Accuhaler 100 (SA100) and 500 (SA500) aerosolised at 67 and 90 L.min
-1
 (n = 3 per batch, values are within 
the range mean ± 15 % deviation, except     where the deviation was ± 20 % and     where the deviation exceeded ± 20 %). 
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5.5.1.1.2 STRENGTH AND FLOW RATE EFFECTS 
A summary of the recovery, FPF (% ED), FPM, MMAD, and GSD of the SA100 and 
SA500 batches are shown in Table 5.3 and Table 5.4. In order to ascertain the effect of 
product strength and flow rate on aerosolisation performance, the data from the three 
batches were pooled according to the product strength i.e. SA100 (n = 9) and SA500 (n 
= 9) for SX and FP. A two-way ANOVA was then employed post-hoc to determine the 
statistical effects (p < 0.05, using GraphPad Prism 5) of product strength and flow rate 
on the aerodynamic deposition profile. 
 
For SX, there was no change in the FPF or FPM with either product strength or flow 
rate (interaction term p > 0.05 for both). This indicates good reproducibility of the 
delivered dose regardless of flow rate or the amount of FP in the inhaler formulation. 
There was however a change in the MMAD (interaction term p > 0.05) with flow rate 
only, in which for both the SA100 and SA500 inhaler an increase in the MMAD 
occurred at higher flow rates. Although the MMAD was smaller for the SA500 than the 
SA100 at both flow rates, this difference was not significant (p > 0.05).  
 
For FP, the FPF was also unaffected between flow rates or product strength (interaction 
term p > 0.05); the FPM (interaction term p > 0.05), however, increased significantly 
which is not unexpected as the higher strength product contains a greater proportion of 
FP. A change in the MMAD was also observed for FP (interaction term p > 0.05). The 
MMAD from the higher strength product was smaller than the lower strength product at 
both flow rates (p < 0.05). An increase in the MMAD of FP was also seen at higher 
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Table 5.3 The recovery (% of the actuated dose), fine particle fraction (FPF; % < 5 µm), fine particle mass (FPM) per actuation (< 5 µm), mass 
median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of salmeterol xinafoate (SX) from Seretide Accuhaler 100 (SA100) 
and 500 (SA500) inhalers aerosolised into the Next Generation Impactor at airflow rates of 67 and 90 L.min
-1
 (mean ± SD, n = 3 – 4). 
Inhaler  Flow Rate (L.min
-1
) Batch  Date of Experiment 
(month.year) 
Recovery (%) FPF  (% ED) FPM (µg) MMAD (µm) GSD  
 
SA100 67 B1 06.2011 83.1 ± 2.26 17.4 ± 1.29 10.5 ± 1.03 4.21 ± 0.14 2.15 ± 0.06 
 67 B2 10.2012 88.9 ± 1.68 16.0 ± 0.62 10.3 ± 0.50 4.70 ± 0.16 2.23 ± 0.04 
 67 B3 10.2012 91.2 ± 1.50 23.6 ±1.21 15.6 ± 0.95 3.38 ± 0.18 2.19 ± 0.02 
 Mean of n = 9 NGI runs 19.0 ± 3.60 12.1 ± 2.69 4.10 ± 0.60 2.19 ± 0.05 
 90 B1 06.2011 79.3 ± 5.40 14.9 ± 1.72 8.59 ± 1.56 4.43 ± 0.36 2.33 ± 0.01 
 90 B2 10.2012 88.0 ± 4.36 14.6 ± 0.34 9.30 ± 0.31 5.44 ± 0.12 2.36 ± 0.03 
 90 B3 10.2012 102 ± 2.03 23.8 ± 1.16 13.2 ± 8.82 3.68 ± 0.11 2.15 ± 0.04 
 Mean of n = 9 NGI runs 17.8 ± 4.65 11.8 ± 4.42 4.52 ± 0.79 2.28 ± 0.10 
SA500 67 B1 06.2011 75.6 ± 3.20 18.4 ± 1.24 9.84 ± 0.84 3.69 ± 0.12 2.09 ± 0.03 
 67 B2 10.2012 95.0 ± 0.95 15.6 ± 0.28 8.06 ± 5.38 4.18 ± 0.04 2.14 ± 0.02 
 67 B3 10.2012 93.9 ± 7.07 21.1 ± 1.45 14.3 ± 0.95 3.46 ± 0.03 1.99 ± 0.03 
 Mean of n = 9 NGI runs 18.4 ± 2.57 11.6 ± 2.16 3.78 ± 0.32 2.07 ± 0.07 
 90 B1 06.2011 74.4 ± 1.72 16.9 ± 1.13 9.11 ± 0.82 3.95 ± 0.12 2.20 ± 0.03 
 90 B2 10.2012 96.0 ± 3.25 14.3 ± 0.34 9.92 ± 0.33 4.66 ± 0.24 2.17 ± 0.13 
 90 B3 10.2012 101 ± 5.27 22.0 ± 1.25 16.1 ± 1.08 3.90 ± 0.10 2.02 ± 0.03 
 Mean of n = 9 NGI runs 17.7 ± 3.50 11.7 ± 3.40 4.17 ± 0.11 2.13 ± 0.11 
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Table 5.4 The recovery (% of the actuated dose), fine particle fraction (FPF; % < 5 µm), fine particle mass (FPM) per actuation (< 5 µm), mass 
median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of fluticasone propionate (FP) from Seretide Accuhaler 100 
(SA100) and 500 (SA500) inhalers aerosolised into the Next Generation Impactor at airflow rates of 67 and 90 L.min
-1
 (mean ± SD, n = 3 – 4).  
Inhaler Flow Rate (L.min
-1
) Batch  Date of Experiment 
(month.year) 
Recovery (%) FPF (% ED) FPM (µg) MMAD (µm) GSD 
SA100 67 B1 06.2011 94.7 ± 3.04 18.5 ± 0.98 17.6 ± 0.42 4.00 ± 0.11 2.17 ± 0.07 
 67 B2 10.2012 105 ± 4.14 16.2 ± 0.63 17.1 ± 1.00 4.36 ± 0.02 2.22 ± 0.16 
 67 B3 10.2012 115 ± 12.0 18.4 ± 1.35 21.3 ± 3.20 3.77 ± 0.51 2.17 ± 0.20 
 Mean of n = 9 NGI runs 17.7 ± 1.43 18.6 ± 2.64 4.04 ± 0.37 2.19 ± 2.64 
 90 B1 06.2011 94.9 ± 7.88 16.4 ± 1.60 15.6 ± 2.56 4.23 ± 0.27 2.23 ± 0.04 
 90 B2 10.2012 89.7 ± 9.73 16.9 ± 1.51 15.1 ± 0.68 5.01 ± 0.12 2.36 ± 0.04 
 90 B3 10.2012 114 ± 8.02 23.4 ± 1.38 20.0 ± 13.3 3.70 ± 0.10 2.05 ± 0.03 
 Mean of n = 9 NGI runs 18.9 ± 3.59 19.1 ± 5.81 4.31 ± 0.59 2.21 ± 0.14 
SA500 67 B1 06.2011 88.7 ± 1.42 20.8 ± 1.49 92.3 ± 5.69 3.61 ± 0.10 2.02 ± 0.06 
 67 B2 10.2012 93.3 ± 5.47 18.0 ± 0.76 62.7 ± 41.8 3.94 ± 0.04 2.06 ± 0.05 
 67 B3 10.2012 96.7 ± 11.7 22.1 ± 2.17 106 ± 6.43 3.43 ± 0.05 2.00 ± 0.02 
 Mean of n = 9 NGI runs 20.3 ± 2.30 94.0 ± 10.8 3.66 ± 0.23 2.03 ± 0.05 
 90 B1 06.2011 86.5 ± 1.48 19.6 ± 0.98 84.7 ± 4.38 3.68 ± 0.08 2.21 ± 0.03 
 90 B2 10.2012 90.2 ± 1.99 17.3 ± 0.24 77.9 ± 1.69 4.32 ± 0.18 2.16 ± 0.03 
 90 B3 10.2012 96.0 ± 9.92 23.4 ± 2.19 112 ± 2.74 3.76 ± 0.04 2.08 ± 0.03 
 Mean of n = 9 NGI runs 20.1 ± 2.92 91.4 ± 15.6 3.92 ± 0.32 2.15 ± 0.06 
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5.5.1.1.3 SALMETEROL XINAFOATE:FLUTICASONE PROPIONATE RATIO 
The deviation from the nominal SX:FP ratio in the deposited mass across the NGI of the 
Seretide Accuhalers is shown in Figure 5.3. A deviation value greater than 0.0 would 
indicate more SX in the deposited mass, and a value smaller than 0.0 would indicate 
more FP in the deposited mass, compared to the nominal ratio. The SA100 inhalers 
showed a greater deviation than the SA500 inhalers in the SX:FP ratio of the deposited 
masses. However, for both inhaler strengths, there was proved to be negligible 
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Figure 5.3 Deviation in the salmeterol xinafoate:fluticasone propionate (SX:FP) ratio 
of the deposited mass across the Next Generation Impactor for the  Seretide Accuhaler 
100 (SA100) and 500 (SA500) at 68 L.min
-1
 and 90 L.min
-1
 (mean ± SD, n = 3 – 4). 
 
5.5.1.2 DE-AGGLOMERATION ANALYSIS BY SYMPATEC HELOS/RODOS 
The particle size data (i.e. Dv50 values) for the SA100 (B3, BN. 0241-1) and SA500 (B3, 
BN. 1412-2-1) were empirically modelled as described in Chapter 2. Although the data 
showed excellent linearity and DAmax close to 1, the DA50 of the SA100 product was -
0.04 Bar (Table 5.5). The DA50 of the SA500 was 0.60 Bar. The CPP, a measure of 
powder cohesivity, of the SA100 product was 1.2 Bar. For the SA500 inhaler the 
particle size, in terms of the Dv50, remained consistent when pressures of 1.2 – 1.5 Bar, 
3.0 – 3.5 Bar, and 4.5 – 5.0 Bar were employed. Examination of the particle size-
primary pressure profile suggested that the plateau was likely to be in the range 3.0 – 
3.5 Bar, therefore 3.0 Bar was assigned as the CPP. 
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Table 5.5 The R
2
, primary pressure for 50 % de-agglomeration (DA50) and maximum 
degree of de-agglomeration (DAmax) of Seretide Accuhaler 100 (SA100) and 500 
(SA500) dry powder inhaler products by dry dispersion laser diffraction analysis . 
Sample Batch R
2
 DAmax DA50 (Bar) CPP (Bar) 
SA100 0241-1 0.9951 1.06 -0.04 1.2 
SA500 1413-2-1 0.9869 1.10 0.60 3.0* 
*Particle size consistent for 2 increases in PP only within the pressure ranges 1.2 – 1.5 Bar, 3.0 – 3.5 Bar 
and 4.5 – 5.0 Bar. Examination of the particle size-primary pressure profile suggested that 3.0 – 3.5 Bar 
represented the plateau region and 3.0 Bar the CPP value. 
 
5.5.1.3 DE-AGGLOMERATION ANALYSIS BY SYMPATEC INHALER 
5.5.1.3.1 PRODUCT STRENGTH 
The Copt, fine fraction (FF; % < 5 µm) and intermediate fraction (IF; % < 15 µm) of the 
Seretide Accuhalers at 67 L.min
-1
 ± 5 % over a typical 4 s inhalation was measured 
using the Sympatec INHALER (Figure 5.4 and Figure 5.5, respectively). For both the 
SA100 (B1, BN. R174041) and SA500 (B1; BN. R177573), the peak emission of fines 
was recorded after 0.5 s. The fraction then reduced and remained constant from 1.75 s 
onwards. During the first 1.75 s of the measurement, the higher strength SA500 product 
produced a higher fine (AUC = 11.1 ± 6.07 %.s
-1
) and intermediate (AUC = 25.6 ± 13.6 
%.s
-1
) fraction compared to the SA100 (AUC = 8.49 ± 1.99 %.s
-1
 and 19.7 ± 5.23 %.s
-1
, 
respectively). The FF peak maximum (11.1 ± 2.73 % and 14.0 ± 6.63 %, respectively) 
and total AUC (11.5 ± 4.14 %.s
-1 
and 14.7 ± 8.83 %.s
-1
, respectively) were higher for 
the SA500 compared to the SA100. However, when expressed as a cumulative AUC 
undersize distribution, the curves for the two products overlapped. Furthermore, the Copt 
traces over the 4 s period were almost identical (Figure 5.4). The Copt can provide an 
indication of the relative amount of powder emitted by the inhaler over the 
measurement time, therefore indicating similar emissions between the inhaler strengths. 
It is therefore likely that a higher fine particle content in the higher strength product 
resulted in the larger AUC values, rather than a greater efficiency in fine particle 
generation. 
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Figure 5.4 The optical concentration (Copt) of the Seretide Accuhaler 100 (SA100) and 
500 (SA500) operated at airflow rates of 67 and 90 L.min
-1
 (mean ± SD, n = 3). 
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Figure 5.5 The fine fraction (% < 5 µm) and intermediate fraction (% < 15 µm) and 
the cumulative area under the curve (AUC; normalised to the total AUC) of the fine 
fraction only, of the Seretide Accuhaler 100 (SA100) and 500 (SA500) operated at an 
airflow rate of 67 L.min
-1
 over a 4 s measurement, split into 250 ms timeslices, 
following sizing in the Sympatec INHALER (mean ± SD, n = 3). 
 
5.5.1.3.2 FLOW RATE 
The influence of flow rate on the fine and intermediate fraction of the SA500 (B1, BN. 
R177573) is shown in Figure 5.6. Whereas at 67 L.min
-1
 the fraction of fines detected 
peaked at 0.5 s, this did not occur at 90 L.min
-1
. The highest fraction was found to be 
present at the first measurement point (i.e. 0.25 s) and this was subsequently reduced to 
a plateau value after 1.75 s. At the higher flow rate, the contents of the inhaler may have 
therefore emptied quicker, corresponding to the lower Copt values observed at the higher 
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flow rate (Figure 5.4). The AUC at 90 L.min
-1
 was smaller than at 67 L.min
-1 
for the 
fine fraction only (AUC = 8.51 ± 8.83 %.s
-1
 and 14.7 ± 8.83 %.s
-1
, respectively). 
Despite this, when expressed as the cumulative AUC undersize distribution, the 
reduction in the AUC was apparent suggesting that de-agglomeration efficiency may 
have worsened. 
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Figure 5.6 The fine fraction (% < 5 µm) and intermediate fraction (% < 15 µm) and 
the cumulative area under the curve (AUC; normalised to the total AUC) of the fine 
fraction only, of the Seretide Accuhaler 500 (SA500) over a 4 s measurement, split 
into 250 ms timeslices, following sizing in the Sympatec INHALER (mean ± SD, n = 




5.5.2  MANUFACTURED DRY POWDER INHALER BLENDS 
5.5.2.1 BLEND HOMOGENEITY OF PRE-BLENDS 
The blend homogeneity and drug content of SX:FP pre-blends used to prepared the DPI 
blends is summarised in Table 5.6. In all instances the CV of n = 6 samples was < 10 %. 
 
Table 5.6 Blend homogeneity expressed as the % coefficient of variance (% CV), drug 
content (mean ± SD) and detected drug ratio of salmeterol xinafoate (SX) and 
fluticasone propionate (FP) in fine particle blends (n = 6). 
SX:FP ratio Homogeneity (% CV) Drug Content (µg.mg
-1
) Detected 
 SX FP SX FP Drug Ratio 
1:8 3.93 1.39 100.0 ± 3.53 909.9 ± 16.2 1.0:9.1 
1:1 4.59 6.22 512.9 ± 22.6 492.3 ± 29.2 1.0:1.0  
8:1 2.68 7.07 879.0 ± 22.4 109.6 ± 7.41 8.0:1.0 
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5.5.2.2 BLEND HOMOGENEITY OF DRY POWDER INHALER BLENDS 
The homogeneity and drug content of the DPI blends is shown in Table 5.7. 
Homogeneity was assessed at two time points, prior to and post-tumbling. Prior to 
tumbling the homogeneity was very poor. Following tumbling, the homogeneity 
improved. Apart from the 1:1 blend, in all instances the CV was less than 4 %. The 1:1 
blend had the poorest homogeneity for both SX and FP at 7.40 and 6.07 %, respectively.  
 
Table 5.7 Blend homogeneity expressed as the % coefficient of variance (% CV), drug 
content (mean ± SD) and detected drug ratio of unfractionated salmeterol xinafoate 
(SX) and fluticasone propionate (FP) carrier based dry powder inhaler (DPI) blends 
prior to (n = 10) and post tumbling (n = 6). 




Pre-tumbling SX FP SX FP  
SX:FP 1:8 32.1 24.8   
SX:FP 1:1 33.0 20.5   
SX:FP 8:1 19.5 74.0   
Post-tumbling SX FP SX FP  
SX:FP  0:1 n.a. 1.42 n.a. 13.6 ± 0.20 n.a. 
SX:FP 1:8 2.45 3.57 1.39 ± 0.04 12.0 ± 0.41 1.0:8.7 
SX:FP 1:1 7.40 6.07 6.53 ± 0.47 6.68 ± 0.44 1.0:1.0 
SX:FP 8:1 3.78 2.59 12.3 ± 0.45 1.44 ± 0.04 8.6:1.0 
SX:FP 1:0 1.83 n.a. 12.7 ± 0.23 n.a. n.a. 
 
5.5.3 SCANNING ELECTRON MICROSCOPY  
5.5.3.1 PRE-BLENDS 
The SEM images of the pre-blends containing micronised (i.e. unfractionated) SX and 
FP particles are shown in Figure 5.7. Each blend consisted of agglomerates. The blend 
containing SX and FP in the ratio 8:1 formed agglomerates predominantly containing 
flat SX particles, and the 1:8 blend had predominantly more rounded FP particles. The 
agglomerates in the 1:1 blend appeared to be mixed, with particle morphology 
characteristic of each drug (SEM images of micronised SX and FP are shown again for 
reference in Figure 5.8 and Figure 5.9). 
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Figure 5.7 Scanning electron microscopy images of pre-blends containing salmeterol 
xinafoate (SX) and fluticasone propionate (FP) in the SX:FP ratio (a) 8:1, (b) 1:1 and 
(c) 1:8 at x 10500 magnification. Mixed SXFP agglomerates are present. Examples of 
flat, plate-like SX particles are circled in white and smaller, rounded FP particles are 
circled in black within mixed agglomerates.  
 
5.5.3.2 DRY POWDER INHALER BLENDS  
Figure 5.8, Figure 5.9, and Figure 5.10 show the SEM images of the 1.38 % DPI blends. 
In all instances individual drug particles were observed on the surface of the lactose 
carrier particles, as well as smaller drug-only agglomerates, again either on the surface 
of the carrier or free standing in the blend. The SX-only and FP-only blends could be 
distinguished by the shape of the drug particles; SX was flat and plate-like, whereas FP 
was more rounded in morphology. The blend containing SX and FP in the ratio 8:1 
contained predominantly flatter SX particles, and the 1:8 ratio blend had an abundance 
of more rounded FP particles. The 1:1 blend did not have a predominance of either drug 
particle shape. Based on particle shape, in the combination blends, some drug 
agglomerates appeared to consist of both SX and FP. 
 
 
Figure 5.8 Scanning electron microscopy images of (a) micronised salmeterol 
xinafoate (SX) (taken from Chapter 4, Figure 4.4) and (b) 1.38 % w/w SX-only dry 
powder inhaler (DPI) blend. Drug agglomerates are circled with solid lines and 
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Figure 5.9 Scanning electron microscopy images of (a) micronised fluticasone 
propionate (FP) (taken from Chapter 4, Figure 4.4) and (b) 1.38 % w/w FP-only dry 
powder inhaler (DPI) blend. Drug agglomerates are circled with solid lines and 




Figure 5.10 Scanning electron microscopy images of the dry powder inhaler  (DPI) 
blends containing 1.38 % w/w salmeterol xinafoate (SX) and fluticasone propionate 
(FP) in the SX:FP ratio (a) 8:1, (b) 1:1 and (c) 1:8 at x 2500 magnification. Examples 
of drug agglomerates are circled with solid lines and individual particles are circled 
with dashed lines; inset images are at x 5000 magnification except SX:FP 1:1 x 10000 
magnification. 
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5.5.4 WORK OF COHESION AND ADHESION 
The work of cohesion between SX, FP and CL, and the work of adhesion between each 
component is shown in Figure 5.11. The values were calculated from the surface energy 
distributions of each drug determined by IGC, and represent the total surface energy 
(i.e. arising from both specific and dispersive interactions). Differences in the work of 
cohesion/adhesion occurred, revealing a different tendency for interaction. The work of 
adhesion for SX-FP was higher than the work of cohesion of SX, but lower than the 
work of cohesion of FP.  Furthermore FP showed a stronger interaction with CL than 
SX with CL. Despite the larger particle size of CL relative to the drugs, CL was found 
to display the highest work of cohesion. 







































 SX-SX  SX-FP  FP-FP 
 SX-CL  FP-CL  CL-CL
 
Figure 5.11 The work of cohesion and work of adhesion of salmeterol xinafoate (SX), 
fluticasone propionate (FP) and coarse lactose (CL) determined from the total surface 
energy distributions of the powders obtained by finite dilution inverse gas 
chromatography.  
 
5.5.5  DISPERSIBILITY ASSESSMENT BY CASCADE IMPACTION  
5.5.5.1 DRUG RATIO EFFECTS ON THE AEROSOLISATION OF PRE-
BLENDS 
Different aerosolisation behaviours were seen for micronised (i.e. unfractionated) SX 
and FP depending on whether delivery was alone or in combination into the NGI. 
Differences also appeared to depend on the drug ratio. For SX there was a reduction in 
the FPF when delivered in combination (Figure 5.12). The reduction in the FPF RD and 
ED was not significant except at the SX:FP ratio 1.0:9.1, in which it reduced by almost 
half that of SX alone (p < 0.05, Kruskal Wallis ANOVA with Dunn’s post-test, 
GraphPad Prism 5). Furthermore, the MMAD of SX increased when aerosolised in 
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combination with FP (Table 5.8). The largest MMAD occurred in the blend containing 
the largest amount of FP (p < 0.05 at SX:FP 1.0:9.1 only, compared to SX alone). For 
FP, the small reduction in the FPF (RD or ED, Figure 5.13) was not significant (p < 
0.05) and there was no change in the MMAD (p > 0.05, Table 5.8). The emission of 
neither drug was changed when aerosolised in combination (p > 0.05). 
 
Table 5.8 The recovery (% of the actuated dose), mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD) of salmeterol xinafoate (SX) and 
fluticasone propionate (FP) aerosolised into the Next Generation Impactor from fine  
particle blends with different SX:FP ratios (mean ± SD, n = 3). 
SX:FP Ratio Recovery (%) MMAD (µm) GSD 
Salmeterol xinafoate 
1.0:0.0 77.8 ± 6.47 2.66 ± 0.08 1.80 ± 0.02 
8.0:1.0 92.6 ± 4.04 3.14 ± 0.22 1.86 ± 0.05 
1.0:1.0 94.0 ± 2.80 3.51 ± 0.11 1.79 ± 0.03 
1.0:9.1 101 ± 5.94 3.81 ± 0.09 1.80 ± 0.02 
Fluticasone propionate 
0.0:1.0 78.0 ± 3.08 4.06 ± 0.25 2.00 ± 0.06 
1.0:9.1 83.7 ± 3.67 3.81 ± 0.12 1.99 ± 0.04 
1.0:1.0 91.5 ± 0.84 3.70 ± 0.09 2.00 ± 0.04 
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Figure 5.12 The fine particle fraction (FPF < 5 µm, expressed as a percentage of the 
emitted dose, ED, and recovered dose, RD) and emission (% RD) of salmeterol 
xinafoate (SX) in fine particle blends co-formulated with fluticasone propionate (FP) 
at different SX:FP ratios (mean ± SD, n = 3); * = p < 0.05 for co-formulation vs. SX 
alone by Kruskal Wallis with Dunn’s post-test. 
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Figure 5.13 The fine particle fraction (FPF < 5 µm, expressed as a percentage of the 
emitted dose, ED, and recovered dose, RD) and emission (% RD) of fluticasone 
propionate (FP) in fine particle blends co-formulated with salmeterol xinafoate (SX) 
at different SX:FP ratios (mean ± SD, n = 3); * = p < 0.05 for co-formulation vs. FP 
alone by Kruskal Wallis with Dunn’s post-test. 
* 
* 
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5.5.5.2 DRUG RATIO EFFECTS ON THE AEROSOLISATION OF DRY 
POWDER INHALER BLENDS 
When aerosolised in combination from DPI blends, no difference in the aerosolisation 
behaviour of SX and FP was observed compared to single drug delivery. Considering 
SX, when aerosolised in combination at any SX:FP ratio, there was no significant 
difference in the FPF RD, FPF ED, emission or MMAD (p > 0.05, Kruskal Wallis 
ANOVA with Dunn’s post-test) compared to the SX-only DPI (Figure 5.14, Table 5.9). 
However, for internal group comparisons between combination blends only, higher 
FPFs (both ED and RD) of SX were obtained from the 8.6:1.0 ratio compared to the 
1.0:8.7 ratio, suggesting that the particles may be interacting (Figure 5.14). For FP, 
there were no significant differences between any of the parameters when comparing FP 
alone with FP in combination at all SX:FP ratios (Figure 5.15). 
 
Table 5.9 The recovery (% of the actuated dose), mass median aerodynamic diameter 
(MMAD), and geometric standard deviation (GSD) of salmeterol xinafoate (SX) and 
fluticasone propionate (FP) from dry powder inhaler (DPI) blends with a 1.38 % w/w 
drug content composed of varying SX:FP drug ratios aerosolised into the Next 
Generation Impactor (mean ± SD, n = 3). 
SX:FP Ratio Recovery (%) MMAD (µm) GSD 
Salmeterol xinafoate 
1.0:0.0 108 ± 6.01 3.08 ± 0.03 2.07 ± 0.11  
8.6:1.0 92.7 ± 4.23 2.92 ± 0.11 2.09 ± 0.05 
1.0:1.0 91.6 ± 8.94 2.97 ± 0.12 2.75 ± 0.18 
1.0:8.7 102 ± 9.89 3.03 ± 0.15 2.28 ± 0.12 
Fluticasone propionate 
0.0:1.0 94.0 ± 2.13 4.22 ± 0.07 2.01 ± 0.77 
1.0:8.7 92.0 ± 4.10 4.09 ± 0.09 2.18 ± 0.03 
1.0:1.0 83.0 ± 2.90 3.80 ± 0.25 2.15 ± 0.07 
8.6:1.0 104 ± 20.6 3.69 ± 0.11 2.26 ± 0.03 
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Figure 5.14 The fine particle fraction (FPF < 5 µm, expressed as a percentage of the 
emitted dose, ED, and recovered dose, RD) and emission (% RD) of salmeterol 
xinafoate (SX) from 1.38 % w/w total drug content dry powder inhaler blends 
containing SX and FP in different SX:FP ratios (1:0, 8.6:1.0, 1.0:1.0 and 1.0:8.7) 
assessed by Next Generation Impactor analysis (mean ± SD, n = 3). 
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Figure 5.15 The fine particle fraction (FPF < 5 µm, expressed as a percentage of the 
emitted dose, ED, and recovered dose, RD) and emission (% RD) of fluticasone 
propionate from 1.38 % w/w total drug content dry powder inhaler blends containing 
SX and FP in different SX:FP ratios (0.0:1.0, 1.0:8.7, 1.0:1.0 and 8.6:1.0) assessed by 
Next Generation Impactor analysis (mean ± SD, n = 3). 
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Figure 5.16 shows the SX:FP ratios of the deposited masses across the NGI for the pre-
blends and DPI blends. Considering the device, capsules, throat and pre-separator, 
across all the blends the greatest deviation in the ratio occurred in the capsules, in which 
there was greater SX retention than FP retention when compared to the nominal values. 
Differences between the deviations in the ratios were seen between the blend 
compositions and blend types. For pre-blends and DPIs, the greatest deviation occurred 
as the amount of SX in the blend increased. Whereas for the SX:FP 1:8 pre-blend there 
was negligible deviation from 1:8 in terms of deposition across the NGI stages, for the 
1:1 blend deviations occurred beyond stage 3, and for the 8:1 ratio deviations occurred 
beyond stage 2; greater amounts of SX deposited on these stages relative to the nominal 
amount in the blend. When formulated as DPI blends the magnitude of the deviations 
increased. Furthermore, for the stages corresponding to the larger aerodynamic particle 
sizes (i.e. stages 1 – 2), there was a shift towards greater FP deposition relative to the 
nominal blend ratio in the DPI containing SX and FP in the ratio 8:1. 
 
5.5.6 DISPERSIBILITY OF DRY POWDER INHALER BLENDS BY DRY 
DISPERSION LASER DIFFRACTION  
The R
2
, DA50 and DAmax of the DPI blends are shown in Table 5.10. In all instances the 
linearity of the modelled data was good (R
2
 > 0.94) and the DAmax was < 1.20. Higher 
DA50 values are associated with poorer ease of de-agglomeration, therefore the data 
indicated that an FP-only DPI blend has a greater propensity for de-agglomeration than 
an SX-only DPI blend. Relative to these values, the SX:FP 8:1 DPI had the poorest de-
agglomeration of all the blends and the SX:FP 1:1 DPI dispersed with intermediate 












































































































































































































Figure 5.16 The deviation in the salmeterol xinafoate :fluticasone propionate (SX:FP) ratio of the deposited mass in the Next Generation Impactor 
for pre-blends and dry powder inhaler blends containing SX and FP in the  nominal ratios 1:8, 1:1 and 8:1 (mean ± SD, n = 3). 
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It was not possible to deduce a CPP for the SX-only and SX:FP 8:1 ratio DPI (Table 
5.10). For these blends, the measured size reduced with increasing PP, but did not 
remain at a constant value for three (or even two) consecutive increases in pressure. For 
the 1:1, 1:8 and FP-only blends, a gradual increase in the CPP was observed, coinciding 
with a higher FP content, and indicating less efficient de-agglomeration to primary 
particles, particularly of the most cohesive particles in the blend. This was corroborrated 
by the trend in the CPP of the Seretide Accuhalers, in that a higher FP content blend had 
higher bulk cohesivity.. The FP-only blend showed consistancy in the measured size in 
the PP range 0.2 – 1.5 Bar (5 PPs), 2.5 – 3.0 Bar (2 PPs), and 4.0 – 4.5 Bar (2 PPs). 
Upon inspection of the particle size-primary pressure profile, it was deduced that the 
latter range most closely resembled the plateau region in the pressure range studied and 
thus the CPP was asigned as 4.0 Bar. Considering both the DA50 and CPP values, this 
indicated a greater heterogeniety in agglomerate strengths/inter-particulate forces with 
increasing FP content in the blend.  
 
Table 5.10 The R
2
, primary pressure for 50 % de-agglomeration (DA50), and maximum 
degree of de-agglomeration (DAmax) of carrier based dry powder inhaler blends 
containing 1.38 % w/w drug comprising SX and FP in varying SX:FP ratios assessed 
by dry dispersion laser diffraction analysis . 
SX:FP Ratio R
2
 DAmax  DA50 (Bar) CPP (Bar) 
1.0:0.0 0.9378 1.13 1.01 - 
8.6:1.0 0.9385 1.13 1.36 - 
1.0:1.0 0.9856 1.06 0.66 3.0 
1.0:8.7 0.9897 1.02 0.46 3.5 
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5.6 DISCUSSION AND CONCLUSIONS 
Combination DPIs are complex systems and contain multiple components. This 
includes the drug, carrier particle and in some cases a ternary agent. Understanding the 
physicochemical interactions between the particles, and the resultant aerosolisation 
performance, can aid in the optimisation of DPI characteristics for maximum 
therapeutic effect. The combination product Seretide®/Advair®, manufactured by 
GlaxoSmithKline, was introduced to the market in 2002, having received product 
approval in November 1999 (Hickey, 2013). The inhalers contains 50 µg SX and either 
100, 250 or 500 µg FP (BNF, 2013). The aerodynamic deposition profiles of SX and FP 
from SA inhalers measured in the current study (Table 5.3 and Table 5.4) were 
generally in good agreement with those reported in the literature, as summarised in 
Table 5.11. These studies utilised a range of cascade impactors; only Taki et al. (2011) 
report the aerodynamic deposition profiles of SA100 and SA500 in the NGI. In a 
separate study Taki et al. (2010) determined the deposition profiles of the inhalers using 
different impactors (i.e. the ACI, MSLI and NGI), and although showing broadly 
similar trends, significant differences in the PSD was observed. It would therefore not 
be appropriate to make direct comparisons between the data reported in the literature. 
For this reason, the influence of product strength and flow rate on SX and FP 
aerosolisation were investigated in this study. 
 
5.6.1 DISPERSION BEHAVIOUR OF THE SERETIDE ACCUHALER 
Prior to probing the influence of product strength and flow rate on aerosolisation 
performance, it was necessary to establish equivalence between different batches of 
inhalers. This would ensure that any differences observed were not attributable to inter-
batch variability. The BP (2012) stipulates that when assessing the uniformity of the 
delivered dose from a multi-dose inhaler, it is not sufficient to test a single inhaler, and 
inter- (and intra-) inhaler dose uniformity must be taken into account. Three batches of 
the SA100 and SA500 strength inhaler were therefore tested, each having different 
expiry dates. Batch 1 for both strength of inhaler was tested outside of its expiry date 
(Table 5.2). Under ambient conditions, the inhalers have shown good reproducibility in 
fine particle delivery. Following storage at 25 
o
C and 30 % RH for 3 months, Borgström 
et al. (2005a) reported no change in the FPF of SX or FP (19 and 20 %, respectively) 
from an SA100 product. Only storage under hot and humid conditions (40 
o
C, 75 % RH 
for 3 months) resulted in a reduction in the FPF (Borgström et al., 2005a). 
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Table 5.11 A summary of the aerodynamic deposition profiles of Seretide Accuhaler products reported in the literature  in terms of the fine particle 
dose or mass (FPD or FPM), fine particle fraction (FPF) and mass median aerodynamic diameter (MMAD). 
Product Impactor Flow Rate (L.min
-1
) Parameter Results  Reference 
    Salmeterol xinafoate Fluticasone propionate  
SA100 MSLI 60 FPD
1
 (% < 5 µm of label dose) 21 22 Borgström et al. 
(2005a) 





 (% < 5.8 µm of label dose) 
MMAD (µm) 
18.4 ± 4.4 
3.54 ± 0.47 
20.4 ± 4.8 
3.57 ± 0.48 
Tarsin et al. (2006) 
SA250* ACI 60 FPM
3
 (µg  per dose, 0.8 – 6.2 µm) 12.8  66.2  Daley-Yates et al. 
(2009) 
SA100 NGI 60 FPF
4
 (% < 5 µm) 
MMAD (µm) 
19.33 ± 0.81 
4.08 ± 0.04 
17.99 ± 0.75  
4.50 ± 0.08 
Taki et al. (2011)  
SA500 NGI 60 FPF
4
 (% < 5 µm) 
MMAD (µm) 
20.18 ± 1.09 
3.46 ± 0.08 
21.34 ± 0.99 
3.60 ± 0.05 




 (% < 5 µm) 
MMAD (µm) 
8.50 ± 0.19 / 23.98 ± 0.97 
6.81 ± 0.03 / 3.71 ± 0.63 
10.70 ± 0.27 / 22.53 ± 0.88 
6.39 ± 0.06 / 4.16 ±  0.07 
Taki et al. (2010) 




 (% < 5 µm) 
MMAD (µm) 
11.92 ± 0.47 / 12.23 ± 0.40 
6.12 ± 0.40 / 4.50 ± 0.12 
14.22 ± 0.71 / 21.54 ± 0.36 
5.62 ± 0.41 / 4.08 ± 0.15 




 (% < 5 µm) 
MMAD (µm) 
10.66 ± 0.64 / 20.01 ± 1.27 
5.21 ± 0.15 / 3.13 ± 0.12 
14.68 ± 1.01 / 21.17 ± 1.18 
4.81 ± 0.13 / 2.97 ± 0.01 




 (% < 5 µm) 
MMAD (µm) 
13.34 ± 0.03 / 25.12 ± 1.27  
4.96 ± 0.16 / 3.23 ± 0.05 
16.14 ± 0.52 / 26.44 ± 1.14 
4.78 ± 0.13 / 3.30 ± 0.04 




 (% < 5 µm) 
MMAD (µm) 
16.00 ± 0.02 / 17.35 ± 1.13 
4.15 ± 0.09 / 3.05 ± 0.12 
18.25 ± 0.63 / 22.53 ± 1.30 
4.20 ± 0.05 / 3.07 ± 0.06 




 (% < 5 µm) 
MMAD (µm) 
15.58 ± 0.51 / 18.19 ± 1.63 
4.05 ± 0.12 / 3.78 ± 0.13 
21.61 ± 0.42 / 23.22 ± 0.67 
3.87 ± 0.17 / 3.43 ± 0.02 




mass of drug < 5 µm as a percentage of label 
claim, mean of n = 3. 
2
mass of drug < 5.8 µm as a percentage of label claim, mean ± SD of n = 20. 
3
mass of drug 0.8 – 6.2 µm, mean of n = 4. 4percentage of drug < 5 µm, mean ± 
SD of n = 4, 
5
percentage of drug < 5 µm of the total recovered dose, mean ± SD of n = 4. 
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To assess equivalence between the batches, the EMEA guidance for bioequivalence was 
adopted. The guidance requires deposition across the upper and lower stages of the 
impactor to be considered, comprising both lung and non-lung deposition sites, and with 
a suggested acceptable level of variation of ± 15 % (EMEA, 2009). For the analysis, the 
amount deposited was normalised to the recovered dose (Section 5.5.1.1.1). The reasons 
for this were two-fold, firstly to account for differences in the recovered doses between 
NGI experiments (Table 5.3 and Table 5.4) and secondly, due to the design of the 
Accuhaler device, it was not possible to determine the amount of drug that was retained 
in the device/foil strip without dismantling the device. Therefore it was only possible to 
determine the emitted dose and not the total recovered dose, which would include drug 
retention in the device, for each NGI experiment. The percentage of stages showing 
equivalence ranged from 83.3 – 100 % for SX and 91.7 – 100 % for FP. Despite 100 % 
equivalence not being found in all instances, for the purpose of this study the batches 
were considered equivalent. The data for the batches were therefore pooled according to 
product strength and flow rate prior to statistical analysis. 
 
Considering the aerosolisation characteristics of the SA products, the FPF of SX and FP 
was unchanged between product strengths and flow rates (p > 0.05) indicating 
consistent fine particle delivery. This finding is corroborated by Taki et al. (2010) where 
only small changes in the FPF between these product strengths was observed. 
Differences, although small, were also reported between flow rates in the latter study, 
when a higher flow rate was found to improve the FPF of both drugs in the NGI. The 
Diskus/Accuhaler device is generally considered to show minimal flow rate 
dependence, and has demonstrated consistent performance across different inhalation 
profiles (Bisgaard et al., 1998; Tarsin et al., 2006). To probe co-association, the SX:FP 
ratio of the deposited masses through the NGI were compared to the nominal values for 
the inhalers. Where the ratio of SX and FP deposition matched that of the formulation, 
this could be considered as a possible marker for co-association of the particles. For 
both inhaler strengths, the flow rate had only minor effects on the SX:FP ratio 
depositing on each stage. However, the SA500 inhaler not only showed a smaller 
magnitude in the deviation from the nominal ratio compared to the SA100, but the ratio 
also closely matched the nominal ratio. The ability to match the ratio of deposition to 
that in the formulation may therefore depend on the amount of SX and FP in the 
formulation.  
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Both SX and FP also displayed differences in MMAD. For SX, at both flow rates the 
SA500 inhaler produced a smaller MMAD than the SA100 inhaler, but the difference 
was not significant (p > 0.05). For both the SA100 and SA500, the MMAD values of 
SX at 90 L.min
-1
 were larger than at 67 L.min
-1
, and this change was significant (p < 
0.05). For FP, the trends were the same but the statistics were the converse i.e. a larger 
MMAD occurred at 90 L.min
-1
 compared to 67 L.min
-1
 but the difference was not 
significant (p > 0.05). However, the smaller MMAD from the SA500 compared to 
SA100 inhaler at both flow rates was found to be significant (p < 0.05). These changes 
in the MMAD suggested a level of interaction between SX and FP in these 
formulations. For both drugs a higher FP content was beneficial in terms of reducing the 
MMAD, a finding also reported by Taki et al. (2011). The larger MMAD at the higher 
flow rate demonstrated that there is an inter-play between formulation properties, flow 
rate and inhaler design on the dispersion of inhalable powders (Chew and Chan, 1999; 
Chew et al., 2000). Despite higher flow rates increasing turbulence and the number and 
intensity of particle impactions in an inhaler device, higher inhaler exit velocities are 
associated with higher deposition in the throat of the impactor for the Aerolizer. It has 
been suggested therefore that for maximal overall inhaler performance, an optimal flow 
rate will exist, which will be specific to the device and cohesivity of the drug (Coates et 
al., 2005). 
 
Laser diffraction particle sizing in the dry state was used to probe further the 
aerosolisation behaviours of the SA inhalers. Particle size-primary pressure curves were 
generated using the Sympatec HELOS/RODOS to determine the dispersibility of the 
bulk powder. Following empirical modelling, the SA100 inhaler had a DA50 of 0.60 
Bar. Despite good linearity and DAmax values, the DA50 of the SA500 inhaler was -0.04 
Bar. This arose due to the negative intercept of the linearised data and the relatively 
small change in the Dv50 across the dispersing pressures (i.e. Dv50 at 0.2 Bar = 12.72 µm 
and Dv50 at 5.0 Bar = 8.84 µm).  It was not possible to assign a CPP for the SA500 using 
the criteria in Chapter 2; instead three regions were identified in which the particle size 
remained constant for two consecutive PP increases. Following a visual assessment of 
the curve, a CPP of 3.0 Bar was assigned. This was higher than the CPP of SA100 (CPP 
= 1.2 Bar) indicating that the SA500 was a more cohesive powder. Although providing 
some useful information, the technique may therefore be less suitable for powder 
mixtures containing particles with a wide range of particle sizes compared to fine 
particle mixtures, which would contain smaller particles and narrower overall PSDs in 
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the bulk blend. However, clearly more work is required using a wider range of DPI 
formulations. 
   
The Sympatec INHALER provided insight into the emptying kinetics of the powders 
from within the inhaler device. The particle size of the formulations was recorded over 
4 s and the fine and intermediate fraction was monitored. At 67 L.min
-1
 there was no 
difference in the onset of the peak maximum of the fractions between the SA100 and 
SA500 inhalers. To provide a quantitative measure of emptying, the area under the 
curve (AUC) was calculated. Cumulative AUC curves indicated identical emptying of 
the inhaler formulations at this flow rate (Figure 5.5). The fine and intermediate 
fractions were higher from the SA500 inhaler than from the SA100, whereas when 
aerosolised into the NGI the FPFs were similar for SX or higher for FP from the SA500 
(p > 0.05). The Copt, a measure of the relative amount of powder emitted, was identical 
between the inhalers (Figure 5.4) therefore higher fine/intermediate fractions may have 
arisen from better bulk dispersibility and a higher fine particle content for the SA500, as 
the inhalers contain the respective amount of drug per 12.5 mg of formulation 
containing the lactose carrier (GSK, 2011). Differences were also observed for the 
SA500 inhaler between flow rates. At the higher flow rate, the peak maximum occurred 
earlier and there was a reduction in the emptying efficiency of the inhaler (Figure 5.6). 
NGI analysis revealed similar or lower FPFs (for SX and FP, respectively, p > 0.05) and 
larger MMADs at 90 L.min
-1
 compared to 68 L.min
-1
, further suggesting that the de-
agglomeration efficiency may be altered. A comparison of the Copt between flow rates 
also revealed that less powder was emitted at 90 L.min
-1
, or alternatively it is possible 
that some of the powder emptying process may have been missed during the sizing 
measurement due to very rapid emptying of the inhaler.  
 
5.6.2 DISPERSION BEHAVIOUR OF SALMETEROL XINAFOATE AND 
FLUTICASONE PROPIONATE IN CO-FORMULATED PRE-
BLENDS AND DRY POWDER INHALER BLENDS 
In order to probe the origin of potential SX-FP interactions which may have led to the 
differing MMAD values between the different SA inhaler strengths, a series of DPI 
blends were prepared. It is necessary to control as many variables as possible in the 
design of such studies, such that the influence of individual factors can be determined 
(Taki, 2008a). For example, in Diskus formulations the size of the lactose carrier can 
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range from 50 – 150 µm (Borgström et al., 2005b), and the grade of the lactose, and 
concentration of lactose fines, are not known (Taki et al., 2011). By matching the blends 
in terms of their manufacturing methodology, storage history and drug content, 
differences in aerosolisation behaviour could then be attributed to particulate 
interactions (Taki, 2008a). Despite extensive research relating to DPI performance, 
there has been little focus on the aerosolisation efficiency of combination formulations 
in relation to drug ratios (Jetmalani et al., 2012). SX-FP pre-blends of varying drug 
ratios were therefore prepared, and showed adequate homogeneity. In all instances the 
% CV was less than 10. This value was higher than that typically used for DPI 
formulations; however, SX and FP have previously demonstrated poor 
mixing/homogeneity requiring the accepted limit of homogeneity for small scale low 
shear mixing to be increased to 7 – 10 % (Louey et al., 2004b; Murnane et al., 2009). 
For FP, the homogeneity became poorer as the SX content of the blend increased (from 
1.39 %, 6.22 % to 7.07 % CV at nominal SX:FP ratios of 1:8, 1:1 and 8:1, respectively), 
whereas the homogeneity of SX was less than 5 % CV across the different ratios. When 
viewed by SEM, the pre-blends formed mixed agglomerates. Based on the particle 
shape, it was possible to identify agglomerates consisting of both SX and FP, and the 
proportion of SX/FP particles in the agglomerates reflected the composition of the pre-
blend. Poorer FP homogeneity may therefore have arisen due to segregation as highly 
cohesive FP particles can form strong, FP-only agglomerates during blending, 
particularly at high FP concentrations (Sebti et al., 2007; Le et al., 2012b; Le et al., 
2012d). During blending, highly cohesive particles require high shear forces to initially 
disrupt drug-drug interactions and promote mixing. However, where particle properties 
within a mixture differ for example in size, density or surface characteristics, and when 
subjected to the progressive formation and disruption of drug agglomerates during 
processing such as Turbula blending, particle de-mixing can occur leading to poor 
homogeneity (Sebti et al., 2007). 
 
When aerosolised into the NGI, the composition of the pre-blend affected the 
aerosolisation performance of the drugs. For SX, although the emission was unchanged, 
the FPF (ED and RD) reduced and the MMAD increased with increasing FP content; 
this effect was significant only at the highest FP content. For FP, conversely, there was 
no change in the emission, FPF (ED or RD) or MMAD in the presence of SX, and 
regardless of the SX content. Mixed agglomerates viewed by SEM are formed randomly 
upon mixing dependent upon the composition and strength of the powder mix and on 
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the balance of cohesive and adhesive forces within the blend (Jetmalani et al., 2012). 
Both SX and FP tend to adhere to each other but a higher SX adhesivity towards FP 
compared to that of FP to SX suggested that SX would be more likely to interact with 
and thus demonstrate altered dispersibility when in combination with FP. Furthermore, 
an SX-rich blend demonstrated better bulk dispersibility (DA50 = 0.20 Bar) compared to 
an FP-rich blend (DA50 = 0.87 Bar) as shown by the results presented in Section 3.5.4. 
The dominance of weaker adhesive SX-FP interactions compared to stronger cohesive 
FP-FP interactions in an SX-rich and FP-rich blend, respectively, would have led to 
better dispersion of the bulk SX-rich blend. 
 
As a measure of co-association, the SX:FP ratios of the deposited masses upon the 
successive stages of the NGI were compared to the nominal ratios of the blends. For all 
the pre-blends, a large deviation in the ratio was observed after aerosolisation of the 
powders from the capsules, potentially due to high SX adhesion to the capsule walls. 
Across the NGI stages 1 - 6, the SX:FP 1:8 blend showed negligible deviation in the 
ratio suggesting that the particles could be co-associated during aerosolisation and thus 
deposited in these proportions across the NGI. For the SX:FP 1:1 and 8:1 blend, the 
ratio was maintained on stages 1 – 3 and 1 – 2, respectively. Beyond these stages, the 
amount of SX depositing relative to FP was greater than the nominal ratio. For these 
blends, it is likely that a proportion of the particles were not co-associated during 
aerosolisation and therefore the smaller (Dv50 = 1.42 ± 0.08 µm, MMAD = 2.7 ± 0.1 
µm; Chapter 4) and more dispersible SX particles (DA50 = 1.45 Bar, work of cohesion = 
83.8 – 79.5 mJ.m-2) were able to travel further into the NGI compared to the larger, less 
dispersible FP particles (Dv50 = 2.94 ± 1.22 µm, MMAD = 4.1 ± 0.3 µm, DA50 = 1.75 
Bar, work of cohesion = 90.1 – 97.2 mJ.m-2). Furthermore, it was only when the SX:FP 
ratio of the deposited masses matched the nominal ratio (i.e. 1:8) in which the 
dispersibility of SX became worse compared to that of SX alone, suggesting co-
association may be playing in role in altering the dispersion behaviour of SX when co-
formulated with FP. 
 
When preparing DPI blends from the SX:FP pre-blends, a fixed drug content of 1.38 % 
w/w was selected. DPI blends containing SX or FP have been prepared with drug 
concentrations in the range 0.58 – 5 % (e.g. Shekunov et al., 2003; Islam et al., 2004;  
Tong et al., 2006; Das et al., 2009a, Das et al., 2009b; Murnane et al., 2009) whereas 
combination SX:FP formulations have contained 1.6 %  and 5 % total drug (Taki, 2008; 
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Pitchayajittipong et al., 2009; Kubavat et al., 2012). The SA 50/100 strength inhaler 
contains 72.5 µg SX (equivalent to 50 µg salmeterol base) and 100 µg FP per 12.5 mg 
pre-metered dose. Therefore, in keeping with this composition, a drug content of 1.38 % 
and capsule fill weight of 12.5 mg was selected for the study. 
 
In order to follow the process of SX-FP interaction, blend homogeneity was assessed 
prior to and post-tumbling in a Turbula mixer. Prior to tumbling the homogeneity was 
extremely poor, ranging from 19.5 – 74.0 % CV. The low level energy input from the 
whirlimixer was insufficient to disrupt SX-SX, FP-FP, SX-FP and CL-CL interactions 
and promote mixing between the particle types to obtain a homogenously mixed carrier-
based blend, despite the adequate homogeneity of the pre-blends. CL was found to have 
a high, heterogeneous, surface energy (γD = 46.2 – 65.3 mJ.m
-2
) which corresponded 
with a high, heterogeneous, work of cohesion (Figure 5.11). The surface energy and 
heterogeneity of lactose can vary depending on the grade (e.g. 40 – 48 mJ.m-2, Ho et al., 
2010), processing (e.g. 42 – 53 mJ.m-2 at infinite dilution, Thielmann et al., 2007) and 
pseudo-polymorphic form (e.g. 36 – 46 mJ.m-2 at infinite dilution, Traini et al., 2008), 
and this may influence the mixing and segregation rate during blending (Saleem et al., 
2008). Where formulations contain a low concentration of a cohesive drug blended with 
a coarse excipient, for optimal homogeneity, ‘powerful’ shear mixers are required and 
approaches such as increasing the mixing speed (in rpm) can improve homogeneity by 
increasing the forces associated with particle collisions and enabling cohesive 
interactions to be overcome (Sebti et al., 2007; Le et al., 2012c).  Post-tumbling, the % 
CV values reduced dramatically to 2.45 – 7.40 % CV. Therefore the combination of 
additional shear forces in the Turbula mixer and the propensity for SX-CL and FP-CL 
adhesive interactions, led to the formation of relatively homogeneously mixed blends. 
This finding was confirmed by SEM imaging, where predominantly individual drug 
particles and drug agglomerates distributed over the surface of lactose particles were 
observed (Figure 5.8, Figure 5.9 and Figure 5.10). 
 
Differences in the bulk powder dispersibility of the combination DPI blends were 
found. Considering the single-drug DPIs, a paradoxical effect in terms of the DA50 and 
FPF was seen, for which the bulk dispersibility of the FP-only blend was better (DA50 = 
0.40 Bar) than the SX-only blend (DA50 = 1.01 Bar), despite FP producing a lower FPF 
when aerosolised into the NGI (FPF ED 9.3 ± 0.77 % and 19.9 ± 0.78 % for FP and SX, 
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respectively). When considering the absolute particle sizes (with forced stability 9), the 
Dv50 ranged from 16.3 – 26.3 µm for the FP-only blend compared to 8.5 – 25.5 µm for 
the SX-only blend. Therefore, although the bulk powder dispersibility was better, 
stronger inter-particulate interactions between the individual particles within 
agglomerates resulted in larger measured particle sizes compared to the SX-only blend. 
Furthermore, a high CPP of 4.0 Bar for the FP-only blend indicated that the powder was 
highly cohesive and that the most tightly associated agglomerates within the powder 
bulk had strong inter-particulate forces. Although it was not possible to determine a 
CPP value for the SX-only DPI, the magnitude of FP-CL and FP-FP interactions were 
higher than SX-CL and SX-SX interactions as determined by IGC, thus supporting the 
proposal that the interactive forces between particles in the FP blend were stronger. 
When in combination, as the FP content of the DPI blend increased, the DA50 reduced 
from 1.36 Bar to 0.66 Bar and 0.46 Bar, approaching that of the FP-only DPI (DA50 = 
0.41 Bar). It was not possible to determine a CPP value for the SX-only or SX:FP 8:1 
DPI. However, the CPP increased for the SX:FP 1:1, 1:8 and 0:1 ratio DPIs from 3.0, 
3.5 to 4.0 Bar indicating increasingly cohesive powders and greater heterogeneity in 
agglomerate strengths. The rank order in the magnitude of particle interactions deduced 
from surface energy analysis was: FP-CL > SX-CL > FP-FP > FP-SX > SX-SX 
according to the work of cohesion and adhesion. Therefore, the overall magnitude of the 
interactive forces in an FP-rich blend were likely to be greater than those in an SX-rich 
blend.  
 
When aerosolised into the NGI, the emission, FPF (ED or RD) and MMAD of SX and 
FP from a DPI blend were not affected by the DPI containing either a single drug or a 
co-formulation. Examining the effect of drug ratio on aerosolisation, by internal group 
analysis of the combination blends only, a similar trend to the pre-blend behaviour was 
observed. Hence, FP was unaffected by the presence of SX in terms of any of the 
calculated parameters. For SX, the emission did not change between ratios, indicating 
that SX was detached from the carrier with equal efficiency regardless of the SX:FP 
ratio, and that similar amounts of SX entered the stages of the impactor below the pre-
separator (Podczeck, 1998). However, the FPF (ED and RD) of SX was lower in the 
nominal SX:FP ratio 1:8 compared to the ratio 8:1 (p < 0.05), and the MMAD was 
larger (p > 0.05). If fine particle agglomerates are able to detach from the carrier intact, 
although the emission may be high, the FPF may be low due to poor dispersion of 
tightly associated agglomerates (Podczeck, 1998). Agglomerates consisting 
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predominantly of FP in the SX:FP ratio 1:8 may therefore have been more difficult to 
disperse than agglomerates containing smaller proportions of FP in the SX:FP ratio 8:1 
upon the release of agglomerates from the carrier. The interactive forces were in the 
following rank in terms of their magnitude: FP-FP > SX-FP > SX-SX, and FP-rich fine 
particle blends had a higher DA50 values than SX-rich fine particle blends (Table 3.6). 
The deposition of agglomerates rather than dispersed individual particles in the NGI 
would also have had a more detrimental effect on the FPF of SX than FP due to the 
former’s inherently smaller particle size. 
 
5.6.3 CONCLUSIONS 
In conclusion, this study has probed the co-association of SX and FP in combination 
formulations. The FPF of SX and FP from Seretide Accuhalers was found to be 
consistent regardless of the inhaler strength or flow rate tested using NGI analysis. 
However, differences in the MMAD and SX:FP ratio of the deposited masses between 
the product strengths suggested that the two component drugs may undergo some 
physicochemical interaction which alters the deposition profiles of the drugs. When 
formulated as pre-blends, the presence of FP was detrimental to the dispersibility of SX 
but not the converse, and this effect was further dependent on the SX:FP ratio. When 
formulated as DPIs, co-formulation did not alter the dispersion of either drug compared 
to single drug delivery, however, intergroup analysis of the combination ratios only 
found an FP concentration-dependent worsening in the dispersibility of SX from these 
formulations in the NGI. Analysis of the SX:FP ratios through the impactor revealed 
that FP-rich (i.e. SX:FP 1:8) blends showed the smallest deviation in the SX:FP ratio of 
the deposited mass compared to the nominal value, and had a detrimental effect on the 
dispersibility of SX from the blend. Furthermore, the deviation increased in the 
presence of a carrier for all the formulations. The occurrence of co-association between 
SX and FP, as represented by the deviation from the nominal ratios where no deviation 
would indicate particle co-association, may therefore be influenced by the formulation 
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6.1 INTRODUCTION 
The development of dry powder inhaler technology towards optimal performance has 
taken two routes, the design of novel devices with enhanced efficiency, and the 
improvement of existing powder formulations. Although sophisticated device designs 
such as active dispersion are possible, they are complex and costly. A more favourable 
option is therefore to optimise the formulation for use with simple, user-friendly devices 
(Chow et al., 2007). Engineering approaches can therefore involve either advancing the 
formulation or the particle manufacturing process in order to attain critical features in 
the particles. The aim of particle engineering can be to improve stability, increase 
dispersibility, achieve controlled release or increase drug permeability or bioavailability 
(Weers et al., 2010).  
 
The engineering of combination formulations for dry powder delivery has taken a 
number of routes. These include the production of combination particles containing 
both of the constituent drugs in a single particle either through controlled crystallisation 
(e.g. Westmeier and Steckel, 2008; Pitchayajittipong et al., 2009), co-spray drying (e.g. 
Corrigan et al., 2006; Tajber et al., 2009a; Tajber et al., 2009b; Kumon et al., 2010; 
Traini et al., 2012) or inducing the agglomeration of drug nanoparticles (El-Gendy et 
al., 2011). To date, combination particles have demonstrated similar aerosolisation to 
micronised drug blends following aerosolisation from DPIs, however, not only is the 
physical and chemical stability of these novel particles not yet known, obtaining scale 
up and regulatory acceptance of new particle engineering technologies will remain a 
challenge (Weers et al., 2010). In combination formulations consisting of physically 
mixed particles, re-crystallisation to yield particles with defined surface properties has 
been used to investigate the implications of interfacial chemistry on drug aerosolisation 
(Kubavat et al., 2012), and the effect of drug ratio has been studied in carrier free blends 
(Jetmalani et al., 2012). The inclusion of drug particles with different aerodynamic 
particle sizes has also been shown to influence dispersion when formulated in 
combination blends (Taki, 2008a).   
 
In Chapter 4, the intra-batch variability in the particle properties of micronised powders 
was demonstrated through the isolation of aerodynamic size fractions. These properties 
were found to have implications for the aerosolisation of salmeterol xinafoate (SX) and 
fluticasone propionate (FP) sub-populations. In Chapter 5, the SX:FP ratio was found to 
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influence the aerosolisation of SX but not FP in pre-blends prepared from bulk, 
unfractioned drug particles, however, upon formulation with a lactose carrier, co-
formulation did not alter the aerosolisation of either drug particle type compared to 
single drug delivery. Studies have shown that when aerodynamic size fractions are 
formulated as carrier-based blends, the aerosolisation behaviour of the drug particles is 
affected, in both single drug and co-formulated blends. However, the potential reasons 
for the changes in dispersion behaviour were not studied (Taki, 2008).  In this chapter, 
the variability in SX and FP particle properties within bulk micronised powders will be 
exploited in an attempt to engineer aerosolisation performance without the need for 
complex particle engineering technologies. Such an approach may also provide insight 
into the properties that may be favourable for the dispersion of micronised particles 
when formulated in combination, in addition to identifying the key properties which 
could be monitored in order to direct formulation engineering for a quality by design 
approach to DPI development and manufacture. 
 
Following deposition in the lungs, drug particles that are not cleared by innate 
mechanisms such as mucocillary clearance or phagocytosis must be in solution in order 
to elicit their local (and/or systemic) effects. Particles therefore need to undergo 
dissolution and cellular uptake/absorption across the epithelium in order to reach their 
site of action (Davies and Feddah, 2003; Bur et al., 2010). Although the small particle 
size of deposited particles would be expected to facilitate high dissolution rates due to a 
large surface area to weight ratio, poor water solubility is often a rate limiting step 
(Davies and Feddah, 2003). Furthermore, the small volumes of aqueous fluid 
(approximately 10 – 20 mL/100 m2) can further hinder dissolution (May et al., 2012). 
The lung is a complex organ, and the thickness of the fluid lining varies according to the 
site; it can be 20 µm in the upper airways, compared to 0.1 - 10 µm or less in the lower 
airways i.e. bronchioles and alveoli. In these latter airways the layer can be extremely 
thin or even absent (Pryor, 1992). Therefore depending on the site of deposition, a 
micronised particle may only have a proportion of its diameter immersed in the liquid 
layer (Bur et al., 2010). The composition of the fluid also varies across the lungs. In the 
conducting airways of the upper respiratory tract, the fluid is composed of two 
phases/layers. A viscous gel phase which is the mucus blanket and removes particles, 
cells and cell debris by mucociliary clearance. Below the gel layer is a less viscous sol 
phase, referred to as the periciliary sol that facilitates efficient cilia beating and the 
movement of the mucus blanket to the mouth (Gehr et al., 1993; Widdicombe, 2002). In 
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the respiratory bronchioles, the mucus-secreting cells are absent therefore there is no 
mucus blanket, but the cilia and periciliary sol is present (Widdicombe, 2002). The 
alveolar lining fluid comprises an aqueous subphase which is covered by a film of 
pulmonary surfactant; the surfactant prevents collapse of the alveoli by reducing the air-
liquid interfacial tension, (Bastacky et al., 1995), and may play a role in the wetting and 
translocation of deposited particles into the aqueous layer (Gehr et al., 1993). Although 
the alveolar lining layer is very thin, it can also vary in depth (few hundredths to several 
micrometres in the rat lung, Bastacky et al., 1995). The microenvironment in which the 
particle is exposed within the lung will therefore further determine the dissolution and 
availability of the inhaled particle for therapeutic action. 
 
Using in vitro approaches, it has been demonstrated that particle dissolution of inhaled 
corticosteroids in a limited volume of aqueous fluid differs not only depending on drug 
solubility, but also particle size, aerosol mass and formulation. The potential to engineer 
particles for their dissolution behaviour therefore warrants further investigation (Arora 
et al., 2010). The effect of particle size has been demonstrated; aerodynamic size 
fractions of hydrocortisone, salbutamol sulphate and budesonide have shown faster 
dissolution rates as the particle size reduced (Cartier et al, 2008; Son and McConville, 
2009; Arora et al., 2010), as have nanoparticles compared to nanoparticle agglomerates 
and micronised particles of budesonide and fluticasone, attributed to the higher surface 
areas of the non-agglomerated nanoparticles (El-Gendy et al., 2009; El-Gendy et al., 
2011). In addition to differences, although small, between the particle sizes of 
fractionated SX particles isolated in Chapter 4, more dramatic differences in their bulk 
and surface disorder were observed, presenting a potential opportunity to engineer SX 
dissolution. Amorphous particles demonstrate improved solubility (e.g. Sakagami et al., 
2001) and faster dissolution than crystalline particles (e.g. Pilcer et al., 2013). Changes 
in the dispersive and specific surface energy of the particles, relating to changes in the 
surface chemistry of the exposed crystal facet, can also alter the wettability of the 
particles (e.g. Heng et al., 2006a). 
 
Combination formulation of DPIs, and the potential for mixed drug agglomerates, may 
further alter the dissolution rate of one or both drugs. This may be through 
modifications in agglomerate structure altering the exposure of drug surfaces to 
dissolution media and/or the proportion of dispersed particles, or changes to the MMAD 
altering the site of deposition in the lungs. For example, co-delivery from a Seretide 
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Accuhaler reduced SX deposition on stage 5 of the NGI compared to the Serevent 
Accuhaler (Taki et al., 2011). If in vivo this corresponded to a change in SX deposition 
site to an area with a different lining layer volume/composition, there may be alterations 
in the dissolution profile of the drug. Although research in this area is beginning (e.g. 
Haghi et al., 2013) there is limited understanding on the implications of co-formulation 
on the dissolution and cell layer transport of drugs in combination, and the potential to 
engineer the dissolution of one or both drugs in the formulation.    
 
6.2 AIM AND OBJECTIVES 
The aim of this study was to investigate the ability to engineer particle aerosolisation 
performance and/or dissolution by controlling particle properties. The objectives were 
to: 
a) Measure the aerosol PSD of SX and FP in pre-blends (1:1 ratio) compared to SX 
alone or FP alone to determine the influence of particle physicochemical 
properties as follows: 
a. Crystallised particles, 
b. Aerodynamically size fractionated particles. 
b) Investigate the ability to engineer SX aerosolisability in DPI formulations using 
crystallised and/or fractionated particles. 
c) Determine the dissolution profile of micronised SX particles following dry 
powder aerosolisation using dissolution media containing methanol and water in 
varying compositions. 
d) Determine how the dissolution profile of aerodynamically fractionated SX 
particles (from Stage 4 and Stage 5) and re-crystallised particles is altered 
compared to micronised (unfractionated) SX particles. 
e) Determine how the dissolution profile of micronised SX changes following co-
delivery with micronised FP particles. 
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6.3 MATERIALS  
The materials and equipment used in Chapter 6, not listed in Section 2.3, 3.3, 4.3 and 
5.3, are shown in Table 6.1. 
 
Table 6.1 Suppliers of materials and equipment (Chapter 6).  
Material / Equipment Supplier 
Transwells
®  
(6.5 mm diameter, 0.4 µm 
pore size, tissue culture treated, 
polyester membrane, polystyrene plates) 
Costar
®
, Corning Incorporated, Corning,  USA 
(supplied by Sigma-Aldrich Company Ltd, UK) 
Shaker Plate Orbital Model R100 Rotatest Shaker, Luckham Ltd, 
UK 




6.4.1 BLEND PREPARATION AND HOMOGENEITY 
Engineered pre-blends and DPI blends were prepared as described in Chapter 5, Section 
5.4.1. All co-formulations were prepared with an SX:FP ratio of 1:1, and all DPI blends 
had a total drug content of 1.38 % w/w. Fine particle blends were prepared using stage 
fractionated particles i.e. Stage 4 and Stage 5 for SX and Stage 3 and Stage 4 for FP, 
and re-crystallised SX and FP particles, which were prepared and tested for their 
individual dispersion behaviours in Chapter 4. This enabled the effects of co-
formulation to be compared to that of single drug aerosolisation for each particle type 
(Figure 4.11 and Table 4.9), and therefore identify whether inter-particulate interactions 
can be engineered by controlling the physicochemical properties of the particles. DPI 
blends were prepared in order to investigate the ability to engineer SX aerosolisation. 
Firstly, the ability to engineer aerosolisation from single drug formulations was 
investigated using DPIs containing unfractionated, crystallised, Stage 4 and Stage 5 SX 
only. DPIs were prepared containing crystallised SX (CSX) and crystallised FP (CFP), 
and Stage 4 SX and Stage 3 FP in combination to further determine the influence of 
particle properties on SX aerosolisation in co-formulation.  A summary of the blends 
prepared is shown in Table 6.2. The homogeneity of the blends was assessed as 
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described in Chapter 5, Section 5.4.2. Quantification of homogeneity samples was 
according to the HPLC method detailed in Chapter 3, Section 3.4.1.1. Freshly prepared 
mixed calibration curves were prepared in the range 20 – 400 µg.mL-1 and 0.5 - 50 
µg.mL
-1
 for quantification of homogeneity samples for pre-blends and DPI blends, 
respectively.  
 
Table 6.2 A summary of the pre-blends and dry powder inhaler (DPI) blends prepared 
and tested in Chapter 6, and the engineered particles (prepared and tested in Chapter 
4) employed in the study. 














Crystallised n.a. 1:0 
Stage 4 n.a. 1:0 
Stage 5 n.a. 1:0 
n.a. Crystallised 0:1 
n.a. Stage 3 0:1 













s Crystallised Crystallised 1:1 
Stage 4 Stage 3 1:1 
Stage 4 Stage 4 1:1 
Stage 5 Stage 3 1:1 









Crystallised n.a. 1:0 
Crystallised Crystallised 1:1 
Stage 4 n.a. 1:0 
Stage 4 Stage 3 1:1 
Stage 5 n.a. 1:0 
n.a = not applicable. 
 
6.4.2 NEXT GENERATION IMPACTOR ANALYSIS 
NGI analysis of the fine particle blends and DPI blends was as described in Chapter 5, 
Section 5.4.5. Powder blend was filled into size 3 gelatin capsules and aerosolised using 
a Monodose inhaler device at 60 L.min
-1
 (ΔP = 1.4 kPa) for 4 s. Capsule fill weights 
were 10.0 ± 1.0 mg and 12.5 ± 0.5 mg for pre-blends and DPI blends, respectively. One, 
six and fifteen capsules were actuated per NGI experiment for pre-blends, single drug 
DPI blends, and combination DPI blends, respectively. Quantification of NGI samples 
was undertaken using the HPLC method described in Chapter 3, Section 3.4.1.1, using 
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freshly prepared mixed calibration curves in the range 0.5 – 50 µg.mL-1 (20 – 400 
µg.mL
-1
 for individual samples outside this range), either pooled for fine particle blends 
(n = 5) or prepared on the day for DPI blends. For the latter, dilutions of the lowest 
standard were undertaken to lower the LOQ; the calibration range was selected based on 
the concentration of the samples, and was typically 0.1 – 25 µg.mL-1.  
 
6.4.3 DISPERSIBILITY BY DRY DISPERSION LASER DIFFRACTION 
The bulk dispersibility of the DPI blends was assessed by Sympatec HELOS/RODOS 
laser diffraction with protruding aspiration tube and rotary feeder, as described in 
Chapter 5, Section 5.4.6.1.  
 
6.4.4 WORK OF COHESION AND ADHESION 
The surface energy distributions of bulk micronised (i.e. unfractionated), crystallised 
and stage-fractionated SX and FP particles and CL from Chapters 4 and 5 were used to 
calculate the work of cohesion and adhesion between the different particle types 
according to Equation 2.11. 
 
6.4.5 SOLUBILITY DETERMINATION 
The solubility of SX was determined in methanol, water, and methanol-water mixtures 
in the ratios 75:25, 50:50 and 25:75. Solvent mixtures were prepared by measuring the 
required volume of solvent in a measuring cylinder, transferring into a Duran bottle, and 
gently shaking. A visible excess of SX was added to a 1.5 mL centrifuge tube and 1 mL 
of solvent was added. The tube was sealed and placed on a plate shaker set at speed 
control setting 3 at room temperature. After 24 h the samples were removed and 
visually checked for saturation. Following centrifugation at 10,000 rpm for 5 min, 0.5 
mL of supernatant was diluted as necessary with the respective methanol-water mixture 
(1 in 10, 1 in 100 or 1 in 200) and analysed by HPLC according to the method in 
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6.4.6 AERODYNAMIC DEPOSITION USING THE TWIN STAGE 
IMPINGER  
SX particles were aerodynamically deposited onto Transwell inserts using the TSI as 
described by Grainger et al. (2009) with the following modifications. The TSI was 
assembled as described in the BP (2012), and shown in Figure 6.1. A Transwell filter 
was wetted with 100 µL of the solvent mixture and attached to the end of the connecting 
tube. Parafilm was wrapped around the base of the tube to ensure a tight fit, the 
Transwell was checked for horizontal alignment and that the air ports were not 
occluded. 7 mL of the solvent mixture was added to the upper chamber only. The TSI 
was connected to a vacuum pump, and a flow meter attached to the throat using a tightly 
fitting mouthpiece. The vacuum pump was switched on and the airflow adjusted to 60 
L.min
-1
 ± 5 % using the flow meter. Size 3 gelatin capsules were filled with 12.5 ± 0.5 
mg of DPI blend, transferred into the Monodose inhaler device, and the side buttons 
depressed to pierce the capsule. The flow meter was replaced with the inhaler and the 
vacuum pump was switched on for 5 s. Three capsules were actuated per experiment for 
single drug DPI formulations, and six capsules were actuated for the combination DPI 




Figure 6.1  (a) The assembled Twin Stage Impinger (TSI); the Monodose inhaler was 
attached at position A and following actuation particles travel and deposit by inertial 
impaction onto the porous filter of a Transwell insert which is attached at position B. 
(b) The Transwell insert attached to the end of the connecting tube. Image taken from 
Grainger et al. (2009). 
 
Connecting Tube of the TSI 
Transwell Insert 
Porous Filter 
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6.4.7 DISSOLUTION PROFILE 
Following aerodynamic deposition of the particles, the TSI was dismantled. The 
Transwell was carefully removed from the connecting tube and placed in the well of a 
baseplate containing 600 µL of solvent mixture. 100 µL of solvent mixture was added 
to the apical chamber of the Transwell and the lid was replaced. At pre-defined time 
points, the Transwell was moved into an adjacent well containing 600 µL of fresh 
solvent mixture, and a sample was removed from the preceding well for HPLC analysis. 
For dissolution profiling of unfractionated SX in the various methanol-water mixtures, 
the time points were 5, 15, 30, 60, 120, 180, 240, 300, 360 and 420 min. For the 
engineered particles (i.e. CSX, Stage 4 SX and Stage 5 SX), and the co-formulation 
(unfractionated SX:FP, 1:1), the intervals were 30, 60, 120, 240 and 360 min. Sample 
recovery at the final time point, i.e. 480 min, differed between the solvent mixture 
compositions. For the 50:50 methanol:water composition, at the final time point, the 
solvent in the apical and basolateral chamber was removed and transferred into a 5 mL 
volumetric flask such that the solvent from the two chambers was combined. The 
chambers were washed by adding 100 µL and 600 µL of the solvent mixture to the 
apical and basolateral chamber, respectively, three times and transferring it into the 
volumetric flask. The sample was made to volume and analysed by HPLC. Due to very 
low detected concentrations for this sample due to the high dilution factor, for the 75:25 
solvent composition, solvent in the apical and basolateral chamber was removed and 
transferred into a small glass vial. A 1 mL graduated glass pipette was used to 
determine the volume of the sample, which was then analysed by HPLC. The wash was 
conducted as above and analysed separately by HPLC. For the 25:75 solvent 
composition sampling was as for the 75:25 composition except 600 – 1000 µL of 
methanol was added to the fluid removed from the apical and basolateral chambers to 
aid SX dissolution whilst trying to maintain as low a sample volume as possible. The 
wash was conducted as above except using methanol instead of the solvent mixture. The 
samples were sonicated (approx. 5 min) prior to analysis by HPLC. Dissolution 
experiments were conducted in triplicate. 
 
6.4.7.1 CONSTRUCTION OF DISSOLUTION PROFILE CURVES 
To construct the dissolution profile curves, the detected concentration at each sampling 
time point, including at the final time point, was used to calculate the mass of SX that 
had dissolved at each time point. The masses were summed to determine the total mass 
of SX that had dissolved during the experiment. To account for differences in the 
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deposited mass between experiments, the amount of SX dissolved at each time point 
was expressed as a percentage of the total amount of SX that had dissolved during the 
course of the experiment, and plotted to generate a cumulative dissolution profile curve.     
 
6.4.7.1.1 SIMILARITY FACTOR 
To determine whether there were differences between the dissolution profiles, a 
similarity factor (f2) was calculated. The f2 value is a measure of the similarity of two 
dissolution curves in terms of the percentage of drug that dissolved. The value is 
calculated according to Equation 6.1, where N is the number of time points, Rt is the 
mean percentage of drug dissolved in the reference sample at a specific time point, and 
Tt is the mean percentage of drug dissolved in the test sample at a specific time point. 
When the f2 value is ≥ 50, the dissolution curves are considered to be similar (FDA, 
2000). 
 
Equation 6.1              {[   (
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6.4.8 RECOVERY VALIDATION 
A 100 µg.mL
-1
 stock solution of SX in methanol:water 75:25 was prepared by 
accurately weighing 5 mg of SX and dissolving in 50 mL solvent mixture with initial 
sonication (approx. 10 min). The sample was then made to final volume. Dilutions of 
the stock solution were made (1 in 2 and 1 in 5) to prepare 50 µg.mL
-1
 and 20 µg.mL
-1
 
SX solutions, respectively. A Transwell insert was placed in the well of a baseplate 
containing 600 µL of the 75:25 solvent mixture. 100 µL of solution, containing either 
10 µg, 5 µg or 2 µg of SX, was added to the apical chamber (n = 3) and the lid replaced. 
After 8 h, the solvent from the apical and basolateral chambers was removed and the 
volume determined as described in Section 6.4.7. The chambers were washed three 
times with 75:25 methanol-water mixture (100 µL and 600 µL per wash for the apical 
and basolateral chamber, respectively) and the samples analysed by HPLC.  
 
In order to determine SX recovery, the stock and standard solutions were analysed by 
HPLC to determine the amount of SX that was present in the 100 µL of solution which 
had been placed in the apical chamber of the Transwell insert for each experiment. The 
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total amount of SX recovered was calculated by summing the mass of SX in the 
basolateral and apical chamber sample, and in the washing. This was then expressed as 
a percentage of the amount of SX in 100 µL of the stock/standard solution used in the 
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6.5 RESULTS 
6.5.1 BLEND HOMOGENEITY OF ENGINEERED FINE PARTICLE 
BLENDS 
Overall the homogeneity of the aerodynamically fractionated particles was superior to 
the crystallised (Table 6.3) and micronised pre-blends (Table 5.6). The crystallised 
particles had the poorest homogeneity; following tumbling the % CV of CSX and CFP 
was 14.1 and 13.9 %, respectively, and was much higher than that which is typically 
accepted for DPI formulations, although in this instance the blends did not contain a 
coarse carrier. The blend was tumbled a second time (62 rpm, 40 min) which reduced 
the % CV to 10.6 and 7.0 %, respectively, and the particles were deemed adequately 
mixed for the purposes of this study.  
 
Table 6.3 Blend homogeneity, expressed as the % coefficient of variance (% CV), 
drug content (mean ± SD) and detected drug ratio of salmeterol xinafoate (SX) and 
fluticasone propionate (FP) in co-formulated fine particle blends in the SX:FP ratio 
1:1 (n = 6).  
SX:FP ratio Homogeneity (% CV) Drug Content (µg.mg
-1
) Detected 
 SX FP SX FP Drug  Ratio 
Crystallised particles 
SX:FP* 10.6 7.00 517.9 ± 52.1  473.2 ± 31.6 1.0:0.9 
Fractionated particles 
Stage 4 SX:Stage 3 FP 1.08 2.02 507.1 ± 6.18 485.9 ± 9.76 1.0:1.0 
Stage 4SX:Stage 4 FP 2.61 1.42 513.7 ± 13.5 455.6 ± 116 1.0:0.9 
Stage 5 SX:Stage 3 FP 2.37 3.39 518.1 ± 12.7 479.7 ± 15.8 1.0:0.9 
Stage 5 SX:Stage 4 FP 1.86 1.01 508.2 ± 10.3 485.4 ± 6.95 1.0:1.0 
*The blend was tumbled twice at 62 rpm for 40 min to improve homogeneity. 
 
6.5.2 PARTICLE TYPE EFFECTS IN FINE PARTICLE BLENDS 
6.5.2.1 UNFRACTIONATED AND CRYSTALLISED POWDERS 
The aerodynamic deposition of crystallised SX and FP alone and in combination is 
shown in Figure 6.2 and Table 6.4. When aerosolised in combination, unfractionated 
SX and FP showed a non-significant reduction and no change in the FPF (RD and ED), 
respectively, as shown in Chapter 5 (Figure 5.12, Figure 5.13, and Table 5.8). However, 
for crystallised particles, the FPF of SX was reduced significantly (p < 0.05) and for FP 
increased significantly (p < 0.05, two sample t-test, OriginPro 8) when in combination. 
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The emission also changed, and was lower for CSX when combined with CFP (p < 
0.05) but increased for FP crystals (p < 0.05) when combined with CSX. Changes were 
also observed in the MMAD, increasing in combination for CSX (p < 0.05) whilst 
reducing for CFP (p < 0.05) when in combination. 
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Figure 6.2 The fine particle fraction (FPF < 5 µm, expressed as a percentage of the 
emitted dose, ED, and recovered dose, RD) and emission (% RD) of crystallised 
salmeterol xinafoate (CSX) and crystallised fluticasone propionate (CFP) aerosolised 
alone and in combination (1:1) into the Next Generation Impactor (mean ± SD, n = 3); 
* = p < 0.05 using an un-paired t-test. 
 
Table 6.4 The recovery (% of the actuated dose), mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD) of crystallised salmeterol xinafoate 
and fluticasone propionate aerosolised alone and in combination  into the Next 
Generation Impactor (mean ± SD, n = 3). 
SX:FP Ratio Recovery (%) MMAD (µm) GSD 
Salmeterol xinafoate 
1.0:0.0 87.1 ± 1.25 3.50 ± 0.24 2.07 ± 0.01 
1.0:0.9 94.1 ± 2.59 4.09 ± 0.20 1.93 ± 0.05 
Fluticasone propionate 
0.0:1.0 89.5 ± 1.98 4.12 ± 0.22 2.02 ± 0.05 
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6.5.2.2 FRACTIONATED POWDERS 
The aerodynamically fractionated particles demonstrated a change in their 
aerosolisation depending on whether the particles were aerosolised alone or in 
combination. The ratios of the mean FPF RD and ED of SX or FP between single and 
co-delivery are shown in Figure 6.3 and Figure 6.4; the standard deviations were 
obtained using propagation of errors (Lindberg, 2000). A ratio of 1.0 would indicate no 
difference in the FPF, ratios > 1.0 indicated a lower FPF, and ratios < 1.0 indicated a 
higher FPF when in combination compared to drug aerosolised alone.  Stage 4 SX 
particles exhibited an improvement in their emission when combined with Stage 3 FP 
particles (p < 0.05, two sample t test) but not with Stage 4 FP particles (p > 0.05). Stage 
5 SX exhibited improved emission regardless of FP particle type (p < 0.05 for Stage 3 
and 4 FP).  For Stage 4 SX, despite the improved emissions, the FPF was lower when 
combined with Stage 3 and Stage 4 FP particles (p < 0.05, Figure 6.3); the FPF reduced 
the most when in combination with Stage 3 FP. Stage 5 SX did not show a difference in 
the FPF when in combination with either FP particle type (p > 0.05). For both Stage 4 
and Stage 5 SX the MMAD increased (p < 0.05, Table 6.4), regardless of FP particle 
type.  
 
For both FP types, there was no change in emission when in combination with either 
Stage 4 or Stage 5 SX particles compared to single drug delivery (p > 0.05, Figure 6.4). 
For Stage 3 FP, the FPF RD was reduced in combination blends regardless of SX 
particle type (p < 0.05), despite no change in the MMAD of Stage 3 FP (p > 0.05, Table 
6.4). Although FP retention in the device and capsules was unchanged in co-formulation 
compared to single drug delivery (40.5 ± 3.44 % RD for Stage 3 FP alone, 40.2 ± 4.21 
% RD and 44.4 ± 0.54 % RD for combined delivery with Stage 4 and Stage 5 SX, 
respectively) overall the non-sizable fraction i.e. deposition of Stage 3 FP in the device, 
capsules, throat and pre-separator increased. This is because in combination there was 
greater Stage 3 FP deposition in the throat and pre-separator (33.9 ± 4.93 % RD and 
33.3 ± 5.37 % RD when combined with Stage 4 and Stage 5 SX, respectively), 
compared to single drug delivery (12.4 ± 0.93 % RD). 
 
For Stage 4 FP particles there was also a lower FPF RD when combined with both 
Stage 4 and Stage 5 SX (p < 0.05), corresponding with a higher non-sizable fraction 
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when in combination (65.4 ± 1.00 % RD and 73.1 ± 2.32 % RD, respectively) compared 
to Stage 4 FP aerosolised alone (56.3 ± 0.42 % RD) despite similar device and capsule 
retention. The MMAD did not change when in combination with Stage 5 SX but was 
smaller in the presence of Stage 4 SX. Therefore, although when in combination with 
Stage 5 SX there was a greater reduction in the sizable fraction of FP (i.e. deposition on 
the stages) compared to in combination with Stage 4 SX, in the latter the aerodynamic 
particle size of the deposited FP particles was smaller. 
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Figure 6.3 The fine particle fraction (% of the emitted dose, ED and recovered dose, 
RD) of salmeterol xinafoate (SX) expressed as a ratio of drug alone versus  drug co-
formulated with fluticasone propionate (FP) for fractionated SX (i.e. Stage 4 and 
Stage 5). Ratios > 1.0 indicate a poorer FPF. 
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Salmeterol xinafoate (SX) Fraction  
Figure 6.4 The fine particle fraction (% of the emitted dose, ED and recovered dose, 
RD) of fluticasone propionate (FP) expressed as a ratio of drug alone versus drug co-
formulated with salmeterol xinafoate (SX) for fractionated FP (i.e. Stage 3 and Stage 
4). Ratios > 1.0 indicate a poorer FPF. 
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Table 6.5 The recovery (% of the actuated dose), fine particle fraction (FPF < 5 µm, 
expressed as a percentage of the emitted dose, ED), mass median aerodynamic 
diameter (MMAD) and geometric standard deviation (GSD) of fractionated salmeterol 
xinafoate (SX) and fluticasone propionate (FP) when aerosolised alone and in 











SXS4- alone 78.9 ± 6.70 47.3 ± 3.93 71.3 ± 5.96 2.47 ± 0.11 1.75 ± 0.02 
SXS4- FPS3 91.4 ± 0.36 56.5 ± 2.13 31.6 ± 9.68 3.61 ± 0.19 1.76 ± 0.05 
SXS4- FPS4 90.3 ± 0.65 51.5 ± 1.81 45.1 ± 4.93 3.45 ± 0.07 1.70 ± 0.03 
SXS5- alone 71.5 ± 2.62 44.8 ± 2.59 45.9 ± 2.86 2.67 ± 0.06 1.98 ± 0.02 
SXS5- FPS3 87.7 ± 3.31 54.1 ± 1.90 35.6 ± 7.50 3.28 ± 0.14 1.81 ± 0.04 
SXS5- FPS4 91.8 ± 1.69 56.9 ± 2.09 33.7 ± 5.32 3.24 ± 0.10 1.79 ± 0.02 
Fluticasone propionate 
FPS3- alone 78.6 ± 3.50 59.6 ± 3.44 52.2 ± 2.08 3.74 ± 0.05 1.94 ± 0.02 
FPS3- SXS4 88.7 ± 1.44 59.6 ± 2.14 28.8 ± 9.46 3.75 ± 0.24 2.02 ± 0.05 
FPS3- SXS5 83.1 ± 3.12 58.4 ± 2.16 36.7 ± 7.59 3.50 ± 0.15 1.95 ± 0.04 
FPS4- alone 77.7 ± 1.70 58.7 ± 3.58 53.3 ± 3.37 3.50 ± 0.12 1.89 ± 0.02 
FPS4- SXS4 92.3 ± 3.19 54.4 ± 1.81 40.7 ± 6.15 3.46 ± 0.08 1.91 ± 0.04 
FPS4- SXS5 86.6 ± 1.81 60.2 ± 1.03 31.4 ± 4.65 3.31 ± 0.11 1.92 ± 0.03 
 
 
6.5.3 ENGINEERING SALMETEROL XINAFOATE AEROSOLISATION 
Having observed in Chapter 5 that SX and FP co-formulation, in the presence of a 
lactose carrier, mitigated against the reduction in SX dispersibility that occurred in the 
respective combination SX:FP pre-blends, the ability to engineer SX aerosolisation in 
DPI formulations by using SX particles with distinct physicochemical properties was 
investigated.  
 
6.5.3.1 BLEND HOMOGENEITY OF DRY POWDER INHALER BLENDS 
The homogeneity of the SX-only and combination DPI blends prior to and post-
tumbling, and detected drug contents, are shown in Table 6.6. Prior to tumbling the 
homogeneity was poor, however, following tumbling all the blends demonstrated 
adequate homogeneity with CV values less than 6 % . 
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Table 6.6 Blend homogeneity expressed as the % coefficient of variance (% CV), 
detected drug content (mean ± SD) and detected drug ratio of fractionated and 
crystallised salmeterol xinafoate (SX) co-formulated with fluticasone propionate (FP) 
in carrier based dry powder inhaler blends prior to (n = 10) and post tumbling (n = 6). 
Blend Homogeneity (% CV) Drug Content  (µg.mg
-1
)  Detected 
Drug Ratio 
Pre-tumbling SX FP SX FP  
Stage 4 SX:Stage 3 FP  46.2 41.6    
CSX:CFP  28.8 18.2    
Post-tumbling SX FP SX FP  
Stage 5 SX- alone 5.44 n.a. 12.5 ± 0.64 n.a. n.a. 
Stage 4 SX- alone 1.13 n.a. 12.3 ± 0.16 n.a. n.a. 
Stage 4 SX:Stage 3FP 3.75 1.94 6.67 ± 0.24 6.98 ± 0.13 1.0:1.0 
CSX- alone 2.75 n.a. 13.6 ± 0.37 n.a. n.a. 
CSX:CFP  4.69 4.48 6.84 ± 0.30 6.84 ± 0.22 1.0:1.0 
n.a. = not applicable. 
 
6.5.3.2 DE-AGGLOMERATION ANALYSIS BY LASER DIFFRACTION 
The de-agglomeration parameters for the engineered DPI blends from dry dispersion 
laser diffraction are shown in Table 6.7. In all instances the R
2
 was ≥ 0.99 and the 
DAmax was 1.0 ± 0.1 indicating an adequate fit of the data following empirical 
modelling. Considering the single drug formulations, the rank in terms of improving 
dispersibility (assigned according to the magnitude of the DA50) was: Stage 5 SX = 
Crystallised SX < Stage 4 SX; there was negligible difference in the DA50 between 
Stage 5 and crystallised particles. Considering the co-formulations, the bulk 
dispersibility of both the fractionated and crystallised DPI blends improved compared to 
the respective single drug formulation, such that an improvement in powder 
entrainability and de-agglomeration efficiency would be likely. The latter, however, 
would also depend on the cohesivity of the powder, represented by the CPP. As 
indicated in the table, on some occasions the particle size did not remain constant for 3 
consecutive increases in PP for determination of the CPP using the criteria assigned in 
Chapter 2 therefore two consistent PPs were used instead. The CPP had the following 
rank order for the single drug formulations with regards to increasing cohesivity, 
according to the magnitude of the CPP: Crystallised SX < Stage 5 SX < Stage 4 SX. 
Upon co-formulation, whereas the CPP of the fractionated blend did not change, the 
CPP increased for the blend prepared from crystallised particles. A high CPP represents 
a proportion of particles within the bulk powder which disperse poorly and thus require 
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high dispersal forces for de-agglomeration. Therefore, despite a low DA50, a high CPP 
may be detrimental to the overall de-agglomeration efficiency of the bulk powder due to 
a proportion of tightly agglomerated, poorly dispersible particles. 
 
Table 6.7 The R
2
, primary pressure for 50 % de-agglomeration (DA50) and maximum 
degree of de-agglomeration (DAmax) of 1.38 % w/w dry powder inhaler formulations 
containing crystallised or stage fractionated salmeterol xinafoate (SX) alone or in 
combination with fluticasone propionate. Stage 4 SX was co -formulated with stage 3 
FP, and crystallised SX was co-formulated with crystallised FP. 
DPI Formulation R
2
 DAmax  DA50 (Bar) CPP (Bar) 
Stage 4 SX – alone 0.9922 1.11 0.48 3.0 
Stage 4 SX:Stage 3 FP 0.9939 1.03 0.39 3.0 
Stage 5 SX – alone 0.9863 1.12 0.61 3.5* 
Crystallised SX – alone 0.9888 1.10 0.62 1.2 / 2.5* 
Crystallised SX:Crystallised FP  0.9937 1.04 0.35 3.0 
*The particle size remained consistent for two consecutive increases in PP only in plateau region. 
 
6.5.3.3 DISPERSIBILITY ASSESSMENT BY CASCADE IMPACTION 
The aerodynamic deposition of the SX particles when formulated with a lactose carrier 
either alone or in the presence of FP (in a 1:1 ratio) are shown in Figure 6.5 and Table 
6.8. Comparing between the different SX particle physicochemical properties, there was 
no change in the FPF (RD or ED), emission, MMAD or FPM of crystallised, Stage 4 or 
Stage 5 SX compared to the micronised (i.e. unfractionated) SX (p > 0.05, Kruskal-
Wallis test with Dunn’s post-test).  There were however differences between the latter 
three particle types. Crystallised SX had a lower FPF (RD and ED) compared to Stage 4 
SX (p < 0.05), and a larger MMAD compared to Stage 5 SX (p < 0.05).  
 
Differences between single and co-delivery were observed for crystallised and 
fractionated SX. For CSX, there was an increase in the emission and FPF ED in 
combination (p < 0.05 unpaired t-test), but no change in the FPF RD or MMAD 
compared to single drug delivery. These changes were the converse to those observed in 
the pre-blends, indicating that an altered balance in particulate interactions in the 
presence of lactose may have affected SX dispersibility. For Stage 4 SX, there was an 
increase in emission and a reduction in FPF ED following co-delivery with Stage 3 FP 
from a carrier-based blend suggesting changes to the de-agglomeration behaviour 
occurred. These changes were similar to those observed in the fine particle blends i.e. 
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there was an increase in emission and a reduction in the FPF ED for Stage 4 SX when in 
combination with Stage 3 FP in the absence of a carrier. In the DPI combination 
formulation there was no change in the MMAD or FPF RD of Stage 4 SX compared to 
single delivery, however, in the pre-blend the FPF RD was lower and MMAD larger 
compared to single drug delivery. Therefore, upon co-formulation of the particles in a 
carrier based blend, the detrimental effects on Stage 4 SX dispersion as a result of 
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Figure 6.5 The fine particle fraction (FPF < 5 µm, expressed as a percentage of the 
emitted dose, ED, and recovered dose, RD) and emission (% RD) of 1.38 % w/w 
crystallised, stage 4 and stage 5 salmeterol xinafoate (CSX, S4SX and S5SX, 
respectively) formulated with a lactose carrier alone and in combination with 
fluticasone propionate (FP; in the SX:FP ratio 1:1) assessed by Next Generation 
Impactor analysis (mean ± SD, n = 3). CSX was combined with CFP, and S4SX 
combined with S3FP. For comparison between single drug and co-delivery, ^ = p < 
0.05 by unpaired t-test; for comparison between particle types, * = p < 0.05 vs. CSX 
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Table 6.8 The recovery (% of the actuated dose), mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD) of 1.38% w/w crystallised, Stage 4 
and Stage 5 salmeterol xinafoate (CSX, S4SX and S5SX, respectively) formulated 
with a lactose carrier in the absence and presence of fluticasone propionate (FP; in the 
SX:FP ratio 1:1). CSX was co-formulated with CFP, and S4SX was co-formulated 
with S3FP (mean ± SD, n = 3). 
SX Particle Type Recovery (%) MMAD (µm) GSD 
CSX-alone 111 ± 21.4 4.34 ± 0.42 2.21 ± 0.10 
CSX-combination 93.0 ± 0.51 3.86 ± 0.14 2.20 ± 0.05 
S4SX-alone 91.1 ± 1.9 7 2.69 ± 0.04 2.11 ± 0.04 
S4SX-combination with S3FP 91.7 ± 2.37 2.85 ± 0.09 2.17 ± 0.06 
S5SX-alone 89.7 ± 0.81 2.56 ± 0.07 2.43 ± 0.10 
 
6.5.4 WORK OF COHESION AND ADHESION 
Figure 6.6 shows the work of cohesion and adhesion of the various SX and FP particles 
and CL. The values were calculated from the total surface energy distributions obtained 
from IGC at finite dilution (generated in Chapter 4 and 5), and therefore take into 
account dispersive and specific interactions. Overall, the magnitude of FP-FP cohesive 
interactions was larger than SX-SX cohesive interactions across all of the particle types. 
Generally the crystallised particles of SX and FP had a lower work of cohesion than the 
fractionated particles. Considering the cohesivity of SX, the work of cohesion between 
Stage 5 SX particles was higher than between Stage 4 SX particles, and they also 
exhibited regions on the particle surface with very high cohesive strength. For FP, 
conversely, there was negligible difference in the work of cohesion between Stage 3 and 
Stage 4 particles. Considering the adhesivity, all the particles (i.e. both SX and FP) 
demonstrated drug-CL adhesive interactions that were larger in magnitude than the 
corresponding drug-drug cohesive interactions. Across the engineered particles, the 
magnitude of SX-CL interactions was smaller than FP-CL interactions. Differences 
were also observed between the adhesivity of SX and FP towards each other. The work 
of adhesion between Stage 4 SX particles and fractionated FP particles was lower than 
the work of adhesion between Stage 5 SX and fractionated FP particles. At low surface 
coverages, the adhesivity of Stage 5 SX was greater than Stage 4 SX towards 
fractionated FP, but this diminished as the surface coverage of the probes increased. 
This indicated that the Stage 5 SX powder exhibited some very high surface energy 
regions which would dictate the inter-particulate interactions in the blends and 
potentially form strong interactions with any FP particles present. 
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Figure 6.6 The work of cohesion and work of adhesion between crystallised and stage fractionated salmeterol xinafoate (SX) and fluticasone 
propionate (FP) powders, and coarse lactose (CL), determined from the total surface energy distributions  obtained from inverse gas chromatography 
at finite dilution. Please note the different axes between the plots. 
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6.5.5 SALMETEROL XINAFOATE SOLUBILITY 
The solubility of SX in various methanol and water systems is shown in Table 6.9. The 
solubility of SX reduced as the amount of water in the system increased.  
 
Table 6.9 The solubility of salmeterol xinafoate (SX) in water  and methanol systems 
determined at room temperature (mean ± SD, n = 3). 
Methanol to Water Ratio Solubility (mg.mL
-1
) 
100:0 35.4 ± 2.72 
75:25 7.81 ± 1.25 
50:50 1.21 ± 0.13 
25:75 0.19 ± 0.00 
0:100 0.04 ± 0.01 
 
6.5.6 DRUG RECOVERY FROM DISSOLUTION MEDIA 
The amount of SX recovered from the Transwell insert (including the well of the 
baseplate) following the application of a known amount of SX in solution is shown in 
Table 6.10. The percentage recovered varied from 75.8 to 92.2 %; the recovery 
therefore increased with greater amounts of SX added to the insert. It is therefore likely 
that there were sites of loss due to SX adsorption onto the plastic of the insert/well. 
Upon reaching a threshold amount of SX, above the saturable level of adsorption, SX 
recovery from the Transwell became higher and closer to 100 %.  
 
Table 6.10 The amount (in µg) and percentage of salmeterol xinafoate (SX) recovered 
following the application of known amounts of SX onto a Transwell insert in a 
methanol-water mixture with composition 75:25 methanol:water (mean ± SD, n = 3). 
Amount of SX (µg) Amount Recovered (µg) Percentage Recovered (%) 
9.94  9.16 ± 0.58  92.2 ± 5.87 
4.97 4.31 ± 0.11  86.6 ± 2.30  
1.99 1.51 ± 0.15  75.8 ± 7.42  
 
6.5.7 DISSOLUTION PROFILE OF SALMETEROL XINAFOATE  
The dissolution profile of micronised SX in methanol:water mixtures is shown in Figure 
6.7. The amount of SX actuated into the TSI, along with the amount deposited on the 
Transwell insert are shown in Table 6.11. The amount of SX depositing on the insert 
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was comparable between the solvent compositions. SX dissolution appeared to alter 
depending on the solvent composition; the dissolution rate was fastest in the methanol 
to water ratio 75:25, and slowest in the ratio 25:75. The similarity factors indicated that 
the dissolution curves were different between solvent compositions. Compared to the 
25:75 composition, the f2 values were 32 and 25 for the 50:50 and 75:25 compositions, 
respectively. Considering the latter two compositions, the profiles were also dissimilar 
with an f2 value of 47. 
 
In some instances, the detected concentration of the samples was at or below the LOQ 
of the calibration curve (circled in Figure 6.7) and in most instances at the final time 
point (480 min) and/or wash. In the case of the 75:25 and 50:50 compositions, this 
indicated that dissolution was likely to be complete from 360 min onwards, and for the 
50:50 composition, that dissolution was negligible before 5 min. For the 25:75 
composition, the low detected concentrations at 5, 15 and 30 min again indicated little 
dissolution occurring initially, and that dissolution slowed beyond 300 min. The amount 
of SX dissolved in the dissolution media at these latter time points indicated that 
saturation had not occurred; i.e. at 300 min the total amount of SX was 4.12 ± 1.47 µg, 
and at 360 min it was 7.00 ± 2.12 µg and 8.08 ± 3.10 µg for the 25:75, 50:50 and 75:25 
methanol-water compositions, respectively. For each methanol-water composition there 
was also a high degree of variability between repeat experiments. The variability was 
particularly high for the 25:75 methanol:water composition.   
 
Table 6.11 The amount of salmeterol xinafoate actuated into the Twin Stage Impinger, 
and the amount deposited on the Transwell insert , in dissolution experiments utilising 










75:25 477.8 ± 4.63 8.74 ± 3.35 1.83 ± 0.71 
50:50 475.9 ± 3.90 8.32 ± 3.20 1.75 ± 0.68 
25:75 473.6 ± 2.92 9.96 ± 5.22 2.11 ± 1.11 
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Figure 6.7 The dissolution profile of micronised salmeterol xinafoate (SX) in 
methanol:water mixtures (75:25, 50:50, 25:75) expressed as the cumulative amount of 
SX dissolved over 480 min (mean ± SD, n = 3). Circled data points were on or below 
the limit of quantification of the calibration curve on at least one occasion. 
 
6.5.8 EFFECT OF PARTICLE PROPERTIES AND CO-FORMULATION 
ON THE DISSOLUTION PROFILE OF SALMETEROL 
XINAFOATE 
The dissolution profile of the varying SX particle types, as well as the micronised (i.e. 
unfractionated) SX:FP co-formulation is shown in Figure 6.8. The amount of SX 
actuated into the TSI and the amount deposited on the Transwell insert are shown in 
Table 6.12. The dissolution media was methanol and water in the ratio 25:75. This 
composition was selected to ensure that differences in the dissolution profiles of the 
particles would not be masked by high drug solubility in the dissolution media (El-
Gendy et al., 2011). Using this media, there remained a high degree of variability 
between repeat experiments. The data for the micronised (i.e. unfractionated) SX is a 
repetition of the data presented in Figure 6.7, which is included for comparison. 
Compared to unfractionated SX, there was no change in the dissolution profile of 
crystallised, Stage 4 or Stage 5 SX as indicated by the f2 values, which were 67, 66 and 
58, respectively. There was also no change is the dissolution profile when comparing 
between any of the particle types; in all instances the f2 value was ≥ 50. In co-
formulation, the dissolution rate of unfractionated SX appeared to increase compared to 
single drug delivery, and was corroborated by an f2 value of 40. 
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Table 6.12 The amount of salmeterol xinafoate (SX) actuated into the Twin Stage 
Impinger, and the amount deposited on the Transwell insert from dry powder inhaler 
formulations using methanol:water 25:75 as the dissolution media  (mean ± SD, n = 3 
except Stage 5 SX, n =2). 






Micronised SX co-formulation 462.2 ± 45.2 4.67 ± 0.93 1.01 ± 0.22 
Crystallised SX 513.6 ± 2.61 6.19 ± 1.77 1.20 ± 0.34 
Stage 4 SX 472.2 ± 20.5 8.53 ± 1.48 1.78 ± 0.38 
Stage 5 SX 464.0 ± 3.47 4.49 ± 0.02 0.96 ± 0.01 
 


























 Micronised SX - co-formulation
 Crystallised SX
 Stage 4 SX 
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Figure 6.8 The dissolution profile of micronised, stage 4, stage 5 and crystallised 
salmeterol xinafoate (SX) in methanol and water (25:75), and micronised (i.e. 
unfractionated) SX when in combination with fluticasone propionate,  expressed as the 
cumulative amount of SX dissolved over 480 min (mean ± SD, n = 3 except stage 5 
SX, n = 2). Circled data points were on or below the limit of quantification of the 
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6.6  DISCUSSION AND CONCLUSIONS 
The ability to engineer the aerosolisation performance of drug particles from 
combination inhalers would enable these complex formulations to be designed for 
optimal drug dispersion and deposition at the target sites in the lungs. The additional 
component in these formulations presents the opportunity for drug agglomerates 
consisting of one or both drugs, as well as the carrier particles. It was postulated that by 
understanding the agglomeration behaviour in drug-drug pre-blends prior to formulating 
with a carrier, it may be possible to manipulate the deposition profiles of the drugs 
when blended as representative DPI formulations. Specifically, by controlling the 
physicochemical properties of the component particles (i.e. size, crystalinity, surface 
energy and initial cohesive agglomeration tendency), it would be possible to direct the 
formulation behaviour of combination DPI formulations.  
 
6.6.1 ENGINEERING DRUG PARTICLE DISPERSION BEHAVIOUR 
USING RE-CRYSTALLISED DRUG POWDERS 
The drug pre-blends had adequate homogeneity. The crystallised blend had the poorest 
homogeneity with CV values of 10.6 and 7.00 % for SX and FP, respectively. This is 
typical for crystallised particles in which smoother particle surfaces have lower 
interactive forces, and there are greater drug losses during handling, storage and mixing 
(Kaialy et al., 2012). When aerosolised into the NGI, co-formulation had different 
effects on each drug. Co-formulation was detrimental to the emission and FPF (ED and 
RD) of CSX, and resulted in an increase in the MMAD. Conversely, for CFP there was 
an increase in the emission and FPF (RD and ED) and reduction in the MMAD when 
aerosolised in combination. The work of cohesion and adhesion, derived from the 
surface energy of the particles, was lower in magnitude compared to the micronised 
particles, but the relative cohesivity and adhesivity of the particles was the same i.e. the 
magnitude of CSX-CFP adhesive interactions was greater than CSX-CSX cohesive 
interactions and smaller than CFP-CFP cohesive interactions (Figure 6.6). In 
combination carrier-based formulations, the performance of FP (in terms of the FPF) 
was optimal when FP particles were less adhesive towards SX particles and more 
cohesive towards itself (Kubavat et al., 2012). The work of cohesion/adhesion 
distributions were used to calculate the cohesion:adhesion (C:A) ratios based on the 
cohesive adhesive balance principle (Kubavat et al., 2012); at each surface coverage the 
 Page | 236  
 
ratio between the work of cohesion and work of adhesion was calculated, a value > 1.00 
would indicate a cohesive led system whereas a value < 1.00 would indicate an adhesive 
led system. For both micronised (i.e. unfractionated) particles and crystallised particles, 
the overall balance of interactions was dominated by cohesive interactions i.e. C:A > 
1.0. The micronised particles were marginally more cohesive and thus less adhesive 
(1.08 – 1.10) than crystallised (1.02 – 1.06) FP particles, despite no change in FP 
dispersion following co-formulation in micronised pre-blends but improved dispersion 
in crystallised pre-blends. There were, however, other differences in the properties of 
the particles which may have contributed to the aerosolisation behaviours. A distinctive 
change in particle shape occurred for CFP and particles were elongated and needle-like 
after crystallisation. Carrier particles exhibiting this morphology have fewer drug-
carrier contact points, less stable contact, and experience lower press-on forces during 
mixing (Kaialy et al., 2012). CFP particles exhibiting this morphology may therefore 
also exhibit weaker agglomeration with other fine particles in the pre-blend due to these 
structural factors and thus may promote their dispersion. Particles of this shape are also 
able to remain airborne for longer compared to particles of the same geometric size but 
different morphology (Kaialy et al., 2012). Therefore, CFP agglomerates as well as any 
CFP-CSX agglomerates that may have formed during mixing would be easier to 
disperse, and the released CFP particles would have a high propensity to remain 
airborne. Dry dispersion laser diffraction analysis also revealed that CFP was more 
dispersible than MFP; the DA50 was lower, indicating that 50 % of the CFP particles 
dispersed at a lower dispersing pressure than the MFP particles. The CFP particles were 
also less cohesive than the micronised particles when assessed by IGC. CFP particles 
would therefore be more easily entrained, and due to lower cohesive interactions require 
lower dispersion forces for complete de-agglomeration. 
 
For SX, higher FPFs have been obtained in carrier-based formulations when there is a 
higher adhesive tendency between SX and FP particles compared to SX cohesivity 
(Kubavat et al., 2012). The plate-like, highly crystalline, smooth surfaces of crystallised 
SX particles are known to exhibit low surface energy (Rehman et al., 2003), and this 
was observed in the current study (Chapter 4, Figure 4.10). Both crystallised and 
micronised SX were more adhesive to FP than cohesive to itself, and the crystallised SX 
particles had a marginally higher cohesive tendency relative to the adhesive tendency 
towards FP (0.94 – 0.98) compared to micronised SX (0.91 – 0.93). Dry dispersion laser 
diffraction analysis also revealed than CSX was more dispersible than MSX, and IGC 
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revealed lower cohesive interactions between CSX particles compared to MSX 
particles. This highlighted the interplay between bulk powder and particulate properties 
in determining aerosolisation behaviour. Although the large particle size and lower 
magnitude in the cohesive strength of CSX particles compared to MSX resulted in good 
flow and low device/capsule retention (9.0 ± 2.07 % RD), CSX deposition was high in 
the throat and pre-separator (51.0 ± 4.54 % RD) due to the deposition of both CSX 
agglomerates and large, de-agglomerated CSX particles. In the CSX-CFP pre-blend, 
CSX deposition in the throat and pre-separator was comparably high (51.3 ± 1.21 % 
RD), and there was a doubling in device/capsule retention (18.3 ± 1.37 % RD) 
compared to that of CSX alone. The combination pre-blend therefore contained 
agglomerated CSX particles which exhibited poorer flow and were less dispersible than 
in the pure CSX powder, due to stronger CSX-CFP interactions compared to CSX-CSX 
interactions in the powders. 
 
6.6.2 ENGINEERING DRUG PARTICLE DISPERSION BEHAVIOUR 
USING SIZE-FRACTIONATED DRUG POWDERS 
Pre-blends containing aerodynamically fractionated particles also showed good blend 
homogeneity with CV values less than 3.5 %. Significant changes to the aerosolisation 
behaviour were seen following co-formulation, and appeared to be influenced by the 
particle type. For Stage 4 SX, when in combination with either Stage 3 or Stage 4 FP, 
there was a lower FPF and a bigger MMAD. The magnitude of the reduction of the FPF 
depended on the size of the FP particle; when combined with the larger Stage 3 FP there 
was a bigger reduction in the FPF and increase in the MMAD. Despite this, there was 
an increase in SX emission when in combination with Stage 3 FP but no change when 
in combination with Stage 4 FP. Stage 4 SX particles were more adhesive towards FP 
than cohesive, but there was little change in the relative SX adhesivity depending on the 
FP particle type (Figure 6.6). Improved flowability of larger S4SX-S3FP agglomerates 
(S3FP; liquid dispersion Dv50 2.14 ± 0.18 µm) compared to S4SX-S4FP agglomerates 
(S4FP; Dv50 1.91 ± 0.09 µm) may have contributed towards the reduction in 
device/capsule retention and increase in the emitted dose through improved flow 
properties (Shariare et al., 2011). However, incomplete dispersion of the larger S4SX-
S3FP agglomerates compared to the smaller S4SX-S4FP agglomerates, both of which 
would have experienced similar intra-agglomerate forces (based on the work of 
cohesion and adhesion of the particles), would have resulted in a greater reduction in the 
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FPF and increase in MMAD due to greater deposition occurring in the throat, pre-
separator and stages relating to larger aerodynamic particle sizes (stage 1 – 3) for S4SX-
S3FP compared to S4SX-S4FP (48.5 ± 4.40 % and 41.2 ± 2.08 % RD, respectively). 
 
Conversely, for Stage 5 SX particles there was no change in the FPF when combined 
with Stage 3 or Stage 4 FP particles. There was however an increase in the MMAD and 
higher emission following co-formulation with either FP particle type. Stage 5 SX 
particles also showed an adhesive tendency for FP, and there was marginally higher 
adhesivity towards Stage 3 FP compared to Stage 4 FP. Unlike Stage 4 SX, there was 
no difference in the magnitude of the changes in the aerosolisation parameters 
depending on the FP particle. Overall the aerosolisation parameters of Stage 5 SX 
particles were affected to a lesser extent by co-formulation compared to Stage 4 SX 
particles. Despite having a smaller geometric particle size (Dv50 1.12 ± 0.04 µm and 
1.51 ± 0.06 µm, for Stage 5 SX and Stage 4 SX, respectively), Stage 5 SX particles had 
a higher agglomeration tendency as demonstrated by dry dispersion particle sizing. The 
Dv50 at 0.2 Bar was 7.64 µm and 23.06 µm for Stage 4 and Stage 5 SX, respectively. 
Coupled with the higher cohesivity of Stage 5 particles (in terms of the overall 
magnitude of the forces of cohesion and relative magnitude of the forces of adhesion 
towards FP), there may have been less pronounced changes in aerosolisation behaviour 
when in combination with FP due to a lower propensity for interaction/disruption of SX 
agglomerates by FP particles, as demonstrated by the non-sizable fractions obtained in 
the NGI. Due to the high agglomeration tendency of Stage 5 SX, the non-sizable 
fraction was high (75.3 ± 1.83 % RD). However, when co-formulated with Stage 3 or 
Stage 4 FP the non-sizable fraction did not change (74.9 ± 3.84 % RD and 75.3 ± 2.46 
% RD, respectively). For Stage 4 SX, the non-sizable fraction was lower (62.3 ± 4.98 % 
RD), however, upon co-formulation with Stage 3 or Stage 4 FP there was an increase in 
the non-sizable fraction (75.5 ± 5.21 % RD and 69.3 ± 3.32 % RD, respectively), 
indicating disruptions/alterations to the agglomeration of the blend, particularly in terms 
of the proportion of large, poorly dispersible agglomerates. 
 
In the case of FP fractions, unlike the behaviour observed with SX, neither Stage 3 nor 
Stage 4 FP demonstrated changes in emission when in combination with either Stage 4 
or Stage 5 SX but the FPF was observed to decrease. Whereas for Stage 3 FP a bigger 
reduction in the FPF occurred when in combination with the larger Stage 4 SX particles, 
for Stage 4 FP a bigger reduction occurred with the smaller Stage 5 SX particles. There 
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was no change in the MMAD, except for Stage 4 FP in combination with Stage 4 SX, in 
which the MMAD was smaller than for FP alone (p < 0.05). The overall consistency in 
the MMAD between the blends, while changes in the FPF were observed, indicates that 
this parameter cannot alone be used to predict drug aerosolisation behaviour. Were this 
a carrier-based system, it would indicate similar drug particle agglomeration and 
differences in the adhesive rather than cohesive interactions for the drug in the 
formulation (Kaialy et al., 2012). Of the co-formulations, FP deposition in the throat 
and pre-separator was lowest from the S4FP-S4SX pre-blend (21.9 ± 2.19 % RD) 
compared to the other combinations (33.3 ± 5.37 % RD to 33.9 ± 4.93 % RD); FP 
deposition in the throat and pre-separator was 16.7 ± 0.77 % RD and 12.4 ± 0.14 % RD 
for Stage 4 and Stage 3 FP, when aerosolised alone, respectively. In the absence of a 
carrier, deposition in the throat and pre-separator represents the deposition of large, 
undispersed drug agglomerates. In all the carrier-free co-formulations, there was 
therefore a higher proportion of large, difficult to disperse agglomerates compared to 
single drug delivery, demonstrated by the high throat and pre-separator deposition. For 
the S4FP-S4SX pre-blend however there was a smaller proportion of these 
agglomerates compared to the other combination pre-blends and thus an increase in the 
sizable fraction. Although this did not increase the FPF of Stage 4 FP relative to single 
drug delivery, there was a shift in the aerodynamic particle size of the deposited sizable 
fraction towards a smaller particle size. All the co-formulations are therefore likely to 
have experienced a change in their powder structure, in terms of the agglomeration 
state, compared to the single drug powder fractions. 
 
Fractionated FP particles, similar to bulk micronised (i.e. unfractionated) particles, were 
more cohesively balanced than adhesive to SX. The magnitude of the cohesive FP-FP 
interaction, and its heterogeneity, did not differ dramatically between the 
unfractionated, Stage 3 and Stage 4 FP particles. However, it was only in blends 
containing fractionated SX and FP particles in which the aerosolisation of FP changed 
and the FPF was lower compared to single drug delivery, and the reasons for this were 
unclear. Both SX and FP showed heterogeneity in their surface energy distributions and 
therefore work of cohesion. In pre-blends containing unfractionated particles, SX may 
therefore have only been able to disrupt the more weakly associated FP agglomerates, 
and thus did not impact the overall dispersibility of FP from the pre-blend. However, 
when formulated with Stage 5 SX, for example, which had much higher surface energy 
and thus magnitude of interactive forces, SX particles may have been able to disrupt 
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even the most cohesive FP-FP agglomerates within the pre-blend, and thus the 
consequence was a reduction in the dispersibility of the FP particles. Stage 4 SX 
particles conversely had a similar magnitude in the cohesive/adhesive forces compared 
to unfractionated SX, and therefore would also only have been able to disrupt the more 
weakly associated FP agglomerates. Therefore, it is also important to consider the 
differences in the fractionated FP particles compared to the unfractionated FP particles.  
Agglomerate strength is determined not only by the work of cohesion/adhesion between 
the component particles, but also the particle size and packing fraction (Kendall and 
Stainton, 2001). Stage-fractionated FP was more dispersible than the unfractionated FP 
particles (DA50 = 0.85 Bar, 1.50 Bar and 1.72 Bar, respectively, for Stage 3, Stage 4 and 
unfractionated FP, respectively, Chapter 4, Table 4.8), potentially arising due to 
changes in packing fraction, agglomerate and/or powder structure. More dispersible FP 
agglomerates would therefore have been more favourable for promoting SX interactions 
with FP during blending. This may have contributed towards the superior homogeneity 
of the fractionated pre-blends compared to the unfractionated pre-blends (Chapter 5, 
Table 5.6), however, a consequence of this as observed in the study was a detrimental 
effect on the dispersion of FP from the blend. Although low shear Turbula mixing is 
able to generate homogenously mixed blends containing FP (Le et al., 2012b), and was 
demonstrated in the current work, there may also still remain drug agglomerates 
comprising very cohesive particles within the final blend. Therefore, using optimal 
amounts of mixing aids (e.g. silica-gel beads) or high hear mixers it has been shown to 
enable further improvement in homogeneity due to disruption of these highly cohesive 
agglomerates (Sebti et al., 2007; Le et al., 2012b). In fractionated pre-blends, a 
combination of highly cohesive FP agglomerates and SX-FP mixed agglomerates 
present within the powder structure which hindered FP dispersion may have dictated the 
poor aerosolisation of FP. Furthermore, SX-FP adhesive interactions may have altered 
following blending, as the balance of cohesive and adhesive interactions has been 
shown to be sensitive to processing conditions for FP (Kubavat et al., 2012). 
Blending/handling of these particle sub-populations may therefore also have 
unfavourably altered the balance of interactions with regards to FP dispersion. The 
blending process itself, including use of the low shear Turbula mixer, can induce 
changes in particle properties such as amorphisation of particle surfaces and even 
altered particle morphology, with plate-like SX showing plastic deformation to near 
spherical particles and FP fragmenting to needle-like particles, although occurring 
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following much longer mixing times (420 min for SX, 780 min for FP) compared to 
those in the current study (Grasmeijer et al., 2013).  
 
The trends in aerosolisation performance observed for the aerodynamically fractionated 
particles differed to those seen for the micronised (i.e. unfractionated) particles 
following co-formulation. Although overall the aerosolisation behaviour of the 
unfractionated SX and FP particles did not change when formulated as combination pre-
blends in a 1:1 ratio (p > 0.05), there existed a proportion of particles within the bulk 
powder for which aerosolisation efficiency was compromised when in combination, as 
demonstrated by the pre-blends prepared from size-fractionated powders. Furthermore, 
the extent of the change in aerosolisation performance depended on the specific 
fractions that were co-formulated. When considering the aerosolisation performance of 
combination inhalers, it is therefore too simplistic an approach to consider the behaviour 
of the bulk micronised particles, as powder sub-populations demonstrate different 
aerosol behaviours. It is the behaviour of these sub-populations which may contribute 
towards inter-batch variability between the aerosol performance of inhaled 
powders/formulations despite apparent similarity between measured bulk properties 
such as surface energy, AFM force measurements, and particle size analysis. To fully 
understand both inter- and intra-batch variability in powder aerosolisation performance 
and the consequences for the final inhaler product, it may therefore be necessary to 
undertake thorough physicochemical analysis using sufficiently sensitive techniques to 
enable the variability in particle properties, including those arising due to damage upon 
micronisation, within a bulk powder to be assessed. 
 
6.6.3 ENGINEERING SALMETEROL XINAFOATE DISPERSION 
BEHAVIOUR; THE INFLUENCE OF DRUG PARTICLE 
PROPERTIES IN CARRIER BASED BLENDS 
In Chapter 5 it was observed that when unfractionated SX and FP particles were co-
formulated in the presence of a lactose carrier the detrimental effects on SX 
dispersibility that occurred in the respective combination SX:FP pre-blends were no 
longer present. In both Chapter 3 and Chapter 5, unfractionated SX appeared to be more 
sensitive to changes in aerosolisation due to the presence of the FP powder compared to 
FP in the presence of the SX powder. Therefore, the ability to engineer SX 
aerosolisation in carrier-based DPI formulations was investigated by using SX particles 
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with distinct physicochemical properties generated in Chapter 4. The aerosolisation 
behaviour of the unformulated SX particles was found to not be representative of the 
aerosolisation of ‘engineered’ SX when formulated with a lactose carrier. Whereas 
significant differences were observed in the emission, FPF (ED and RD) and MMAD of 
micronised (i.e. unfractionated) SX particles and crystallised, Stage 4 and Stage 5 SX 
when aerosolised into the NGI in the absence of a carrier (as described in Chapter 4), 
when formulated with a lactose carrier, the engineered SX particles exhibited no change 
in any of the aerosolisation parameters compared to micronised (i.e. unfractionated) SX 
particles. Changes in the bulk dispersibility determined from laser diffraction however 
were apparent for the single drug DPI blends. In all instances the blends showed better 
bulk dispersibility than the micronised (i.e. unfractionated) SX DPI blend (DA50 = 1.01 
Bar), indicating a change in powder structure and agglomeration occurred. 
 
Considering the fractionated particles, Stage 4 and Stage 5 SX produced the same FPF 
(p > 0.05, although there was a non-significant reduction) and emission when 
formulated as a DPI. Similar FPFs may arise in two situations. Firstly, when there is 
lack of saturation of active binding sites on the carrier such that adhesive forces between 
the drug and carrier dominate any differences in drug properties (e.g. cohesivity, 
agglomeration state) in determining the FPF (Murnane et al., 2009). Assessment of the 
SEM images of the DPI blends containing 1.38 % w/w unfractionated SX particles 
revealed large areas of the carrier surface with no drug associated (Chapter 5, Figure 
5.9). Similar FPFs may also arise from similar SX agglomeration within the blends, 
such that de-agglomeration efficiency in the turbulent air stream is not enhanced by 
larger agglomerate masses and/or sizes (Murnane et al., 2009). Similar agglomeration 
would also lead to similar press-on forces during blending, which occur as a drug is 
loaded onto a carrier surface; highly agglomerated particles experience stronger press-
on forces due to a larger area of contact between the individual particles, and this results 
in lower levels of drug detachment from a carrier (Selvam and Smyth, 2011). Despite 
the similarities in the FPF and emission, bulk blend dispersibility measurements 
indicated that the Stage 5 SX DPI was less dispersible (DA50 = 0.61 Bar), marginally 
more cohesive (CPP = 3.5 Bar) and showed greater heterogeneity in agglomeration than 
the Stage 4 SX DPI (DA50 = 0.48 Bar, CPP = 3.0 Bar), indicating different bulk powder 
structures. The improvement in powder flow as a result of inclusion of a carrier resulted 
in equivalent emissions in the NGI despite different SX physicochemical properties. 
The non-significant reduction in the FPF of Stage 5 SX compared to Stage 4 SX may 
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have arisen from the marginally higher S5SX-CL adhesion compared to SXS4-CL 
adhesion, and lower detachment and dispersibility of the smaller, more cohesive Stage 5 
particles.  
 
Stage 5 SX particles also exhibited a non-significant smaller MMAD (p > 0.05) 
compared to Stage 4 SX and a significantly smaller MMAD than crystallised SX (p < 
0.05) following aerosolisation from a DPI blend, which may have arisen due to the 
inherently smaller geometric particle size of this sample. The effect of particle size on 
aerosolisation in the literature has been variable. For example, when formulated as 
binary drug-lactose blends, smaller SX particles (in terms of geometric and 
aerodynamic particle size, comprising fractions of the same powder) had lower FPFs in 
the NGI (Taki, 2008a). Smaller salbutamol particles have generated similar emissions, 
higher FPFs, FPMs and smaller MMADs compared to larger drug particles (Adams et 
al., 2012); whereas larger SS particles (aerosolised without a carrier) have generated 
higher emissions (Shariare et al., 2011). Mannitol particles prepared by jet-milling or 
spray drying with Dv50 values in the range 1 – 10 µm, had optimal FPFs when the Dv50 
was 2 – 5 µm (Louey et al., 2004a). The effect of particle size (and thus mass) on 
detachment from a carrier has also been shown to be less critical with increasing inhaler 
device de-agglomeration efficiency (Dickhoff et al., 2002). The factors responsible for 
changes in the dispersion of powder aerosols therefore arise from a complex inter-play 
of the particle size of the drug, particle properties, airflow and inhaler design (Chew and 
Chan, 1999; Chew et al., 2000) and relate to the specific set of conditions employed in 
the particular study. The bulk powder properties, which are determined by the 
component particles, also influence dispersiblity (i.e. DA50), in addition to the 
heterogeneity in the dispersion behaviours of sub-populations of particles within the 
bulk (i.e. contrasting DA50 and CPP parameters). 
 
Stage 4 SX particles produced had a higher FPF than crystallised SX particles when 
formulated as single drug DPIs (p < 0.05), but the emission and MMAD were the same 
(p > 0.05). Stage 4 SX also had a lower DA50 and thus was more dispersible than CSX. 
The bulk dispersibility of the crystallised and Stage 5 SX DPI blends was equivalent 
(DA50 0.62 Bar and 0.61 Bar, respectively), as were the aerosolisation parameters 
(excluding the MMAD) following NGI analysis. The CSX DPI was marginally less 
cohesive (CPP = 2.5 Bar) than the Stage 4 (CPP = 3.0 Bar) and Stage 5 (CPP = 3.5 Bar) 
SX DPI blends, and this rank was in agreement with the cohesivity of the component 
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SX particles determined from surface energy measurements (Figure 6.6). When 
formulated with a lactose carrier, CSX has shown equivalent FPFs to micronised 
particles despite having a larger particle size and PSD, and demonstrated no difference 
in throat deposition (Murnane et al., 2009). The lower FPF of CSX observed in the 
current study compared to Stage 4 SX resulted from a larger non-sizable fraction (i.e. 
SX retention in the device, capsules, throat and pre-separator) for the crystallised 
particles (82.1 ± 0.18 % RD) compared to the Stage 4 SX particles (74.0 ± 0.35 % RD). 
Despite a smaller crystal particle size in the current work compared to that of Murnane 
et al. (2009) (Dv50 = 4.93 ± 0.37 µm and 6.59 ± 0.31 µm, respectively), a higher drug 
content in the blends (1.38 % w/w and 0.58 % w/w, respectively) would result in a 
blend in which cohesive interactions play a more dominant role. CSX agglomeration 
would show favourable competition over CSX-CL adhesion at higher drug contents, 
such there would be a larger proportion of drug agglomerates, as well as agglomerates 
with larger diameters (Murnane et al., 2009). The component particles of the 
agglomerates would also be larger for crystallised compared to Stage 4 particles. 
Therefore undispersed CSX agglomerates, in addition to any dispersed CSX particles, 
due to their large particle size, would both deposit on NGI stages corresponding to 
larger aerodynamic particle sizes resulting in an increase in the non-sizable fraction.  
 
When formulated as a combination DPI, CSX exhibited an increase in emission and 
FPF RD, and no change in MMAD, when combined with CFP. These changes were in 
direct contrast to those observed for CSX formulated with CFP in a pre-blend. 
Furthermore, the bulk dispersibility improved when in combination (DA50 = 0.35 Bar 
compared to 0.62 Bar for the CSX-only DPI) and there was an increase in cohesivity. 
The reasons for this change in aerosolisation behaviour were a little unclear. During 
blending, drug agglomeration on a carrier surface occurs due to press on i.e. inertial and 
frictional forces resulting from carrier particle collisions and relative displacements (De 
Boer et al., 2004). During the first 0.5 min, drug particles/agglomerates reside in carrier 
surface irregularities. As mixing time increases, they redistribute over the entire carrier 
surface, and there is the generation of further drug agglomerates (Grasmeijer et al., 
2013).  De Boer et al. (2004) suggest that there are two types of drug agglomerates: 
‘natural’ agglomerates in the starting material which are not disrupted during mixing or 
inhalation, even after removal from the carrier, and newly formed agglomerates on the 
carrier surface. These latter agglomerates are weaker and disperse under relatively weak 
de-agglomeration forces (De Boer et al., 2004). Blending would therefore result in 
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restructuring of the CSX or CSX:CFP pre-blend starting material such that there would 
be a proportion of more weakly associated agglomerates.  
 
In the combination blend, due to the higher adhesive rather than cohesive tendency of 
CSX towards CFP, the newly formed weaker agglomerates may comprise mixed CSX-
CFP agglomerates. In this instance, these mixed agglomerates may have altered 
properties such as size, shape and packing fraction compared to CSX-CSX 
agglomerates that may have been favourable for de-agglomeration.  If, for example, the 
mixed agglomerates were larger than the single drug agglomerates, larger diameters and 
thus larger detachment masses would increase the ratio of the removal force to the 
adhesive force, further increasing the chance of agglomerate removal (De Boer et al., 
2004). Dry dispersion laser diffraction provided evidence for agglomerate re-structuring 
between the crystallised DPI blends; in combination blends the DA50 was lower but the 
CPP higher than the single drug, CSX-only blend (Table 6.7). The low DA50 
represented a fraction of the powder which dispersed well at low dispersion forces thus 
comprising weakly held agglomerates, however, the high CPP indicated that there 
remained a fraction of powder within the bulk comprising strongly-associated 
agglomerates which required much higher dispersion forces for de-agglomeration. 
Despite this, there was no change between SX aerosolisation for single drug and co-
formulated DPIs prepared with micronised (i.e. unfractionated) particles which are also 
likely to have undergone a degree of agglomerate re-structuring. This further indicates 
that the properties and aerosolisation of mixed agglomerates in a combination DPI may 
differ post-blending, and that the fundamental agglomerate properties depend on the 
particle type in the formulation. 
 
When formulated as combination pre-blends, changes to the dispersibility of 
fractionated SX were dependent on the SX and FP particle type included in the blend. 
The biggest change in SX dispersion, in terms of the emission, FPF ED/RD and MMAD 
occurred when Stage 4 SX was combined with Stage 3 FP (Figure 6.3, Figure 6.4 and 
Table 6.5). This combination was therefore selected to investigate the ability to engineer 
SX aerosolisation using fractionated particles in combination DPI blends. Stage 4 SX 
had a higher emission but a lower FPF ED in combination with Stage 3 FP, and no 
change in the MMAD or FPF RD, when formulated as a carrier-based DPI blend. The 
trends seen in the NGI aerosolisation were similar to those observed in the pre-blend. 
Although blending with a carrier was unable to overcome the detrimental effect on the 
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FPF ED upon co-formulation, the emission improved, and unlike in the pre-blend, the 
FPF RD and MMAD did not change between the single drug and combination DPI 
blends, suggesting that despite worsening dispersibility with combination delivery, the 
changes were less severe. These findings were in contrast to those of Taki (2008a), in 
which upon co-formulation of aerodynamic size fractions of SX and FP, there was no 
change in the FPF of SX particles. When assessed by laser diffraction, there was no 
change in the bulk cohesivity of the powder blend (i.e. CPP = 3.0 Bar) but an increase 
in the dispersibility from DA50 = 0.48 Bar for the single drug DPI compared to DA50 = 
0.39 Bar for the combination DPI. This difference also highlighted an increase in the 
heterogeneity in agglomerate strengths within the powder bulk as the dispersing 
pressure required to achieve 50 % de-agglomeration (i.e. DA50) was lower despite the 
dispersing pressure for 100 % de-agglomeration (i.e. CPP) remaining the same. 
Therefore, the lower DA50 may have been more favourable for powder entrainment into 
the airstream as it represented a population of more dispersible agglomerates within the 
blend. However, there still remained a proportion of tightly associated agglomerates that 
did not disperse well, and these ultimately dictated the FPF. These strongly associated 
agglomerates may have been the ‘natural’ agglomerates which pre-existed in the 
powder/blend prior to formulating with lactose, as explained above. Strong inter-
particulate interactions between Stage 4 SX and Stage 3 FP particles (work of adhesion 
= 84.5 – 91.3 mJ.m-2) and high S4SX-S4SX cohesion (80.5 – 83.1 mJ.m-2) may have 
limited the disruption of ‘natural’ agglomerates in the powder during blending with a 
carrier. However, due to the greater heterogeneity in the work of adhesion compared to 
the work of cohesion of Stage 4 SX, newly formed drug agglomerates in the 
combination blend comprising one or both drugs would be like ly to show a wider range 
in agglomerate strengths compared to S4SX-only agglomerates in the single drug blend. 
 
6.6.4 THE INFLUENCE OF DRUG PARTICLE PROPERTIES AND CO-
FORMULATION ON SALMETEROL XINAFOATE DISSOLUTION 
Following deposition, aerosolised drug particles must undergo dissolution in the fluid 
lining of the lungs in order to become available for therapeutic action. Dissolution 
involves the transfer of molecules or ions from the solid state into a solution. The rate of 
dissolution of solid particles is dependent on the surface area available for contact with 
the dissolution media, and is therefore affected by the particle size and degree of 
agglomeration (Aulton, 2002). The physicochemical properties of the drug are therefore 
 Page | 247  
 
anticipated to dictate the rate of dissolution and subsequent absorption, metabolism and 
elimination of inhaled drugs (Davies and Feddah, 2003). Despite the small particle size 
of inhaled drugs, poor solubility is often a rate limiting step in the dissolution process 
(Davies and Feddah, 2003).  The solubility values determined for SX showed slight 
variation to those reported in the literature. SX is known to be practically insoluble in 
water but soluble in methyl alcohol (Martindale, 2013). The aqueous solubility was 
lower than reported values of 61.70 µg.mL
-1
 (Tong et al., 2001) and ~ 70 µg.mL
-1
 (am 
Ende, 2011) however the high solubility in methanol was comparable to the literature (~ 
40 mg.mL
-1
, am Ende, 2011). Differences between solubility values may arise from the 
relative proportions of the SX polymorph present, in which metastable SX-II has higher 
aqueous solubility than the more stable SX-I polymorph (Tong et al., 2001). 
Alternatively, the 24 h period may not have been long enough to achieve equilibrium in 
water, compared to the 72 h period employed by Tong et al. (2001), or there may have 
been differences in the sensitivity of the analytical method used. The degree of 
mechanical stress imparted as a result of manufacturing and processing may also alter 
between batches of powders and can alter solubility, for example, subjecting SX to 
different mixing times resulted in an increase in the apparent solubility potentially 
arising from amorphisation of the initially crystalline particles (Grasmeijer et al., 2013). 
 
The dissolution rate of micronised (i.e. unfractionated) SX when formulated with a 
lactose carrier appeared to be dependent on the composition of the dissolution media. 
The use of different dissolution media enabled the influence of SX solubility on the 
dissolution rate to be determined. The composition of the airway lining fluid changes 
according to the site in the lungs (Gehr et al., 1993; Bastacky et al., 1995; Widdicombe, 
2002); if particle/formulation engineering changed the deposition site of the drug 
particles, a change in drug solubility in the fluid may occur. For example the presence 
of surfactant in the fluid can increase dissolution by improving wettability and reducing 
the agglomeration of particles in the media (Son and McConville, 2009), and may 
therefore dictate dissolution rates. SX solubility was found to be sensitive to changes in 
the amount of methanol and water in the media, and reduced with the rank: 75:25 > 
50:50 > 25:75 for the different methanol:water compositions. This corresponded with a 
reduction in dissolution rate of SX and was corroborated by f2 values that were less 
than 50 between all the dissolution media compositions. High standard deviations (SD) 
were also observed between repeat experiments, particularly for the 25:75 composition. 
High SD values have been reported for the Franz diffusion cell method which similar to 
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the Transwell system mimics the diffusion controlled air-liquid interface of the lung 
(May et al., 2012). High variability was attributed to poor, or lack of, particle wetting 
due to the experimental set-up, and which would also arise from poor solubility of the 
drug in the media. There may also have been a degree of solvent evaporation and losses 
during the experiment and sampling steps. Variability in agglomerate sizes and/or the 
PSD < 5 µm, as well as non-uniform drug loading due to irregular powder deposition, 
are also factors which may be responsible for high variability between dissolution 
experiments (Son and McConville, 2009; May et al., 2012). 
 
There was no difference in the dissolution rate of unfractionated SX compared to 
crystallised, Stage 4 and Stage 5 particles, as indicated by f2 values ≥ 50. There was 
also no change in the dissolution rate between any of the latter engineered particle types 
(f2 values ≥ 50), despite there being differences in the aerodynamic deposition profiles 
of crystallised SX and the SX fractions in the NGI, and differences in the bulk 
dispersibility, of the DPI blends. The larger MMAD (p < 0.05) of CSX compared to 
Stage 5 SX (arising in part due to the larger geometric Dv50 of CSX), and lower FPF (p 
< 0.05) and DA50 compared to Stage 4 SX would suggest that the dispersion of CSX 
particles was poorer than that of the fractions. Different deposition patterns, in terms of 
different agglomerate sizes and particle/agglomerate size distributions, may have 
occurred between the samples following aerosolisation into the TSI. Any deposited 
agglomerates would need to first undergo dispersion to individual particles prior to 
dissolution. The rate of dissolution may therefore be limited either by the 
disintegration/dispersion of the deposited agglomerates in the media and/or the 
properties of the individual particles once they are dispersed in the media. Microscopy 
would therefore be required to determine the deposited state (i.e. as 
particles/agglomerates and the PSD) of the formulations on the Transwell insert. For 
example, the most cohesive Stage 5 SX particles may have deposited predominantly as 
agglomerates when compared to Stage 4 or crystallised SX. However, upon adequate 
wetting and liberation of the particles into the dissolution media, the smaller particle 
size (i.e. Dv50 following complete dispersion) and higher surface area of Stage 5 SX, and 
higher disorder (in terms of both bulk and surface disorder, as observed in Chapter 4) of 
the particles may have demonstrated higher solubility and thus promoted faster 
dissolution, such that overall there was no alteration in dissolution rate between the 
particle types. In the literature, stage fractionated hydrocortisone, salbutamol sulphate 
and budesonide have shown faster dissolution rates as particle size reduced, and was 
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attributed to the larger exposed surface area per unit mass of deposited drug for smaller 
particles (Cartier et al., 2008; Son and McConville, 2009; Arora et al., 2010). 
Significant differences in the initial release rates of budesonide have also been observed 
between stage fractions of different sizes (Son et al., 2010).  Despite differences in the 
geometric Dv50 of CSX, Stage 4 and Stage 5 SX, this did not appear to alter the 
dissolution rate of the particles, potentially due to the deposition of powder 
agglomerates rather than individual particles on the Transwell insert, which would 
require microscopy for confirmation.  
 
A lack of more pronounced differences between the particles may have arisen from 
experimental factors. For example, drug loading has been shown to affect dissolution 
rate. Higher drug loadings slow dissolution, and have the biggest impact on large 
particles and more hydrophobic drugs (Son and McConville, 2009; Arora et al., 2010; 
Son et al., 2010). Highly agglomerated drug particles have also shown slower 
dissolution rates due to large agglomerate sizes and high packing fractions which limit 
the exposure of particle surfaces to the dissolution medium (Kale et al., 2009). There 
was a high level of variability between repeat experiments, and the methodological 
parameters may not have been fully optimal. SX recovery from the insert following 
application of known amounts of SX in solution varied from 75.8 ± 7.42 % to 92.2 ± 
5.87 % for 2 µg and 10 µg of SX, respectively, suggesting there may be SX adsorption 
and/or sampling errors, particularly at low drug concentrations. At a number of 
sampling time points, including the final time point and wash, the detected 
concentration was at or below the LOQ of the calibration curve.  Dissolution studies, 
particularly when attempting to match as closely as possible the likely in vivo dosing, 
require more sensitive analytical techniques such as HPLC-MS in order to enable 
quantification of small amounts of drug. Despite these limitations, following co-
formulation there appeared to be an increase in the dissolution rate and total cumulative 
amount dissolved for micronised (i.e. unfractionated) SX compared to the single drug 
DPI formulation, and this was confirmed by an f2 value ≤ 50. A greater adhesive (rather 
than cohesive) tendency for SX towards FP may have resulted in modifications in 
agglomerate structures such that SX was exposed to a greater extent to the dissolution 
media. Adhesive interactions between SX and FP may have disrupted SX-only 
agglomerates held together by SX-SX interactions that were weaker than both SX-FP 
and FP-FP interactions, and therefore increased the surface area available for SX 
dissolution. Due to the heterogeneity in surface energy and therefore the work of 
 Page | 250  
 
cohesion and adhesion, FP may have interrupted even the most cohesive SX 
agglomerates and thus exposed SX particles with higher degrees of disorder and 
therefore wettability to the dissolution media. 
 
6.6.5 CONCLUSIONS 
In this study, an attempt was made to engineer the aerosolisation performance of 
combination DPI formulations by controlling the physicochemical properties of 
physically mixed drug particles. In the absence of a carrier, fractionated particles 
exhibited different aerosolisation behaviours in co-formulation compared with the 
unformulated fractionated powders. Furthermore, the changes that occurred were 
specific to the fractions that were blended together. Generally, the co-formulation of 
fractions in a 1:1 ratio was detrimental to the aerosolisation performance of SX and FP 
particles, whereas no change in aerosolisation behaviour occurred for co-formulated 
unfractionated particles as described in Chapter 5. Fractionated particles were therefore 
able to modify the dispersion behaviour of SX and FP in combination pre-blends, and 
indicated that within a bulk micronised powder there would be populations of particles 
for which aerosolisation would be affected to a different extent. The aerosolisation 
behaviour of the unformulated engineered SX particles and formulated combination pre-
blends, however, was not fully representative of SX aerosolisation when formulated as 
carrier-based DPI blends. Upon assessment of SX dissolution following aerodynamic 
deposition from a DPI formulation, whereas SX particle properties were found to have 
no effect on the dissolution profile, co-formulation of unfractionated particles seemed to 
increase the dissolution rate of SX. Combination delivery may therefore have benefits in 
terms of the dissolution profile of SX, warranting further investigation into the cause of 
the improvement. Further studies would also benefit from generating dissolution 
profiles in media more representative of the in vivo environment, and using 
particle/formulation engineering to attempt to further improve the dissolution profile of 
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Fixed dose combination dry powder inhaler (DPI) formulations containing inhaled 
corticosteroids (ICs) and long-acting bronchodilators (LABAs) are now in routine use 







 Turbohaler, the number of combination inhalers commercially 
available has steadily increased. A pharmacological synergistic effect between ICs and 
LABAs has been suggested to occur, however, whether this occurs in reality remains a 
controversial area for research and discussion. Nevertheless and regardless of any 
possible synergism, the two classes of drugs will have at least a complementary effect in 
managing disease due to their different modes of action: the IC administered to control 
airway inflammation and the LABA to treat smooth muscle dysfunction (Nelson et al., 
2003). The inhalation of two drugs from a single inhaler device may also simplify 
medication regimens, improve compliance (Taki et al., 2011a) and therefore provide 
greater patient acceptability. There is also the potential for physicochemical interactions 
to occur between the component particles, which may lead to altered aerosolisation of 
one or both drugs in the formulation. 
 
LABAs currently formulated in combination inhalers include salmeterol xinafoate (SX) 
and formoterol fumarate, and the ICs budesonide, beclometasone dipropionate and 
fluticasone propionate (FP) (Tamm et al., 2012). In the current work, SX and FP were 
studied as representative drugs in order to determine the influence of particle 
physicochemical properties and inter-particulate interactions on powder dispersion upon 
co-formulation. Studies have suggested that combination delivery of SX and FP from 
DPI formulations may alter the aerosolisation and deposition patterns of the drugs (Taki 
et al., 2010; Taki et al., 2011). Significant differences in the stage deposition of the 
commercial single active and combination formulations led the authors to conclude that 
separate and combined delivery may not be pharmaceutically equivalent (Taki et al., 
2011). A cause of this non-equivalence may arise from particle co-association within 
the formulation thus altering the dispersion and deposition profile of the drugs. 
Interactions between SX and FP have been identified upon aerosolisation in pMDI and 
DPI formulations (Theophilus et al., 2006; New et al., 2008; Rogueda et al., 2011) 
which may increase the likelihood of the drugs depositing at the same location in the 
lungs simultaneously. Whereas an interactive affinity has been identified between SX 
and FP powders (Young et al., 2004a; Vernall et al., 2012) which may promote co-
agglomeration of the particles, this interaction will also depend on particle properties 
such as the surface inter-facial chemistry, which has recently been shown to alter the 
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balance of cohesive and adhesive forces in a combination formulation (Kubavat et al., 
2012).  
 
Inhalation powders are traditionally produced by micronisation which is well known to 
induce changes in particle properties which are difficult to control; these include the 
generation of a wide PSD (Steckel et al., 2003a; Steckel et al., 2003b), increased 
amorphous content (Brodka-Pfeiffer et al., 2003; Gaisford et al., 2010), and higher 
surface energy (Feeley et al., 1998; Gamble et al., 2012). This can result in a 
heterogeneous powder, which may exhibit sub-populations of particles with distinct 
microstructure, and different propensities for particulate interactions when formulated 
(e.g. with a carrier or particles of a second drug type). Whereas batch-to-batch variation 
in powder properties have been identified and characterised (e.g. Ticehurst et al., 1994; 
Feeley et al., 1998; Le et al., 2012) the characterisation of intra-batch variability and the 
subsequent consequences for aerosolisation behaviour have not been extensively 
investigated, and the particular implications for complex combination formulations have 
not been widely considered. Despite the growing option of the use of particle 
engineering as a means of producing respirable particles, the batch production of 
micronised drug powders is likely to be of prime importance to inhalation formulation 
over the coming years. There remains merit therefore in understanding the implications 
of co-formulation on the deposition patterns of physically mixed micronised particles. 
In particular, there is merit in identifying the particle properties in powder batches that 
contribute towards the heterogeneity of interactions with co-formulated drug, carrier 
and ternary particles. By understanding and characterising drug agglomeration 
behaviour, there may be the potential to modify aerosolisation in combination 
formulations without the need for alternative particle production methodologies. In 
order to address these issues, a systematic study was undertaken in order to ascertain the 
influence of co-formulation and intra-batch variability of SX and FP particles on their 
aerosolisation behaviour in powder formulations. An in-depth analysis of the 
physicochemical and agglomeration properties of the bulk powders and their intra-batch 
variability would allow for a fundamental understanding of the consequences of co-
formulation to be achieved. 
 
Prior to determining the aerosol performance of a combination, or indeed any type of 
DPI formulation, it is important to gain an understanding of the inherent dispersibility 
of the bulk drug powders. This information provides an indication of fundamental 
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powder behaviour and can aid the formulation process in terms of selecting the most 
appropriate excipients or device technology to achieve efficient drug dispersion. The 
techniques currently available for this purpose exhibit drawbacks which include 
complex methodologies, the requirement for a large quantity of material, and the need 
for specialist equipment. A data analysis technique was therefore developed in the 
current study to characterise the inherent dispersibility of fine particle powders using 
dry dispersion laser diffraction and an airflow titration approach. Unlike previous 
applications in which the analysis was mainly qualitative (e.g. Adi et al., 2008) or 
involved the powder being actuated from an inhaler device (e.g. Adi et al., 2006, Adi et 
al., 2008; Behara et al., 2011b), the developed analysis technique generated two 
parameters which described the dispersion and de-agglomeration behaviour of the bulk 
powder from a static bed, such that the natural powder structure was subjected to 
minimal disturbance.  
 
A series of eight individual inhaled powdered drugs/excipients were screened and found 
to have different dispersion behaviours that could be linked to differences in powder 
structure and heterogeneity in particle properties. These dispersion characteristics would 
aid in dictating the formulation approaches and inhaler device technology that would be 
required to achieve efficient de-agglomeration of individual particles during delivery. 
For example, salbutamol base (SB) and tofimilast (Tof) dispersed readily (DA50 = 0.25 
and 0.28 Bar, respectively) and required relatively low dispersal forces to achieve 50 % 
powder de-agglomeration. A higher CPP for Tof compared to SB (3.0 and 1.0 Bar, 
respectively) indicated a heterogeneous population of agglomerates within the bulk 
powder for Tof. Therefore, higher dispersal forces are required in order to achieve 
complete dispersion of this powder, as is also the case for the most tightly associated 
agglomerates. Both SX and FP dispersered poorly in their natural state (DA50 = 1.45 
and 1.15 Bar, respectively) and had high bulk cohesivity (CPP = 3.5 and 3.0 Bar, 
respectively). These powders would require formulation/device approaches that would 
lower the bulk cohesivity of the powder (e.g. particle engineering or inclusion of a 
carrier) and/or provide high forces for dispersion (e.g. devices which generate high 
turbulence and numbers of impactions). Further characterisation of the latter powders 
revealed that FP had a larger particle size than SX (Dv50 = 2.81 ± 0.03 µm and 2.05 ± 
0.12 µm, respectively) and different morphology; FP particles appeared rounder 
compared to the flatter, more plate-like SX. FP was also found to have a higher and 
more heterogeneous surface energy than SX, which corresponded to a higher work of 
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cohesion for FP than SX. When aerosolised into the NGI, FP displayed a higher 
emission but was found to exhibit both a lower FPF and larger MMAD than SX. These 
observations confirmed the inherent cohesive and agglomerative behaviour of the SX 
and FP particles. However, differences in the agglomeration state, agglomeration 
tendencies and agglomerate strength would affect the particle interactions between SX 
and FP when co-formulated.  
 
The higher emission for FP than SX may derive from the highly cohesive nature of FP 
agglomerates that display good flowability and entrainment (Steckel et al., 2003b), but 
for which de-agglomeration is poor at low airflow rates. This leads to low FPFs (Steckel 
et al., 2003b; Louey et al., 2004) and high MMADs, as confirmed in the present study. 
Micronised SX (Adi et al., 2008) aerosolised in the absence of a carrier also 
demonstrated low FPFs. Unlike FP, this was predominantly due to low emissions for 
SX that may arise due to a high adhesive tendency of SX towards the device and 
capsule (Adi et al., 2008). Despite a lower emission for SX, more dispersible SX 
agglomerates resulted in a higher FPF ED (and lower MMAD) than FP. These findings 
were corroborated by surface energy analysis, which indicated that SX-SX cohesive 
interactions were weaker than FP-FP cohesive interactions, and thus it would be 
expected that lower dispersal forces would be required to overcome cohesive SX 
interactions between the particles. A lower DA50 and CPP value for SX compared to FP 
(following tumbling of the powders) also supported better SX dispersibility compared to 
that of FP.  Analogous to there always being a size distribution within any powder 
sample, there will inevitably be a distribution of agglomerate strengths within the bulk 
of a powder structure (Das et al., 2012). This was exemplified by the surface energy 
distributions and differences in the magnitude of the DA50 and CPP values of the SX 
and FP powders. Although both showed a degree of heterogeneity, this was greater for 
FP than SX, whereby poor dispersion of the most cohesive agglomerates may also have 
contributed towards the lower FPF values observed for FP than SX. It is therefore 
important to understand both the inherent behaviour and the heterogeneity of 
agglomeration behaviour of drug powders in order to control formulation behaviour 
when micronised drug particles are blended with further particles. Such blends include 
carrier containing formulations and co-formulated drug particles in combination 
formulations. 
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Upon aerosolisation into the NGI, FP deposition was generally not affected by 
combined formulation in carrier-free blends, but a reduction in the MMAD suggested 
some minor benefit in co-formulation. SX conversely showed worsening dispersibility 
in the presence of FP. The MMAD of SX increased as the amount of FP in the blend 
increased, and the FPF was significantly lower at the highest SX:FP ratio employed 
compared to single drug delivery. In the absence of a carrier, interactive forces would 
arise from the cohesivity and adhesivity of the drug particles. To the author’s 
knowledge, this was the first investigation of the dispersion modifying effects of SX 
and FP at various ratios in the absence of a carrier. Such investigations for SS and BDP 
particles formulated in combination in the absence of a carrier indicated that while for 
both drugs the emission was altered by co-formulation, only BDP exhibited a change in 
its FPF compared to BDP alone, despite both drugs being relatively more adhesive 
towards each other than cohesive (Jetmalani et al., 2012). Using the surface energy 
distributions to derive the work of cohesion and adhesion of the powders, the adhesive 
SX-FP interactions were found to be lower than cohesive FP-FP interactions but higher 
than SX-SX interactions. Therefore, it was postulated that SX de-agglomeration would 
be affected by co-formulation with FP to a greater extent than FP de-agglomeration by 
co-formulation with SX. The weaker SX-SX interactions would be more easily 
disrupted than stronger FP-FP interactions in the respective powders upon co-
formulation. This balance of interactions differed to those reported previously. For 
example, using the atomic force microscope (AFM), SX-FP adhesive interactions were 
reported to be larger than the cohesive interactions of both drugs (Young et al., 2004a). 
In another study also using AFM, SX was found to have stronger cohesive interactions 
than adhesive interactions towards FP, whereas FP formed stronger interactions with 
SX than FP cohesive interactions (Vernall et al., 2012). These differences may arise due 
to different batches of powder being tested, which may also have been subjected to 
different processing histories. For example, it has been reported that the cohesive-
adhesive properties of FP towards SX varied as a result of different interfacial 
chemistries which arose with increasing numbers of passes through a microniser 
(Kubavat et al., 2012). Furthermore, the use of AFM, which is a single particle 
technique, may have been unable reveal the heterogeneity in particle properties which, 
as demonstrated in the current work, are present within the bulk of a powder. 
 
The micronisation process itself, and any secondary processing, therefore has the 
potential to alter the balance of interactive forces not only between different batches of 
 Page | 257  
 
powder, but also within a single batch of powder. The interactive nature of the particles 
in a blend can also lead to a change in powder structure (Jetmalani et al., 2012), and this 
was exemplified by the changes in bulk dispersibility of the combination particle 
mixtures determined by laser diffraction analysis, compared to the dispersibilities of the 
single drug entities. As the proportion of FP in the blend increased, the dispersibility 
worsened, as demonstrated by the DA50 values (i.e. the dispersing pressure required to 
achieve 50 % de-agglomeration). The DA50 values gradually increased according to 
increasing proportions of FP from 0.20 Bar for the highest SX content blend to 0.89 Bar 
for the highest FP content blend. The powders also became more cohesive. The CPP 
values (i.e. the dispersing pressure required to achieve 100 % de-agglomeration) were 
1.00 – 1.20 Bar for the SX-rich blends compared to 1.20 – 1.70 Bar for the FP-rich 
blends. This also represented a change in agglomerate heterogeneity. A reduction in the 
magnitude of the difference between the DA50 and CPP values was observed as the 
amount of FP in the blend increased, indicating less variable agglomerate strengths 
within the bulk powder. The structure of powder mixtures will comprise of a range of 
agglomerates including mixed and single component agglomerates with differing 
dispersibilities (Behara et al., 2011a). Mixed SX-FP agglomerates, SX-only and FP-
only agglomerates would therefore be present in varying proportions within the 
mixtures, some of which would be poorly dispersible (and represented by a high CPP). 
Higher FP content blends therefore consisted of larger proportions of poorly dispersible 
agglomerates, demonstrated by higher CPPs, compared to high SX content blends, and 
less variability in agglomerate strengths as the DA50 values were also higher for these 
blends. 
 
The intra-batch variability of the powders was characterised quantitatively using a 
recently developed fractionating technique in which cascade impaction is used to isolate 
aerodynamic size fractions of bulk powders (Taki et al., 2011b). Both SX and FP 
powders were found to comprise sub-populations of particles with distinct properties. 
Of particular importance was the identification of a sub-population of SX particles with 
higher bulk and surface disorder and a reduction in dispersibility compared to the bulk, 
unfractionated powder. Conversely for FP, sub-populations were identified with 
comparable disorder to the bulk powder but improved dispersibility. Micronisation is 
well known to generate particles with heterogeneity in their properties (Steckel et al., 
2003a; Steckel et al., 2003b) but to date this has not been fully quantified. Studies have 
however shown that powders may respond differently to processing pressures and that 
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this will affect the aersolisation performance between batches; differences might 
therefore also be expected within batches due to the unequal pressures experienced by 
the particles during manufacturing (Marek et al., 2011). Such a finding was identified 
within bulk SX and FP powders and hence this may also be a consequence for all 
powders subjected to micronisation. Not only may this affect the variability of DPI 
performance, but may also have implications for drug aerosolisation when formulated 
with a carrier either alone or in combination with a second drug. 
 
Prior to probing the implications of intra-batch variability on drug aerosolisation, single 
drug and combination DPI blends were prepared using the bulk (i.e. unfractionated) 
powders. The FP-only DPI was found to be more dispersible than the SX-only DPI 
according to laser diffraction de-agglomeration analysis. When aerosolised into the 
NGI, despite FP being found to have a higher emission, the FPF ED and RD were lower 
and the MMAD larger than SX. This indicated that the FP-only DPI blend contained 
higher proportions of drug agglomerates that were more poorly dispersible than those in 
the SX-only DPI blend, and it was this that dictated the poorer fine particle delivery of 
FP. Comparing the aerosolisation behaviour of SX:FP pre-blends before and after 
blending with a coarse carrier, it was found that when formulated with a carrier, the 
detrimental effects on SX dispersion upon co-formulation was no longer manifest, and 
there proved to be no change in the dispersion of FP, across the three SX:FP ratios 
employed. These findings were in contrast to those of the commercial carrier-based 
Seretide Accuhaler formulations reported in the literature. In the latter study, SX caused 
a small but significant increase in the aerosolisation of FP, generating higher FPFs in 
co-formulation, whereas SX was found to have a smaller FPF from the combination in 
comparison to the single drug product (Taki et al., 2011). The results presented in the 
current study suggest that by pre-mixing SX and FP particles prior to blending with the 
carrier, it may be possible to negate changes in dispersion behaviour (in terms of the 
emission, FPF and MMAD) that may occur upon co-formulation of the drug particles at 
different SX:FP ratios. When internal group analysis of the combination DPI blends 
only was effected, to ascertain whether there were differences in aerosolisation 
performance between the co-formulated blends only, no change in FP dispersion was 
again demonstrated. This therefore, was in keeping with the previous observations 
derived from aerosolising fine particle blends and pre-blends. However, for SX, despite 
there being no change in the emission, the FPF RD and ED were lower when SX was 
present in the 1:8 SX:FP ratio compared to the 8:1 ratio (p < 0.05, Kruskal Wallis 
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ANOVA with Dunns post-test). Therefore, although SX entrainment may have been 
similar between the ratios, the agglomerate properties of the drug particles may have 
differed, resulting in different efficiencies for de-agglomeration. It therefore may be 
possible to modify the aerosolisation performance of SX from combination blends by 
altering the SX:FP ratio. 
 
The dispersibility of the combination DPI blends, according to the DA50 from laser 
diffraction analysis, was also found to alter; becoming worse as the amount of SX in the 
blend increased. This trend was opposite to that observed in the fine particle blends in 
which the bulk dispersibility (i.e. DA50) of the bulk powder improved with increasing 
SX content. There also seemed to be a shift towards greater heterogeneity in 
agglomerate strengths in the DPI blends containing increasing amounts of SX. This 
could be attributable to changes in powder structure and the balance of inter-particulate 
interactions within the blend. The dispersion of carrier blends to produce individual 
particles would be dictated by the ease in which drug particles/agglomerates are 
liberated from the surface of the carrier, as well as to how efficiently and effectively 
they disperse once released. This is in contrast to fine particle blends, when 
dispersibility will only be dictated by the dissociation of drug agglomerates. Therefore, 
in addition to interactions between SX and FP particles, interactions with the lactose 
particles in the formulation would also contribute towards the aerosolisation behaviour 
of the drugs. This would be affected by the specific physicochemical properties of the 
drug particles, as well as the carrier or any ternary agent particles that may be present in 
the formulation. These properties may differ between and even within batches of 
powders, and hence warrant thorough characterisation in order to fully determine the 
effects of co-formulation on powder systems of interest.   
 
FPF and MMAD values only represent two metrics of formulation performance that 
might be predictive of in vivo deposition. One aim of this thesis was to investigate 
whether co-association of particles occurs within combination DPI blends. It was 
found that an heterogeneity of agglomerate strengths and structures is present in bulk 
micronised materials and therefore it is likely that the degree of mixing of two drugs in 
mixed agglomerates would also be heterogeneous. As a measure of co-association, the 
SX:FP ratio of the deposited masses across the NGI were calculated for both the co-
formulated pre-blends and DPI blends. In the absence of a carrier, the SX:FP ratio of 
the deposited mass was maintained in the throat, pre-separator and on stages 1 – 6 of 
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the NGI when the nominal SX:FP ratio was 1:8. There were deviations in the ratio of 
the deposited mass for blends containing SX:FP in the proportion 1:1 and 8:1 beyond 
stage 3 and stage 2 of the impactor, respectively. In the presence of a carrier, the 
magnitude of the deviations increased further. Physically mixed combination 
formulations have demonstrated deposition profiles in which different amounts of each 
drug were deposited on the impactor stages. These have included salbutamol base and 
beclometasone dipropionate (Traini et al., 2012) and SX and FP combinations 
(Pitchayajittipong et al., 2009), and has been overcome by the formulation of 
combination particles where it was possible to achieve uniformity of the ratio of 
deposition of the respective drugs on each impactor stage (e.g. Westmeier and Steckel., 
2008; Pitchayajittipong et al., 2009; Kumon et al., 2010; Traini et al., 2012). The 
current study suggests that the deposition patterns, in terms of the drug ratio on the 
impactor stages, may also be influenced by the drug ratio of the formulation and the 
formulation type (i.e. carrier-based vs. carrier-free formulation). It has also recently 
been reported that following aerosolisation of the Seretide Accuhaler 50/250 into the 
NGI, approximately 45 – 50 % of the particles depositing on stage 3 of the impactor 
were free standing, and that a much smaller proportion were agglomerated, either with 
fine lactose or drug particles (Vernall et al., 2012). The change in the ratios of the 
deposited masses observed in the current study may therefore be due to changes in the 
aerosolisation behaviour which do not arise due to association between the particles 
(which may cause them to deposit as mixed agglomerates), and therefore warrants 
further investigation.   
 
Inhaled powders have been shown to contain a distribution of powder strengths within 
the bulk which have different propensities for de-agglomeration, resulting from a 
distribution in particle properties such as particle size, density and surface energy (Das 
et al., 2012). In order to investigate the heterogeneity of agglomeration state of 
micronised particles in DPI blends, fractionated sub-populations were investigated in 
isolation and in co-formulated blends, with and without a lactose carrier. When 
formulated in combination in the absence of a carrier, the fractions displayed changes in 
their dispersibility when compared to the individual drug fractions. Furthermore, the 
trends were different to those seen for the unfractionated powders, and the magnitude of 
the changes varied depending on the specific combination of particles employed.  
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An improvement in the emission of Stage 5 SX upon co-formulation with either Stage 3 
or Stage 4 FP powders was observed, and also improvement in the emission of Stage 4 
SX upon co-formulation with Stage 3 FP powder. A smaller MMAD for Stage 4 FP co-
formulated with Stage 4 SX also resulted. Although, in the majority of instances, the 
emission, FPF and MMAD of the drug fractions were either worsened or did not change 
upon co-formulation. Therefore, it was not possible to optimise (i.e. improve) 
aerosolisation performance using the specific combination of fractions employed. There 
were also differences in the SX:FP ratios of the deposited masses in the NGI. The 
magnitude of the deviation from the nominal ratio (present in the powder mixtures) was 
small and comparable for all the blends when considering the deposition on the throat, 
pre-separator and stages 1 - 4 of the impactor. From stage 5 onwards, however, whereas 
the Stage 4 SX:Stage 4 FP blend displayed negligible deviation in the ratio of the 
deposited mass from the nominal ratio, the magnitude of the deviation appeared to 
increase with the following rank order: Stage 4 SX:Stage 3 FP < Stage 5 SX:Stage 4 FP 
< Stage 5 SX:Stage 3 FP. The most striking outcome of this study was therefore that 
within the bulk powder there were populations of particles that responded differently to 
co-formulation. These different responses of the powder sub-populations may 
contribute towards batch to batch variability in inhaler performance, and even result in 
sub-optimal drug delivery. For example, whereas unfractionated FP exhibited no change 
in its emission, FPF or MMAD upon co-formulation in a 1:1 ratio, Stage 3 and Stage 4 
FP samples both exhibited a significant reduction in the FPF upon co-formulation with 
either Stage 4 or Stage 5 SX. If a bulk FP powder batch contained large proportions of 
these Stage 3 or 4 particles, it may be the case that upon co-formulation with SX the 
aerosolisation performance of FP would be dramatically different (and possibly poorer) 
than an FP powder containing fewer of the particle agglomerates produced by blending 
powders within these size ranges.  
 
As a comparator, the aerosolisation of co-formulated SX and FP crystals was compared 
to single drug delivery of the recrystallised powders. Unlike the unfractionated or 
fractionated FP powders, co-formulation improved the dispersion of crystallised FP 
(CFP) beyond that of CFP alone. Conversely for crystallised SX (CSX), the dispersion 
worsened upon co-formulation. Further optimisation of the properties (such as size and 
size distribution) of the recrystallised particles may therefore provide the most 
promising route in which to improve the aerosolisation efficiency of combination 
formulations. Furthermore, when the crystals were formulated with a carrier, the effects 
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of co-formulation on CSX particles were opposite to those of the pre-blend; the 
emission and FPF ED improved, and the intrinsic dispersibility of the bulk powder 
improved. Where concomitant deposition of multiple actives across the different regions 
of the lung (as appears would be likely for engineered combination particles, 
Pitchayajittipong et al., 2009) may not be favourable, physically mixed recrystallised 
particles may provide a means of generating high fine particle delivery in complex 
combination formulations whilst maintaining individual deposition profiles for the 
drugs in the formulation.  
 
In order to further elucidate the particulate factors that affected SX drug dispersion, 
single drug DPIs containing crystallised, Stage 4 or Stage 5 SX particles were prepared 
and aerosolised into the NGI. Compared to the DPI prepared from the unfractionated 
powder, the aerosolisation behaviour of SX in the NGI (in terms of the emission, 
MMAD and FPF) was unchanged for these blends. There were subtle differences 
between the aerosolisation of the latter blends, in which use of the crystallised SX 
sample produced a lower FPF and larger MMAD than Stage 4 and Stage 5 SX, 
respectively. The presence of the carrier therefore offset the different SX 
physicochemical properties which resulted in different aerosolisation behaviours when 
the powders were aerosolised into the NGI in the absence of a carrier. There were 
however differences in the values of the DA50, CPP and the relative magnitude of the 
values following dry dispersion laser diffraction. Therefore, although there were 
changes in the bulk dispersibility and agglomerate heterogeneity between the blends, 
this was insufficient to alter SX dispersion in the NGI in this instance. By developing 
optimal formulation and delivery systems, it may therefore be possible to exploit the 
differences in the bulk dispersibility of the powder blends to engineer the aerosolisation 
performance of SX particles for improved dispersion. 
  
When co-formulated with Stage 3 FP in a DPI blend, Stage 4 SX exhibited changes in 
dispersion compared to the single drug Stage 4 SX containing DPI. These changes were 
comparable to those observed between the aerosolisation of the Stage 4 SX powder 
alone and from the Stage 4 SX:Stage 3 FP pre-blend. SX emission increased and the 
FPF was lower in combination compared to the Stage 4 SX-only DPI. An improvement 
in the bulk dispersibility of the combination DPI blend was also observed compared to 
the single drug DPI. Therefore, for the co-formulated fractions, formulating with a 
carrier was unable to mitigate changes in SX dispersibility as occurred for the 
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unfractionated SX powders upon co-formulation. Furthermore, a comparison of the 
aersolisation performance of SX in a DPI containing unfractionated SX co-formulated 
with unfractionated FP, and Stage 4 SX co-formulated with Stage 3 FP indicated that 
SX from the latter formulation generated a higher emission, FPF RD and FPF ED (p < 
0.05, unpaired t test), compared to the unfractionated SX. Similar to the behaviour 
observed in the pre-blends, this indicated that bulk micronised drug particles may 
demonstrate a distribution in aerosolisation performance upon co-formulation in DPI 
blends, arising from intra-batch variation in powder properties, which may contribute 
towards variability in DPI performance.   
 
Considering the dissolution of SX particles, when formulated as single drug DPIs, there 
were no differences in dissolution depending on SX particle properties, despite 
pronounced differences being observed previously for stage fractions of hydrocortisone, 
salbutamol sulphate and budesonide (Cartier et al., 2008; Son and McConville, 2009; 
Arora et al., 2010). However, when co-formulated with FP, the dissolution of 
unfractionated SX increased compared to the dissolution of SX from the single drug 
formulation. The ability to increase dissolution rate, which can be a rate limiting step in 
determining the availability of inhaled drugs, may therefore be an important finding. 
Upon co-formulation, the MMAD, FPF, and emission of SX did not differ (p > 0.05) 
compared to the single drug DPI when aerosolised into the NGI. There was however a 
change in the bulk dispersibility of the blends, suggesting that there may have been 
differences in the agglomeration and agglomerate properties (e.g. strength and 
structure). A lower DA50 for the combination blend indicated the presence of more 
dispersible agglomerates. Drug particles landing on the Transwell insert for dissolution 
testing would be detached from the carrier, and SEM imaging of the pre-blends and DPI 
blends indicated the presence of mixed SX-FP drug agglomerates. A change in 
agglomerate structure may therefore have altered the exposure of SX to the dissolution 
media, increased exposure of the more disordered regions on the particle surface, or 
disrupted the most damaged, and most cohesive, agglomerated SX particles, thus 
enhancing SX dissolution. Studies to elucidate the causes of the increased dissolution 
are required, as well as further investigations into the ability to modify the dissolution 
rate of SX following combination delivery using particle/formulation engineering 
approaches.   
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7.1 FUTURE WORK 
A continuation of the project designed to build on the findings reported in this thesis 
could therefore progress along two linked thematic pathways. The bulk powder 
dispersibility, particulate and agglomeration properties (dictated by factors such as 
particle size, morphology, surface energy, crystalline content and powder structure) and 
powder heterogeneity were found to influence drug dispersion from combination 
formulations. Therefore, further investigations into the ability to engineer SX and FP 
dispersion in physically mixed formulations could be undertaken. This could involve 
use of the Raman microscope since this would allow particle association to be identified 
and traced during the manufacturing and aerosolisation process. Examination of Raman 
spectra and images of drug powders during blending (in co-formulation, both with and 
without a carrier), and prior to and post-aerosolisation could be carried out. This would 
enable identification of whether co-association, if it does indeed occur, exhibits a 
dynamic nature and therefore changes during the formulation and/or dispersion process. 
It would also provide insight into the role of the carrier in mitigating the dispersion 
modifying effects that occurred in drug pre-blends. The development of a quantitative 
analysis technique would also allow SX:FP ratios to be determined and related back to 
chemical analysis from cascade impactor testing, to determine whether the composition 
of the deposited masses reflected association between the particles and hence provide a 
novel tool to assess combination formulations. As described above it has been found 
that combination pre-blends containing different aerodynamic size fractions of SX and 
FP with distinct properties exhibited different aerosolisation compared to single drug 
delivery. It would therefore be of interest to investigate different SX:FP ratios, inhaler 
devices, flow rates and formulations in terms of, for example, carrier properties and 
fines content, as a means of further engineering the deposition profiles of the drugs, in 
particular using Raman microscopy. Alternative drugs and drug combinations could 
also be tested to determine if the findings of the current study are generic across 
combination formulations or whether they are drug-specific. A second theme could 
involve further investigation of the biopharmaceutics of the drugs, and evaluation of the 
dissolution and cell layer transport of SX and FP upon co-formulation. Having observed 
that SX dissolution may be altered by co-formulation, SX dissolution experiments can 
be designed that provide a more realistic comparison with the in vivo environment, for 
example, using simulated lung fluids and undertaking the experiments at a temperature 
and humidity representative of the lungs. Analysis can also be extended to include FP. It 
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has recently been shown that co-delivery of SX and FP may have implications on drug 
transport across an epithelial cell layer, particularly for FP (Haghi et al., 2013). The 
influence of intra-batch variability and particle properties, represented by the 
aerodynamic size fractions, on the epithelial cell layer transport could be assessed. The 
implications of co-formulation of these engineered particles, in addition to bulk (i.e. 
unfractionated) particles could also be assessed, as a means to optimise the dissolution 
and transport profiles of the drugs.  
 
7.2 OVERALL SUMMARY OF FINDINGS 
The work detailed in this thesis has made a number of key contributions towards the 
area of respiratory drug delivery. A de-agglomeration analysis using laser diffraction 
was developed which will provide a tool for inhalation scientists to rapidly screen fine 
particles and powder mixtures for their inherent powder dispersibility. Eight inhaled 
powders were found to demonstrate different dispersion behaviours, which would aid in 
selecting the formulation and device approaches necessary to achieve efficient 
dispersion. Upon co-formulation in carrier-free blends, SX was affected by co-
formulation to a greater extent than FP, which was generally unaffected. SX dispersion 
became worse, particularly when blended with large amounts of FP, and was attributed 
to a greater adhesive tendency of SX for FP compared to FP for SX. The drug powders 
were also found to display intra-batch variability: powder sub-populations had distinct 
physicochemical and dispersibility properties and thus different agglomeration 
behaviours which may have consequences for aerosolisation performance upon 
formulation with a carrier, ternary agent, or a second drug particle type. However, when 
the bulk (i.e. unfractionated) powders were formulated with a carrier, there was no 
change in SX or FP dispersion between single drug and co-delivery, at various SX:FP 
ratios. This was despite differences in SX dispersion occurring between the co-
formulated pre-blends (which were subsequently blended with the lactose carrier) and 
the individual drug powders. It was therefore possible to mitigate drug ratio effects on 
drug dispersion by formulating the drug powders with a carrier. The practical 
implications of intra-batch powder variability were demonstrated further upon co-
formulation in the absence of a carrier, in which SX and FP fractions responded 
differently to co-formulation compared to the unfractionated powders, and depending 
on the specific combination of fractions blended together. Furthermore, when 
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formulated as carrier-based DPIs, the response to co-formulation of stage fractionated 
SX differed to that of the unfractionated SX. The different responses to co-formulation 
within a bulk powder indicated an additional source of variability in DPI performance, 
and demonstrated that both bulk and particulate factors influence the aerosolisation 
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